Document:

Master Transaction Agreement

 Exhibit 10.44 
 [EXECUTION COPY] 
 MASTER TRANSACTION AGREEMENT 
 dated as of 
 October 25, 2006

 by and among 
 AMERISOURCEBERGEN CORPORATION, 
 PHARMERICA, INC., 
 KINDRED HEALTHCARE, INC., 
 KINDRED PHARMACY SERVICES, INC., 

KINDRED HEALTHCARE OPERATING, INC., 
 SAFARI HOLDING CORPORATION, 
 HIPPO MERGER CORPORATION, 
 and 
 RHINO MERGER CORPORATION 
  

 TABLE OF CONTENTS 
  

					
	 	 	 	  	PAGE
		 	ARTICLE 1	  	
		 	DEFINITIONS	  	
			
	Section 1.01.	 	Definitions	  	2
	Section 1.02.	 	Other Definitional and Interpretative Provisions	  	29
			
		 	ARTICLE 2	  	
		 	SEPARATION OF ASSETS; DISTRIBUTION OF HIPPORX	  	
			
	Section 2.01.	 	Timing of HippoRx Distribution	  	30
	Section 2.02.	 	Transfer of Assets; Assumption of Liabilities.	  	30
	Section 2.03.	 	Governmental Approvals; Consents.	  	31
	Section 2.04.	 	Termination of Agreements.	  	31
	Section 2.05.	 	HippoRx Distribution.	  	32
			
		 	ARTICLE 3	  	
		 	SEPARATION OF ASSETS; DISTRIBUTION OF RHINORX	  	
			
	Section 3.01.	 	Timing of RhinoRx Distribution	  	33
	Section 3.02.	 	Transfer of Assets; Assumption of Liabilities.	  	33
	Section 3.03.	 	Governmental Approvals; Consents.	  	34
	Section 3.04.	 	Termination of Agreements.	  	35
	Section 3.05.	 	RhinoRx Distribution.	  	36
			
		 	ARTICLE 4	  	
		 	ORGANIZATION OF NEWCO	  	
			
	Section 4.01.	 	Organization of Newco	  	36
	Section 4.02.	 	Directors and Officers of Newco	  	37
	Section 4.03.	 	Organization of Merger Subs	  	37
	Section 4.04.	 	Approvals of Hippo and Rhino	  	37
			
		 	ARTICLE 5	  	
		 	THE MERGERS	  	
			
	Section 5.01.	 	The Hippo Merger.	  	37
	Section 5.02.	 	The Rhino Merger.	  	38
	Section 5.03.	 	Certificates of Incorporation; Bylaws.	  	38
	Section 5.04.	 	Directors and Officers	  	39

  

 i 

					
		  	ARTICLE 6	  	
		  	CONVERSION AND EXCHANGE OF SHARES	  	
			
	 Section 6.01.
	  	Conversion of Shares	  	39
	 Section 6.02.
	  	Exchange Procedures.	  	40
	 Section 6.03.
	  	Fractional Shares	  	41
	 Section 6.04.
	  	Adjustments Related to IRS Ruling	  	41
	 Section 6.05.
	  	Withholding Rights	  	42
	 Section 6.06.
	  	Transferring Hippo Employee Stock Options.	  	42
	 Section 6.07.
	  	Transferring Rhino Employee Stock Options.	  	43
	 Section 6.08.
	  	Restricted Stock.	  	44
	 Section 6.09.
	  	Newco Actions	  	45
			
		  	ARTICLE 7	  	
		  	REPRESENTATIONS AND WARRANTIES OF HIPPO	  	
			
	 Section 7.01.
	  	Corporate Existence and Power	  	45
	 Section 7.02.
	  	Corporate Authorization.	  	46
	 Section 7.03.
	  	Governmental Authorization	  	47
	 Section 7.04.
	  	Non-contravention	  	47
	 Section 7.05.
	  	Capitalization.	  	47
	 Section 7.06.
	  	HippoRx Entities.	  	48
	 Section 7.07.
	  	SEC Filings and the Sarbanes-Oxley Act.	  	49
	 Section 7.08.
	  	Financial Statements.	  	51
	 Section 7.09.
	  	Information Supplied	  	51
	 Section 7.10.
	  	Absence of Certain Changes	  	52
	 Section 7.11.
	  	No Undisclosed Liabilities	  	54
	 Section 7.12.
	  	Compliance with Laws and Court Orders.	  	54
	 Section 7.13.
	  	Litigation.	  	56
	 Section 7.14.
	  	Finders’ Fees	  	56
	 Section 7.15.
	  	Taxes.	  	57
	 Section 7.16.
	  	Employee Benefit Plans; Employees.	  	57
	 Section 7.17.
	  	Environmental Matters.	  	59
	 Section 7.18.
	  	Property Matters.	  	60
	 Section 7.19.
	  	Intellectual Property.	  	61
	 Section 7.20.
	  	HippoRx Material Contracts.	  	62
	 Section 7.21.
	  	Insurance	  	65
	 Section 7.22.
	  	Intercompany Transactions	  	66
	 Section 7.23.
	  	Sufficiency of Transferred Assets	  	66
	 Section 7.24.
	  	Tax Treatment	  	66
	 Section 7.25.
	  	Opinion of Financial Advisor	  	66
	 Section 7.26
	  	Lexicon Pharmacy Services	  	66
			
		  	ARTICLE 8	  	
		  	REPRESENTATIONS AND WARRANTIES OF RHINO	  	
			
	 Section 8.01.
	  	Corporate Existence and Power	  	67

  

 ii 

					
	 Section 8.02.
	  	Corporate Authorization.	  	67
	 Section 8.03.
	  	Governmental Authorization	  	68
	 Section 8.04.
	  	Non-contravention	  	68
	 Section 8.05.
	  	Capitalization.	  	69
	 Section 8.06.
	  	RhinoRx Entities.	  	69
	 Section 8.07.
	  	SEC Filings and the Sarbanes-Oxley Act.	  	70
	 Section 8.08.
	  	Financial Statements.	  	72
	 Section 8.09.
	  	Information Supplied	  	72
	 Section 8.10.
	  	SAbsence of Certain Changes	  	73
	 Section 8.11.
	  	No Undisclosed Liabilities	  	75
	 Section 8.12.
	  	Compliance with Laws and Court Orders.	  	75
	 Section 8.13.
	  	Litigation.	  	77
	 Section 8.14.
	  	Finders’ Fees	  	77
	 Section 8.15.
	  	Taxes.	  	78
	 Section 8.16.
	  	Employee Benefit Plans; Employees.	  	78
	 Section 8.17.
	  	Environmental Matters.	  	80
	 Section 8.18.
	  	Property Matters.	  	80
	 Section 8.19.
	  	Intellectual Property.	  	82
	 Section 8.20.
	  	RhinoRx Material Contracts.	  	83
	 Section 8.21.
	  	Insurance	  	86
	 Section 8.22.
	  	Intercompany Transactions	  	86
	 Section 8.23.
	  	Sufficiency of Transferred Assets	  	87
	 Section 8.24.
	  	Tax Treatment	  	87
	 Section 8.25.
	  	Opinion of Financial Advisor	  	87
			
		  	ARTICLE 9	  	
		  	COVENANTS OF HIPPO	  	
			
	 Section 9.01.
	  	Conduct of Hippo and HippoRx	  	87
	 Section 9.02.
	  	No Solicitation; Other Offers.	  	90
	 Section 9.03.
	  	Intercompany Accounts	  	91
	 Section 9.04.
	  	HippoRx Financing	  	91
	 Section 9.05.
	  	Hippo Financial Statements	  	91
			
		  	ARTICLE 10	  	
		  	COVENANTS OF RHINO	  	
			
	 Section 10.01.
	  	Conduct of Rhino and RhinoRx	  	92
	 Section 10.02.
	  	No Solicitation; Other Offers.	  	94
	 Section 10.03.
	  	Intercompany Accounts	  	95
	 Section 10.04.
	  	RhinoRx Financing	  	95
	 Section 10.05.
	  	Rhino Financial Statements	  	96
			
		  	ARTICLE 11	  	
		  	COVENANTS OF HIPPO, RHINO AND NEWCO	  	
			
	 Section 11.01.
	  	Reasonable Best Efforts.	  	96

  

 iii 

					
	 Section 11.02.
	  	Certain Filings	  	97
	 Section 11.03.
	  	Public Announcements	  	98
	 Section 11.04.
	  	Further Assurances	  	98
	 Section 11.05.
	  	Access to Information.	  	99
	 Section 11.06.
	  	Notices of Certain Events	  	99
	 Section 11.07.
	  	Confidentiality.	  	100
	 Section 11.08.
	  	Governance of Newco	  	101
	 Section 11.09.
	  	Non-Competition; Non-Solicitation.	  	101
	 Section 11.10.
	  	Transition Planning Committee.	  	103
	 Section 11.11.
	  	Tax-Free Transaction.	  	104
	 Section 11.12.
	  	Director and Officer Liability.	  	104
	 Section 11.13.
	  	Stock Exchange Listing	  	105
	 Section 11.14.
	  	Certain Agreements	  	105
			
		  	ARTICLE 12	  	
		  	EMPLOYEE MATTERS	  	
			
	 Section 12.01.
	  	Hippo Employee Matters.	  	107
	 Section 12.02.
	  	Rhino Employee Matters.	  	109
	 Section 12.03.
	  	No Third Party Beneficiaries	  	111
	 Section 12.04.
	  	Severance	  	111
	 Section 12.05.
	  	Intention and Scope	  	111
	 Section 12.06.
	  	Cooperation	  	112
			
		  	ARTICLE 13	  	
		  	CONDITIONS TO THE OBLIGATIONS OF THE PARTIES	  	
			
	 Section 13.01.
	  	Conditions to the Obligations of Each Party.	  	112
	 Section 13.02.
	  	Conditions to the Obligations of Hippo	  	114
	 Section 13.03.
	  	Conditions to the Obligations of Rhino	  	115
			
		  	ARTICLE 14	  	
		  	TERMINATION	  	
			
	 Section 14.01.
	  	Termination	  	116
	 Section 14.02.
	  	Effect of Termination	  	117
			
		  	ARTICLE 15	  	
		  	SURVIVAL AND INDEMNIFICATION; RELEASES	  	
			
	 Section 15.01.
	  	Survival	  	117
	 Section 15.02.
	  	Indemnification.	  	118
	 Section 15.03.
	  	Indemnification Procedures.	  	120
	 Section 15.04.
	  	Calculation of Damages	  	122
	 Section 15.05.
	  	Release of Pre-Closing Claims.	  	122
	 Section 15.06.
	  	Exclusivity	  	123

  

 iv 

					
		 	ARTICLE 16	  	
		 	MISCELLANEOUS	  	
	 Section 16.01.
	 	Representations and Warranties	  	124
	 Section 16.02.
	 	Notices	  	125
	 Section 16.03.
	 	Amendments and Waivers	  	126
	 Section 16.04.
	 	Fees and Expenses	  	126
	 Section 16.05.
	 	Disclosure Schedule References	  	127
	 Section 16.06.
	 	Binding Effect; Benefit; Assignment	  	127
	 Section 16.07.
	 	Governing Law	  	127
	 Section 16.08.
	 	Jurisdiction	  	127
	 Section 16.09.
	 	WAIVER OF JURY TRIAL	  	128
	 Section 16.10.
	 	Counterparts; Effectiveness	  	128
	 Section 16.11.
	 	Entire Agreement	  	128
	 Section 16.12.
	 	Severability	  	128
	 Section 16.13.
	 	Specific Performance	  	129

  

			
	 Hippo Disclosure Schedule

	 Rhino Disclosure Schedule

	Annex A	  	Adjustments
		
	Exhibit A	  	Form of Hippo Newco Transition Services Agreement
	Exhibit B	  	HippoRx Balance Sheet
	Exhibit C	  	Information Services Agreement Term Sheet
	Exhibit D	  	Form of Newco Hippo Transition Services Agreement
	Exhibit E	  	Form of Newco Supply Agreement
	Exhibit F	  	Form of Rhino Hippo Transition Services Agreement
	Exhibit G	  	Form of Rhino Newco Transition Services Agreement
	Exhibit H	  	RhinoRx Balance Sheet
	Exhibit I	  	Form of Trademark License Agreement
	Exhibit J	  	Newco Charter
	Exhibit K	  	Newco Bylaws
	Exhibit L	  	Hippo Merger Sub Charter
	Exhibit M	  	Hippo Merger Sub Bylaws
	Exhibit N	  	Rhino Merger Sub Charter
	Exhibit O	  	Rhino Merger Sub Bylaws
	Exhibit P	  	Hippo Institutional Pharmacy Business Unaudited Financials as of June 30, 2006
	Exhibit Q	  	Hippo Institutional Pharmacy Business Unaudited Financials as of September 30, 2006 (excluding Hippo Retail Pharmacies)
	Exhibit R	  	Rhino Institutional Pharmacy Business Unaudited Financials as of September 30, 2006
	Exhibit S	  	MPPA Sideletter
	Exhibit T	  	Hippo IRS Rulings
	Exhibit U	  	Rhino IRS Rulings

  

 v 

 MASTER TRANSACTION AGREEMENT 
 THIS MASTER TRANSACTION AGREEMENT (this “Agreement”), dated as of October 25, 2006, is by and among AmerisourceBergen Corporation,
a Delaware corporation (“Hippo”), PharMerica, Inc., a Delaware corporation and wholly-owned subsidiary of Hippo (“HippoRx”), Kindred Healthcare, Inc., a Delaware corporation (“Rhino”), Kindred
Healthcare Operating, Inc., a Delaware corporation and wholly-owned subsidiary of Rhino (“Rhino Parent Sub”), Kindred Pharmacy Services, Inc., a Delaware corporation and wholly-owned subsidiary of Rhino Parent Sub
(“RhinoRx”), Safari Holding Corporation, a Delaware corporation (“Newco”), Hippo Merger Corporation, a Delaware corporation and wholly-owned subsidiary of Newco (“Hippo Merger Sub”), and Rhino
Merger Corporation, a Delaware corporation and wholly-owned subsidiary of Newco (“Rhino Merger Sub”). 
 WHEREAS, the Board
of Directors of Hippo has determined that it is advisable and in the best interests of Hippo and its stockholders to separate Hippo’s institutional pharmacy business from Hippo pursuant to a spin-off of HippoRx to the stockholders of Hippo,
followed immediately by the merger of Hippo Merger Sub with and into HippoRx (the “HippoRx Merger”); 
 WHEREAS, the Board
of Directors of Rhino has determined that it is advisable and in the best interests of Rhino and its stockholders to separate Rhino’s institutional pharmacy business from Rhino pursuant to a spin-off of RhinoRx to the stockholders of Rhino,
followed immediately by the merger of Rhino Merger Sub with and into RhinoRx (the “RhinoRx Merger”); 
 WHEREAS, the Board
of Directors of each of HippoRx, RhinoRx, Hippo Merger Sub, Rhino Merger Sub and Newco has determined that it is advisable and in the best interests of the stockholders of HippoRx, RhinoRx, Hippo Merger Sub, Rhino Merger Sub and Newco, respectively,
to effect the HippoRx Merger and the RhinoRx Merger, as applicable; 
 WHEREAS, it is the intention of the parties hereto that each of the
spin-offs of HippoRx and RhinoRx qualifies as a tax-free transaction described in Section 355 of the Internal Revenue Code of 1986, as amended (the “Code”), and that Section 355(e) of the Code not apply to either spin-off
as a result of the HippoRx Merger or the RhinoRx Merger; and 
 WHEREAS, it is the intention of the parties hereto that the HippoRx Merger
and RhinoRx Merger shall constitute exchanges described in Section 351 of the Code. 
 NOW, THEREFORE, in consideration of the foregoing
and the respective representations, warranties, covenants and agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby 

 
acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows: 
 ARTICLE 1 
 DEFINITIONS 
 Section 1.01. Definitions. (a) As used herein, the following terms have the following meanings: 
 “Action” means any demand, action, suit, countersuit, arbitration, inquiry, proceeding or investigation by or before any federal, state,
local, foreign or international Governmental Authority or any arbitration or mediation tribunal. 
 “Active Transferring Hippo
Employee” means a Transferring Hippo Employee who, as of immediately prior to the HippoRx Distribution, is then a current employee of Hippo or its Subsidiaries. 
 “Active Transferring Rhino Employee” means a Transferring Rhino Employee who, as of immediately prior to the RhinoRx Distribution, is then a current employee of Rhino or its Subsidiaries. 

“Affiliate” means, with respect to any Person, any other Person directly or indirectly controlling, controlled by, or under common
control with such Person. 
 “Applicable Law” means, with respect to any Person, any federal, state or local law (statutory,
common or otherwise), constitution, treaty, convention, ordinance, code, rule, regulation, order, injunction, judgment, decree, ruling or other similar requirement enacted, adopted, promulgated or applied by a Governmental Authority that is binding
upon or applicable to such Person, as amended unless expressly specified otherwise. 
 “Assets” means assets, properties and
rights (including goodwill), wherever located (including in the possession of vendors or other third parties or elsewhere), whether real, personal or mixed, tangible, intangible or contingent, in each case whether or not recorded or reflected or
required to be recorded or reflected on the books and records or financial statements of any Person, including the following: 
  

	 	(i)	all accounting and other books, records and files whether in paper, computer, electronic or any other form; 

  

	 	(ii)	all personal property and interests therein, including machinery, equipment, furniture, office equipment, communications equipment, vehicles, storage tanks, spare and replacement
parts, special and general tools, test devices and other tangible personal property; 

  

 2 

	 	(iii)	all inventories of materials, parts, raw materials, supplies, work-in-process and finished goods and products; 

  

	 	(iv)	all interests in real property of whatever nature, including fee simple and leasehold interests and interests in easements and rights of way, whether as owner, mortgagee or holder
of a Lien in real property, lessor, sublessor, lessee, sublessee or otherwise, and copies of all related documentation; 

  

	 	(v)	all license agreements, leases of personal property, open purchase orders for raw materials, supplies, parts or services, unfilled orders for the manufacture and sale of products
and other contracts, agreements or commitments; 

  

	 	(vi)	all deposits (including deposits with vendors), letters of credit and performance and surety bonds; 

  

	 	(vii)	all domestic and foreign patents, copyrights, trade names, trademarks, service marks and registrations and applications for any of the foregoing, mask works, trade secrets,
inventions, other proprietary information and licenses from third Persons granting the right to use any of the foregoing; 

  

	 	(viii)	all computer applications, programs and other software, including operating software, network software, firmware, middleware, design software, design tools, systems documentation
and instructions; 

  

	 	(ix)	all cost information, sales and pricing data, customer prospect lists, supplier records, customer and supplier lists, records pertaining to customers and customer accounts, customer
and vendor data, correspondence and lists, product literature, artwork, design, development and manufacturing files, vendor and customer drawings, formulations and specifications, quality records and reports and other books, records, studies,
surveys, reports, plans and documents; 

  

	 	(x)	all prepaid expenses, trade accounts and other accounts and notes receivable; 

  

	 	(xi)	all rights under contracts or agreements, all claims or rights against any Person arising from the ownership of any Asset, all rights in connection with any bids or offers and all
claims, choices in action or similar rights, whether accrued or contingent; 

  

 3 

	 	(xii)	all insurance proceeds and rights under insurance policies and all rights in the nature of insurance, indemnification or contribution; and 

  

	 	(xiii)	all licenses, permits, approvals and authorizations that have been issued by any Governmental Authority. 

 “Base Confidentiality Agreement” means the Confidentiality Agreement dated as of January 11, 2006 between Hippo and Rhino.

 “Benefit Plan” means each material “employee benefit plan”, as defined in Section 3(3) of ERISA, each
employment, change in control, severance or similar contract, plan, arrangement or policy and each other material plan or arrangement (written or oral) providing for compensation, bonuses, profit-sharing, stock option or other stock related rights
or other forms of incentive or deferred compensation (whether funded or unfunded), vacation benefits, insurance (including any self-insured arrangements), health or medical benefits, employee assistance program, disability or sick leave benefits,
workers’ compensation, supplemental unemployment benefits, severance benefits and post-employment or retirement benefits (including compensation, pension, health, medical or life insurance benefits). 
 “Business Day” means a day, other than Saturday, Sunday or other day on which commercial banks in New York, New York are authorized or
required by Applicable Law to close. 
 “Cash Distribution Amount” means the sum of the HippoRx Final Financing Amount and
the RhinoRx Final Financing Amount. 
 “Clean Team Confidentiality Agreement” means the Confidentiality Agreement dated as
of June 8, 2006 between Hippo and Rhino. 
 “Consents” means any consents, waivers or approvals from, or notification
requirements to, any third parties, other than Governmental Approvals. 
 “Contract” means any legally binding contract,
lease, license, arrangement, commitment or agreement. 
 “Delaware Law” means the General Corporation Law of the State of
Delaware. 
 “Distribution Time” means such time as is mutually agreed by Hippo and Rhino for the consummation of the
Distributions on the Closing Date. 
 “Distributions” means the HippoRx Distribution and the RhinoRx Distribution.

  

 4 

 “Environmental Laws” means any Applicable Laws or any agreement with any Governmental
Authority relating to the environment or to pollutants, contaminants, wastes or chemicals or any toxic or otherwise hazardous substances, wastes or materials. 
 “Environmental Liabilities” means Liabilities or obligations of or relating to any entity, whether accrued, contingent, absolute, determined, determinable or otherwise, arising under or relating to
any Environmental Law or any Hazardous Substance. 
 “Environmental Permits” means all Governmental Approvals required by
Environmental Laws and relating to the business of any entity as currently conducted. 
 “ERISA” means the Employee
Retirement Income Security Act of 1974, as amended. 
 “ERISA Affiliate” of any entity means any other entity that, together
with such entity, would be treated as a single employer under Section 414 of the Code. 
 “Excluded Employee” means any
individual who would otherwise be a Transferring Hippo Employee or Transferring Rhino Employee, as applicable, but who is retained by Hippo or Rhino, as applicable, and whose employment is not transferred to Newco in connection with the transactions
contemplated by this Agreement, as consented to in writing by Hippo or Rhino, as applicable, which consent shall not unreasonably be withheld. Section 1.01 of the Hippo Disclosure Schedule and Section 1.01 of the Rhino Disclosure Schedule,
as applicable, set forth the Excluded Employees, as such schedules may be updated from time to time prior to the Distribution Time, under the heading “Excluded Employees”. 
 “GAAP” means generally accepted accounting principles in the United States. 
 “Governmental Approvals” means any notices, reports or other filings to be made with, or any consents, registrations, approvals,
permits, licenses, authorizations and waivers to be obtained from, any Governmental Authority. 
 “Governmental Authority”
means any transnational, domestic or foreign federal, state or local, governmental authority, department, court, agency or official, including any political subdivision thereof, including any contractors of a governmental authority, department or
agency as authorized by law, and acting pursuant to the terms and conditions of any such contract. 
 “Hazardous Substance”
means any pollutant, contaminant, waste or chemical or any toxic, radioactive, ignitable, corrosive, reactive or otherwise hazardous substance, waste or material, or any substance, waste or material having any constituent elements displaying any of
the foregoing characteristics, 

  

 5 

 
including any substance, waste or material regulated under any Environmental Law. 
 “Hippo Benefit Plan” means any Benefit Plan, other than a HippoRx Benefit Plan, sponsored, maintained or contributed to by Hippo or any
of its Subsidiaries. 
 “Hippo Common Stock” means the Common Stock, par value $0.01 per share, of Hippo. 
 “Hippo Credit Agreement” means the Credit Agreement dated as of December 2, 2004 among Hippo, the Lenders party thereto and
JPMorgan Chase Bank, N.A., as Administrative Agent, and the other Loan Documents referred to therein, each as amended. 
 “HippoDC” means AmerisourceBergen Drug Corporation, a Delaware corporation. 
 “Hippo Institutional
Pharmacy Business” means the business of providing independent pharmaceutical dispensing services to long-term care facilities and alternate site settings, including skilled nursing facilities, assisted living facilities and residential
living communities, which services include the purchasing, repackaging and dispensing of pharmaceuticals, both prescription and non-prescription, and the delivery of such pharmaceuticals to healthcare facilities for administration, as well as
various supplemental healthcare services that complement such pharmacy services, and also including the HippoRx Retail Pharmacies, but excluding (i) the Hippo Retail Pharmacies, (ii) the Hippo Workers’ Compensation Business,
(iii) the Hippo Specialty Pharmacy Business, (iv) the Hippo Packaging and Repackaging Services and (v) the Hippo Solutions Business. 
 “Hippo Lender Approval” means any and all waivers, consents, amendments and releases required under the Hippo Credit Agreement to permit consummation of the Transactions contemplated hereby. 
 “Hippo Newco Transition Services Agreement” means the Transition Services Agreement between Newco and Hippo substantially in the form
attached hereto as Exhibit A and providing for the provision by Hippo to Newco of the services to be determined pursuant to Section 11.14. 
 “Hippo Operating Sub” means Pharmacy Corporation of America, a California corporation. 
 “Hippo Packaging and Repackaging Services” means the business of delivering unit dose, punch card, unit-of-use and other packaging solutions to institutional and retail healthcare providers and providing contracted
packaging services for pharmaceutical manufacturers. 
  

 6 

 “Hippo Pre-Distribution Stock Value” means the closing per-share price of Hippo Common
Stock trading “regular way with due bills” as listed on the NYSE as of 4:00 p.m. Eastern Standard Time or Eastern Daylight Time (whichever shall then be in effect) on the Closing Date; provided, however that if the HippoRx
Distribution occurs at a time when the NYSE is open for trading, Hippo Pre-Distribution Stock Value shall mean the price at which the Hippo Common Stock trading “regular way with due bills” last trades immediately before the HippoRx
Distribution; provided further that if the HippoRx Distribution occurs prior to the first trade of Hippo Common Stock on the Closing Date, Hippo Pre-Distribution Stock Value shall mean the price at which Hippo Common Stock trading
“regular way with due bills” last trades on the trading date immediately prior to the Closing Date. If listing of the Newco Common Stock on the NYSE is not approved, references in this definition to the NYSE shall be to the NASDAQ Stock
Market. 
 “Hippo Restricted Stock” means Hippo Common Stock that is Restricted Stock. 
 “Hippo Retail Pharmacies” means the (i) three retail pharmacies of HippoRx located in Hawaii and (ii) one retail pharmacy of
HippoRx located in Fowler, California. 
 “Hippo Retained Subsidiaries” means PMSI, Inc., a Florida corporation, and TMESYS,
Inc., a Florida corporation. 
 “Hippo Solutions Business” means the business of providing automation solutions, pharmacy
management services, consulting services (including pharmacy consulting services), temporary leadership and staffing services (including leadership and staffing services for pharmacies), training services and other related services (including
training services and other related services for pharmacies). 
 “Hippo Specialty Pharmacy Business” means the business of
providing distribution and other services, including group purchasing services, to physicians and alternate care providers; dispensing specialty pharmaceutical products, including, without limitation, orally-administered specialty
pharmaceutical products, pharmaceutical products administered by infusion, injectable pharmaceutical products (including without limitation vaccines) and plasma and other blood products, to physicians and patients (including patients residing in
long-term care or other alternate care facilities) but not directly to alternate care or long-term care facilities pursuant to pharmacy services agreements with such facilities; providing commercialization, third party logistics and other services
to biotech and other pharmaceutical manufacturers; and providing reimbursement and healthcare consulting, practice management, market research and analytics, and physician education. 
  

 7 

 “Hippo Stock Option” means any option to purchase shares of Hippo Common Stock granted
under any employee stock option or compensation plan or arrangement of Hippo. 
 “Hippo Workers’ Compensation Business”
means the business of providing pharmacy benefit management services, prescription medications, medical equipment, medical supplies and in-home medical services for the workers’ compensation, chronically ill and catastrophically injured
populations. 
 “HippoRx Acquisition Proposal” means, other than the transactions contemplated by this Agreement, any offer,
proposal or inquiry relating to, or any Third Party indication of interest in, (i) any acquisition or purchase, direct or indirect, of 5% or more of the consolidated assets of the Hippo Institutional Pharmacy Business or over 5% of any class of
equity or voting securities of Hippo or any of its Subsidiaries whose assets, individually or in the aggregate, constitute more than 5% of the consolidated assets of the Hippo Institutional Pharmacy Business, (ii) any tender offer (including a
self-tender offer) or exchange offer that, if consummated, would result in such Third Party’s beneficially owning 5% or more of any class of equity or voting securities of Hippo or any of its Subsidiaries whose assets, individually or in the
aggregate, constitute more than 5% of the consolidated assets of the Hippo Institutional Pharmacy Business, (iii) a merger, consolidation, share exchange, business combination, sale of substantially all the assets, reorganization,
recapitalization, liquidation, dissolution or other similar transaction involving Hippo or any of its Subsidiaries whose assets, individually or in the aggregate, constitute more than 5% of the consolidated assets of the Hippo Institutional Pharmacy
Business or (iv) any other transaction the consummation of which could reasonably be expected to impede, interfere with, prevent or materially delay the transactions contemplated hereby; provided that notwithstanding anything in the
foregoing, “HippoRx Acquisition Proposal” shall not include any transaction (x) involving the Non-HippoRx Group (that does not also involve the Hippo Institutional Pharmacy Business) or (y) involving an acquisition of at least a
majority of the outstanding shares of Hippo Common Stock or a majority of Hippo’s consolidated assets by a Third Party (whether by purchase, tender offer, exchange offer, merger, consolidation, business combination or otherwise), if in the case
of each of (x) and (y), the consummation of such transaction would not prevent or materially impede, interfere with or delay the transactions contemplated hereby. 
 “HippoRx Assets” means any Assets that are owned, used or held for use by Hippo or any of its Subsidiaries primarily in connection with the Hippo Institutional Pharmacy Business, including:

 (i) the Assets reflected on the HippoRx Balance Sheet, unless disposed of to Third Parties after the date thereof, but
excluding any Non-HippoRx Assets; 
 (ii) any HippoRx Contracts; 
  

 8 

 (iii) any capital stock or other ownership interests in the HippoRx Entities; 

(iv) all right, title and interest of Hippo and its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business)
in the HippoRx Leases set forth in Section 7.18(a) of the Hippo Disclosure Schedule and in the HippoRx Owned Properties set forth on Section 7.18(b) of the Hippo Disclosure Schedule; 
 (v) any Assets that are expressly contemplated by the Transaction Agreements (or the Schedules thereto) as Assets to be retained by or
assigned to the Hippo Institutional Pharmacy Business or any HippoRx Entity; 
 (vi) any governmental licenses, permits,
approvals, certificates and other governmental authorizations held in the name of Hippo or any of its Subsidiaries that are primarily related to the Hippo Institutional Pharmacy Business, except for licenses, permits, approvals, certificates or
other governmental authorizations that are used in the business of the Non-HippoRx Group; and 
 (vii) any Assets listed or
described on Section 1.01 of the Hippo Disclosure Schedule under the heading “HippoRx Assets”. 
 Subject to
the foregoing sentence, in the event that any Asset is included in both the definition of “HippoRx Asset” and “Non-HippoRx Asset” then (i) if it is specifically referred to in a definition or schedule or otherwise (including
in any other Transaction Agreement), it shall be treated in accordance with such specific reference and (ii) otherwise it shall be treated as a HippoRx Asset or Non-HippoRx Asset based upon whether it is used or held for use primarily in
connection with the Hippo Institutional Pharmacy Business or primarily in connection with the business of the Non-HippoRx Group. 
 “HippoRx Audited EBITDA” means the earnings before interest, taxes, depreciation and amortization of the Hippo Institutional Pharmacy Business for the nine months ended June 30, 2006, as derived from the financial
information contained in the notes to the audited financial statements of the Hippo Institutional Pharmacy Business as of and for the fiscal year ended September 30, 2006, but excluding the effect of any audit adjustments reflected in such
financial statements solely relating to the timing of recognition of liabilities accrued pursuant to Statement of Financial Accounting Standards No. 5. 
 “HippoRx Balance Sheet” means the unaudited balance sheet of the Hippo Institutional Pharmacy Business as of June 30, 2006 as attached as Exhibit B hereto. 
  

 9 

 “HippoRx Balance Sheet Date” means June 30, 2006. 
 “HippoRx Benefit Plan” means any Benefit Plan sponsored or maintained solely by a HippoRx Entity. 
 “HippoRx Common Stock” means the Common Stock, par value $0.01 per share, of HippoRx. 
 “HippoRx Contracts” means the following Contracts to which Hippo or any of its Subsidiaries is a party or by which it or any of its
Subsidiaries or any of their respective Assets is bound, whether or not in writing: 
 (i) any Contract that relates primarily
to the Hippo Institutional Pharmacy Business; 
 (ii) any Contract or other instrument representing HippoRx Liabilities;

 (iii) any Contract that is expressly contemplated pursuant to this Agreement or any of the other Transaction Agreements to
be assigned or transferred to or retained by a HippoRx Entity; and 
 (iv) any guarantee, indemnity, representation, warranty
or other Liability of Hippo or any of its Subsidiaries (other than any HippoRx Entity) in respect of any other HippoRx Contract, any HippoRx Liability or the Hippo Institutional Pharmacy Business. 
 Notwithstanding the preceding sentence, “HippoRx Contracts” do not include any such Contract that is expressly contemplated to
be assigned to or retained by Hippo or any of its Subsidiaries (other than the HippoRx Entities) pursuant to any Transaction Agreement. 
 With respect to any Contract that relates in material part to both the Hippo Institutional Pharmacy Business and the business of the Non-HippoRx Group and that is not specifically contemplated by this Agreement to be
assigned to or retained by the HippoRx Entities or Hippo and its Subsidiaries (other than the HippoRx Entities), the parties will cooperate in good faith to apportion the rights and obligations thereunder to the Hippo Institutional Pharmacy Business
and the Non-HippoRx Group, and to treat such Contract as a HippoRx Contract only to the extent relating to the Hippo Institutional Pharmacy Business. 
 “HippoRx Distribution” means the distribution on the Closing Date by Hippo to the holders of Hippo Common Stock of all the outstanding shares of HippoRx Common Stock upon the terms and conditions more
fully set forth in Section 2.05. 
  

 10 

 “HippoRx Entities” means HippoRx and each of its Subsidiaries, other than the Hippo
Retained Subsidiaries. 
 “HippoRx Estimated EBITDA” means $32,769,679. 
 “HippoRx Final Financing Amount” has the meaning set forth on Annex A hereto. 
 “HippoRx Group” means the direct or indirect interest of Hippo (either itself or through its direct or indirect Subsidiaries, or any of
their predecessors or successors) in (i) the Hippo Institutional Pharmacy Business and (ii) any business or operations that were terminated, divested or discontinued by the HippoRx Entities (and their respective predecessors and
successors). 
 “HippoRx Liabilities” means any Liabilities (regardless of when or where such Liabilities arose or arise, or
whether the facts on which they are based occurred prior to, on or subsequent to the Closing Date, regardless of where or against whom such Liabilities are asserted or determined or whether asserted or determined prior to the Closing Date, and
regardless of whether arising from or alleged to arise from negligence, recklessness, violation of law, fraud or misrepresentation) relating to, arising out of, or resulting from the business of the HippoRx Group, including: 
 (i) the Liabilities reflected on the HippoRx Balance Sheet, subject to any discharge of such Liabilities subsequent to the HippoRx Balance
Sheet Date; 
 (ii) any Liabilities that are expressly contemplated by the Transaction Agreements (or the Schedules thereto)
as Liabilities to be retained or assumed by any HippoRx Entity, subject to discharge of such Liabilities subsequent to the HippoRx Balance Sheet Date, and all agreements, obligations and Liabilities of any HippoRx Entity under the Transaction
Agreements; 
 (iii) all Liabilities listed or described in Section 1.01 of the Hippo Disclosure Schedule under the
heading “HippoRx Liabilities”; and 
 (iv) any Liabilities, including, except as expressly set forth in Article 12
hereof, any employee-related Liabilities and Environmental Liabilities, primarily relating to, arising out of or resulting from (whether arising before, on or after the Closing Date): 
 (A) the HippoRx Group, including the operation of the Hippo Institutional Pharmacy Business, as conducted at any time prior to, on or
after the Closing Date (including any Liability relating to, arising out of or resulting from any act or failure to act by any director, officer, employee, agent or representative 

  

 11 

 
(whether or not such act or failure to act is or was within such Person’s authority)); 
 (B) the operation of any business conducted by any HippoRx Entity at any time after the Closing Date (including any Liability relating to,
arising out of or resulting from any act or failure to act by any director, officer, employee, agent or representative (whether or not such act or failure to act is or was within such Person’s authority)); or 
 (C) any HippoRx Assets. 
 Subject to the foregoing sentence, in the event that any Liability is included in both the definition of “HippoRx Liability” and “Non-HippoRx Liability” then (i) if it is specifically referred
to in a definition or schedule or otherwise (including in any of the other Transaction Agreements), it shall be treated in accordance with such specific reference and (ii) otherwise it shall be treated as a HippoRx Liability or Non-HippoRx
Liability to the extent it relates to the business of the HippoRx Group or the Non-HippoRx Group, respectively. 
 “HippoRx Retail
Pharmacies” means the HippoRx retail pharmacy in Phoenix, Arizona and the five HippoRx retail pharmacies in Baltimore, Maryland. 
 “HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 
 “Information
Services Agreement” means the Information Services Agreement between Newco and Rhino substantially on the terms set forth in the term sheet attached hereto as Exhibit C. 
 “knowledge” of Hippo or Rhino, as the case may be, means to the knowledge after reasonable inquiry of such Person’s employees set
forth on Section 1.01 of the Hippo Disclosure Schedule or Rhino Disclosure Schedule, as the case may be, under the heading “Knowledge of Hippo” or “Knowledge of Rhino”, as the case may be. 
 “Liabilities” means any and all losses, claims, charges, debts, demands, Actions, damages, obligations, payments, costs and expenses,
bonds, indemnities and similar obligations, covenants, controversies, promises, omissions, guarantees, make whole agreements and similar obligations, and other liabilities, including all contractual obligations, whether absolute or contingent,
inchoate or otherwise, matured or unmatured, liquidated or unliquidated, accrued or unaccrued, known or unknown, whenever arising, and including those arising under any law, rule, regulation, Action, threatened or contemplated Action (including the
costs and expenses of demands, assessments, judgments, settlements and compromises relating thereto and attorneys’ fees and any and all 

  

 12 

 
costs and expenses (including allocated costs of in-house counsel and other personnel), whatsoever reasonably incurred in investigating, preparing or
defending against any such Actions or threatened or contemplated Actions), order or consent decree of any Governmental Authority or any award of any arbitrator or mediator of any kind, and those arising under any contract, commitment or undertaking,
including those arising under the Transaction Agreements or incurred by a party thereto in connection with enforcing its rights to indemnification thereunder, in each case, whether or not recorded or reflected or required to be recorded or reflected
on the books and records or financial statements of any Person. 
 “Lien” means, with respect to any property or asset, any
mortgage, lien, pledge, charge, security interest, encumbrance or other adverse claim of any kind in respect of such property or asset. For purposes of this Agreement, a Person shall be deemed to own subject to a Lien any property or asset that it
has acquired or holds subject to the interest of a vendor or lessor under any conditional sale agreement, capital lease or other title retention agreement relating to such property or asset. 
 “Material Adverse Effect” means, with respect to (a) HippoRx, a material adverse effect on the condition (financial or otherwise),
business, assets or results of operations of the Hippo Institutional Pharmacy Business, taken as a whole, excluding any such effect resulting from or arising in connection with (i) changes or conditions generally affecting the industries in
which the Hippo Institutional Pharmacy Business (including the HippoRx Entities) operate, but only to the extent the effect on the Hippo Institutional Pharmacy Business, taken as a whole, is not materially worse than the effect on the Rhino
Institutional Pharmacy Business, taken as a whole, (ii) changes in general economic, regulatory (including changes in Applicable Laws, accounting rules or interpretations of the foregoing) or political conditions, including the engagement by
the United States in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military or terrorist attack upon or within the United States, but only to the extent the effect on the Hippo
Institutional Pharmacy Business, taken as a whole, is not materially worse than the effect on the Rhino Institutional Pharmacy Business, taken as a whole, or (iii) the announcement of this Agreement or of the transactions contemplated hereby or
by the other Transaction Agreements; and (b) RhinoRx, a material adverse effect on the condition (financial or otherwise), business, assets or results of operations of the Rhino Institutional Pharmacy Business, taken as a whole, excluding any
such effect resulting from or arising in connection with (x) changes or conditions generally affecting the industries in which the Rhino Institutional Pharmacy Business (including the RhinoRx Entities) operate, but only to the extent the effect
on the Rhino Institutional Pharmacy Business, taken as a whole, is not materially worse than the effect on the Hippo Institutional Pharmacy Business, taken as a whole, (y) changes in general economic, regulatory (including changes in Applicable
Laws, accounting rules or interpretations of the 

  

 13 

 
foregoing) or political conditions, including the engagement by the United States in hostilities, whether or not pursuant to the declaration of a national
emergency or war, or the occurrence of any military or terrorist attack upon or within the United States, but only to the extent the effect on the Rhino Institutional Pharmacy Business, taken as a whole, is not materially worse than the effect on
the Hippo Institutional Pharmacy Business, taken as a whole, or (z) the announcement of this Agreement or of the transactions contemplated hereby or by the other Transaction Agreements. 
 “Mergers” means the HippoRx Merger and the RhinoRx Merger. 
 “Merger Subs” means Hippo Merger Sub and Rhino Merger Sub. 
 “Newco Common Stock” means the Common Stock, par value $0.01 per share, of Newco. 
 “Newco Hippo Transition Services Agreement” means the Transition Services Agreement between Hippo and Newco substantially in the form
attached hereto as Exhibit D and providing for the provision by Newco to the Hippo Workers’ Compensation Business of the services to be determined pursuant to Section 11.14. 
 “Newco Non-Compensation Share Number” means the total number of Newco shares to be issued at Closing, including fractional shares (but
not including post-Closing issuances of equity to new management and any shares of Restricted Stock), as such number is mutually agreed by Hippo and Rhino prior to Closing. 
 “Newco Price Ratio” means the quotient obtained by dividing the Newco Stock Value by the Hippo Pre-Distribution Stock Value or Rhino
Pre-Distribution Stock Value, as applicable. 
 “Newco Share Ratio” means the quotient obtained by dividing the Hippo
Pre-Distribution Stock Value or Rhino Pre-Distribution Stock Value by the Newco Stock Value. 
 “Newco Stock Value” means
the closing per-share price of Newco Common Stock as listed on the NYSE as of the closing of trading on the first trading date following the Closing Date; provided, however that if the Effective Time occurs at a time when the NYSE is open for
trading, Newco Stock Value shall mean the price at which the Newco Common Stock trades immediately after the Effective Time; and provided further, that if the Effective Time occurs prior to opening of trading on the NYSE on the Closing Date,
the Newco Stock Value shall mean the price at which Newco Common Stock first trades on the Closing Date. If listing of the Newco Common Stock on the NYSE is not approved, references in this definition to the NYSE shall be to the NASDAQ Stock Market.

  

 14 

 “Newco Supply Agreement” means the Prime Vendor Agreement between Newco and HippoDC in
the form attached hereto as Exhibit E. 
 “Newco Total Share Number” means the total number of shares of Newco Common Stock
required to be issued pursuant to Section 6.01. 
 “NYSE” means the New York Stock Exchange LLC. 
 “1933 Act” means the Securities Act of 1933, as amended. 
 “1934 Act” means the Securities Exchange Act of 1934, as amended. 
 “Non-HippoRx
Assets” means all Assets of Hippo and its Subsidiaries other than the HippoRx Assets and including: 
 (i) all
capital stock or other ownership interests in the Hippo Retained Subsidiaries; 
 (ii) all cash and cash equivalents held by
the Hippo Institutional Pharmacy Business; 
 (iii) any Assets that are expressly contemplated by the Transaction Agreements
(or the Schedules thereto) as Assets to be retained by or assigned to Hippo or a Subsidiary of Hippo (other than the HippoRx Entities), including all Assets primarily related to the Hippo Workers’ Compensation Business; 
 (iv) any Assets listed or described on Section 1.01 of the Hippo Disclosure Schedule under the heading “Non-HippoRx
Assets”; 
 (v) the minute books, stock ledgers and Tax records of Hippo and its Subsidiaries (other than the Hippo
Institutional Pharmacy Business); 
 (vi) all claims, causes of action and rights of Hippo and its Subsidiaries against any
Third Party to the extent relating to any Non-HippoRx Liabilities or to any Liabilities for which Hippo or its Subsidiaries (other than the HippoRx Entities) is responsible under this Agreement (including rights of set-off, rights to refunds and
rights of recoupment from or against any such Third Party); 
 (vii) all rights relating to Hippo’s name and website,
including the right to use Hippo’s name in any format; 
 (viii) all bank accounts; 
 (ix) all stock or other equity interests in any Person (other than in the HippoRx Entities other than HippoRx); 
  

 15 

 (x) unless otherwise expressly set forth in Article 12, any and all Hippo Benefit Plans
and any assets related thereto or intended to assist in the funding thereof; and 
 (xi) Assets related to any Overhead and
Shared Services. 
 Subject to the foregoing sentence, in the event that any Asset is included in both the definition of
“HippoRx Asset” and “Non-HippoRx Asset” then (i) if it is specifically referred to in a definition or schedule or otherwise (including in any other Transaction Agreement), it shall be treated in accordance with such specific
reference and (ii) otherwise it shall be treated as a HippoRx Asset or Non-HippoRx Asset based upon whether it is used or held for use primarily in connection with the Hippo Institutional Pharmacy Business or primarily in connection with the
business of the Non-HippoRx Group. 
 “Non-HippoRx Group” means the direct or indirect interest of Hippo (either itself or
through its direct or indirect Subsidiaries, or any of their predecessors or successors) in all businesses, Assets and Liabilities of Hippo and its Subsidiaries, other than the Hippo Institutional Pharmacy Business. 
 “Non-HippoRx Liabilities” means all Liabilities of Hippo and its Subsidiaries other than the HippoRx Liabilities and including, for the
avoidance of doubt: 
 (i) any Liabilities that are expressly contemplated by the Transaction Agreements (or the Schedules
thereto) as Liabilities to be retained or assumed by Hippo or a Subsidiary of Hippo (other than any HippoRx Entity), and all agreements, obligations and Liabilities of Hippo or a Subsidiary of Hippo (other than any HippoRx Entity) under the
Transaction Agreements; 
 (ii) all Liabilities primarily related to the Hippo Workers’ Compensation Business;

 (iii) all Liabilities of the Hippo Retained Subsidiaries; 
 (iv) all Liabilities to the extent related to Non-HippoRx Assets; and 
 (v) all Liabilities listed or described in Section 1.01 of the Hippo Disclosure Schedule under the heading “Non-HippoRx
Liabilities”. 
 Subject to the foregoing sentence, in the event that any Liability is included in both the definition of
“HippoRx Liability” and “Non-HippoRx Liability” then (i) if it is specifically referred to in a definition or schedule or otherwise (including in any of the other Transaction Agreements), it 

  

 16 

 
shall be treated in accordance with such specific reference and (ii) otherwise it shall be treated as a HippoRx Liability or Non-HippoRx Liability to
the extent it relates to the business of the HippoRx Group or the Non-HippoRx Group, respectively. 
 “Non-RhinoRx Assets”
means all Assets of Rhino and its Subsidiaries other than the RhinoRx Assets and including: 
 (i) all cash and cash
equivalents held by the Rhino Institutional Pharmacy Business; 
 (ii) any Assets that are expressly contemplated by the
Transaction Agreements (or the Schedules thereto) as Assets to be retained by or assigned to Rhino or a Subsidiary of Rhino (other than the RhinoRx Entities); 
 (iii) the prepay deposit paid by Rhino to HippoDC relating to the purchase of pharmaceutical products by RhinoRx on a prepay basis from
HippoDC; 
 (iv) any Assets listed or described on Section 1.01 of the Rhino Disclosure Schedule under the heading
“Non-RhinoRx Assets”; 
 (v) the minute books, stock ledgers and Tax records of Rhino and its Subsidiaries (other
than the Rhino Institutional Pharmacy Business); 
 (vi) all claims, causes of action and rights of Rhino and its Subsidiaries
against any Third Party to the extent relating to any Non-RhinoRx Liabilities or to any Liabilities for which Rhino or its Subsidiaries (other than the RhinoRx Entities) is responsible under this Agreement (including rights of set-off, rights to
refunds and rights of recoupment from or against any such Third Party); 
 (vii) all rights relating to Rhino’s name and
website, including the right to use Rhino’s name in any format; 
 (viii) all bank accounts; 
 (ix) all stock or other equity interests in any Person (other than in the RhinoRx Entities other than RhinoRx); 
 (x) unless otherwise expressly set forth in Article 12, any and all Rhino Benefit Plans and any assets related thereto or intended to
assist in the funding thereof; 
 (xi) Assets related to any Overhead and Shared Services; and 
  

 17 

 (xii) licenses related to Rhino’s hospitals. 
 Subject to the foregoing sentence, in the event that any Asset is included in both the definition of “RhinoRx Asset” and
“Non-RhinoRx Asset” then (i) if it is specifically referred to in a definition or schedule or otherwise (including in any other Transaction Agreement), it shall be treated in accordance with such specific reference and
(ii) otherwise it shall be treated as a RhinoRx Asset or Non-RhinoRx Asset based upon whether it is used or held for use primarily in connection with the Rhino Institutional Pharmacy Business or primarily in connection with the business of the
Non-RhinoRx Group. 
 “Non-RhinoRx Group” means the direct or indirect interest of Rhino (either itself or through its
direct or indirect Subsidiaries, or any of their predecessors or successors) in all businesses, Assets and Liabilities of Rhino and its Subsidiaries, other than the Rhino Institutional Pharmacy Business. 
 “Non-RhinoRx Liabilities” means all Liabilities of Rhino and its Subsidiaries other than the RhinoRx Liabilities and including, for the
avoidance of doubt: 
 (i) any Liabilities that are expressly contemplated by the Transaction Agreements (or the Schedules
thereto) as Liabilities to be retained or assumed by Rhino or a Subsidiary of Rhino (other than any RhinoRx Entity), and all agreements, obligations and Liabilities of Rhino or a Subsidiary of Rhino (other than any RhinoRx Entity) under the
Transaction Agreements; 
 (ii) all Liabilities to the extent related to Non-RhinoRx Assets; and 
 (iii) all Liabilities listed or described in Section 1.01 of the Rhino Disclosure Schedule under the heading “Non-RhinoRx
Liabilities”. 
 Subject to the foregoing sentence, in the event that any Liability is included in both the definition of
“RhinoRx Liability” and “Non-RhinoRx Liability” then (i) if it is specifically referred to in a definition or schedule or otherwise (including in any of the other Transaction Agreements), it shall be treated in accordance
with such specific reference and (ii) otherwise it shall be treated as a RhinoRx Liability or Non-RhinoRx Liability to the extent it relates to the business of the RhinoRx Group or the Non-RhinoRx Group, respectively. 
 “Overhead and Shared Services” means (i) in the case of the Rhino Institutional Pharmacy Business, ancillary corporate or shared
services provided by Rhino and its Subsidiaries (other than the RhinoRx Entities) to or in support of the Rhino Institutional Pharmacy Business that are general corporate or other 

  

 18 

 
overhead services or provided to both the Rhino Institutional Pharmacy Business and other businesses of Rhino and its Subsidiaries and (ii) in the case
of the Hippo Institutional Pharmacy Business, ancillary corporate or shared services provided by Hippo and its Subsidiaries (other than the HippoRx Entities) to or in support of the Hippo Institutional Pharmacy Business that are general corporate or
other overhead services or provided to both the Hippo Institutional Pharmacy Business and other businesses of Hippo and its Subsidiaries, in the case of either (i) or (ii), which may include, as applicable, access to hardware and software
related to general corporate or overhead functions, travel and entertainment services, temporary or contract labor services, office supplies services (including copiers), computer hardware and software services, fleet services, energy/utilities
services, procurement, sales and marketing services, treasury and cash processing services, public relations, legal and risk management (including insurance) services (including workers’ comp), executive office expense, payroll services,
information technology and telecommunications services, consolidation and technical accounting, tax services, accounting and internal audit services, employee benefits services, credit, billing, collections, accounts receivable and accounts payable
services, freight, logistics and expediter services, property management services and environmental support services, in each case including services relating to the provision of access to information, operating and reporting systems and databases
and all hardware and software used in connection therewith. 
 “Person” means an individual, corporation, partnership,
limited liability company, association, trust or other entity or organization, including a government or political subdivision or an agency or instrumentality thereof. 
 “Record Date” means the close of business on such date as is mutually agreed upon by Hippo and Rhino. 
 “Registration Statement” means the registration statement on Form 10 pursuant to which shares of Newco Common Stock will be registered with the SEC. 
 “Restricted Stock” means stock issued in connection with the performance of services that is not transferable or is subject to a
substantial risk of forfeiture within the meaning of Section 83 of the Code. 
 “Rhino Benefit Plan” means any Benefit
Plan, other than a RhinoRx Benefit Plan, sponsored, maintained or contributed to by Rhino or any of its Subsidiaries. 
 “Rhino
Common Stock” means the Common Stock, par value $0.25 per share, of Rhino. 
 “Rhino Credit Agreement” means the
Amended and Restated Credit Agreement dated as of June 28, 2004 among Rhino, JPMorgan Chase Bank, N.A., as Agent, and the other agents and Lenders party thereto, and the other Financing Documents referred to therein, each as amended.

  

 19 

 “Rhino Hippo Transition Services Agreement” means the Transition Services Agreement
between Rhino and Hippo substantially in the form attached hereto as Exhibit F and providing for the provision by Rhino to the Hippo Workers’ Compensation Business of the services to be determined pursuant to Section 11.14.

 “Rhino Institutional Pharmacy Business” means the business of providing independent pharmaceutical dispensing services to
long-term care facilities and alternative site settings, including skilled nursing facilities, assisted living facilities and residential living communities, which services include the purchasing, repackaging and dispensing of pharmaceuticals, both
prescription and non-prescription, and the delivery of such pharmaceuticals to healthcare facilities for administration, as well as various supplemental healthcare services that complement such pharmacy services such as hospital pharmacy management
services, consulting services and enteral therapy and infusion services. 
 “Rhino Lender Approval” means any and all
waivers, consents, amendments and releases required under the Rhino Credit Agreement to permit consummation of the Transactions contemplated hereby. 
 “Rhino Newco Transition Services Agreement” means the Transition Services Agreement between Newco and Rhino substantially in the form attached hereto as Exhibit G and providing for the provision by
Rhino to Newco of the services to be determined pursuant to Section 11.14. 
 “Rhino Pre-Distribution Stock Value”
means the closing per-share price of Rhino Common Stock trading “regular way with due bills” as listed on the NYSE on the Closing Date; provided, however that if the RhinoRx Distribution occurs at a time when the NYSE is open for
trading, Rhino Pre-Distribution Stock Value shall mean the price at which the Rhino Common Stock trading “regular way with due bills” last trades immediately before the RhinoRx Distribution; provided further that if the RhinoRx
Distribution occurs prior to the first trade of Rhino Common Stock on the Closing Date, Rhino Pre-Distribution Stock Value shall mean the price at which Rhino Common Stock trading “regular way with due bills” last trades on the trading
date immediately prior to the Closing Date. If listing of the Newco Common Stock on the NYSE is not approved, references in this definition to the NYSE shall be to the NASDAQ Stock Market. 
 “Rhino Restricted Stock” means Rhino Common Stock that is Restricted Stock. 
 “Rhino Stock Option” means any option to purchase shares of Rhino Common Stock granted under any employee stock option or compensation
plan or arrangement of Rhino. 
  

 20 

 “RhinoRx Acquisition Proposal” means, other than the transactions contemplated by this
Agreement, any offer, proposal or inquiry relating to, or any Third Party indication of interest in, (i) any acquisition or purchase, direct or indirect, of 5% or more of the consolidated assets of the Rhino Institutional Pharmacy Business or
over 5% of any class of equity or voting securities of Rhino or any of its Subsidiaries whose assets, individually or in the aggregate, constitute more than 5% of the consolidated assets of the Rhino Institutional Pharmacy Business, (ii) any
tender offer (including a self-tender offer) or exchange offer that, if consummated, would result in such Third Party’s beneficially owning 5% or more of any class of equity or voting securities of Rhino or any of its Subsidiaries whose assets,
individually or in the aggregate, constitute more than 5% of the consolidated assets of the Rhino Institutional Pharmacy Business, (iii) a merger, consolidation, share exchange, business combination, sale of substantially all the assets,
reorganization, recapitalization, liquidation, dissolution or other similar transaction involving Rhino or any of its Subsidiaries whose assets, individually or in the aggregate, constitute more than 5% of the consolidated assets of the Rhino
Institutional Pharmacy Business or (iv) any other transaction the consummation of which could reasonably be expected to impede, interfere with, prevent or materially delay the transactions contemplated hereby; provided that
notwithstanding anything in the foregoing, “RhinoRx Acquisition Proposal” shall not include any transaction (x) involving the Non-RhinoRx Group (that does not also involve the Rhino Institutional Pharmacy Business) or
(y) involving an acquisition of at least a majority of the outstanding shares of Rhino Common Stock or a majority of Rhino’s consolidated assets by a Third Party (whether by purchase, tender offer, exchange offer, merger, consolidation,
business combination or otherwise) if in the case of each of (x) and (y), the consummation of such transaction would not prevent or materially impede, interfere with or delay the transactions contemplated hereby. 
 “RhinoRx Assets” means any Assets that are owned, used or held for use by Rhino or any of its Subsidiaries primarily in connection with
the Rhino Institutional Pharmacy Business as the same shall exist on the Closing Date, including: 
 (i) the Assets reflected
on the RhinoRx Balance Sheet, unless disposed of to Third Parties after the date thereof, but excluding any Non-RhinoRx Assets; 
 (ii) any RhinoRx Contracts; 
 (iii) any capital stock or other ownership interests in the RhinoRx Entities;

 (iv) all right, title and interest of Rhino and its Subsidiaries (to the extent relating to the Rhino Institutional
Pharmacy Business) in the RhinoRx Leases set forth in Section 8.18(a) of the Rhino Disclosure 

  

 21 

 
Schedule and in the RhinoRx Owned Properties set forth on Section 8.18(b) of the Rhino Disclosure Schedule; 
 (v) any Assets that are expressly contemplated by the Transaction Agreements (or the Schedules thereto) as Assets to be retained by or
assigned to the Rhino Institutional Pharmacy Business or any RhinoRx Entity; 
 (vi) any governmental licenses, permits,
approvals, certificates and other governmental authorizations held in the name of Rhino or any of its Subsidiaries that are primarily related to the Rhino Institutional Pharmacy Business, except for licenses, permits, approvals, certificates or
other governmental authorizations that are used in the business of the Non-RhinoRx Group; and 
 (vii) any Assets listed or
described on Section 1.01 of the Rhino Disclosure Schedule under the heading “RhinoRx Assets”. 
 Subject to
the foregoing sentence, in the event that any Asset is included in both the definition of “RhinoRx Asset” and “Non-RhinoRx Asset” then (i) if it is specifically referred to in a definition or schedule or otherwise (including
in any other Transaction Agreement), it shall be treated in accordance with such specific reference and (ii) otherwise it shall be treated as a RhinoRx Asset or Non-RhinoRx Asset based upon whether it is used or held for use primarily in
connection with the Rhino Institutional Pharmacy Business or primarily in connection with the business of the Non-RhinoRx Group. 
 “RhinoRx Audited EBITDA” means the earnings before interest, taxes, depreciation and amortization of the Rhino Institutional Pharmacy Business for the nine months ended September 30, 2006, as derived from the financial
information contained in the notes to the audited financial statements of the Rhino Institutional Pharmacy Business as of and for the fiscal year ended December 31, 2006. 
 “RhinoRx Balance Sheet” means the unaudited balance sheet of the RhinoRx Group as of September 30, 2006, as attached as Exhibit H
hereto. 
 “RhinoRx Balance Sheet Date” means September 30, 2006. 
 “RhinoRx Benefit Plan” means any Benefit Plan sponsored or maintained solely by a RhinoRx Entity. 
 “RhinoRx Common Stock” means the Common Stock, par value $100 per share, of RhinoRx. 
  

 22 

 “RhinoRx Contracts” means the following Contracts to which Rhino or any of its
Subsidiaries is a party or by which it or any of its Subsidiaries or any of their respective Assets is bound, whether or not in writing: 
 (i) any Contract that relates primarily to the Rhino Institutional Pharmacy Business; 
 (ii)
any Contract or other instrument representing RhinoRx Liabilities; 
 (iii) any Contract that is expressly contemplated
pursuant to this Agreement or any of the other Transaction Agreements to be assigned or transferred to or retained by a RhinoRx Entity; and 
 (iv) any guarantee, indemnity, representation, warranty or other Liability of Rhino or any of its Subsidiaries (other than any RhinoRx Entity) in respect of any other RhinoRx Contract, any RhinoRx Liability or the
Rhino Institutional Pharmacy Business. 
 Notwithstanding the preceding sentence, “RhinoRx Contracts” do not include
any such Contract that is expressly contemplated to be assigned to or retained by Rhino or any of its Subsidiaries (other than the RhinoRx Entities) pursuant to any Transaction Agreement. 
 With respect to any Contract that relates in material part to both the Rhino Institutional Pharmacy Business and the business of the
Non-RhinoRx Group and that is not specifically contemplated by this Agreement to be assigned to or retained by the RhinoRx Entities or Rhino and its Subsidiaries (other than the RhinoRx Entities), the parties will cooperate in good faith to
apportion the rights and obligations thereunder to the Rhino Institutional Pharmacy Business and the Non-RhinoRx Group, and to treat such Contract as a RhinoRx Contract only to the extent relating to the Rhino Institutional Pharmacy Business.

 “RhinoRx Distribution” means the distribution on the Closing Date by Rhino to the holders of Rhino Common Stock of all
the outstanding shares of RhinoRx Common Stock upon the terms and conditions more fully set forth in Section 3.05. 
 “RhinoRx
Entities” means RhinoRx and each of its Subsidiaries. 
 “RhinoRx Estimated EBITDA” means $34,669,000. 

“RhinoRx Final Financing Amount” has the meaning set forth on Annex A hereto. 
 “RhinoRx Group” means the direct or indirect interest of Rhino (either itself or through its direct or indirect Subsidiaries, or any of
their predecessors or 

  

 23 

 
successors) in (i) the Rhino Institutional Pharmacy Business and (ii) any business or operations that were terminated, divested or discontinued by
the RhinoRx Entities (and their respective predecessors and successors). 
 “RhinoRx Liabilities” means any Liabilities
(regardless of when or where such Liabilities arose or arise, or whether the facts on which they are based occurred prior to, on or subsequent to the Closing Date, regardless of where or against whom such Liabilities are asserted or determined or
whether asserted or determined prior to the Closing Date, and regardless of whether arising from or alleged to arise from negligence, recklessness, violation of law, fraud or misrepresentation) relating to, arising out of, or resulting from the
business of the RhinoRx Group, including: 
 (i) the Liabilities reflected on the RhinoRx Balance Sheet, subject to any
discharge of such Liabilities subsequent to the RhinoRx Balance Sheet Date; 
 (ii) any Liabilities that are expressly
contemplated by the Transaction Agreements (or the Schedules thereto) as Liabilities to be retained or assumed by any RhinoRx Entity, subject to discharge of such Liabilities subsequent to the RhinoRx Balance Sheet Date, and all agreements,
obligations and Liabilities of any RhinoRx Entity under the Transaction Agreements; 
 (iii) all Liabilities listed or
described in Section 1.01 of the Rhino Disclosure Schedule under the heading “RhinoRx Liabilities”; and 
 (iv)
any Liabilities, including, except as expressly set forth in Article 12 hereof, any employee-related Liabilities and Environmental Liabilities, primarily relating to, arising out of or resulting from (whether arising before, on or after the Closing
Date): 
 (A) the RhinoRx Group, including the operation of the Rhino Institutional Pharmacy Business, as conducted at any
time prior to, on or after the Closing Date (including any Liability relating to, arising out of or resulting from any act or failure to act by any director, officer, employee, agent or representative (whether or not such act or failure to act is or
was within such Person’s authority)); 
 (B) the operation of any business conducted by any RhinoRx Entity at any time
after the Closing Date (including any Liability relating to, arising out of or resulting from any act or failure to act by any director, officer, employee, agent or representative (whether or not such act or failure to act is or was within such
Person’s authority)); or 
  

 24 

 (C) any RhinoRx Assets. 
 Subject to the foregoing sentence, in the event that any Liability is included in both the definition of “RhinoRx Liability” and
“Non-RhinoRx Liability” then (i) if it is specifically referred to in a definition or schedule or otherwise (including in any of the other Transaction Agreements), it shall be treated in accordance with such specific reference and
(ii) otherwise it shall be treated as a RhinoRx Liability or Non-RhinoRx Liability to the extent it relates to the business of the RhinoRx Group or the Non-RhinoRx Group, respectively. 
 “Sarbanes-Oxley Act” means the Sarbanes-Oxley Act of 2002. 
 “SEC” means the Securities and Exchange Commission. 
 “Solvent” means, with respect to any Person on any date of determination, that on such date (a) the fair value of the property of such Person is greater than the total amount of liabilities,
including contingent liabilities, of such Person, (b) the present fair salable value of the assets of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts as they become
absolute and matured, (c) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person’s ability to pay such debts and liabilities as they mature, (d) such Person is not engaged in
business or a transaction, and is not about to engage in business or a transaction, for which such Person’s property would constitute an unreasonably small capital, and (e) such Person is able to pay its debts and liabilities, contingent
obligations and other commitments as they mature in the ordinary course of business. The amount of contingent liabilities at any time shall be computed as the amount that, in the light of all the facts and circumstances existing at such time,
represents the amount that can reasonably be expected to become an actual or matured liability. 
 “Subsidiary” means, with
respect to any Person, any entity of which securities or other ownership interests having ordinary voting power to elect a majority of the board of directors or other persons performing similar functions are at any time directly or indirectly owned
by such Person or that such Person otherwise controls. 
 “Tax” means (i) any tax, governmental fee or other like
assessment or charge of any kind whatsoever (including withholding on amounts paid to or by any Person), together with any interest, penalty, addition to tax or additional amount imposed by any Governmental Authority (a “Taxing
Authority”) responsible for the imposition of any such tax (domestic or foreign), and any liability for any of the foregoing as transferee, (ii) any liability for the payment of any amount of the type described in clause
(i) pursuant to Treasury Regulations Section 1.1502-6 or any comparable provision of state, local or foreign law, or (iii) liability for the payment of any amount as a result of being party to any Tax 

  

 25 

 
Sharing Agreement or with respect to the payment of any amount imposed on any Person of the type described in (i) or (ii) as a result of any
existing express or implied agreement or arrangement (including an indemnification agreement or arrangement). 
 “Tax Matters
Agreement” means the Tax Matters Agreement dated the date hereof by and among Rhino, Hippo, RhinoRx, HippoRx and Newco. 
 “Tax Return” means any report, return, document, declaration or other information or filing required to be supplied to any Taxing Authority with respect to Taxes, including information returns, any documents with respect to
or accompanying payments of estimated Taxes, or with respect to or accompanying requests for the extension of time in which to file any such report, return, document, declaration or other information. 
 “Tax Sharing Agreements” means all existing agreements or arrangements (whether or not written) that provide for the allocation,
apportionment, sharing or assignment of any Tax liability or benefit, or the transfer or assignment of income, revenues, receipts, or gains for the purpose of determining any Person’s Tax liability (excluding any indemnification agreement or
arrangement pertaining to the sale or lease of assets or subsidiaries). 
 “Third Party” means, with respect to any Person,
any other Person, including as defined in Section 13(d) of the 1934 Act, other than such first Person or any of its Affiliates. 
 “Trademark License Agreement” means the Trademark License Agreement between Rhino and RhinoRx in the form attached hereto as Exhibit I. 
 “Transactions” means, collectively, the Distributions and the Mergers. 
 “Transaction Agreements” means (i) this Agreement, (ii) the Information Services Agreement, (iii) the Newco Supply Agreement, (iv) the Tax Matters Agreement, (v) the Rhino Newco Transition Services
Agreement, (vi) the Hippo Newco Transition Services Agreement, (vii) the Rhino Hippo Transition Services Agreement, (viii) the Newco Hippo Transition Services Agreement and (ix) the Trademark License Agreement. 
 “Transferring Hippo Employee” means any individual who, as of the HippoRx Distribution, either (a)(i) is then a current or former
employee of (including any full-time, part-time, temporary employee or an individual in any other employment relationship with), or then on a leave of absence (including, without limitation, paid or unpaid leave, disability, medical, personal or any
other form of leave) from, any HippoRx Entity and (ii) who is, or at the time of termination of employment was, primarily employed in connection with the Hippo Institutional Pharmacy Business, or (b) has been designated by Hippo as a
Transferring Hippo Employee on Section 1.01 of the Hippo Disclosure Schedule, 

  

 26 

 
subject to the consent of Rhino, which consent shall not unreasonably be withheld, as such schedule may be updated from time to time prior to the
Distribution Time, under the heading “Transferring Hippo Employees”. For purposes of this Agreement, Transferring Hippo Employee shall not include any Excluded Employee. 
 “Transferring Rhino Employee” means any individual who, as of the RhinoRx Distribution, either (a)(i) is then a current or former
employee of (including any full-time, part-time, temporary employee or an individual in any other employment relationship with), or then on a leave of absence (including, without limitation, paid or unpaid leave, disability, medical, personal or any
other form of leave) from, any RhinoRx Entity and (ii) who is, or at the time of termination of employment was, primarily employed in connection with the Rhino Institutional Pharmacy Business, or (b) has been designated by Rhino as a
Transferring Rhino Employee on Section 1.01 of the Rhino Disclosure Schedule, subject to the consent of Hippo, which consent shall not unreasonably be withheld, as such schedule may be updated from time to time prior to the Distribution Time,
under the heading “Transferring Rhino Employees”. For purposes of this Agreement, Transferring Rhino Employee shall not include any Excluded Employee. 
 (b) Each of the following terms is defined in the Section set forth opposite such term: 
  

			
	 Term
	  	Section
	 Asserted Liabilities
	  	15.03(b)
	 Claim
	  	15.03(a)
	 Closing Date
	  	2.01
	 Code
	  	Preamble
	 Covenant Breach
	  	15.02(a)
	 D&O Indemnified Losses
	  	11.12(a)
	 D&O Indemnified Person
	  	11.12(a)
	 Damages
	  	15.02(a)
	 Disclosing Party
	  	11.07(b)
	 DOJ
	  	11.01(c)
	 Effective Time
	  	5.01(b)
	 End Date
	  	14.01(b)(i)
	 Excess Shares
	  	6.03
	 Exchange Agent
	  	6.02(a)
	 Excluded Covenants
	  	15.01
	 FTC
	  	11.01(c)
	 Government Medical Reimbursement Program
	  	7.12(d)
	 Hippo
	  	Preamble
	 Hippo D&O Indemnified Person
	  	11.12(a)
	 Hippo Indemnified Parties
	  	15.02(d)
	 Hippo Merger Sub
	  	Preamble
	 Hippo Plans
	  	7.16(a)

  

 27 

			
	 Term
	  	Section
	 Hippo Representatives
	  	11.10(a)
	 Hippo SEC Documents
	  	7.07
	 Hippo Securities
	  	7.05(b)
	 HippoRx
	  	Preamble
	 HippoRx Exchange Ratio
	  	6.01(c)
	 HippoRx Intellectual Property
	  	7.19(a)
	 HippoRx Leased Premises
	  	7.18(a)
	 HippoRx Leases
	  	7.18(a)
	 HippoRx Licensed Service Provider
	  	7.12(c)
	 HippoRx Material Contracts
	  	7.20(b)
	 HippoRx Merger
	  	Preamble
	 HippoRx Owned Properties
	  	7.18(b)
	 HippoRx Permits
	  	7.12(b)
	 HippoRx Securities
	  	7.06(b)
	 HippoRx Stock Option
	  	6.06(a)
	 HippoRx Surviving Corporation
	  	5.01(a)
	 Indemnified Party
	  	15.03(a)
	 Indemnifying Party
	  	15.03(a)
	 Intellectual Property
	  	7.19(a)
	 internal controls
	  	7.07(f)
	 Lexicon
	  	7.26
	 Multiemployer Plan
	  	7.16(b)
	 Newco
	  	Preamble
	 Newco Bylaws
	  	4.01
	 Newco Charter
	  	4.01
	 Newco Financing
	  	11.10(b)
	 Newco Incentive Plan
	  	6.09
	 Newco Indemnified Parties
	  	15.02(a)
	 Newco Stock Option
	  	6.06(a)
	 Non-HippoRx Employees
	  	12.01(c)
	 Non-RhinoRx Employees
	  	12.02(c)
	 Owned HippoRx Intellectual Property
	  	7.19(a)
	 Owned RhinoRx Intellectual Property
	  	8.19(a)
	 Prior Plan
	  	12.01(f)
	 Receiving Party
	  	11.07(b)
	 Registered HippoRx Intellectual Property
	  	7.19(b)
	 Registered RhinoRx Intellectual Property
	  	8.19(b)
	 Rhino
	  	Preamble
	 Rhino D&O Indemnified Person
	  	11.12(a)
	 Rhino Indemnified Parties
	  	15.02(g)
	 Rhino Merger Sub
	  	Preamble
	 Rhino Parent Sub
	  	Preamble
	 Rhino Plans
	  	8.16(a)
	 Rhino Representatives
	  	11.10(a)
	 Rhino SEC Documents
	  	8.07(a)

  

 28 

			
	 Term
	  	Section
	 Rhino Securities
	  	8.05(b)
	 RhinoRx
	  	Preamble
	 RhinoRx Exchange Ratio
	  	6.01(f)
	 Rhino Rx Intellectual Property
	  	8.19(a)
	 RhinoRx Leased Premises
	  	8.18(a)
	 RhinoRx Leases
	  	8.18(a)
	 RhinoRx Licensed Service Provider
	  	8.12(c)
	 RhinoRx Material Contracts
	  	8.20(b)
	 RhinoRx Merger
	  	Preamble
	 RhinoRx Owned Properties
	  	8.18(b)
	 RhinoRx Permits
	  	8.12(b)
	 RhinoRx Securities
	  	8.06(b)
	 RhinoRx Stock Option
	  	6.07(a)
	 RhinoRx Surviving Corporation
	  	5.02(a)
	 Successor Plan
	  	12.01(f)
	 Transferring Hippo Option
	  	6.06(a)
	 Transferring Rhino Option
	  	6.07(a)
	 Warranty Breach
	  	15.02(a)

 Section 1.02. Other Definitional and Interpretative Provisions. The words
“hereof”, “herein” and “hereunder” and words of like import used in this Agreement shall refer to this Agreement as a whole and not to any particular provision of this Agreement. The captions herein are included for
convenience of reference only and shall be ignored in the construction or interpretation hereof. References to Articles, Sections, Exhibits and Schedules are to Articles, Sections, Exhibits and Schedules of this Agreement unless otherwise specified.
All Exhibits and Schedules annexed hereto or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth in full herein. Any capitalized terms used in any Exhibit or Schedule but not otherwise defined therein,
shall have the meaning as defined in this Agreement. Any singular term in this Agreement shall be deemed to include the plural, and any plural term the singular. Whenever the words “include”, “includes” or “including”
are used in this Agreement, they shall be deemed to be followed by the words “without limitation”, whether or not they are in fact followed by those words or words of like import. “Writing”, “written” and comparable
terms refer to printing, typing and other means of reproducing words (including electronic media) in a visible form. References to any agreement or contract are to that agreement or contract as amended, modified or supplemented from time to time in
accordance with the terms hereof and thereof; provided that with respect to any agreement or contract listed on any schedules hereto, all such amendments, modifications or supplements must also be listed in the appropriate schedule.
References to any Person include the successors and permitted assigns of that Person. References from or through any date mean, unless otherwise specified, from and including or through and including, respectively. References to “law”,
“laws” or to a particular statute or law shall be deemed also to include any Applicable Law. 
  

 29 

 ARTICLE 2 
 SEPARATION OF ASSETS; DISTRIBUTION OF HIPPORX 
 Section 2.01. Timing of HippoRx Distribution. On the Closing Date, Hippo and HippoRx shall consummate the HippoRx Distribution at the Distribution Time. As used herein, “Closing Date”
means the date on which the Distributions and the Mergers become effective, which date shall be mutually agreed by Hippo and Rhino and shall be a date occurring as soon as practicable (and in any event, within five Business Days (assuming that each
of the HippoRx Working Capital and the RhinoRx Working Capital have been finally determined in accordance with Annex A, or if not so determined, within five Business Days after such final determination)) after satisfaction or, to the extent
permitted hereunder, waiver of all conditions set forth in Article 13 (other than conditions that by their nature are to be satisfied on the Closing Date and will in fact be satisfied on the Closing Date). 
 Section 2.02. Transfer of Assets; Assumption of Liabilities.  
 (a) Subject to Section 2.03, as of the Distribution Time, (i) the right, title and interest in all HippoRx Assets will be owned by the HippoRx Entities and (ii) all HippoRx Liabilities will be the
obligation of the HippoRx Entities. Prior to the Distribution Time, subject to Section 2.03, Hippo and the HippoRx Entities shall take all such actions as are necessary or appropriate (including executing and delivering such bills of sale,
assignments, deeds, stock powers, certificates of title and instruments of assumption) to cause (i) the HippoRx Entities to own all of the HippoRx Assets and (ii) the HippoRx Entities to assume and be subject to all of the HippoRx
Liabilities. 
 (b) Subject to Section 2.03, as of the Distribution Time, (i) the right, title and interest in all Non-HippoRx
Assets will be owned and retained by Hippo or its Subsidiaries (other than the HippoRx Entities) and (ii) all Non-HippoRx Liabilities will be the obligation of Hippo or its Subsidiaries (other than the HippoRx Entities). Prior to the
Distribution Time, subject to Section 2.03, Hippo and the HippoRx Entities shall take all such actions as are necessary or appropriate (including executing and delivering such bills of sale, stock powers, certificates of title and instruments
of assumption) to cause (i) Hippo or its Subsidiaries (other than the HippoRx Entities) to own all of the Non-HippoRx Assets and (ii) Hippo or its Subsidiaries (other than the HippoRx Entities) to assume and be subject to all of the
Non-HippoRx Liabilities. 
 (c) In the event that at any time or from time to time (whether prior to or after the Closing Date) Hippo or
HippoRx (or any of their respective Subsidiaries) shall receive or otherwise possess any Asset that is allocated to any other Person pursuant to this Agreement, subject to Section 2.03, such party shall promptly transfer, or cause to be
transferred, such Asset to the Person so entitled thereto. Prior to any such transfer, the Person receiving or possessing such Asset shall hold such Asset in trust for any such other Person. 
  

 30 

 Section 2.03. Governmental Approvals; Consents.  
 (a) If and to the extent that the valid, complete and perfected transfer or assignment to HippoRx of any HippoRx Assets or to Hippo of any Non-HippoRx
Assets as contemplated by Section 2.02 would be a violation of Applicable Law or require any Consent or Governmental Approval, then the applicable transfer or assignment shall be automatically deemed deferred and any such purported transfer or
assignment shall be null and void until such time as all legal impediments are removed and/or such Consents or Governmental Approvals have been obtained. Notwithstanding the foregoing, any such Asset shall be deemed an Asset of the transferee for
purposes of determining whether any Liability is a Liability of the transferee. 
 (b) If the transfer or assignment of any Asset intended to
be transferred or assigned hereunder is not consummated prior to or at the Closing Date, whether as a result of the provisions of Section 2.03(a) or for any other reason, then the Person retaining such Asset shall thereafter hold such Asset for
the use and benefit, insofar as reasonably possible, of the Person entitled thereto (at the expense of the Person entitled thereto). In addition, the Person retaining such Asset shall take such other actions as may be reasonably requested by the
Person to whom such Asset is to be transferred in order to place such Person, insofar as reasonably possible, in the same position as if such Asset had been transferred as contemplated hereby and so that all the benefits and burdens relating to such
Asset, including possession, use, risk of loss, potential for gain, and dominion, control and command over such Asset, inure from and after the Closing Date to the Person to whom such Asset is to be transferred. To the extent permitted by Applicable
Law and to the extent otherwise permissible in light of any required Consent and/or Governmental Approval, the Person to whom such Asset is to be transferred shall be entitled to, and shall be responsible for, the management of any Asset not yet
transferred to it as a result of this Section and the parties agree to use commercially reasonable efforts to cooperate and coordinate with respect thereto. 
 (c) If and when the Consents and/or Governmental Approvals, the absence of which caused the deferral of transfer of any Asset pursuant to Section 2.03(a), are obtained, the transfer of the applicable Asset shall
be effected in accordance with the terms of this Agreement. 
 (d) The Person retaining an Asset due to the deferral of the transfer of such
Asset shall not be obligated, in connection with the foregoing, to expend any money unless the necessary funds are advanced by the Person entitled to the Asset, other than reasonable out-of-pocket expenses, attorneys’ fees and recording or
similar fees, all of which shall be promptly reimbursed by the Person entitled to such Asset. 
 Section 2.04. Termination of
Agreements.  
  

 31 

 (a) Except as set forth in Section 2.04(b), effective as of the Closing Date, Hippo, for itself and
each of its Subsidiaries (other than the HippoRx Entities), on the one hand, and HippoRx, for itself and each other HippoRx Entity, on the other hand, hereby terminate any and all agreements, arrangements, commitments or understandings, whether or
not in writing, between or among Hippo and/or any of its Subsidiaries (other than the HippoRx Entities), on the one hand, and HippoRx and/or any other HippoRx Entity, on the other hand. No such terminated agreement, arrangement, commitment or
understanding (including any provision thereof that purports to survive termination) shall be of any further force or effect after the Closing Date. Each of Hippo and HippoRx shall, at the reasonable request of any other party, take, or cause to be
taken, such other actions as may be necessary to effect the foregoing, including having its Subsidiaries execute such additional instruments, if any, as shall be necessary to effect the foregoing. 
 (b) The provisions of Section 2.04(a) shall not apply to any of the following agreements, arrangements, commitments or understandings (or to any of
the provisions thereof): 
 (i) the Transaction Agreements and each other agreement or instrument expressly contemplated by
any of the Transaction Agreements to be entered into by the parties thereto or any of their Affiliates; 
 (ii) any agreement,
arrangement, commitment or understanding listed on Section 2.04(b)(ii) of the Hippo Disclosure Schedule; 
 (iii) any
intercompany accounts settled in accordance with Section 9.03; and 
 (iv) any other agreements, arrangements,
commitments or understandings that any of the agreements listed in clause (i) or (ii) expressly contemplates will survive the Closing Date. 
 Section 2.05. HippoRx Distribution.  
 (a) At the Distribution Time, Hippo will deliver to the
Exchange Agent for the benefit of holders of record of Hippo Common Stock (other than Hippo Common Stock held by Hippo in its treasury or Hippo Common Stock held by any Subsidiary of Hippo) on the Record Date, a single stock certificate, endorsed by
Hippo in blank, representing the shares of HippoRx Common Stock issuable in the HippoRx Distribution (which shall constitute all of the shares of HippoRx Common Stock outstanding as of the Closing Date), and shall cause the transfer agent for the
shares of HippoRx Common Stock to instruct the Exchange Agent to hold in trust (pending conversion of such shares of HippoRx Common Stock into shares of Newco Common Stock pursuant to the HippoRx Merger) the appropriate number of such shares of
HippoRx Common Stock (as set forth in 

  

 32 

 
Section 2.05(b)) for each such holder or designated transferee or transferees of such holder. 
 (b) Each holder of Hippo Common Stock (including Hippo Restricted Stock) on the Record Date will be entitled to receive in the HippoRx Distribution a
number of shares of HippoRx Common Stock equal to (i) 100 divided by the number of shares of Hippo Common Stock outstanding on the Record Date multiplied by (ii) the number of shares of Hippo Common Stock held by such holder on the Record
Date. 
 (c) Hippo and HippoRx, as the case may be, will provide to the Exchange Agent all share certificates and any information reasonably
required in order to complete the HippoRx Distribution on the basis specified above. 
 (d)(i) Prior to the cash distribution described below
and the transactions described in Section 2.05(a), Section 2.05(b) and Section 2.05(c), HippoRx shall cause Hippo Operating Sub to transfer all of the outstanding shares of the Hippo Retained Subsidiaries to Hippo or a Subsidiary of
Hippo (other than a HippoRx Entity) and (ii) following the transfer described in clause (i) and immediately prior to the transactions described in Section 2.05(a), Section 2.05(b) and Section 2.05(c), HippoRx shall make a
cash distribution to Hippo in the amount of the HippoRx Final Financing Amount that is not used to pay intercompany account balances pursuant to Section 9.03. 
 ARTICLE 3 
 SEPARATION OF ASSETS; DISTRIBUTION
OF RHINORX 
 Section 3.01. Timing of RhinoRx Distribution. On the Closing Date, Rhino and RhinoRx
shall consummate the RhinoRx Distribution at the Distribution Time. 
 Section 3.02. Transfer of Assets; Assumption of Liabilities.
 
 (a) Subject to Section 3.03, as of the Distribution Time, (i) the right, title and interest in all RhinoRx Assets will be
owned by the RhinoRx Entities and (ii) all RhinoRx Liabilities will be the obligation of the RhinoRx Entities. Prior to the Distribution Time, subject to Section 3.03, Rhino and the RhinoRx Entities shall take all such actions as are
necessary or appropriate (including executing and delivering such bills of sale, assignments, deeds, stock powers, certificates of title and instruments of assumption) to cause (i) the RhinoRx Entities to own all of the RhinoRx Assets and
(ii) the RhinoRx Entities to have assumed and be subject to all of the RhinoRx Liabilities. 
 (b) Subject to Section 3.03, as of
the Distribution Time, (i) the right, title and interest in all Non-RhinoRx Assets will be owned and retained by Rhino or its Subsidiaries (other than the RhinoRx Entities) and (ii) all Non-RhinoRx 

  

 33 

 
Liabilities will be the obligation of Rhino or its Subsidiaries (other than the RhinoRx Entities). Prior to the Distribution Time, subject to
Section 3.03, Rhino and the RhinoRx Entities shall take all such actions as are necessary or appropriate (including executing and delivering such bills of sale, stock powers, certificates of title and instruments of assumption) to cause
(i) Rhino or its Subsidiaries (other than the RhinoRx Entities) to own all of the Non-RhinoRx Assets and (ii) Rhino or its Subsidiaries (other than the RhinoRx Entities) to assume and be subject to all of the Non-RhinoRx Liabilities.

 (c) In the event that at any time or from time to time (whether prior to or after the Closing Date) Rhino or RhinoRx (or any of their
respective Subsidiaries) shall receive or otherwise possess any Asset that is allocated to any other Person pursuant to this Agreement, subject to Section 3.03, such party shall promptly transfer, or cause to be transferred, such Asset to the
Person so entitled thereto. Prior to any such transfer, the Person receiving or possessing such Asset shall hold such Asset in trust for any such other Person. 
 Section 3.03. Governmental Approvals; Consents.  
 (a) If and to the extent that the valid,
complete and perfected transfer or assignment to RhinoRx of any RhinoRx Assets or to Rhino of any Non-RhinoRx Assets as contemplated by Section 3.02 would be a violation of Applicable Law or require any Consent or Governmental Approval, then
the applicable transfer or assignment shall be automatically deemed deferred and any such purported transfer or assignment shall be null and void until such time as all legal impediments are removed and/or such Consents or Governmental Approvals
have been obtained. Notwithstanding the foregoing, any such Asset shall be deemed an Asset of the transferee for purposes of determining whether any Liability is a Liability of the transferee. 
 (b) If the transfer or assignment of any Asset intended to be transferred or assigned hereunder is not consummated prior to or at the Closing Date,
whether as a result of the provisions of Section 3.03(a) or for any other reason, then the Person retaining such Asset shall thereafter hold such Asset for the use and benefit, insofar as reasonably possible, of the Person entitled thereto (at
the expense of the Person entitled thereto). In addition, the Person retaining such Asset shall take such other actions as may be reasonably requested by the Person to whom such Asset is to be transferred in order to place such Person, insofar as
reasonably possible, in the same position as if such Asset had been transferred as contemplated hereby and so that all the benefits and burdens relating to such Asset, including possession, use, risk of loss, potential for gain, and dominion,
control and command over such Asset, inure from and after the Closing Date to the Person to whom such Asset is to be transferred. To the extent permitted by Applicable Law and to the extent otherwise permissible in light of any required Consent
and/or Governmental Approval, the Person to whom such Asset is to be transferred shall be entitled to, and shall be responsible for, the management of any Asset not yet transferred to it as a result of this Section and the parties agree 

  

 34 

 
to use commercially reasonable efforts to cooperate and coordinate with respect thereto. 
 (c) If and when the Consents and/or Governmental Approvals, the absence of which caused the deferral of transfer of any Asset pursuant to
Section 3.03(a), are obtained, the transfer of the applicable Asset shall be effected in accordance with the terms of this Agreement. 
 (d) The Person retaining an Asset due to the deferral of the transfer of such Asset shall not be obligated, in connection with the foregoing, to expend any money unless the necessary funds are advanced by the Person entitled to the Asset,
other than reasonable out-of-pocket expenses, attorneys’ fees and recording or similar fees, all of which shall be promptly reimbursed by the Person entitled to such Asset. 
 Section 3.04. Termination of Agreements.  
 (a) Except as set forth in Section 3.04(b), effective as of the Closing Date, Rhino, for itself and each of its Subsidiaries (other than the RhinoRx Entities), on the one hand, and RhinoRx, for itself and each
other RhinoRx Entity, on the other hand, hereby terminate any and all agreements, arrangements, commitments or understandings, whether or not in writing, between or among Rhino and/or any of its Subsidiaries (other than the RhinoRx Entities), on the
one hand, and RhinoRx and/or any other RhinoRx Entity, on the other hand. No such terminated agreement, arrangement, commitment or understanding (including any provision thereof that purports to survive termination) shall be of any further force or
effect after the Closing Date. Each of Rhino and RhinoRx shall, at the reasonable request of any other party, take, or cause to be taken, such other actions as may be necessary to effect the foregoing, including having its Subsidiaries execute such
additional instruments, if any, as shall be necessary to effect the foregoing. 
 (b) The provisions of Section 3.04(a) shall not apply
to any of the following agreements, arrangements, commitments or understandings (or to any of the provisions thereof): 
 (i)
the Transaction Agreements and each other agreement or instrument expressly contemplated by any of the Transaction Agreements to be entered into by the parties thereto or any of their Affiliates; 
 (ii) any agreement, arrangement, commitment or understanding listed on Section 3.04(b)(ii) of the Rhino Disclosure Schedule;

 (iii) any intercompany accounts settled in accordance with Section 10.03; and 
  

 35 

 (iv) any other agreements, arrangements, commitments or understandings that any of the
agreements listed in clause (i) or (ii) expressly contemplates will survive the Closing Date. 
 Section 3.05. RhinoRx
Distribution.  
 (a) At the Distribution Time, Rhino will deliver to the Exchange Agent for the benefit of holders of record of Rhino
Common Stock (other than Rhino Common Stock held by Rhino in its treasury or Rhino Common Stock held by any Subsidiary of Rhino) on the Record Date, a single stock certificate, endorsed by Rhino in blank, representing the shares of RhinoRx Common
Stock issuable in the RhinoRx Distribution (which shall constitute all of the shares of RhinoRx Common Stock outstanding as of the Closing Date), and shall cause the transfer agent for the shares of RhinoRx Common Stock to instruct the Exchange
Agent to hold in trust (pending conversion of such shares of RhinoRx Common Stock into shares of Newco Common Stock pursuant to the RhinoRx Merger) the appropriate number of such shares of RhinoRx Common Stock (as set forth in Section 3.05(b))
for each such holder or designated transferee or transferees of such holder. 
 (b) Each holder of Rhino Common Stock (including Rhino
Restricted Stock) on the Record Date will be entitled to receive in the RhinoRx Distribution a number of shares of RhinoRx Common Stock equal to (i) 10 divided by the number of shares of Rhino Common Stock outstanding on the Record Date
multiplied by (ii) the number of shares of Rhino Common Stock held by such holder on the Record Date. 
 (c) Rhino and RhinoRx, as the
case may be, will provide to the Exchange Agent all share certificates and any information reasonably required in order to complete the RhinoRx Distribution on the basis specified above. 
 (d) Immediately prior to the transactions described in Section 3.05(a), Section 3.05(b) and Section 3.05(c), (i) RhinoRx shall make a
cash distribution to Rhino Parent Sub in the amount of the RhinoRx Final Financing Amount that is not used to pay intercompany account balances pursuant to Section 10.03 and (ii) immediately following the distribution described in clause
(i), Rhino shall cause Rhino Parent Sub to distribute all of the outstanding shares of RhinoRx to Rhino. 
 ARTICLE 4 
 ORGANIZATION OF NEWCO 
 Section 4.01. Organization of Newco. Hippo and Rhino have caused Newco to be organized under the laws of the State of Delaware. The authorized capital stock of Newco consists of 200 shares, of which 100
shares are Common Stock and 100 shares are preferred stock. As of the date of this Agreement and prior to the Effective Time, one share of Common Stock has been issued to Hippo 

  

 36 

 
and one share of Common Stock has been issued to Rhino, each at a price of $1.00 per share. At the Effective Time, each of Hippo and Rhino shall return its
share of Newco Common Stock to Newco for cancellation without the payment of any consideration therefor. Attached as Exhibits J and K, respectively, are the certificate of incorporation of Newco (the “Newco Charter”) and the bylaws
of Newco (the “Newco Bylaws”). Prior to the Effective Time, the Newco Charter will be amended to increase the number of shares of authorized capital stock to a number that will be equal to at least the Newco Total Share Number,
which number of authorized shares, as well as the Newco Total Share Number, shall be mutually agreed by Hippo and Rhino sufficiently in advance of the Closing Date to avoid any delay in the occurrence of the Closing. 
 Section 4.02. Directors and Officers of Newco. Prior to the Effective Time, unless otherwise agreed, the directors and officers of Newco
shall consist of the Hippo and Rhino employees set forth on Section 4.02 of the Hippo Disclosure Schedule. Hippo and Rhino shall take all requisite action to cause the directors and officers of Newco as of the Effective Time to be as provided
in Section 11.08. 
 Section 4.03. Organization of Merger Subs. Newco has caused each of Hippo Merger Sub and Rhino Merger
Sub to be organized for the sole purpose of effectuating the Mergers. The authorized capital stock of Hippo Merger Sub consists of 100 shares of Common Stock, par value $0.01 per share, all of which shares have been issued to Newco at a price of
$1.00 per share. The authorized capital stock of Rhino Merger Sub consists of 100 shares of Common Stock, par value $0.01 per share, all of which shares have been issued to Newco at a price of $1.00 per share. 
 Section 4.04. Approvals of Hippo and Rhino. Hippo and Rhino, as the holders of all the outstanding shares of Newco capital stock, have
approved and adopted this Agreement and the transactions contemplated hereby and have caused Newco, as the sole stockholder of each of the Merger Subs, to approve and adopt this Agreement (including the HippoRx Merger and the RhinoRx Merger) and the
transactions contemplated hereby. Each of Hippo and Rhino shall cause Newco to perform its obligations under this Agreement, and Newco shall cause the Merger Subs to perform their respective obligations under this Agreement. 
 ARTICLE 5 
 THE
MERGERS 
 Section 5.01. The Hippo Merger. 
 (a) At the Effective Time, Hippo Merger Sub shall be merged with and into HippoRx in accordance with Delaware Law and upon the terms set forth in this
Agreement, whereupon the separate existence of Hippo Merger Sub shall 

  

 37 

 
cease, and HippoRx shall be the surviving corporation (the “HippoRx Surviving Corporation”). 
 (b) On the Closing Date, HippoRx and Hippo Merger Sub shall file a certificate of merger with the Secretary of State of the State of Delaware and make
all other filings or recordings required by Delaware Law in connection with the HippoRx Merger. The HippoRx Merger shall become effective at the Effective Time. As used herein, the term “Effective Time” means such time on the
Closing Date as is mutually agreed by Hippo and Rhino and is specified in the certificates of merger filed pursuant to Section 5.01(b) and Section 5.02(b); provided that the Effective Time shall be a time occurring after the
Distribution Time. 
 (c) From and after the Effective Time, the HippoRx Surviving Corporation shall possess all the rights, powers,
privileges and franchises and be subject to all of the obligations, liabilities, restrictions and disabilities of HippoRx and Hippo Merger Sub, all as provided under Delaware Law. 
 Section 5.02. The Rhino Merger.  
 (a) At the Effective Time, Rhino Merger Sub shall be merged with and into RhinoRx in accordance with Delaware Law and upon the terms set forth in this Agreement, whereupon the separate existence of Rhino Merger Sub shall cease, and RhinoRx
shall be the surviving corporation (the “RhinoRx Surviving Corporation”). 
 (b) On the Closing Date, RhinoRx and Rhino
Merger Sub shall file a certificate of merger with the Secretary of State of the State of Delaware and make all other filings or recordings required by Delaware Law in connection with the RhinoRx Merger. The RhinoRx Merger shall become effective at
the Effective Time. 
 (c) From and after the Effective Time, the RhinoRx Surviving Corporation shall possess all the rights, powers,
privileges and franchises and be subject to all of the obligations, liabilities, restrictions and disabilities of RhinoRx and Rhino Merger Sub, all as provided under Delaware Law. 
 Section 5.03. Certificates of Incorporation; Bylaws.  
 (a) Attached as Exhibits L and M, respectively, are the certificate of incorporation of Hippo Merger Sub and the bylaws of Hippo Merger Sub. The certificate of incorporation of HippoRx Surviving Corporation shall be
amended at the Effective Time to be identical to the certificate of incorporation of Hippo Merger Sub as in effect immediately prior to the Effective Time, except that the name of the corporation set forth in Section FIRST of the certificate of
incorporation of HippoRx Surviving Corporation shall be a name that is mutually agreed by Hippo and Rhino. The bylaws of Hippo Merger Sub in effect at the 

  

 38 

 
Effective Time shall be the bylaws of HippoRx Surviving Corporation, until amended in accordance with applicable law. 
 (b) Attached as Exhibits N and O, respectively, are the certificate of incorporation of Rhino Merger Sub and the bylaws of Rhino Merger Sub. The
certificate of incorporation of RhinoRx Surviving Corporation shall be amended at the Effective Time to be identical to the certificate of incorporation of Rhino Merger Sub as in effect immediately prior to the Effective Time, except that the name
of the corporation set forth in Section FIRST of the certificate of incorporation of RhinoRx Surviving Corporation shall be a name that is mutually agreed by Hippo and Rhino. The bylaws of Rhino Merger Sub in effect at the Effective Time shall be
the bylaws of RhinoRx Surviving Corporation, until amended in accordance with applicable law. 
 Section 5.04. Directors and
Officers. Prior to the Effective Time, unless otherwise agreed, the directors and officers of Rhino Merger Sub and Hippo Merger Sub shall consist of the Hippo and Rhino employees set forth on Section 5.04 of the Hippo Disclosure Schedule.
From and after the Effective Time, until successors are duly elected or appointed and qualified in accordance with applicable law, (a) the directors of Rhino Merger Sub at the Effective Time shall be the directors of the RhinoRx Surviving
Corporation, (b) the officers of RhinoRx at the Effective Time shall be the officers of the RhinoRx Surviving Corporation, (c) the directors of Hippo Merger Sub at the Effective Time shall be the directors of the HippoRx Surviving
Corporation and (d) the officers of HippoRx at the Effective Time shall be the officers of the HippoRx Surviving Corporation. 
 ARTICLE
6 
 CONVERSION AND EXCHANGE OF SHARES 
 Section 6.01. Conversion of Shares. At the Effective Time, by virtue of the Mergers and without any action on the part of any of the parties
hereto or the holders of any of the following securities: 
 (a) Each issued and outstanding share of capital stock of Hippo Merger Sub shall
be converted into and become one fully paid and nonassessable share of Common Stock, par value $0.01 per share, of the HippoRx Surviving Corporation. 
 (b) Each share of HippoRx Common Stock held in the treasury of HippoRx immediately prior to the Effective Time shall be canceled and retired without any conversion thereof, and no payment shall be made with respect
thereto. 
 (c) Subject to Section 6.01(b), each share of HippoRx Common Stock outstanding immediately prior to the Effective Time after
giving effect to the 

  

 39 

 
HippoRx Distribution shall be converted into the right to receive a number of shares of Newco Common Stock (the “HippoRx Exchange Ratio”)
equal to fifty percent (50%) of the Newco Non-Compensation Share Number divided by the number of shares of HippoRx Common Stock outstanding immediately prior to the Effective Time after giving effect to the HippoRx Distribution (other than
shares of HippoRx Common Stock distributed with respect to Hippo Restricted Stock). 
 (d) Each issued and outstanding share of capital stock
of Rhino Merger Sub shall be converted into and become one fully paid and nonassessable share of Common Stock, par value $0.01 per share, of the RhinoRx Surviving Corporation. 
 (e) Each share of RhinoRx Common Stock held in the treasury of RhinoRx immediately prior to the Effective Time shall be canceled and retired without any
conversion thereof, and no payment shall be made with respect thereto. 
 (f) Subject to Section 6.01(e), each share of RhinoRx Common
Stock outstanding immediately prior to the Effective Time after giving effect to the RhinoRx Distribution shall be converted into the right to receive a number of shares of Newco Common Stock (the “RhinoRx Exchange Ratio”) equal to
fifty percent (50%) of the Newco Non-Compensation Share Number divided by the number of shares of RhinoRx Common Stock outstanding immediately prior to the Effective Time after giving effect to the RhinoRx Distribution. 
 Section 6.02. Exchange Procedures.  
 (a) At or prior to the Effective Time, Newco shall deposit with a bank or trust company jointly designated by Hippo and Rhino (the “Exchange Agent”), for the benefit of the holders of shares of HippoRx Common Stock and
RhinoRx Common Stock, for exchange in accordance with this Article 6, through the Exchange Agent, the shares of Newco Common Stock issuable pursuant to Section 6.01 in exchange for outstanding shares of HippoRx Common Stock and RhinoRx Common
Stock. 
 (b) At the Effective Time, Newco, Hippo and Rhino shall instruct the Exchange Agent to make book-entry credits for, on or as soon
as practicable after the Effective Time, the shares of Newco Common Stock that each holder of Hippo Common Stock as of the Record Date and each holder of Rhino Common Stock as of the Record Date is entitled to pursuant to this Article 6. Newco shall
take all necessary actions to adopt a book-entry stock transfer and registration system for Newco effective as of the Effective Time. Shares of Newco Common Stock shall be in uncertificated book-entry form unless a physical certificate is requested
or is otherwise required by Applicable Law. 
  

 40 

 Section 6.03. Fractional Shares. No fractional shares of Newco Common Stock shall be
distributed to holders of shares of HippoRx Common Stock or RhinoRx Common Stock in the Mergers. All fractional shares of Newco Common Stock that a holder of shares of HippoRx Common Stock or RhinoRx Common Stock would otherwise be entitled to
receive pursuant to the Mergers shall be aggregated, and if a fractional share results from such aggregation, in lieu of receiving such fractional share, a shareholder will be entitled to receive, from the Exchange Agent and in accordance with the
provisions of this Section 6.03, a cash payment representing such shareholder’s proportionate interest, if any, in the net proceeds from the sale by the Exchange Agent in one or more transactions (which sale transactions shall be made at
such times, in such manner and on such terms as the Exchange Agent shall determine in its reasonable discretion) on behalf of all such shareholders of the aggregate of the fractional shares of Newco Common Stock which otherwise would have been
distributed to such shareholders (the “Excess Shares”). The sale of the Excess Shares by the Exchange Agent shall be executed on the New York Stock Exchange through one or more member firms of the New York Stock Exchange and shall
be executed in round lots to the extent practicable. Until the net proceeds of such sale or sales have been distributed to such shareholders, the Exchange Agent will hold such proceeds in trust for such shareholders. Newco shall pay all commissions,
transfer taxes and other out-of-pocket transaction costs, including, without limitation, the expenses and compensation of the Exchange Agent, incurred in connection with such sale of the Excess Shares. As soon as practicable after the determination
of the amount of cash, if any, to be paid to such shareholders in lieu of any fractional shares of Newco Common Stock, the Exchange Agent shall make available such amounts to such shareholders without interest. 
 Section 6.04. Adjustments Related to IRS Ruling. Notwithstanding anything to the contrary herein, the parties hereto (i) will reasonably
cooperate, including by making any necessary and reasonable modifications to the provisions of this Agreement and (ii) to the extent necessary and permitted under Applicable Law, will amend or modify the terms of any applicable equity incentive
plan, program, arrangement or agreement, in each case in order to obtain the private letter rulings from the Internal Revenue Service described in Section 13.02(c) and Section 13.03(c); provided, however, that neither Hippo nor
Rhino shall be required to make any amendments which would require the approval of its stockholders; provided, further, that to the extent any such amendment requires the consent of participants in any applicable plan, Hippo or Rhino, as the
case may be, will use, and shall not be required by anything herein to use more than, its reasonable best efforts to obtain such consent. If necessary, modifications to Section 6.03 could include only pooling and selling the Excess Shares of
record holders of HippoRx Common Stock and RhinoRx Common Stock in the sale made pursuant to Section 6.03. In addition, in the event that any party hereto has any reasonable basis, based on either formal or informal discussions with the
Internal Revenue Service, to believe that the Internal Revenue Service will not 

  

 41 

 
issue any of the private letter rulings described herein, such party shall use reasonable best efforts to notify the other parties hereto. 
 Section 6.05. Withholding Rights. Newco shall be entitled to deduct and withhold from the consideration otherwise payable to any Person
pursuant to this Article 6 such amounts as it is required to deduct and withhold with respect to the making of such payment under any provision of federal, state, local or foreign tax law. If Newco so withholds amounts, such amounts shall be treated
for all purposes of this Agreement as having been paid to the holder of the shares of HippoRx Common Stock or RhinoRx Common Stock, as the case may be, in respect of which Newco made such deduction and withholding. 
 Section 6.06. Transferring Hippo Employee Stock Options.  
 (a) With respect to outstanding Hippo Stock Options held by Active Transferring Hippo Employees, for purposes of each applicable employee stock option plan, compensation plan, individual award agreement or other
arrangement of Hippo, the employment of each Active Transferring Hippo Employee shall be deemed to have terminated without cause immediately following the HippoRx Distribution. Each outstanding Hippo Stock Option held by an Active Transferring Hippo
Employee (each, a “Transferring Hippo Option”) that is vested as of the Distribution Time shall remain exercisable for Hippo Common Stock for the period of time following the Closing Date as permitted by, and in accordance with, its
terms and conditions. Each Transferring Hippo Option that is unvested as of the Distribution Time shall cease to represent a right with respect to a share of Hippo Common Stock and shall be deemed to be converted in the HippoRx Distribution into an
option to purchase shares of HippoRx Common Stock (each, a “HippoRx Stock Option”), on the same terms and conditions as applied to such Transferring Hippo Option immediately before the Distribution Time. At the Effective Time, each
deemed HippoRx Stock Option shall cease to exist and shall be automatically converted into an option to purchase Newco Common Stock (each, a “Newco Stock Option”) on the same terms and conditions as applied to the original
Transferring Hippo Option immediately before the Distribution Time and Newco shall assume each such Newco Stock Option. The exercise price and number of shares of Newco Common Stock subject to such Newco Stock Option shall be determined in
accordance with Section 424 of the Code as follows: (i) the number of shares of Newco Common Stock subject to each such Newco Stock Option shall be equal to the product of (x) the number of shares of Hippo Common Stock subject to the
original unvested Transferring Hippo Option and (y) the Newco Share Ratio, with fractional shares rounded down to the nearest whole share and (ii) the per-share exercise price of such Newco Stock Option shall be equal to the product of
(x) the per-share exercise price of the original unvested Transferring Hippo Option immediately prior to the Distribution Time and (y) the Newco Price Ratio, rounded up to the nearest whole cent. 
  

 42 

 (b) Prior to the Closing Date, Hippo shall use its reasonable best efforts (i) to obtain any
consents from Active Transferring Hippo Employees and (ii) to make any amendments to the terms of such stock option or compensation plans or arrangements that, in either case, are necessary to give effect to the transactions contemplated by
this Section 6.06; provided, however, Hippo shall not be required to make any amendments which would require the approval of its stockholders; provided, further, that to the extent any such amendment requires the consent of
participants in any applicable plan, Hippo shall use its reasonable best efforts to obtain such consent. 
 Section 6.07.
Transferring Rhino Employee Stock Options.  
 (a) With respect to outstanding Rhino Stock Options held by Active Transferring Rhino
Employees, for purposes of each applicable employee stock option plan, compensation plan, individual award agreement or other arrangement of Rhino, the employment of each Active Transferring Rhino Employee shall be deemed to have terminated without
cause immediately following the RhinoRx Distribution. Each outstanding Rhino Stock Option held by an Active Transferring Rhino Employee (each, a “Transferring Rhino Option”) that is vested as of the Distribution Time shall remain
exercisable for Rhino Common Stock for the period of time following the Closing Date as permitted by, and in accordance with, its terms and conditions. Each Transferring Rhino Option that is unvested as of the Distribution Time shall cease to
represent a right with respect to a share of Rhino Common Stock and shall be deemed to be converted in the RhinoRx Distribution into an option to purchase shares of RhinoRx Common Stock (each, a “RhinoRx Stock Option”), on the same
terms and conditions as applied to such Transferring Rhino Option immediately before the Distribution Time. At the Effective Time, each deemed RhinoRx Stock Option shall cease to exist and shall be automatically converted into a Newco Stock Option
on the same terms and conditions as applied to the original Transferring Rhino Option immediately before the Distribution Time and Newco shall assume each such Newco Stock Option. The exercise price and number of shares of Newco Common Stock subject
to such Newco Stock Option shall be determined in accordance with Section 424 of the Code as follows: (i) the number of shares of Newco Common Stock subject to each such Newco Stock Option shall be equal to the product of (x) the
number of shares of Rhino Common Stock subject to the original unvested Transferring Rhino Option and (y) the Newco Share Ratio, with fractional shares rounded down to the nearest whole share and (ii) the per-share exercise price of such
Newco Stock Option shall be equal to the product of (x) the per-share exercise price of the original unvested Transferring Rhino Option immediately prior to the Distribution Time and (y) the Newco Price Ratio, rounded up to the nearest
whole cent. 
 (b) Prior to the Closing Date, Rhino shall use its reasonable best efforts (i) to obtain any consents from Active
Transferring Rhino Employees and (ii) to make any amendments to the terms of such stock option or compensation plans or arrangements that, in either case, are necessary to give effect to the transactions 

  

 43 

 
contemplated by this Section 6.07; provided, however, Rhino shall not be required to make any amendments which would require the approval of its
stockholders; provided, further, that to the extent any such amendment requires the consent of participants in any applicable plan, Rhino shall use its reasonable best efforts to obtain such consent. 
 Section 6.08. Restricted Stock.  
 (a) Each holder of Hippo Restricted Stock outstanding on the Record Date shall receive the same number of shares of Newco Common Stock by virtue of the HippoRx Distribution and the Merger as a holder of Hippo Common Stock on the terms and
conditions set forth in the applicable sections of Article 2 and this Article 6. Any shares of Newco Common Stock received by the holder of Hippo Restricted Stock shall be subject to the same terms regarding vesting and lapse of restrictions as were
applicable to the Hippo Restricted Stock. Each holder of Rhino Restricted Stock outstanding on the Record Date shall receive the same number of shares of Newco Common Stock by virtue of the RhinoRx Distribution and the Merger as a holder of Rhino
Common Stock on the terms and conditions set forth in the applicable sections of Article 2 and this Article 6. Any shares of Newco Common Stock received by a holder of Rhino Restricted Stock shall be fully vested. For purposes of each equity
incentive plan or arrangement of Hippo or Rhino under which Hippo Restricted Stock or Rhino Restricted Stock, as applicable, was granted, the employment of each Active Transferring Rhino Employee and each Active Transferring Hippo Employee shall be
deemed to have terminated without cause immediately following the RhinoRx Distribution or the HippoRx Distribution, as applicable. Each share of Hippo Restricted Stock held by an Active Transferring Hippo Employee and each share of Rhino Restricted
Stock held by an Active Transferring Rhino Employee that is outstanding on the Closing Date shall be automatically cancelled at the Effective Time for no consideration, as provided for in the applicable equity incentive plan or arrangement of Hippo
or Rhino, as applicable, and substituted with Newco Restricted Stock as set forth below. Newco shall grant to each Active Transferring Hippo Employee and each Active Transferring Rhino Employee who held Hippo Restricted Stock or Rhino Restricted
Stock, as applicable, that was cancelled at the Effective Time as provided herein, a substitution grant of Newco Restricted Stock issued under the Newco Incentive Plan or such other equity incentive plan sponsored and maintained by Newco, on the
same terms and conditions as applied to such award of Hippo Restricted Stock or Rhino Restricted Stock, as applicable, immediately prior to the Effective Time. Each such grant of Newco Restricted Stock shall have an equivalent value to the value of
the cancelled Hippo Restricted Stock or Rhino Restricted Stock, as applicable, based on the value of a share of Hippo Common Stock or Rhino Common Stock, as applicable, immediately prior to the Effective Time and a share of Newco Common Stock
immediately following the Effective Time and in each case without regard to any restrictions or periods of restriction to which such Restricted Stock is subject. 
  

 44 

 (b) Prior to the Closing Date, each of Hippo and Rhino shall make any amendments to the terms of the
applicable equity incentive plans or restricted stock grants that, in either case, are necessary to give effect to the transactions contemplated by this Section 6.08; provided, however, that neither Hippo nor Rhino shall be required to
make any amendments which would require the approval of its stockholders; provided, further, that to the extent any such amendment requires the consent of participants in any applicable plan, Hippo or Rhino, as the case may be, shall use, and
shall not be required by anything herein to use more than, its reasonable best efforts to obtain such consent. 
 Section 6.09. Newco
Actions. Newco shall take such actions as are necessary to effect the transactions contemplated by Section 6.06, Section 6.07 and Section 6.08 hereof, including, without limitation, adoption of an equity incentive plan (the
“Newco Incentive Plan”), the receipt of shareholder approval with respect to such plan prior to the Distributions to the extent necessary to comply with NYSE (or NASDAQ, if applicable) shareholder approval rules, and the
reservation, issuance and listing of Newco Common Stock. Newco shall prepare and file with the SEC a registration statement on an appropriate form with respect to the shares of Newco Common Stock subject to such equity awards and shall use its
reasonable best efforts to have such registration statement declared effective as soon as practicable following the Effective Time and to maintain the effectiveness of such registration statement covering such equity awards (and to maintain the
current status of the prospectus contained therein) for so long as such equity awards remain outstanding. With respect to those individuals, if any, who, subsequent to the Effective Time, will be subject to the reporting requirements under
Section 16(a) of the 1934 Act, where applicable, Newco shall use all reasonable efforts to administer the Newco Incentive Plan in a manner that complies with Rule 16b-3 promulgated under the 1934 Act. 
 ARTICLE 7 
 REPRESENTATIONS
AND WARRANTIES OF HIPPO 
 Except as set forth in the Hippo Disclosure Schedule,
Hippo represents and warrants to Newco and Rhino that: 
 Section 7.01. Corporate Existence and Power. Each of Hippo and its
Subsidiaries that is or will be party to a Transaction Agreement is a corporation or other entity duly organized or formed, validly existing and in good standing under the laws of the state of its organization or formation and has all corporate or
other powers and all governmental licenses, authorizations, permits, consents and approvals required to carry on its business as now conducted. Each of Hippo and its Subsidiaries that is or will be party to a Transaction Agreement is duly qualified
to do business as a foreign corporation or other entity and is in good standing in each jurisdiction where such qualification is necessary. Hippo has heretofore delivered or made available to Rhino true and complete copies of the 

  

 45 

 
certificate of incorporation and bylaws or other organizational documents of Hippo and each of its Subsidiaries that is or will be party to a Transaction
Agreement, as currently in effect. 
 Section 7.02. Corporate Authorization. 
 (a) The execution, delivery and performance by Hippo and its Subsidiaries of the Transaction Agreements to which they are or will be party, and the
consummation by Hippo and its Subsidiaries of the transactions contemplated thereby are within Hippo’s and its applicable Subsidiaries’ corporate or other powers and have been duly authorized by all necessary corporate or other action on
the part of Hippo and such Subsidiaries of Hippo. Each Transaction Agreement to which Hippo or any of its Subsidiaries is or will be a party constitutes, or will when executed constitute, a valid and binding agreement of Hippo and each such
Subsidiary that is a party thereto, enforceable against Hippo and each such Subsidiary in accordance with its terms, except (i) as the same may be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application
relating to or affecting creditors’ rights and (ii) for the limitations imposed by general principles of equity. 
 (b) At a
meeting duly called and held, Hippo’s Board of Directors has (i) unanimously determined that this Agreement and the transactions contemplated hereby are fair to and in the best interests of Hippo’s stockholders, (ii) unanimously
approved and adopted this Agreement and the transactions contemplated hereby and (iii) unanimously determined that if the Effective Time occurred on the date hereof, then the conditions set forth in Section 13.01(i)(iii) would be
satisfied. No vote of the holders of any outstanding capital stock of Hippo is necessary in connection with the consummation of the transactions contemplated by the Transaction Agreements. 
 (c) Hippo Operating Sub’s Board of Directors has unanimously determined that, if the Effective Time occurred on the date hereof, the condition set
forth in Section 13.01(i)(i) would be satisfied. 
 (d) HippoRx’s Board of Directors has (i) unanimously determined that this
Agreement (including the HippoRx Merger) and the transactions contemplated hereby are advisable and fair to and in the best interests of the stockholder of HippoRx, (ii) unanimously approved and adopted this Agreement (including the HippoRx
Merger) and the transactions contemplated hereby, (iii) unanimously resolved to recommend approval and adoption of this Agreement (including the HippoRx Merger) by the sole stockholder of HippoRx and (iv) unanimously determined that if the
Effective Time occurred on the date hereof, then the conditions set forth in Section 13.01(i)(ii) would be satisfied. Hippo, as sole stockholder of HippoRx as of the date hereof, has adopted this Agreement (including the agreement of merger
herein) and the transactions contemplated hereby, including the HippoRx Merger, at a duly called stockholders meeting of HippoRx (and not by action by written consent in lieu of a meeting). 
  

 46 

 Section 7.03. Governmental Authorization. The execution, delivery and performance by Hippo
and its Subsidiaries of the Transaction Agreements to which they are or will be party and the consummation by Hippo and such Subsidiaries of the transactions contemplated thereby require no action by or in respect of, or filing with, any
Governmental Authority other than (i) the filing of a certificate of merger with respect to the HippoRx Merger with the Delaware Secretary of State and appropriate documents with the relevant authorities of other states in which the Company is
qualified to do business, (ii) compliance with any applicable requirements of the HSR Act, (iii) compliance with any applicable requirements of the 1933 Act, the 1934 Act, and any other applicable U.S. state or federal securities laws,
(iv) compliance with any applicable requirements of any relevant state Boards of Pharmacy or other federal or state licensing authority, the U.S. Drug Enforcement Agency, the Medicare program or any relevant state Medicaid program and
(v) any actions or filings the absence of which would not be reasonably expected to have, individually or in the aggregate, an adverse effect on HippoRx or impair the ability of Hippo and its applicable Subsidiaries to consummate the
transactions contemplated by the Transaction Agreements. 
 Section 7.04. Non-contravention. The execution, delivery and
performance by Hippo and its Subsidiaries of the Transaction Agreements to which they are or will be party and the consummation of the transactions contemplated thereby do not and will not (i) contravene, conflict with, or result in any
violation or breach of any provision of the certificate of incorporation, bylaws or other organizational documents of Hippo or any such Subsidiary, (ii) assuming compliance with the matters referred to in Section 7.03, contravene, conflict
with or result in a violation or breach of any provision of any Applicable Law, (iii) assuming compliance with the matters referred to in Section 7.03, require any consent or other action by any Person under, constitute a default, or an
event that, with or without notice or lapse of time or both, would constitute a default, under, or cause or permit the termination, cancellation, acceleration or other change of any right or obligation or the loss of any benefit to which Hippo or
any of its Subsidiaries is entitled under any provision of any agreement or other instrument binding upon Hippo or any of its Subsidiaries or any license, franchise, permit, certificate, approval or other similar authorization affecting, or relating
in any way to, the assets or business of Hippo or any of its Subsidiaries or (iv) result in the creation or imposition of any Lien on any asset of Hippo or any of its Subsidiaries, with such exceptions, in the case of each of clauses
(ii) through (iv), as would not be reasonably expected to have, individually or in the aggregate, an adverse effect on HippoRx or prohibit or impair or delay the ability of Hippo or any of its Subsidiaries to consummate the transactions
contemplated by any of the Transaction Agreements. 
 Section 7.05. Capitalization.  
 (a) The authorized capital stock of Hippo consists of (i) 600,000,000 shares of Common Stock and (ii) 10,000,000 shares of Preferred Stock. As
of 

  

 47 

 
October 23, 2006, there were outstanding (i) 194,907,984 shares of Hippo Common Stock of which 314,339 were shares of Hippo Restricted Stock,
(ii) employee stock options to purchase an aggregate of 14,125,344 shares of Hippo Common Stock (of which options to purchase an aggregate of 8,826,469 shares of Hippo Common Stock were exercisable) and (iii) no shares of Preferred Stock.
All outstanding shares of capital stock of Hippo have been, and all shares that may be issued pursuant to any compensatory plan or arrangement will be, when issued in accordance with the respective terms thereof, duly authorized and validly issued
and are fully paid and nonassessable. No Subsidiary of Hippo owns any shares of capital stock of Hippo. Section 7.05(a) of the Hippo Disclosure Schedule contains a complete and correct list as of October 23, 2006 of (x) each
outstanding Hippo Stock Option held by a Transferring Hippo Employee, including, as applicable, the holder, date of grant, exercise price, vesting schedule and number of shares of Hippo Common Stock subject thereto and (y) each outstanding
share of Hippo Restricted Stock, including the holder, date of issuance, and vesting schedule. 
 (b) Except as set forth in this
Section 7.05 and for changes since October 23, 2006 resulting from the exercise of employee stock options outstanding on such date and with respect to outstanding rights under the Hippo Employee Stock Purchase Plan, there are no
outstanding (i) shares of capital stock or voting securities of Hippo, (ii) securities of Hippo convertible into or exchangeable for shares of capital stock or voting securities of Hippo or (iii) options or other rights to acquire
from Hippo, or other obligation of Hippo to issue, any capital stock, voting securities or securities convertible into or exchangeable for capital stock or voting securities of Hippo (the items in clauses (i), (ii), and (iii) being referred to
collectively as the “Hippo Securities”). There are no outstanding obligations of Hippo or any of its Subsidiaries to repurchase, redeem or otherwise acquire any of the Hippo Securities. 
 Section 7.06. HippoRx Entities.  
 (a) Each HippoRx Entity is a corporation or other entity duly organized or formed, validly existing and in good standing under the laws of its jurisdiction of organization or formation, has all corporate or other powers and all governmental
licenses, authorizations, permits, consents and approvals required to carry on its business as now conducted. Each HippoRx Entity is duly qualified to do business as a foreign corporation or other entity and is in good standing in each jurisdiction
where such qualification is necessary. All HippoRx Entities, the owners of its capital stock (to the extent a less than wholly owned HippoRx Subsidiary) and their respective jurisdictions of organization or formation are identified in
Section 7.06(a) of the Hippo Disclosure Schedule. Hippo beneficially owns no interests in any Person engaged in the Hippo Institutional Pharmacy Business other than the HippoRx Entities. To the knowledge of Hippo, no HippoRx Entity is engaged
in any business other than the Hippo Institutional Pharmacy Business or has any Liabilities relating to any other business. 
  

 48 

 (b) All of the outstanding capital stock of, or other voting securities or ownership interests in,
HippoRx will be (as of immediately prior to the HippoRx Distribution) directly owned by Hippo free and clear of any Lien and free of any other limitation or restriction (including any restriction on the right to vote, sell or otherwise dispose of
such capital stock or other voting securities or ownership interests). All of the outstanding capital stock of, or other voting securities or ownership interests in, each HippoRx Entity (other than HippoRx), will be (as of immediately prior to the
HippoRx Distribution) directly or indirectly owned by HippoRx free and clear of any Lien and free of any other limitation or restriction (including any restriction on the right to vote, sell or otherwise dispose of such capital stock or other voting
securities or ownership interests). There are no outstanding (i) securities of Hippo or any of its Subsidiaries convertible into or exchangeable for shares of capital stock or other voting securities or ownership interests in any HippoRx Entity
or (ii) options or other rights to acquire from Hippo or any of its Subsidiaries, or other obligation of Hippo or any of its Subsidiaries to issue, any capital stock or other voting securities or ownership interests in, or any securities
convertible into or exchangeable for any capital stock or other voting securities or ownership interests in, any HippoRx Entity (the items in clauses (i) and (ii) being referred to collectively as the “HippoRx
Securities”). There are no outstanding obligations of Hippo or any of its Subsidiaries to repurchase, redeem or otherwise acquire any of the HippoRx Securities. 
 (c) After giving effect to the HippoRx Distribution, neither Hippo nor any of its Subsidiaries will own any shares of HippoRx Common Stock or any other capital stock or other equity interest in any HippoRx Entity.

 Section 7.07. SEC Filings and the Sarbanes-Oxley Act.  
 (a) Hippo has delivered or made available to Rhino (i) Hippo’s annual reports on Form 10-K for its fiscal years ended September 30, 2005,
2004 and 2003, (ii) its quarterly reports on Form 10-Q for its fiscal quarters ended December 31, 2005, March 31, 2006 and June 30, 2006, (iii) its proxy or information statements relating to meetings of, or actions
taken without a meeting by, the stockholders of Hippo held since September 30, 2005, and (iv) all of its other reports, statements, schedules and registration statements filed with the SEC since September 30, 2005 (the documents
referred to in this Section 7.07(a), collectively, the “Hippo SEC Documents”). 
 (b) As of its filing date, each Hippo
SEC Document complied, and each such Hippo SEC Document filed subsequent to the date hereof will comply, as to form in all respects with the applicable requirements of the 1933 Act and the 1934 Act, as the case may be. 
 (c) As of its filing date (or, if amended or superseded by a filing prior to the date hereof, on the date of such filing), each Hippo SEC Document filed
pursuant to the 1934 Act did not, and each such Hippo SEC Document filed 

  

 49 

 
subsequent to the date hereof will not, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in the light of the circumstances under which they were made, not misleading. 
 (d) Each Hippo SEC Document that is
a registration statement, as amended or supplemented, if applicable, filed pursuant to the 1933 Act, as of the date such registration statement or amendment became effective, did not contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the statements therein not misleading. 
 (e) Hippo has established and
maintains disclosure controls and procedures (as defined in Rule 13a-15 under the 1934 Act). Such disclosure controls and procedures are designed to ensure that material information relating to Hippo, including its consolidated Subsidiaries, is made
known to Hippo’s principal executive officer and its principal financial officer by others within those entities, particularly during the periods in which the periodic reports required under the 1934 Act are being prepared. Such disclosure
controls and procedures are effective in timely alerting Hippo’s principal executive officer and principal financial officer to material information required to be included in Hippo’s periodic reports required under the 1934 Act.

 (f) Hippo and its Subsidiaries have established and maintain a system of internal control over financial reporting (as defined in Rule
13a-15 under the 1934 Act) (“internal controls”). Such internal controls are sufficient to provide reasonable assurance regarding the reliability of Hippo’s financial reporting and the preparation of Hippo’s financial
statements for external purposes in accordance with GAAP. Hippo has disclosed, based on its most recent evaluation of internal controls prior to the date hereof, to Hippo’s auditors and audit committee (x) any significant deficiencies and
material weaknesses in the design or operation of internal controls which are reasonably likely to adversely affect Hippo’s ability to record, process, summarize and report financial information and (y) any fraud, whether or not material,
that involves management or other employees who have a significant role in internal controls. Hippo has made available to Rhino a summary of any such disclosure made by management to Hippo’s auditors and audit committee since September 30,
2004. 
 (g) There are no outstanding loans or other extensions of credit made by Hippo or any of its Subsidiaries to any executive officer
(as defined in Rule 3b-7 under the 1934 Act) or director of Hippo. Hippo has not, since the enactment of the Sarbanes-Oxley Act, taken any action prohibited by Section 402 of the Sarbanes-Oxley Act. 
 (h) The financial statements included in the Hippo SEC Documents fairly present, in conformity with GAAP applied on a consistent basis (except as may be
indicated in the notes thereto), the consolidated financial position of Hippo and its Subsidiaries as of the dates specified therein and the consolidated 

  

 50 

 
results of operations and cash flows of Hippo and its Subsidiaries for the periods specified therein (subject to normal and immaterial year-end adjustments
in the case of unaudited financial statements). 
 Section 7.08. Financial Statements.  
 (a) The audited balance sheets as of September 30, 2006 and 2005 and the related audited statements of income and cash flows for each of the years
ended September 30, 2006, 2005 and 2004 for the Hippo Institutional Pharmacy Business that will be provided pursuant to Section 9.05, and all the audited and unaudited financial statements of the Hippo Institutional Pharmacy Business
included in the Registration Statement, will fairly present, in conformity with GAAP applied on a consistent basis (except as may be indicated in the notes thereto), the financial position of the Hippo Institutional Pharmacy Business as of the dates
thereof and its results of operations and cash flows for the periods then ended (subject to normal and immaterial year-end adjustments in the case of any unaudited interim financial statements included in the Registration Statement). 
 (b) The HippoRx Audited EBITDA will be not less than 87.5% of the HippoRx Estimated EBITDA. 
 (c) The unaudited balance sheet and statement of operations for the Hippo Institutional Pharmacy Business (and including the Hippo Retail Pharmacies) as
of and for the nine months ended June 30, 2006 attached as Exhibit P hereto (i) are derived from and are consistent with the books and records of HippoRx and its Subsidiaries, (ii) are the financial statements of the Hippo
Institutional Pharmacy Business (and including the Hippo Retail Pharmacies) as of and for such period that were made available to and used by the management of Hippo and HippoRx and (iii) were included in the consolidated financial statements
of Hippo as of and for the nine months ended June 30, 2006 as contained in Hippo’s Quarterly Report on Form 10-Q as of and for such period as filed with the SEC. 
 (d) The unaudited balance sheet and statement of operations for the Hippo Institutional Pharmacy Business as of and for the nine months ended
June 30, 2006 attached as Exhibit Q hereto (i) are derived from and are consistent with the books and records of HippoRx and its Subsidiaries and (ii) sets forth the adjustments made to the balance sheet and statement of operations in
Exhibit P to eliminate from such balance sheet and statement of operations the assets, liabilities and results of operations of the Hippo Retail Pharmacies. 
 Section 7.09. Information Supplied. The information (including all financial data) supplied by Hippo for inclusion or incorporation in the Registration Statement and any amendments or supplements thereto
and, to the knowledge of Hippo, all information related to Newco contained therein shall not at the time the Registration Statement is declared effective by the SEC or at the Effective Time contain any untrue statement of a material fact or omit to
state any 

  

 51 

 
material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made,
not misleading. 
 Section 7.10. Absence of Certain Changes. (a) From the HippoRx Balance Sheet Date until the date of this
Agreement, except as expressly contemplated by the Transaction Agreements, the Hippo Institutional Pharmacy Business has been conducted in the ordinary course consistent with past practices and there has not been: 
 (i) any amendment of the articles of incorporation, bylaws or other similar organizational documents (whether by merger, consolidation or
otherwise) of any of the HippoRx Entities; 
 (ii) any splitting, combination or reclassification of any shares of capital
stock of any of the HippoRx Entities or declaration, setting aside or payment of any dividend or other distribution (whether in cash, stock or property or any combination thereof) in respect of the capital stock any of the HippoRx Entities, or
redemption, repurchase or other acquisition or offer to redeem, repurchase, or otherwise acquire any HippoRx Securities; 
 (iii)(A) any issuance, delivery or sale, or authorization of the issuance, delivery or sale of, any shares of any HippoRx Securities or (B) amendment of any term of any HippoRx Security (in each case, whether by merger, consolidation
or otherwise); 
 (iv) any incurrence of any capital expenditures or any obligations or liabilities in respect thereof by the
Hippo Institutional Pharmacy Business, except for any such incurrence in the ordinary course of business consistent with past practice; 
 (v) any acquisition (by merger, consolidation, acquisition of stock or assets or otherwise), directly or indirectly, by the Hippo Institutional Pharmacy Business of any assets, securities, properties, interests or
businesses, other than any such acquisition in the ordinary course of business in a manner that is consistent with past practice; 
 (vi) any sale, lease or other transfer of, or creation or incurrence of any Lien on, any assets, securities, properties, interests or businesses of the Hippo Institutional Pharmacy Business, other than (A) sales of inventory or leases
of property in the ordinary course of business consistent with past practice and (B) sales of assets, securities, properties, interests or businesses with a sale price (including any related assumed indebtedness) that does not exceed $5,000,000
individually or $10,000,000 in the aggregate; 
  

 52 

 (vii) other than in connection with actions identified in Section 7.10(a)(iv), any
making by the Hippo Institutional Pharmacy Business of any loans, advances or capital contributions to, or investments in, any other Person, other than in the ordinary course of business consistent with past practice; 
 (viii) any creation, incurrence, assumption or sufferance to exist by the Hippo Institutional Pharmacy Business of any indebtedness for
borrowed money or guarantees thereof; 
 (ix) any damage, destruction or other casualty loss (whether or not covered by
insurance) affecting the business or assets of the Hippo Institutional Pharmacy Business; 
 (x)(A) any entering into of any
agreement or arrangement that limits or otherwise restricts in any respect any HippoRx Entity or the Hippo Institutional Pharmacy Business or that could, after the Effective Time, limit or restrict in any respect any HippoRx Entity, the Hippo
Institutional Pharmacy Business, Newco, or any of its Subsidiaries, from engaging or competing in any line of business, in any location or with any Person or (B) any entering into, amendment or modification in any adverse respect or termination
of or any nonrenewal or expiration of any HippoRx Material Contract or waiver, release or assignment of any rights, claims or benefits of the Hippo Institutional Pharmacy Business or the HippoRx Entities; 
 (xi)(A) any grant or increase of any severance or termination pay to (or amend any existing arrangement with) any Transferring Hippo
Employee, (B) any increase in benefits payable under any existing severance or termination pay policies or employment agreements of any Transferring Hippo Employee, (C) any entering into of any employment, deferred compensation, retention,
change in control, tax gross-up, special bonus, stay bonus or other similar agreement (or amendment of any such existing agreement) with any Transferring Hippo Employee, (D) any establishment, adoption or amendment (except as required by
Applicable Law) of any collective bargaining, bonus, profit-sharing, thrift, pension, retirement, deferred compensation, compensation, stock option, restricted stock or other benefit plan or arrangement covering any Transferring Hippo Employee or
(E) any increase in compensation, bonus or other benefits payable to any Transferring Hippo Employee, in each case, other than in the ordinary course of business consistent with past practice; 
 (xii) any labor dispute, other than routine individual grievances, or any activity or proceeding by a labor union or representative
thereof to organize any Transferring Hippo Employees, which employees were not subject to a collective bargaining agreement at the HippoRx Balance Sheet 

  

 53 

 
Date, or any lockouts, strikes, slowdowns, work stoppages or threats thereof by or with respect to such employees; 
 (xiii) any change in Hippo’s or any of its Subsidiaries’ (in each case, to the extent related to the Hippo Institutional
Pharmacy Business) or any HippoRx Entity’s methods of accounting, except as required by concurrent changes in GAAP; 
 (xiv) any settlement, or offer or proposal to settle, (A) any litigation, investigation, arbitration, proceeding or other claim involving or against the Hippo Institutional Pharmacy Business or the HippoRx Entities, (B) any
stockholder litigation or dispute against the Hippo Institutional Pharmacy Business or the HippoRx Entities or any of the officers or directors of the HippoRx Entities or (C) any litigation, arbitration, proceeding or dispute that relates to
the transactions contemplated hereby; 
 (xv) any Tax election, any annual tax accounting period changed, any method of tax
accounting adopted or changed, any Tax Returns amended or claims for Tax refunds filed, any closing agreement entered into, any Tax claim, audit or assessment settled, or any right to claim a Tax refund, offset or other reduction in Tax liability
surrendered; or 
 (xvi) any adverse regulatory events, developments or changes, including recoupments not in the ordinary
course of business, loss of licensure or failure to renew any permits or licenses. 
 (b) Since the HippoRx Balance Sheet Date, there has not
been any event, occurrence, development or state of circumstances or facts that has had or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on HippoRx. 
 Section 7.11. No Undisclosed Liabilities. There are no known or unknown Liabilities of the HippoRx Group of any kind whatsoever, whether
accrued, contingent, absolute, determined, determinable or otherwise, and there is no existing condition, situation or set of circumstances that could reasonably be expected to result in such a Liability, other than: 
 (a) Liabilities disclosed and provided for in the HippoRx Balance Sheet, and 
 (b) Liabilities incurred in the ordinary course of business consistent with past practices since the HippoRx Balance Sheet Date. 
 Section 7.12. Compliance with Laws and Court Orders. 
  

 54 

 (a) Each of Hippo and its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy
Business) is, and since January 1, 2003 has been, in compliance with, and to the knowledge of Hippo is not under investigation by any Governmental Authority with respect to and has not been threatened to be charged with or given notice of any
violation of, any Applicable Law. 
 (b) Each of Hippo and its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy
Business) has duly obtained all permits, concessions, grants, franchises, licenses and other governmental authorizations, consents, and approvals, including Medicare and Medicaid billing and provider numbers (collectively, “HippoRx
Permits”), necessary for the conduct of the Hippo Institutional Pharmacy Business including those relating to Medicare, any relevant state Medicaid program or any other health insurance or health care benefit program sponsored or financed
in whole or in part by any Governmental Authority. Each HippoRx Permit is in full force and effect and each of Hippo and its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) is in full compliance with the terms of
each HippoRx Permit. There are no actions, suits, sanctions, investigations or proceedings (or any basis therefor) pending or, to the knowledge of Hippo, threatened which may result in the revocation, cancellation, suspension or modification of any
such HippoRx Permit. 
 (c) Each Person employed or engaged by each of Hippo and its Subsidiaries (to the extent relating to the Hippo
Institutional Pharmacy Business) to provide services on behalf of the Hippo Institutional Pharmacy Business (each, a “HippoRx Licensed Service Provider”) has obtained and maintains all necessary licensure or certification to provide
such services in compliance with any Applicable Law or the requirements of any Government Medical Reimbursement Program. Each HippoRx Licensed Service Provider is covered by a professional liability insurance policy underwritten by a licensed
insurance company, with coverage limits and terms that are consistent with industry standards. 
 (d) To the knowledge of Hippo, since
January 1, 2003, none of Hippo and its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) nor any of their respective officers, directors, employees or agents has been investigated or charged by any Governmental
Authority in any violation of any laws involving fraudulent or abusive practices relating to its participation in any Medicare, Medicaid, Veterans Administration, Tricare or any other state or federally sponsored health care reimbursement or health
care benefit program (each, a “Government Medical Reimbursement Program”) or in any health care benefit program as defined in 18 U.S.C. § 24(b), including fraudulent billing or recordkeeping practices, and no such person has
been convicted of, charged with or investigated for a violation of any other federal or state law relating to fraud, theft, embezzlement, breach of fiduciary responsibility, financial misconduct, obstruction of an investigation or controlled
substances. Since January 1, 2003, Hippo and its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) have properly and legally billed all individuals, 

  

 55 

 
intermediaries and third party payors, as appropriate, for services rendered through the HippoRx Entities and have maintained all necessary documentation to
support and reflect such billing practices. To the knowledge of Hippo, none of Hippo and its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) nor any of their respective directors, officers, employees, independent
contractors or agents has committed any offense which is reasonably likely to be the basis for suspension, civil monetary penalties, debarment or exclusion of Hippo or any of its Subsidiaries (to the extent relating to the Hippo Institutional
Pharmacy Business) or any of their respective directors, officers, managers, current employees, partners, agents or independent contractors from any Government Medical Reimbursement Program, including, but not limited to, defrauding a government
program, loss of a license to provide health care services or failure to provide quality care. 
 (e) None of Hippo and its Subsidiaries (to
the extent relating to the Hippo Institutional Pharmacy Business) nor any of their respective directors, officers, employees, independent contractors or agents have engaged in any activities which may serve as the grounds for any penalties of any
kind under Sections 1128A, 1128B or 1877 of the Social Security Act (42 U.S.C. §§ 1320a-7a, 1320a-7b and 1395nn), the federal False Claims Act (31 U.S.C. § 3729 et seq.), the False Statements Act (18 U.S.C. § 1001), the Program
Fraud Civil Penalties Act (31 U.S.C. § 3801 et seq.), the Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.) (all as amended or superseded), and the anti-fraud and abuse provisions of the Health Insurance Portability and Accountability
Act of 1996 (18 U.S.C. § 1347, 18 U.S.C. § 669, 18 U.S.C. § 1035, 18 U.S.C. § 1518) and the applicable fraud and abuse, anti-kickback, false claims and anti-self referral statutes and regulations in each state or other
jurisdictions where Hippo and its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) may conduct business or any related regulations or other federal or state laws and regulations. 
 Section 7.13. Litigation. There is no action, suit, investigation or proceeding (or any basis therefor) pending against, or, to the knowledge
of Hippo, threatened against or affecting, Hippo or any of its Subsidiaries or the Hippo Institutional Pharmacy Business, any present or former officer, director or employee of Hippo or any of its Subsidiaries or any Person for whom Hippo or any of
its Subsidiaries may be liable or any of their respective properties before any court or arbitrator or before or by any Governmental Authority, (i) that, could reasonably be expected to have, an adverse effect on the Hippo Institutional
Pharmacy Business or (ii) that, as of the date hereof, in any manner challenges or seeks to prevent, enjoin, alter or delay the transactions contemplated by the Transaction Agreements. For the avoidance of doubt, clause (ii) of the
preceding sentence contains the only representation or warranty in this Article 7 regarding legal challenges to the transactions contemplated by the Transaction Agreements. 
 Section 7.14. Finders’ Fees. Except for Deutsche Bank Securities Inc. (all of whose fees and expenses shall be paid by Hippo and the
obligations to 

  

 56 

 
which shall be Non-HippoRx Liabilities), there is no investment banker, broker, finder or other intermediary that has been retained by or is authorized to
act on behalf of the Hippo or any of its Affiliates who might be entitled to any fee or commission from Hippo or any of its Affiliates in connection with the transactions contemplated by the Transaction Agreements. 
 Section 7.15. Taxes.  
 (a) All
Tax Returns required by Applicable Law to be filed with any Taxing Authority by, or on behalf of, any HippoRx Entity have been filed when due in accordance with all Applicable Law, and all such Tax Returns are true and complete in all respects.

 (b) Each HippoRx Entity has paid (or has had paid on its behalf) or has withheld and remitted to the appropriate Taxing Authority all
Taxes due and payable, or, where payment is not yet due, has established (or has had established on its behalf and for its sole benefit and recourse) in accordance with GAAP an adequate accrual for all Taxes through the end of the last period for
which the HippoRx Entities ordinarily record items on their respective books. 
 (c) The income and franchise Tax Returns of the HippoRx
Entities through the Tax year ended December 31, 1997 have been examined and closed or are Tax Returns with respect to which the applicable period for assessment under Applicable Law, after giving effect to extensions or waivers, has expired.

 (d) There is no claim, audit, action, suit, proceeding or investigation now pending or, to Hippo’s knowledge, threatened against or
with respect to the HippoRx Entities in respect of any Tax or Tax asset. 
 (e) No HippoRx Entity has since January 1, 2003 been a
member of an affiliated, consolidated, combined or unitary group other than one of which Hippo was the common parent. 
 (f)
Section 7.15(f) of the Hippo Disclosure Schedule contains a list of all jurisdictions (whether foreign or domestic) in which any HippoRx Entity currently files Tax Returns. 
 Section 7.16. Employee Benefit Plans; Employees.  
 (a) Section 7.16(a) of the Hippo Disclosure Schedule contains a correct and complete list identifying each Hippo Benefit Plan that covers any Transferring Hippo Employee and each HippoRx Benefit Plan
(collectively, the “Hippo Plans”). Copies of such plans (and, if applicable, related trust or funding agreements or insurance policies) and all amendments thereto and written interpretations thereof have been made available to Rhino
together with the most recent annual report (Form 5500 including, if applicable, Schedule B thereto) and tax return (Form 990) prepared in connection with any such plan or trust. Section 7.16(a) 

  

 57 

 
of the Hippo Disclosure Schedule contains a list of each Hippo Plan that is subject to Title IV of ERISA. 
 (b) None of the HippoRx Entities contributes to or is obligated to contribute to, or has any Liability with respect to, any multiemployer plan, as
defined in Section 3(37) of ERISA (a “Multiemployer Plan”). 
 (c) Each Hippo Plan that is intended to be qualified
under Section 401(a) of the Code has received a favorable determination letter, or has pending an application for such determination from the Internal Revenue Service, and Hippo is not aware of any reason why any such determination letter
should be revoked or not be reissued. Hippo has made available to Rhino copies of the most recent Internal Revenue Service determination letters with respect to each such Hippo Plan. Each Hippo Plan has been maintained in compliance with its terms
and with the requirements prescribed by any and all statutes, orders, rules and regulations, including ERISA and the Code, which are applicable to such Hippo Plan. No events have occurred or are reasonably expected to occur with respect to any Hippo
Plan that could result in payment or assessment by or against Hippo or any HippoRx Entity of any excise taxes under the Code. 
 (d) No
condition exists that would subject any HippoRx Entity, either directly or by reason of its affiliation with any ERISA Affiliate, to any tax (including any excise tax), fine, lien, penalty or other similar Liability imposed by ERISA, the Code or
other Applicable Laws. 
 (e) Neither Hippo nor any of its Subsidiaries has any current or projected Liability in respect of post-employment
or post-retirement health or medical or life insurance benefits for Transferring Hippo Employees, except as required to avoid excise tax under Section 4980B of the Code. 
 (f) The consummation of the transactions contemplated by this Agreement will not (either alone or together with any other event) entitle any Transferring
Hippo Employee to any bonus, severance, retirement, job security or other benefit, or accelerate the time of payment or vesting or trigger any payment of funding (through a grantor trust or otherwise) of compensation or benefits under, increase the
amount payable or trigger any other obligation pursuant to, any Hippo Plan. Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby, either alone or in combination with any other event
(whether contingent or otherwise), will result in any excise tax under Section 4999 of the Code or non-deductibility of any compensation or benefit under Section 280G of the Code with respect to Transferring Hippo Employees. 
 (g) There is no action, suit, investigation, audit or proceeding pending against or involving or, to the knowledge of Hippo, threatened against or
involving any Hippo Plan before any arbitrator or any Governmental Authority. 
  

 58 

 (h) Neither Hippo nor any of its Subsidiaries is a party to or subject to, or is currently negotiating in
connection with entering into, any collective bargaining agreement or other contract or understanding with a labor union or organization with respect to a Transferring Hippo Employee. 
 (i)(i) There is no pending, or to Hippo’s knowledge threatened, labor strike or dispute, walkout, work stoppage, slow down or lockout involving
Transferring Hippo Employees; and (ii) Hippo and its Subsidiaries are in compliance with all Laws governing the employment of Transferring Hippo Employees, including, but not limited to, all such Laws relating to wages, overtime wages, hours,
collective bargaining, discrimination, retaliation, civil rights, safety and health, workers’ compensation and the collection and payment of withholding and/or social security Taxes and similar Taxes. 
 (j) Substantially all of the pharmacists and pharmacy technicians staffing the Hippo Institutional Pharmacy Business are (i) legally employed by a
HippoRx Entity and (ii) not considered leased employees, agency employees, temporary employees or independent contractors under applicable Law. 
 Section 7.17. Environmental Matters.  
 (a) No notice, notification, demand, request for
information, citation, summons or order has been received, no complaint has been filed, no penalty has been assessed, and no investigation, action, claim, suit, proceeding or review (or any basis therefor) is pending or, to the knowledge of Hippo,
is threatened by any Governmental Authority or other Person relating to the HippoRx Group and relating to or arising out of any Environmental Law. 
 (b) Each of the HippoRx Group is and has been in compliance with all Environmental Laws and all Environmental Permits. 
 (c) There
are no Liabilities of the HippoRx Group of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable or otherwise arising under or relating to any Environmental Law or any Hazardous Substance and there is no condition,
situation or set of circumstances that could reasonably be expected to result in or be the basis for any such Liability. 
 (d) There have
been no environmental investigations, studies, audits, tests, reviews or other analyses conducted of which Hippo has knowledge in relation to the current or prior business of the HippoRx Group or any property or facility now or previously owned or
leased by the HippoRx Group that reveal matters that, individually or in the aggregate, have had or could reasonably be expected to have, an adverse effect on the Hippo Institutional Pharmacy Business. 
 (e) The execution of the transactions contemplated hereby require no filings to be made or actions to be taken pursuant to the New Jersey Industrial Site

  

 59 

 
Recovery Act or the “Connecticut Property Transfer Law” (Sections 22a-134 through 22-134e of the Connecticut General Statutes). 
 Section 7.18. Property Matters.  
 (a) Section 7.18(a) of the Hippo Disclosure Schedule sets forth a complete and accurate list as of the date of this Agreement of all real property leased, subleased or licensed by Hippo and its Subsidiaries (to the extent relating
to the Hippo Institutional Pharmacy Business) (collectively, the “HippoRx Leases”), including, with respect to each location, a description of (i) the location of the premises (the “HippoRx Leased Premises”),
(ii) the landlord, (iii) the date of the lease and (iv) the dates of any extensions, amendments, supplements and other modifications thereof. All HippoRx Leases are valid and in full force and effect. Neither Hippo nor any of its
Subsidiaries nor, to the knowledge of Hippo, any other party to any HippoRx Lease has (i) violated any provisions of, or committed or failed to perform any act that, with or without notice, lapse of time or both, would constitute a default
under the provisions of any HippoRx Lease, (ii) received notice of any of the events in clause (i) or (iii) received notice of termination, cancellation or non-renewal of any such HippoRx Lease. Hippo has made available to Rhino true
and complete copies of all the HippoRx Leases, all modifications or amendments thereto or waivers thereunder and all subordination and non-disturbance agreements relating thereto. 
 (b) Section 7.18(b) of the Hippo Disclosure Schedule sets forth a complete and accurate list as of the date of this Agreement of all real property
owned by Hippo and its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) (collectively, the “HippoRx Owned Properties”). With respect to any HippoRx Owned Property, Hippo has provided to Rhino true
and correct copies of the most recent title insurance policy and survey, if any, held by the applicable owner with respect thereto. The HippoRx Owned Properties and the HippoRx Leased Premises constitute all of the real property used or occupied by
Hippo and its Subsidiaries in connection with the Hippo Institutional Pharmacy Business. Each entity listed on Section 7.18(b) of the Hippo Disclosure Schedule as owning a HippoRx Owned Property has good fee simple title to such HippoRx Owned
Property, subject to no Liens other than Liens listed on Section 7.18(b) of the Hippo Disclosure Schedule, and none of the structures on a Hippo Owned Property encroaches upon real property of another Person, and no structure of any other
Person encroaches upon any HippoRx Owned Property. 
 (c) There does not exist any pending condemnation or eminent domain proceedings that
affect any HippoRx Owned Property, or to the knowledge of Hippo, any such proceedings that affect any HippoRx Leased Premises, or to the knowledge of Hippo, any threatened condemnation or any eminent domain proceedings that affect any HippoRx Owned
Property or HippoRx Leased Premises, and neither Hippo nor its Subsidiaries have received any written notice 

  

 60 

 
of the intention of any Governmental Authority or other Person to take or use any HippoRx Owned Property or HippoRx Leased Premises. 
 (d) Other than the HippoRx Leases and any superior leases under which HippoRx Leases that are subleases are created, to the knowledge of Hippo, none of
the HippoRx Owned Property or the HippoRx Leased Premises are subject to any lease, sublease, license or other agreement granting to any Person other than a HippoRx Entity any right to the use, occupancy or enjoyment of such HippoRx Owned Property
or HippoRx Leased Premises or any part thereof. 
 Section 7.19. Intellectual Property.  
 (a) As of the Distribution Time, subject to the provisions of Article 2, the HippoRx Entities will own or otherwise have the right to use all Intellectual
Property necessary to conduct the Hippo Institutional Pharmacy Business as currently conducted (the “HippoRx Intellectual Property”). There exist no restrictions on the disclosure, use, license or transfer of the HippoRx
Intellectual Property owned by Hippo and its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) (the “Owned HippoRx Intellectual Property”). For purposes of this Agreement, the term
“Intellectual Property” means (i) patents, trademarks, service marks, trade names, logos, domain names, copyrights, designs and trade secrets, (ii) applications for and registrations of such patents, trademarks, service
marks, trade names, logos, domain names, copyrights and designs, (iii) know-how, inventions, whether or not patentable, computer software programs and applications (including source code and object code), databases and data collections, and
(iv) any other similar type of proprietary intellectual property right. 
 (b) The execution and delivery of this Agreement by Hippo and
HippoRx and the consummation of the Transactions will not encumber, impair or extinguish any HippoRx Intellectual Property. Section 7.19(b) of the Hippo Disclosure Schedule sets forth a complete and accurate list of all (i) registrations
or applications for registration included in the Owned HippoRx Intellectual Property (the “Registered HippoRx Intellectual Property”) and (ii) all agreements (excluding licenses for commercial off the shelf computer software
that are generally available on nondiscriminatory pricing terms which have an aggregate acquisition cost of $1,000,000 or less) to which Hippo or any of its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) is a
party or otherwise bound and pursuant to which Hippo or any of its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) (A) obtains the right to use or a covenant not to be sued under, any Intellectual Property
and/or (B) grants the right to use, or a covenant not to be sued under, any Intellectual Property. 
 (c) To the knowledge of Hippo, the
conduct of the Hippo Institutional Pharmacy Business as currently conducted does not infringe, violate or constitute a misappropriation of any Intellectual Property of any Third Party in any respect. 

  

 61 

 
Since January 1, 2003, neither Hippo nor any of its Subsidiaries has received any written claim or notice alleging any such infringement, violation
or misappropriation and there is no claim, action, suit, investigation or proceeding pending against, or, to the knowledge of Hippo, threatened against Hippo or any of its Subsidiaries (i) based upon, or challenging or seeking to deny or
restrict, the rights of Hippo or its Subsidiaries in any of the HippoRx Intellectual Property, (ii) alleging that the use of the HippoRx Intellectual Property or any services provided, processes used or products manufactured, used, imported,
offered for sale or sold by the Hippo Institutional Pharmacy Business do or may conflict with, misappropriate, infringe or otherwise violate any Intellectual Property of any Third Party or (iii) alleging that Hippo or any of its Subsidiaries
have infringed, misappropriated or otherwise violated any Intellectual Property of any Third Party. 
 (d) None of the HippoRx Intellectual
Property used in the operation of the Hippo Institutional Pharmacy Business has been adjudged invalid or unenforceable in whole or part, and, to the knowledge of Hippo, all such HippoRx Intellectual Property is valid and enforceable. To the
knowledge of Hippo, no Third Party is infringing, violating or misappropriating any of the HippoRx Intellectual Property in any respect. 
 Section 7.20. HippoRx Material Contracts.  
 (a) Except as set forth on Section 7.20(a) of the Hippo Disclosure
Schedule, as of the date hereof, neither Hippo nor any of its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) is a party to or otherwise bound by: 
 (i) any “material contract” (as such term is defined in Item 601(b)(10) of Regulation S-K of the SEC); 
 (ii) any employment or consulting Contract with any Transferring Hippo Employee providing for base compensation in excess of $175,000,
other than those that are terminable by Hippo on no more than thirty (30) days notice without liability or financial obligation to Hippo; 
 (iii) any Contract containing any covenant (A) limiting the right of Hippo or any of its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) to engage in any line of business or
compete with any person in any line of business or to compete with any party, (B) granting any exclusive rights to make, sell or distribute the products or services of Hippo or any of its Subsidiaries (to the extent relating to the Hippo
Institutional Pharmacy Business) or (C) otherwise prohibiting or limiting the right of Hippo or any of its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) to make, sell or distribute any products or services;

  

 62 

 (iv) any Contract relating to the disposition or acquisition by Hippo or any of its
Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) of an amount of assets or of any business (whether by merger, sale of stock, sale of assets or otherwise) with a value in excess of $5,000,000 or pursuant to which
Hippo or any of its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) has any ownership interest with a value in excess of $5,000,000 in any other person or other business enterprise other than any other HippoRx
Entity; 
 (v) any Contract to provide source code to any Third Party for any product, service or technology that is used by
Hippo or any of its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) that either has required or is anticipated to require payment by any Person in excess of $1,000,000 in the aggregate or is reasonably necessary to
support operations that generate in excess of $10,000,000 in annual revenue; 
 (vi) any Contract to license any Third Party
to manufacture or reproduce any of Hippo’s or any of its Subsidiaries’ (to the extent relating to the Hippo Institutional Pharmacy Business) products, services or technology or any Contract to sell or distribute any of Hippo’s or any
of its Subsidiaries’ (to the extent relating to the Hippo Institutional Pharmacy Business) products, services or technology, except (A) agreements with distributors, sales representatives or other resellers entered into in the ordinary
course of business and (B) agreements allowing internal backup copies made or to be made by end-user customers in the ordinary course of business; 
 (vii) any mortgages, indentures, guarantees, loans or credit agreements, security agreements or other Contracts relating to the borrowing of money or extension of credit, of Hippo or any of its Subsidiaries (to the
extent relating to the Hippo Institutional Pharmacy Business), in each case other than accounts receivables and payables in the ordinary course of business; 
 (viii) any Contract under which Hippo or any of its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) has
licensed its Intellectual Property to a Third Party, other than to customers, distributors and other resellers in the ordinary course of business; 
 (ix) any Contract under which Hippo or any of its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) has received a license to any Intellectual Property owned by a Third Party that is
used in the Hippo Institutional Pharmacy Business that either has required or is anticipated to require payment by any Person in excess of 

  

 63 

 
$5,000,000 in the aggregate or is reasonably necessary to support operations that generate in excess of $10,000,000 in annual revenue; 
 (x) any Contract, or group of Contracts in which the counterparties are within the same consolidated group, providing for the sale by
Hippo or any of its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) of materials, supplies, goods, services, equipment or other assets that provides for either (A) annual payments to Hippo or any of its
Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) of $2,000,000 or more or (B) aggregate payments to Hippo or any of its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) of
$20,000,000 or more; 
 (xi) any Contract (other than Contracts for the purchase of pharmaceutical products) providing for the
purchase by Hippo or any of its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) of materials, supplies, goods, services, equipment or other assets that provides for either (A) annual payments by Hippo or any
of its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) of $5,000,000 or more or (B) aggregate payments by Hippo or any of its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business)
of $20,000,000 or more; 
 (xii) any Contract relating to the leasing of personal property by Hippo or any of its Subsidiaries
(to the extent relating to the Hippo Institutional Pharmacy Business) providing for annual rentals of $5,000,000 or more; 
 (xiii) any Contract relating to a partnership, joint venture or other similar arrangement; 
 (xiv) any Contract
relating to agency, dealer, sales representative, marketing or similar arrangements providing for annual payments of $1,000,000 or more; 
 (xv) any Contract relating to administrative services, management services or professional services with physicians or pharmacists that has required or is anticipated to require payment by any Person in excess of
$250,000 in the aggregate; 
 (xvi) any Contract with any pharmacy benefits manager, group purchasing organization or Third
Party payer of health insurance benefits that has required or is anticipated to require payment by any Person in excess of $5,000,000 in the aggregate; or 
 (xvii) any Contract with Hippo or any of its Subsidiaries or Affiliates (other than any HippoRx Entity), except any HippoRx Lease. 
  

 64 

 (b) The Contracts disclosed or required to be disclosed on Section 7.20(a) of the Hippo Disclosure
Schedule are referred to herein as the “HippoRx Material Contracts”. A true and complete copy of each HippoRx Material Contract (including any modifications and amendments thereto or waivers thereunder) has been made available to
Rhino. 
 (c) All HippoRx Material Contracts are valid and in full force and effect. To the knowledge of Hippo, none of the terms or
conditions in the HippoRx Material Contracts may serve as the ground for any penalties of any kind under the Social Security Act, the federal False Claims Act (31 U.S.C. § 3729 et seq.), the False Statements Act (18 U.S.C. § 1001), the
Program Fraud Civil Penalties Act (31 U.S.C. § 3801 et seq.), the Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.) (all as amended or superseded), and the anti-fraud and abuse provisions of the Health Insurance Portability and
Accountability Act of 1996 (18 U.S.C. § 1347, 18 U.S.C. § 669, 18 U.S.C. § 1035, 18 U.S.C. § 1518), or comparable laws enacted by each state or jurisdiction in which Hippo may conduct business. Neither Hippo nor any of its
Subsidiaries, and, to the knowledge of Hippo, no Third Party to any such Contract, has (i) violated any provision of, or committed or failed to perform any act that, with or without notice, lapse of time or both, would constitute a default
under the provisions of any HippoRx Material Contract, (ii) received notice of any of the events set forth in clause (i) or (iii) received notice of termination, cancellation or non-renewal or any such Contract. Substantially all of
the Contracts pursuant to which a HippoRx Entity provides pharmacy services are in writing. 
 (d) To the extent necessary to operate the
Hippo Institutional Pharmacy Business as it is now being conducted, Hippo and its Subsidiaries (to the extent relating to the Hippo Institutional Pharmacy Business) have current provider agreements with Prescription Drug Plans, Medicare and Medicaid
and private non-governmental programs, including with any private insurance program under which they, directly or indirectly, are presently receiving payments. 
 Section 7.21. Insurance. Hippo has furnished to Rhino a list of, and true and complete copies of, all insurance policies and fidelity bonds relating to the Hippo Institutional Pharmacy Business and its
officers and employees. There is no claim by Hippo or any of its Subsidiaries pending under any of such policies or bonds as to which coverage has been questioned, denied or disputed by the underwriters of such policies or bonds or in respect of
which such underwriters have reserved their rights. All premiums payable under all such policies and bonds have been timely paid and Hippo and its Subsidiaries have otherwise complied fully with the terms and conditions of all such policies and
bonds. Such policies of insurance and bonds are in full force and effect. Hippo does not know of any threatened termination of, premium increase with respect to, or alteration of coverage under, any of such policies or bonds. After the Effective
Time, Hippo shall continue to have coverage under such policies and bonds with respect to events occurring prior to the Effective Time. 
  

 65 

 Section 7.22. Intercompany Transactions. Except as otherwise provided in this Agreement,
since the HippoRx Balance Sheet Date there has not been any transaction between Hippo and its Subsidiaries (other than the Hippo Institutional Pharmacy Business), on the one hand, and the Hippo Institutional Pharmacy Business, on the other hand,
other than in the ordinary course of business consistent with past practice. 
 Section 7.23. Sufficiency of Transferred Assets.
Subject to Section 2.03, as of the Effective Time, no HippoRx Assets will be owned or held by Hippo or any of its Subsidiaries (other than the HippoRx Entities). As of the Effective Time, assuming the consummation of the transactions
contemplated by Article 2 and Article 3 and the availability of any assets and services contemplated to be made available to Newco and its Subsidiaries (including the HippoRx Entities) pursuant to the terms of the Transaction Agreements, the HippoRx
Assets will be sufficient to conduct the Hippo Institutional Pharmacy Business as currently conducted. 
 Section 7.24. Tax
Treatment. Neither Hippo nor any of its Affiliates has taken or agreed to take any action, or has knowledge of any fact or circumstance, that would (i) prevent the HippoRx Distribution from qualifying as a transaction described in
Section 355(a) of the Code, (ii) cause Section 355(e) of the Code to apply to the HippoRx Distribution or the RhinoRx Distribution as a result of the HippoRx Merger or the RhinoRx Merger, (iii) otherwise cause the HippoRx Common
Stock to fail to be treated as “qualified property” for purposes of Section 355(c)(2) or Section 361(c)(2) of the Code, or (iv) prevent the HippoRx Merger or the RhinoRx Merger from qualifying as exchanges described in
Section 351 of the Code. 
 Section 7.25. Opinion of Financial Advisor. The board of directors of Hippo has received a
written opinion of Deutsche Bank Securities Inc. to the effect that, as of the date of such opinion and based upon and subject to the assumptions, qualifications and limitations set forth therein, the HippoRx Exchange Ratio is fair, from a financial
point of view, to the holders of Hippo Common Stock that receive shares of HippoRx Common Stock in the HippoRx Distribution pursuant to this Agreement. 
 Section 7.26. Lexicon Pharmacy Services. The HippoRx Group has no Liabilities relating to Lexicon Pharmacy Services, LLC, a Delaware limited liability company (“Lexicon”) or any investment
in Lexicon. Lexicon conducts no business or operations. 
 ARTICLE 8 
 REPRESENTATIONS AND WARRANTIES OF RHINO 
 Except as set forth in the Rhino Disclosure Schedule, Rhino represents and warrants to Newco and Hippo that: 
  

 66 

 Section 8.01. Corporate Existence and Power. Each of Rhino and its Subsidiaries that is or
will be party to a Transaction Agreement is a corporation or other entity duly organized or formed, validly existing and in good standing under the laws of the state of its organization or formation and has all corporate or other powers and all
governmental licenses, authorizations, permits, consents and approvals required to carry on its business as now conducted. Each of Rhino and its Subsidiaries that is or will be party to a Transaction Agreement is duly qualified to do business as a
foreign corporation or other entity and is in good standing in each jurisdiction where such qualification is necessary. Rhino has heretofore delivered or made available to Hippo true and complete copies of the certificate of incorporation and bylaws
or other organizational documents of Rhino and each of its Subsidiaries that is or will be party to a Transaction Agreement, as currently in effect. 
 Section 8.02. Corporate Authorization.  
 (a) The execution, delivery and performance by Rhino
and its Subsidiaries of the Transaction Agreements to which they are or will be party, and the consummation by Rhino and its Subsidiaries of the transactions contemplated thereby are within Rhino’s and its applicable Subsidiaries’
corporate or other powers and have been duly authorized by all necessary corporate or other action on the part of Rhino and such Subsidiaries of Rhino. Each Transaction Agreement to which Rhino or any of its Subsidiaries is or will be a party
constitutes, or will when executed constitute, a valid and binding agreement of Rhino and each such Subsidiary that is a party thereto, enforceable against Rhino and each such Subsidiary in accordance with its terms, except (i) as the same may
be limited by applicable bankruptcy, insolvency, moratorium or similar laws of general application relating to or affecting creditors’ rights and (ii) for the limitations imposed by general principles of equity. 
 (b) At meetings duly called and held, each of Rhino’s and Rhino Parent Sub’s Boards of Directors has (i) unanimously determined that this
Agreement and the transactions contemplated hereby are fair to and in the best interests of Rhino’s stockholders, (ii) unanimously approved and adopted this Agreement and the transactions contemplated hereby and (iii) unanimously
determined that if the Effective Time occurred on the date hereof, then the conditions set forth in Sections 13.01(j)(ii) and 13.01(j)(iii) would be satisfied. No vote of the holders of any outstanding capital stock of Rhino or Rhino Parent Sub is
necessary in connection with the consummation of the transactions contemplated by the Transaction Agreements. 
 (c) At a meeting duly called
and held, RhinoRx’s Board of Directors has (i) unanimously determined that this Agreement (including the RhinoRx Merger) and the transactions contemplated hereby are advisable and fair to and in the best interests of the stockholder of
RhinoRx, (ii) unanimously approved and adopted this Agreement (including the RhinoRx Merger) and the transactions contemplated hereby, (iii) unanimously resolved to recommend approval and 

  

 67 

 
adoption of this Agreement (including the RhinoRx Merger) by the sole stockholder of RhinoRx and (iv) unanimously determined that if the Effective Time
occurred on the date hereof, then the conditions set forth in Section 13.01(j)(i) would be satisfied. Rhino Parent Sub, as sole stockholder of RhinoRx as of the date hereof, has adopted this Agreement and the transactions contemplated hereby,
including the RhinoRx Merger, at a duly called stockholders meeting of RhinoRx (and not by action by written consent in lieu of a meeting). 
 Section 8.03. Governmental Authorization. The execution, delivery and performance by Rhino and its Subsidiaries of the Transaction Agreements to which they are or will be party and the consummation by Rhino and such Subsidiaries
of the transactions contemplated thereby require no action by or in respect of, or filing with, any Governmental Authority other than (i) the filing of a certificate of merger with respect to the RhinoRx Merger with the Delaware Secretary of
State and appropriate documents with the relevant authorities of other states in which the Company is qualified to do business, (ii) compliance with any applicable requirements of the HSR Act, (iii) compliance with any applicable
requirements of the 1933 Act, the 1934 Act, and any other applicable U.S. state or federal securities laws, (iv) compliance with any applicable requirements of any relevant state Boards of Pharmacy or other federal or state licensing authority,
the U.S. Drug Enforcement Agency, the Medicare program or any relevant state Medicaid program and (v) any actions or filings the absence of which would not be reasonably expected to have, individually or in the aggregate, an adverse effect on
RhinoRx or to impair the ability of Rhino and its applicable Subsidiaries to consummate the transactions contemplated by the Transaction Agreements. 
 Section 8.04. Non-contravention. The execution, delivery and performance by Rhino and its Subsidiaries of the Transaction Agreements to which they are or will be party and the consummation of the
transactions contemplated thereby do not and will not (i) contravene, conflict with, or result in any violation or breach of any provision of the certificate of incorporation, bylaws or other organizational documents of Rhino or any such
Subsidiary, (ii) assuming compliance with the matters referred to in Section 8.03, contravene, conflict with or result in a violation or breach of any provision of any Applicable Law, (iii) assuming compliance with the matters
referred to in Section 8.03, require any consent or other action by any Person under, constitute a default, or an event that, with or without notice or lapse of time or both, would constitute a default, under, or cause or permit the
termination, cancellation, acceleration or other change of any right or obligation or the loss of any benefit to which Rhino or any of its Subsidiaries is entitled under any provision of any agreement or other instrument binding upon Rhino or any of
its Subsidiaries or any license, franchise, permit, certificate, approval or other similar authorization affecting, or relating in any way to, the assets or business of Rhino or any of its Subsidiaries or (iv) result in the creation or
imposition of any Lien on any asset of Rhino or any of its 

  

 68 

 
Subsidiaries, with such exceptions, in the case of each of clauses (ii) through (iv), as would not be reasonably expected to have, individually or in
the aggregate, an adverse effect on RhinoRx or prohibit or impair or delay the ability of Rhino or any of its Subsidiaries to consummate the transactions contemplated by any of the Transaction Agreements. 
 Section 8.05. Capitalization.  
 (a) The authorized capital stock of Rhino consists of (i) 175,000,000 shares of Common Stock and (ii) 1,000,000 shares of Preferred Stock. As of September 30, 2006, there were outstanding (i) 39,889,549 shares of Rhino
Common Stock, of which 807,986 were shares of Rhino Restricted Stock, (ii) employee stock options to purchase an aggregate of 3,162,952 shares of Rhino Common Stock (of which options to purchase an aggregate of 2,370,714 shares of Rhino Common
Stock were exercisable) and (iii) no shares of Preferred Stock. All outstanding shares of capital stock of Rhino have been, and all shares that may be issued pursuant to any compensatory plan or arrangement will be, when issued in accordance
with the respective terms thereof, duly authorized and validly issued and are fully paid and nonassessable. No Subsidiary of Rhino owns any shares of capital stock of Rhino. Section 8.05(a) of the Rhino Disclosure Schedule contains a complete
and correct list as of October 20, 2006 of (x) each outstanding Rhino Stock Option held by a Transferring Rhino Employee, including, as applicable, the holder, date of grant, exercise price, vesting schedule and number of shares of Rhino
Common Stock subject thereto and (y) each outstanding share of Rhino Restricted Stock including the holder, date of issuance and vesting schedule. 
 (b) Except as set forth in this Section 8.05 and for changes since September 30, 2006 resulting from the exercise of employee stock options outstanding on such date, there are no outstanding (i) shares
of capital stock or voting securities of Rhino, (ii) securities of Rhino convertible into or exchangeable for shares of capital stock or voting securities of Rhino or (iii) options or other rights to acquire from Rhino, or other obligation
of Rhino to issue, any capital stock, voting securities or securities convertible into or exchangeable for capital stock or voting securities of Rhino (the items in clauses (i), (ii), and (iii) being referred to collectively as the
“Rhino Securities”). There are no outstanding obligations of Rhino or any of its Subsidiaries to repurchase, redeem or otherwise acquire any of the Rhino Securities. 
 Section 8.06. RhinoRx Entities.  
 (a) Each RhinoRx Entity is a corporation or other entity duly organized or formed, validly existing and in good standing under the laws of its jurisdiction of organization or formation, has all corporate or other powers and all governmental
licenses, authorizations, permits, consents and approvals required to carry on its business as now conducted. Each RhinoRx Entity is duly qualified to do business as a foreign corporation or other entity and is in good standing in each 

  

 69 

 
jurisdiction where such qualification is necessary. All RhinoRx Entities, the owners of its capital stock (to the extent a less than wholly owned RhinoRx
Subsidiary) and their respective jurisdictions of organization or formation are identified in Section 8.06(a) of the Rhino Disclosure Schedule. Rhino beneficially owns no interests in any Person engaged in the Rhino Institutional Pharmacy
Business other than the RhinoRx Entities. To the knowledge of Rhino, no RhinoRx Entity is engaged in any business other than the Rhino Institutional Pharmacy Business or has any Liabilities relating to any other business. 
 (b) All of the outstanding capital stock of, or other voting securities or ownership interests in, RhinoRx will be (as of immediately prior to the
RhinoRx Distribution) directly owned by Rhino free and clear of any Lien and free of any other limitation or restriction (including any restriction on the right to vote, sell or otherwise dispose of such capital stock or other voting securities or
ownership interests). All of the outstanding capital stock of, or other voting securities or ownership interests in, each RhinoRx Entity (other than RhinoRx), will be (as of immediately prior to the RhinoRx Distribution ) directly or indirectly
owned by RhinoRx free and clear of any Lien and free of any other limitation or restriction (including any restriction on the right to vote, sell or otherwise dispose of such capital stock or other voting securities or ownership interests). There
are no outstanding (i) securities of Rhino or any of its Subsidiaries convertible into or exchangeable for shares of capital stock or other voting securities or ownership interests in any RhinoRx Entity or (ii) options or other rights to
acquire from Rhino or any of its Subsidiaries, or other obligation of Rhino or any of its Subsidiaries to issue, any capital stock or other voting securities or ownership interests in, or any securities convertible into or exchangeable for any
capital stock or other voting securities or ownership interests in, any RhinoRx Entity (the items in clauses (i) and (ii) being referred to collectively as the “RhinoRx Securities”). There are no outstanding obligations of
Rhino or any of its Subsidiaries to repurchase, redeem or otherwise acquire any of the RhinoRx Securities. 
 (c) After giving effect to the
RhinoRx Distribution, neither Rhino nor any of its Subsidiaries will own any shares of RhinoRx Common Stock or any other capital stock or other equity interest in any RhinoRx Entity. 
 Section 8.07. SEC Filings and the Sarbanes-Oxley Act.  
 (a) Rhino has delivered or made available to Hippo (i) Rhino’s annual reports on Form 10-K for its fiscal years ended December 31, 2005, 2004 and 2003, (ii) its quarterly reports on Form 10-Q for
its fiscal quarters ended March 31, 2006 and June 30, 2006, (iii) its proxy or information statements relating to meetings of, or actions taken without a meeting by, the stockholders of Rhino held since December 31, 2005, and
(iv) all of its other reports, statements, schedules and registration statements filed with the SEC since December 31, 2005 (the documents referred to in this Section 8.07(a), collectively, the “Rhino SEC Documents”).

  

 70 

 (b) As of its filing date, each Rhino SEC Document complied, and each such Rhino SEC Document filed
subsequent to the date hereof will comply, as to form in all respects with the applicable requirements of the 1933 Act and the 1934 Act, as the case may be. 
 (c) As of its filing date (or, if amended or superseded by a filing prior to the date hereof, on the date of such filing), each Rhino SEC Document filed pursuant to the 1934 Act did not, and each such Rhino SEC
Document filed subsequent to the date hereof will not, contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were
made, not misleading. 
 (d) Each Rhino SEC Document that is a registration statement, as amended or supplemented, if applicable, filed
pursuant to the 1933 Act, as of the date such registration statement or amendment became effective, did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the
statements therein not misleading. 
 (e) Rhino has established and maintains disclosure controls and procedures (as defined in Rule 13a-15
under the 1934 Act). Such disclosure controls and procedures are designed to ensure that material information relating to Rhino, including its consolidated Subsidiaries, is made known to Rhino’s principal executive officer and its principal
financial officer by others within those entities, particularly during the periods in which the periodic reports required under the 1934 Act are being prepared. Such disclosure controls and procedures are effective in timely alerting Rhino’s
principal executive officer and principal financial officer to material information required to be included in Rhino’s periodic reports required under the 1934 Act. 
 (f) Rhino and its Subsidiaries have established and maintain a system of internal controls. Such internal controls are sufficient to provide reasonable assurance regarding the reliability of Rhino’s financial
reporting and the preparation of Rhino’s financial statements for external purposes in accordance with GAAP. Rhino has disclosed, based on its most recent evaluation of internal controls prior to the date hereof, to Rhino’s auditors and
audit committee (x) any significant deficiencies and material weaknesses in the design or operation of internal controls which are reasonably likely to adversely affect Rhino’s ability to record, process, summarize and report financial
information and (y) any fraud, whether or not material, that involves management or other employees who have a significant role in internal controls. Rhino has made available to Hippo a summary of any such disclosure made by management to
Rhino’s auditors and audit committee since December 31, 2004. 
 (g) There are no outstanding loans or other extensions of credit
made by Rhino or any of its Subsidiaries to any executive officer (as defined in Rule 3b-7 under the 1934 Act) or director of Rhino. Rhino has not, since the enactment of 

  

 71 

 
the Sarbanes-Oxley Act, taken any action prohibited by Section 402 of the Sarbanes-Oxley Act. 
 (h) The financial statements included in the Rhino SEC Documents fairly present, in conformity with GAAP applied on a consistent basis (except as may be
indicated in the notes thereto), the consolidated financial position of Rhino and its Subsidiaries as of the dates specified therein and the consolidated results of operations and cash flows of Rhino and its Subsidiaries for the periods specified
therein (subject to normal and immaterial year-end adjustments in the case of unaudited financial statements). 
 Section 8.08.
Financial Statements.  
 (a) The audited balance sheets as of December 31, 2006 and 2005 and the related audited statements of
income and cash flows for each of the years ended December 31, 2006, 2005 and 2004 for the Rhino Institutional Pharmacy Business that will be provided pursuant to Section 10.05, and all the audited and unaudited financial statements of the
Rhino Institutional Pharmacy Business included in the Registration Statement, will fairly present, in conformity with GAAP applied on a consistent basis (except as may be indicated in the notes thereto), the financial position of the Rhino
Institutional Pharmacy Business as of the dates thereof and its results of operations and cash flows for the periods then ended (subject to normal and immaterial year-end adjustments in the case of any unaudited interim financial statements included
in the Registration Statement). 
 (b) The RhinoRx Audited EBITDA will be not less than 87.5% of the RhinoRx Estimated EBITDA. 
 (c) The unaudited balance sheet and statement of income as of and for the period ended September 30, 2006 attached as Exhibit R hereto (i) are
derived from and are consistent with the books and records of RhinoRx and its Subsidiaries, (ii) are the financial statements of the Rhino Institutional Pharmacy Business as of and for such period that were made available to and used by the
management of Rhino and RhinoRx and (iii) will be included in the consolidated financial statements of Rhino as of and for the period ended September 30, 2006 as contained in Rhino’s Quarterly Report on Form 10-Q as of and for such
period to be filed with the SEC. 
 Section 8.09. Information Supplied. The information (including all financial data) supplied
by Rhino for inclusion or incorporation in the Registration Statement and any amendments or supplements thereto and, to the knowledge of Rhino, all information related to Newco contained therein shall not at the time the Registration Statement is
declared effective by the SEC or at the Effective Time contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. 
  

 72 

 Section 8.10. Absence of Certain Changes. (a) From the RhinoRx Balance Sheet Date until
the date of this Agreement, except as expressly contemplated by the Transaction Agreements, the Rhino Institutional Pharmacy Business has been conducted in the ordinary course consistent with past practices and there has not been: 
 (i) any amendment of the articles of incorporation, bylaws or other similar organizational documents (whether by merger, consolidation or
otherwise) of any of the RhinoRx Entities; 
 (ii) any splitting, combination or reclassification of any shares of capital
stock of any of the RhinoRx Entities or declaration, setting aside or payment of any dividend or other distribution (whether in cash, stock or property or any combination thereof) in respect of the capital stock any of the RhinoRx Entities, or
redemption, repurchase or other acquisition or offer to redeem, repurchase, or otherwise acquire any RhinoRx Securities; 
 (iii)(A) any issuance, delivery or sale, or authorization of the issuance, delivery or sale of, any shares of any RhinoRx Securities or (B) amendment of any term of any RhinoRx Security (in each case, whether by merger, consolidation
or otherwise); 
 (iv) any incurrence of any capital expenditures or any obligations or liabilities in respect thereof by the
Rhino Institutional Pharmacy Business, except for any such incurrence in the ordinary course of business consistent with past practice; 
 (v) any acquisition (by merger, consolidation, acquisition of stock or assets or otherwise), directly or indirectly, by the Rhino Institutional Pharmacy Business of any assets, securities, properties, interests or
businesses, other than any such acquisition in the ordinary course of business in a manner that is consistent with past practice; 
 (vi) any sale, lease or other transfer of, or creation or incurrence of any Lien on, any assets, securities, properties, interests or businesses of the Rhino Institutional Pharmacy Business, other than (A) sales of inventory or leases
of property in the ordinary course of business consistent with past practice and (B) sales of assets, securities, properties, interests or businesses with a sale price (including any related assumed indebtedness) that does not exceed $5,000,000
individually or $10,000,000 in the aggregate; 
 (vii) other than in connection with actions identified in
Section 8.10(a)(iv), any making by the Rhino Institutional Pharmacy Business of any loans, advances or capital contributions to, or investments in, any other Person, other than in the ordinary course of business consistent with past practice;

  

 73 

 (viii) any creation, incurrence, assumption or sufferance to exist by the Rhino
Institutional Pharmacy Business of any indebtedness for borrowed money or guarantees thereof; 
 (ix) any damage, destruction
or other casualty loss (whether or not covered by insurance) affecting the Rhino Institutional Pharmacy Business; 
 (x)(A)
any entering into of any agreement or arrangement that limits or otherwise restricts in any respect any RhinoRx Entity or the Rhino Institutional Pharmacy Business or that could, after the Effective Time, limit or restrict in any respect any RhinoRx
Entity, the Rhino Institutional Pharmacy Business, Newco, or any of its Subsidiaries, from engaging or competing in any line of business, in any location or with any Person or (B) any entering into, amendment or modification in any adverse
respect or termination of or any nonrenewal or expiration of any RhinoRx Material Contract or waiver, release or assignment of any material rights, claims or benefits of the Rhino Institutional Pharmacy Business or the RhinoRx Entities; 

(xi)(A) any grant or increase of any severance or termination pay to (or amend any existing arrangement with) any Transferring Rhino
Employee, (B) any increase in benefits payable under any existing severance or termination pay policies or employment agreements of any Transferring Rhino Employee, (C) any entering into of any employment, deferred compensation, retention,
change in control, tax gross-up, special bonus, stay bonus or other similar agreement (or amendment of any such existing agreement) with any Transferring Rhino Employee, (D) any establishment, adoption or amendment (except as required by
Applicable Law) of any collective bargaining, bonus, profit-sharing, thrift, pension, retirement, deferred compensation, compensation, stock option, restricted stock or other benefit plan or arrangement covering any Transferring Rhino Employee or
(E) any increase in compensation, bonus or other benefits payable to any Transferring Rhino Employee, in each case, other than in the ordinary course of business consistent with past practice; 
 (xii) any labor dispute, other than routine individual grievances, or any activity or proceeding by a labor union or representative
thereof to organize any Transferring Rhino Employees, which employees were not subject to a collective bargaining agreement at the RhinoRx Balance Sheet Date, or any lockouts, strikes, slowdowns, work stoppages or threats thereof by or with respect
to such employees; 
 (xiii) any change in Rhino’s or any of its Subsidiaries’ (in each case, to the extent related
to the Rhino Institutional Pharmacy Business) or any RhinoRx Entity’s methods of accounting, except as required by concurrent changes in GAAP; 
  

 74 

 (xiv) any settlement, or offer or proposal to settle, (A) any material litigation,
investigation, arbitration, proceeding or other claim involving or against the Rhino Institutional Pharmacy Business or the RhinoRx Entities, (B) any stockholder litigation or dispute against the Rhino Institutional Pharmacy Business or the
RhinoRx Entities or any of the officers or directors of the RhinoRx Entities or (C) any litigation, arbitration, proceeding or dispute that relates to the transactions contemplated hereby; 
 (xv) any Tax election, any annual tax accounting period changed, any method of tax accounting adopted or changed, any Tax Returns amended
or claims for Tax refunds filed, any closing agreement entered into, any Tax claim, audit or assessment settled, or any right to claim a Tax refund, offset or other reduction in Tax liability surrendered; or 
 (xvi) any adverse regulatory events, developments or changes, including recoupments not in the ordinary course of business, loss of
licensure or failure to renew any permits or licenses. 
 (b) Since the RhinoRx Balance Sheet Date, there has not been any event, occurrence,
development or state of circumstances or facts that has had or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect on RhinoRx. 
 Section 8.11. No Undisclosed Liabilities. There are no known or unknown Liabilities of the RhinoRx Group of any kind whatsoever, whether
accrued, contingent, absolute, determined, determinable or otherwise, and there is no existing condition, situation or set of circumstances that could reasonably be expected to result in such a Liability, other than: 
 (a) Liabilities disclosed and provided for in the RhinoRx Balance Sheet or in the notes thereto, and 
 (b) Liabilities incurred in the ordinary course of business consistent with past practices since the RhinoRx Balance Sheet Date. 
 Section 8.12. Compliance with Laws and Court Orders. 
 (a) Each of Rhino and its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) is, and since January 1, 2003 has been, in compliance with, and to the knowledge of Rhino is not under
investigation by any Governmental Authority with respect to and has not been threatened to be charged with or given notice of any violation of, any Applicable Law. 
 (b) Each of Rhino and its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) has duly obtained all permits, 

  

 75 

 
concessions, grants, franchises, licenses and other governmental authorizations, consents, and approvals, including Medicare and Medicaid billing and
provider numbers (collectively, “RhinoRx Permits”), necessary for the conduct of the Rhino Institutional Pharmacy Business including those relating to Medicare, any relevant state Medicaid program or any other health insurance or
health care benefit program sponsored or financed in whole or in part by any Governmental Authority. Each RhinoRx Permit is in full force and effect and each of Rhino and its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy
Business) is in full compliance with the terms of each RhinoRx Permit. There are no actions, suits, sanctions, investigations or proceedings (or any basis therefor) pending or, to the knowledge of Rhino, threatened which may result in the
revocation, cancellation, suspension or modification of any such RhinoRx Permit. 
 (c) Each Person employed or engaged by each of Rhino and
its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) to provide services on behalf of the Rhino Institutional Pharmacy Business (each, a “RhinoRx Licensed Service Provider”) has obtained and
maintains all necessary licensure or certification to provide such services in compliance with any Applicable Law or the requirements of any Government Medical Reimbursement Program. Each RhinoRx Licensed Service Provider is covered by a
professional liability insurance policy underwritten by a licensed insurance company, with coverage limits and terms that are consistent with industry standards. 
 (d) To the knowledge of Rhino, since January 1, 2003, none of Rhino and its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) nor any of their respective officers, directors,
employees or agents has been investigated or charged by any Governmental Authority in any violation of any laws involving fraudulent or abusive practices relating to its participation in any Government Medical Reimbursement Program or in any health
care benefit program as defined in 18 U.S.C. § 24(b), including fraudulent billing or recordkeeping practices, and no such person has been convicted of, charged with or investigated for a violation of any other federal or state law relating to
fraud, theft, embezzlement, breach of fiduciary responsibility, financial misconduct, obstruction of an investigation or controlled substances. Since January 1, 2003, Rhino and its Subsidiaries (to the extent relating to the Rhino Institutional
Pharmacy Business) have properly and legally billed all individuals, intermediaries and third party payors, as appropriate, for services rendered through the RhinoRx Entities and have maintained all necessary documentation to support and reflect
such billing practices. To the knowledge of Rhino, none of Rhino and its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) nor any of their respective directors, officers, employees, independent contractors or agents
has committed any offense which is reasonably likely to be the basis for suspension, civil monetary penalties, debarment or exclusion of Rhino or any of its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) or any of
their respective directors, officers, 

  

 76 

 
managers, current employees, partners, agents or independent contractors from any Government Medical Reimbursement Program, including, but not limited to,
defrauding a government program, loss of a license to provide health care services or failure to provide quality care. 
 (e) None of Rhino
and its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) nor any of their respective directors, officers, employees, independent contractors or agents have engaged in any activities which may serve as the grounds
for any penalties of any kind under Sections 1128A, 1128B or 1877 of the Social Security Act (42 U.S.C. §§ 1320a-7a, 1320a-7b and 1395nn), the federal False Claims Act (31 U.S.C. § 3729 et seq.), the False Statements Act (18 U.S.C.
§ 1001), the Program Fraud Civil Penalties Act (31 U.S.C. § 3801 et seq.), the Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.) (all as amended or superseded), and the anti-fraud and abuse provisions of the Health Insurance
Portability and Accountability Act of 1996 (18 U.S.C. § 1347, 18 U.S.C. § 669, 18 U.S.C. § 1035, 18 U.S.C. § 1518) and the applicable fraud and abuse, anti-kickback, false claims and anti-self referral statutes and regulations in
each state or other jurisdictions where Rhino and its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) may conduct business or any related regulations or other federal or state laws and regulations. 
 Section 8.13. Litigation. There is no action, suit, investigation or proceeding (or any basis therefor) pending against, or, to the knowledge
of Rhino, threatened against or affecting, Rhino or any of its Subsidiaries or the Rhino Institutional Pharmacy Business, any present or former officer, director or employee of Rhino or any of its Subsidiaries or any Person for whom Rhino or any of
its Subsidiaries may be liable or any of their respective properties before any court or arbitrator or before or by any Governmental Authority, (i) that could reasonably be expected to have an adverse effect on Rhino Institutional Pharmacy
Business or (ii) that, as of the date hereof, in any manner challenges or seeks to prevent, enjoin, alter or delay the transactions contemplated by the Transaction Agreements. For the avoidance of doubt, clause (ii) of the preceding
sentence contains the only representation or warranty in this Article 8 regarding legal challenges to the transactions contemplated by the Transaction Agreements. 
 Section 8.14. Finders’ Fees. Except for Lehman Brothers Inc., (all of whose fees and expenses shall be paid by Rhino and the obligations to which shall be Non-RhinoRx Liabilities), there is no
investment banker, broker, finder or other intermediary that has been retained by or is authorized to act on behalf of the Rhino or any of its Affiliates who might be entitled to any fee or commission from Rhino or any of its Affiliates in
connection with the transactions contemplated by the Transaction Agreements. 
  

 77 

 Section 8.15. Taxes.  
 (a) All Tax Returns required by Applicable Law to be filed with any Taxing Authority by, or on behalf of, any RhinoRx Entity have been filed when due in
accordance with all Applicable Law, and all such Tax Returns are true and complete in all respects. 
 (b) Each RhinoRx Entity has paid (or
has had paid on its behalf) or has withheld and remitted to the appropriate Taxing Authority all Taxes due and payable, or, where payment is not yet due, has established (or has had established on its behalf and for its sole benefit and recourse) in
accordance with GAAP an adequate accrual for all Taxes through the end of the last period for which the RhinoRx Entities ordinarily record items on their respective books. 
 (c) The income and franchise Tax Returns of the RhinoRx Entities through the Tax year ended December 31, 1999 have been examined and closed or are
Tax Returns with respect to which the applicable period for assessment under Applicable Law, after giving effect to extensions or waivers, has expired. 
 (d) There is no claim, audit, action, suit, proceeding or investigation now pending or, to Rhino’s knowledge, threatened against or with respect to the RhinoRx Entities in respect of any Tax or Tax asset.

 (e) No RhinoRx Entity has since January 1, 2003 been a member of an affiliated, consolidated, combined or unitary group other than
one of which Rhino was the common parent. 
 (f) Section 8.15(f) of the Rhino Disclosure Schedule contains a list of all jurisdictions
(whether foreign or domestic) in which any RhinoRx Entity currently files Tax Returns. 
 Section 8.16. Employee Benefit Plans;
Employees.  
 (a) Section 8.16(a) of the Rhino Disclosure Schedule contains a correct and complete list identifying each Rhino
Benefit Plan that covers any Transferring Rhino Employee and each RhinoRx Benefit Plan (collectively, the “Rhino Plans”). Copies of such plans (and, if applicable, related trust or funding agreements or insurance policies) and all
amendments thereto and written interpretations thereof have been made available to Hippo together with the most recent annual report (Form 5500 including, if applicable, Schedule B thereto) and tax return (Form 990) prepared in connection with any
such plan or trust. No Rhino Plan is subject to Title IV of ERISA. 
 (b) None of the RhinoRx Entities contributes to or is obligated to
contribute to, or has any Liability with respect to, any Multiemployer Plan. 
  

 78 

 (c) Each Rhino Plan that is intended to be qualified under Section 401(a) of the Code has received a
favorable determination letter, or has pending an application for such determination from the Internal Revenue Service, and Rhino is not aware of any reason why any such determination letter should be revoked or not be reissued. Rhino has made
available to Hippo copies of the most recent Internal Revenue Service determination letters with respect to each such Rhino Plan. Each Rhino Plan has been maintained in compliance with its terms and with the requirements prescribed by any and all
statutes, orders, rules and regulations, including ERISA and the Code, which are applicable to such Rhino Plan. No events have occurred or are reasonably expected to occur with respect to any Rhino Plan that could result in payment or assessment by
or against Rhino or any RhinoRx Entity of any excise taxes under the Code. 
 (d) No condition exists that would subject any RhinoRx Entity,
either directly or by reason of its affiliation with any ERISA Affiliate, to any tax (including any excise tax), fine, lien, penalty or other similar Liability imposed by ERISA, the Code or other Applicable Laws. 
 (e) Neither Rhino nor any of its Subsidiaries has any current or projected Liability in respect of post-employment or post-retirement health or medical
or life insurance benefits for Transferring Rhino Employees, except as required to avoid excise tax under Section 4980B of the Code. 
 (f) The consummation of the transactions contemplated by this Agreement will not (either alone or together with any other event) entitle any Transferring Rhino Employee to any bonus, severance, retirement, job security or other benefit, or
accelerate the time of payment or vesting or trigger any payment of funding (through a grantor trust or otherwise) of compensation or benefits under, increase the amount payable or trigger any other obligation pursuant to, any Rhino Plan. Neither
the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby, either alone or in combination with any other event (whether contingent or otherwise), will result in any excise tax under Section 4999
of the Code or non-deductibility of any compensation or benefit under Section 280G of the Code with respect to Transferring Rhino Employees. 
 (g) There is no action, suit, investigation, audit or proceeding pending against or involving or, to the knowledge of Rhino, threatened against or involving any Rhino Plan before any arbitrator or any Governmental Authority. 
 (h) Neither Rhino nor any of its Subsidiaries is a party to or subject to, or is currently negotiating in connection with entering into, any collective
bargaining agreement or other contract or understanding with a labor union or organization with respect to a Transferring Rhino Employee. 
 (i)(i) There is no pending, or to Rhino’s knowledge threatened, labor strike or dispute, walkout, work stoppage, slow down or lockout involving 

  

 79 

 
Transferring Rhino Employees; and (ii) Rhino and its Subsidiaries are in compliance with all Laws governing the employment of Transferring Rhino
Employees, including, but not limited to, all such Laws relating to wages, overtime wages, hours, collective bargaining, discrimination, retaliation, civil rights, safety and health, workers’ compensation and the collection and payment of
withholding and/or social security Taxes and similar Taxes. 
 (j) Substantially all of the pharmacists and pharmacy technicians staffing the
Rhino Institutional Pharmacy Business are (i) legally employed by a RhinoRx Entity and (ii) not considered leased employees, agency employees, temporary employees or independent contractors under applicable Law. 
 Section 8.17. Environmental Matters.  
 (a) No notice, notification, demand, request for information, citation, summons or order has been received, no complaint has been filed, no penalty has been assessed, and no investigation, action, claim, suit, proceeding or review (or any
basis therefor) is pending or, to the knowledge of Rhino, is threatened by any Governmental Authority or other Person relating to the RhinoRx Group and relating to or arising out of any Environmental Law. 
 (b) Each of the RhinoRx Group is and has been in compliance with all Environmental Laws and all Environmental Permits. 
 (c) There are no Liabilities of the RhinoRx Group of any kind whatsoever, whether accrued, contingent, absolute, determined, determinable or otherwise
arising under or relating to any Environmental Law or any Hazardous Substance and there is no condition, situation or set of circumstances that could reasonably be expected to result in or be the basis for any such Liability. 
 (d) There have been no environmental investigations, studies, audits, tests, reviews or other analyses conducted of which Rhino has knowledge in relation
to the current or prior business the RhinoRx Group or any property or facility now or previously owned or leased by the RhinoRx Group that reveal matters that, individually or in the aggregate, have had or could reasonably be expected to have, an
adverse effect on the Rhino Institutional Pharmacy Business. 
 (e) The execution of the transactions contemplated hereby require no filings
to be made or actions to be taken pursuant to the New Jersey Industrial Site Recovery Act or the “Connecticut Property Transfer Law” (Sections 22a-134 through 22-134e of the Connecticut General Statutes). 
 Section 8.18. Property Matters.  
 (a) Section 8.18(a) of the Rhino Disclosure Schedule sets forth a complete and accurate list as of the date of this Agreement of all real property leased, subleased or licensed by Rhino and its Subsidiaries (to the extent relating

  

 80 

 
to the Rhino Institutional Pharmacy Business) (collectively, the “RhinoRx Leases”), including, with respect to each location, a description
of (i) the location of the premises (the “RhinoRx Leased Premises”), (ii) the landlord, (iii) the date of the lease and (iv) the dates of any extensions, amendments, supplements and other modifications thereof.
All RhinoRx Leases are valid and in full force and effect. Neither Rhino nor any of its Subsidiaries nor, to the knowledge of Rhino, any other party to any RhinoRx Lease has (i) violated any provisions of, or committed or failed to perform any
act that, with or without notice, lapse of time or both, would constitute a default under the provisions of any RhinoRx Lease, (ii) received notice of the events in clause (i), or (iii) received notice of termination, cancellation or
non-renewal of any such RhinoRx Lease. Rhino has made available to Hippo true and complete copies of all the RhinoRx Leases, all modifications or amendments thereto or waivers thereunder and all subordination and non-disturbance agreements relating
thereto. 
 (b) Section 8.18(b) of the Rhino Disclosure Schedule sets forth a complete and accurate list as of the date of this
Agreement of all real property owned by Rhino and its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) (collectively, the “RhinoRx Owned Properties”). With respect to any RhinoRx Owned Property,
Rhino has provided to Hippo true and correct copies of the most recent title insurance policies and surveys with respect thereto. The RhinoRx Owned Properties and the RhinoRx Leased Premises constitute all of the real property used or occupied by
Rhino and its Subsidiaries in connection with the Rhino Institutional Pharmacy Business. Each entity listed on Section 8.18(b) of the Rhino Disclosure Schedule as owning a RhinoRx Owned Property has good fee simple title to such RhinoRx Owned
Property, subject to no Liens other than Liens listed on Section 8.18(b) of the Rhino Disclosure Schedule, and none of the structures on a Rhino Owned Property encroaches upon real property of another Person, and no structure of any other
Person encroaches upon any RhinoRx Owned Property. 
 (c) There does not exist any pending condemnation or eminent domain proceedings that
affect any RhinoRx Owned Property, or to the knowledge of Rhino, any such proceedings that affect any RhinoRx Leased Premises, or to the knowledge of Rhino, any threatened condemnation or any eminent domain proceedings that affect any RhinoRx Owned
Property or RhinoRx Leased Premises, and neither Rhino nor its Subsidiaries have received any written notice of the intention of any Governmental Authority or other Person to take or use any RhinoRx Owned Property or RhinoRx Leased Premises.

 (d) Other than the RhinoRx Leases and any superior leases under which RhinoRx Leases that are subleases are created, to the knowledge of
Rhino, none of the RhinoRx Owned Property or the RhinoRx Leased Premises are subject to any lease, sublease, license or other agreement granting to any Person other than a RhinoRx Entity any right to the use, occupancy or enjoyment of such RhinoRx
Owned Property or RhinoRx Leased Premises or any part thereof. 
  

 81 

 Section 8.19. Intellectual Property.  
 (a) As of the Distribution Time, subject to the provisions of Article 3, the RhinoRx Entities will own or otherwise have the right to use all Intellectual
Property necessary to conduct the Rhino Institutional Pharmacy Business as currently conducted (the “RhinoRx Intellectual Property”). There exist no restrictions on the disclosure, use, license or transfer of the RhinoRx
Intellectual Property owned by Rhino and its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) (the “Owned RhinoRx Intellectual Property”). 
 (b) The execution and delivery of this Agreement by Rhino and RhinoRx and the consummation of the Transactions will not encumber, impair or extinguish
any RhinoRx Intellectual Property. Section 8.19(b) of the Rhino Disclosure Schedule sets forth a complete and accurate list of all (i) registrations or applications for registration included in the Owned RhinoRx Intellectual Property (the
“Registered RhinoRx Intellectual Property”) and (ii) all agreements (excluding licenses for commercial off the shelf computer software that are generally available on nondiscriminatory pricing terms which have an aggregate
acquisition cost of $1,000,000 or less) to which Rhino and its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) is a party or otherwise bound and pursuant to which Rhino and its Subsidiaries (to the extent relating
to the Rhino Institutional Pharmacy Business) (A) obtains the right to use or a covenant not to be sued under, any Intellectual Property and/or (B) grants the right to use, or a covenant not to be sued under, any Intellectual Property.

 (c) To the knowledge of Rhino, the conduct of the Rhino Institutional Pharmacy Business as currently conducted does not infringe, violate
or constitute a misappropriation of any Intellectual Property of any Third Party in any respect. Since January 1, 2003, neither Rhino nor any of its Subsidiaries has received any written claim or notice alleging any such infringement,
violation or misappropriation and there is no claim, action, suit, investigation or proceeding pending against, or, to the knowledge of Rhino, threatened against Rhino and its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy
Business) (i) based upon, or challenging or seeking to deny or restrict, the rights of Rhino or its Subsidiaries in any of the RhinoRx Intellectual Property, (ii) alleging that the use of the RhinoRx Intellectual Property or any services
provided, processes used or products manufactured, used, imported, offered for sale or sold by the Rhino Institutional Pharmacy Business do or may conflict with, misappropriate, infringe or otherwise violate any Intellectual Property of any Third
Party or (iii) alleging that Rhino or any of its Subsidiaries have infringed, misappropriated or otherwise violated any Intellectual Property of any Third Party. 
 (d) None of the RhinoRx Intellectual Property used in the operation of the Rhino Institutional Pharmacy Business has been adjudged invalid or unenforceable in whole or part, and, to the knowledge of Rhino, all such
RhinoRx 

  

 82 

 
Intellectual Property is valid and enforceable. To the knowledge of Rhino, no Third Party is infringing, violating or misappropriating any of the RhinoRx
Intellectual Property in any respect. 
 Section 8.20. RhinoRx Material Contracts.  
 (a) Except as set forth on Section 8.20(a) of the Rhino Disclosure Schedule, as of the date hereof, neither Rhino nor any of its Subsidiaries (to the
extent relating to the Rhino Institutional Pharmacy Business) is a party to or otherwise bound by: 
 (i) any “material
contract” (as such term is defined in Item 601(b)(10) of Regulation S-K of the SEC); 
 (ii) any employment or
consulting Contract with any Transferring Rhino Employee providing for base compensation in excess of $175,000, other than those that are terminable by Rhino on no more than thirty (30) days notice without liability or financial obligation to
Rhino; 
 (iii) any Contract containing any covenant (A) limiting the right of Rhino or any of its Subsidiaries (to the
extent relating to the Rhino Institutional Pharmacy Business) to engage in any line of business or compete with any person in any line of business or to compete with any party, (B) granting any exclusive rights to make, sell or distribute the
products or services of Rhino or any of its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) or (C) otherwise prohibiting or limiting the right of Rhino or any of its Subsidiaries (to the extent relating to the
Rhino Institutional Pharmacy Business) to make, sell or distribute any products or services; 
 (iv) any Contract relating to
the disposition or acquisition by Rhino or any of its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) of an amount of assets or of any business (whether by merger, sale of stock, sale of assets or otherwise) with a
value in excess of $5,000,000 or pursuant to which Rhino (to the extent relating to the Rhino Institutional Pharmacy Business) has any ownership interest with a value in excess of $5,000,000 in any other person or other business enterprise other
than any other RhinoRx Entity; 
 (v) any Contract to provide source code to any Third Party for any product, service or
technology that is used by Rhino or any of its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) that either has required or is anticipated to require payment by any Person in excess of $1,000,000 in the aggregate or
is reasonably necessary to support operations that generate in excess of $10,000,000 in annual revenue; 
  

 83 

 (vi) any Contract to license any Third Party to manufacture or reproduce any of
Rhino’s or any of its Subsidiaries’ (to the extent relating to the Rhino Institutional Pharmacy Business) products, services or technology or any Contract to sell or distribute any of Rhino’s or any of its Subsidiaries’ (to the
extent relating to the Rhino Institutional Pharmacy Business) products, services or technology, except (A) agreements with distributors, sales representatives or other resellers entered into in the ordinary course of business and
(B) agreements allowing internal backup copies made or to be made by end-user customers in the ordinary course of business; 
 (vii) any mortgages, indentures, guarantees, loans or credit agreements, security agreements or other Contracts relating to the borrowing of money or extension of credit, of Rhino or any of its Subsidiaries (to the extent relating to the
Rhino Institutional Pharmacy Business), in each case other than accounts receivables and payables in the ordinary course of business; 
 (viii) any Contract under which Rhino or any of its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) has licensed its Intellectual Property to a Third Party, other than to customers,
distributors and other resellers in the ordinary course of business; 
 (ix) any Contract under which Rhino or any of its
Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) has received a license to any Intellectual Property owned by a Third Party that is used in the Rhino Institutional Pharmacy Business that either has required or is
anticipated to require payment by any Person in excess of $5,000,000 in the aggregate or is reasonably necessary to support operations that generate in excess of $10,000,000 in annual revenue; 
 (x) any Contract, or group of Contracts in which the counterparties are within the same consolidated group, providing for the sale by
Rhino or any of its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) of materials, supplies, goods, services, equipment or other assets that provides for either (A) annual payments to Rhino or any of its
Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) of $2,000,000 or more or (B) aggregate payments to Rhino or any of its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) of
$20,000,000 or more; 
 (xi) any Contract (other than Contracts for the purchase of pharmaceutical products) providing for the
purchase by Rhino or any of its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) of materials, supplies, goods, services, equipment or other assets that provides for either (A) annual payments by Rhino or any
of its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy 

  

 84 

 
Business) of $5,000,000 or more or (B) aggregate payments by Rhino or any of its Subsidiaries (to the extent relating to the Rhino Institutional
Pharmacy Business) of $20,000,000 or more; 
 (xii) any Contract relating to the leasing of personal property by Rhino or any
of its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) providing for annual rentals of $5,000,000 or more; 
 (xiii) any Contract relating to a partnership, joint venture or other similar arrangement; 
 (xiv) any Contract relating to agency, dealer, sales representative, marketing or similar arrangements providing for annual payments of $1,000,000 or more; 
 (xv) any Contract relating to administrative services, management services or professional services with physicians or pharmacists that
has required or is anticipated to require payment by any Person in excess of $250,000 in the aggregate; 
 (xvi) any Contract
with any pharmacy benefits manager, group purchasing organization or Third Party payer of health insurance benefits that has required or is anticipated to require payment by any Person in excess of $5,000,000 in the aggregate; or 
 (xvii) any Contract with Rhino or any of its Subsidiaries or Affiliates (other than any RhinoRx Entity), except any RhinoRx Lease.

 (b) The Contracts disclosed or required to be disclosed on Section 8.20(a) of the Rhino Disclosure Schedule are referred to herein as
the “RhinoRx Material Contracts”. A true and complete copy of each RhinoRx Material Contract (including any modifications and amendments thereto or waivers thereunder) has been made available to Hippo. 
 (c) All RhinoRx Material Contracts are valid and in full force and effect. To the knowledge of Rhino, none of the terms or conditions in the RhinoRx
Material Contracts may serve as the ground for any penalties of any kind under the Social Security Act, the federal False Claims Act (31 U.S.C. § 3729 et seq.), the False Statements Act (18 U.S.C. § 1001), the Program Fraud Civil Penalties
Act (31 U.S.C. § 3801 et seq.), the Food, Drug and Cosmetic Act (21 U.S.C. § 301 et seq.) (all as amended or superseded), and the anti-fraud and abuse provisions of the Health Insurance Portability and Accountability Act of 1996 (18 U.S.C.
§ 1347, 18 U.S.C. § 669, 18 U.S.C. § 1035, 18 U.S.C. § 1518), or comparable laws enacted by each state or jurisdiction in which Rhino may conduct business. Neither Rhino nor any of its Subsidiaries, and, to the knowledge of
Rhino, no Third Party to any such Contract, has (i) violated any 

  

 85 

 
provision of, or committed or failed to perform any act that, with or without notice, lapse of time or both, would constitute a default under the provisions
of any RhinoRx Material Contract, (ii) received notice of any of the events set forth in clause (i) or (iii) received notice of termination, cancellation or non-renewal of any such Contract. Substantially all of the Contracts pursuant
to which a RhinoRx Entity provides pharmacy services are in writing. 
 (d) To the extent necessary to operate the Rhino Institutional
Pharmacy Business as it is now being conducted, Rhino and its Subsidiaries (to the extent relating to the Rhino Institutional Pharmacy Business) have current provider agreements with Prescription Drug Plans, Medicare and Medicaid and private
non-governmental programs, including with any private insurance program under which they, directly or indirectly, are presently receiving payments. 
 (e) With respect to any of the RhinoRx Material Contracts applicable to the provision of pharmacy services by the Rhino Institutional Pharmacy Business to facilities owned, operated, managed or leased by or otherwise affiliated with Rhino
or any of its Subsidiaries (other than a RhinoRx Entity), the pharmacy services provided by the Rhino Institutional Pharmacy Business, in terms of price, terms and conditions, quality, timeliness and scope, are in accordance with the “prudent
buyer principle” set forth in 42 C.F.R. §413.9 and in Provider Reimbursement Manual §2103 and otherwise with Applicable Law, and the Rhino Institutional Pharmacy Business’ charges for pharmacy services do not exceed those that a
prudent buyer would pay for such services. 
 Section 8.21. Insurance. Rhino has furnished to Hippo a list of, and true and
complete copies of, all insurance policies and fidelity bonds relating to the Rhino Institutional Pharmacy Business and its officers and employees. There is no claim by Rhino or any of its Subsidiaries pending under any of such policies or bonds as
to which coverage has been questioned, denied or disputed by the underwriters of such policies or bonds or in respect of which such underwriters have reserved their rights. All premiums payable under all such policies and bonds have been timely paid
and Rhino and its Subsidiaries have otherwise complied fully with the terms and conditions of all such policies and bonds. Such policies of insurance and bonds are in full force and effect. Rhino does not know of any threatened termination of,
premium increase with respect to, or alteration of coverage under, any of such policies or bonds. After the Effective Time, Rhino shall continue to have coverage under such policies and bonds with respect to events occurring prior to the Effective
Time. 
 Section 8.22. Intercompany Transactions. Except as otherwise provided in this Agreement, since the RhinoRx Balance Sheet
Date there has not been any transaction between Rhino and its Subsidiaries (other than the Rhino Institutional Pharmacy Business), on the one hand, and the Rhino Institutional Pharmacy Business, on the other hand, other than in the ordinary course
of business consistent with past practice. 
  

 86 

 Section 8.23. Sufficiency of Transferred Assets. Subject to Section 3.03, as of the
Effective Time, no RhinoRx Assets will be owned or held by Rhino or any of its Subsidiaries (other than the RhinoRx Entities). As of the Effective Time, assuming the consummation of the transactions contemplated by Article 2 and Article 3 and the
availability of any assets and services contemplated to be made available to Newco and its Subsidiaries (including the RhinoRx Entities) pursuant to the terms of the Transaction Agreements, the RhinoRx Assets will be sufficient to conduct the Rhino
Institutional Pharmacy Business as currently conducted. 
 Section 8.24. Tax Treatment. Neither Rhino nor any of its Affiliates
has taken or agreed to take any action, or has knowledge of any fact or circumstance, that would (i) prevent the RhinoRx Distribution from qualifying as a transaction described in Section 355(a) of the Code, (ii) cause
Section 355(e) of the Code to apply to the HippoRx Distribution or the RhinoRx Distribution as a result of the HippoRx Merger or the RhinoRx Merger, (iii) otherwise cause the RhinoRx Common Stock to fail to be treated as “qualified
property” for purposes of Section 355(c)(2) or Section 361(c)(2) of the Code, or (iv) prevent the HippoRx Merger or the RhinoRx Merger from qualifying as exchanges described in Section 351 of the Code. 
 Section 8.25. Opinion of Financial Advisor. The board of directors of each of Rhino and RhinoRx has received a written opinion of Lehman
Brothers Inc. to the effect that, as of the date of such opinion and based upon and subject to the assumptions, qualifications and limitations set forth therein, the RhinoRx Exchange Ratio is fair, from a financial point of view, to the holders of
Rhino Common Stock that receive shares of RhinoRx Common Stock in the RhinoRx Distribution pursuant to this Agreement. 
 ARTICLE 9

 COVENANTS OF HIPPO 
 Section 9.01. Conduct of Hippo and HippoRx. Except as set forth in Section 9.01 of the Hippo Disclosure Schedule or as expressly
contemplated by the Transaction Agreements, from the date hereof until the Effective Time, Hippo shall (to the extent relating to the HippoRx Group) and shall cause each of the HippoRx Entities (to the extent relating to the HippoRx Group) to,
conduct its business in the ordinary course consistent with past practice and in all material respects for the benefit of the HippoRx Group and use its reasonable best efforts to (i) preserve intact its present business organization,
(ii) maintain in effect all of its foreign, federal, state and local licenses, permits, consents, franchises, approvals and authorizations, (iii) keep available the services of its directors, officers and key employees, subject to
limitations on Hippo’s ability to increase their benefits and compensation under this Agreement, (iv) maintain existing relationships with its customers, lenders, suppliers and others having material 

  

 87 

 
business relationships with it and (v) manage its working capital (including the timing of collection of accounts receivable and of the payment of
accounts payable and the management of inventory) in the ordinary course of business consistent with past practice. Without limiting the generality of the foregoing, prior to the Effective Time, except as set forth in Section 9.01 of the Hippo
Disclosure Schedule or as expressly contemplated by the Transaction Agreements, without the prior written consent of Rhino (such consent not to be unreasonably withheld or delayed), Hippo shall not, nor shall it permit the HippoRx Group or any
HippoRx Entity to: 
 (a) amend its articles of incorporation, bylaws or other similar organizational documents (whether by merger,
consolidation or otherwise) ; provided, however, that Hippo shall be permitted to, and shall permit the Non-HippoRx Group to, make any such amendment insofar as such amendment would not materially impair, impede or delay the transactions
contemplated by this Agreement; 
 (b) split, combine or reclassify any shares of its capital stock or declare, set aside or pay any dividend
or other distribution (whether in cash, stock or property or any combination thereof) in respect of its capital stock, or redeem, repurchase or otherwise acquire, or offer to redeem, repurchase, or otherwise acquire, any HippoRx Securities, except
for (i) regular quarterly cash dividends with customary record and payment dates on the shares of Hippo Common Stock, (ii) repurchases or other acquisitions of any shares of capital stock of Hippo in the ordinary course of business
consistent with past practice or (iii) cash dividends paid to Hippo or its Subsidiaries; provided, however, that Hippo and the Non-HippoRx Group shall be permitted to effect any such split, combination, reclassification, declaration, set
aside, payment, redemption, repurchase or other acquisition or offer so long as it would not materially impair, impede or delay the transactions contemplated by this Agreement; 
 (c)(i) issue, deliver or sell, or authorize the issuance, delivery or sale of, or amend any term of (whether by merger, consolidation or otherwise), any
shares of any Hippo Securities or HippoRx Securities in a manner that would delay or impair any of the transactions contemplated by this Agreement, (ii) issue any Hippo Restricted Stock other than in the ordinary course of business consistent
with past practice or (iii) grant any Hippo Stock Options to any Transferring Hippo Employee; 
 (d) incur any capital expenditures or
any obligations or liabilities in respect thereof, in each case with respect to the HippoRx Group, except for any such incurrence in the ordinary course of business consistent with past practice; 
 (e) acquire (by merger, consolidation, acquisition of stock or assets or otherwise), directly or indirectly, any assets, securities, properties,
interests or businesses, in each case with respect to the HippoRx Group, other than supplies 

  

 88 

 
or leases of property in the ordinary course of business of the HippoRx Group and the HippoRx Entities in a manner that is consistent with past practice;

 (f) sell, lease or otherwise transfer, or create or incur any Lien on, any assets, securities, properties, interests or businesses of the
HippoRx Group, other than sales of inventory or leases of property in the ordinary course of business consistent with past practice; 
 (g)
solely with respect to the HippoRx Group, other than in connection with actions permitted by Section 9.01(d) or Section 9.01(e), make any loans, advances or capital contributions to, or investments in, any other Person, other than in the
ordinary course of business consistent with past practice; 
 (h) create, incur, assume, or otherwise be liable with respect to any HippoRx
Group indebtedness for borrowed money or guarantees thereof having an aggregate principal amount (together with all other indebtedness for borrowed money of the HippoRx Group) outstanding at any time greater than $1,000,000, except for (i) the
guarantees of the HippoRx Group that would be eliminated upon satisfaction of the condition set forth in Section 13.02(d) or (ii) intercompany indebtedness which will be settled in accordance with Section 9.03; 
 (i) enter into any agreement or arrangement that limits or otherwise restricts in any material respect Hippo (to the extent relating to the HippoRx
Group), the HippoRx Group or the HippoRx Entities or any successor thereto or that could, after the Effective Time, limit or restrict in any material respect Newco or any of its Subsidiaries from engaging or competing in any line of business, in any
location or with any Person; 
 (j) other than in the ordinary course of business, enter into, amend or modify in any adverse respect or
terminate or permit non-renewal of any HippoRx Material Contract (or any Contract entered into after the date hereof that would have been a HippoRx Material Contract if such Contract had been entered into prior to the date hereof) or otherwise
waive, release or assign any material rights, claims or benefits of Hippo (to the extent relating to the HippoRx Group), the HippoRx Group or the HippoRx Entities; 
 (k)(i) grant or increase any severance or termination pay to (or amend any existing arrangement with) any Transferring Hippo Employee, (ii) increase benefits payable under any existing severance or termination
pay policies or employment agreements of or applicable to any Transferring Hippo Employee, (iii) enter into any employment, deferred compensation, retention, change in control, tax gross-up, special bonus, stay bonus or other similar agreement
(or amend any such existing agreement) with any Transferring Hippo Employee, (iv) establish, adopt or amend (except as required by Applicable Law) any collective bargaining, bonus, profit-sharing, thrift, pension, retirement, deferred
compensation, compensation, stock option, restricted stock or other benefit plan or arrangement covering any Transferring Hippo Employee or (v) increase 

  

 89 

 
compensation, bonus or other benefits payable to any Transferring Hippo Employee, other than, in the case of this clause (v), increases in the ordinary
course of business consistent with past practice; provided that in no event shall the aggregate amount of any such increases be more than 10% of the aggregate total of such compensation, bonus or other benefits paid to all Transferring Hippo
Employees immediately prior to the date hereof; 
 (l) solely with respect to the HippoRx Group, change in any material respect its methods
of accounting, except as required by concurrent changes in GAAP or Applicable Law, as agreed to by its independent public accountants; 
 (m)
settle, or offer or propose to settle, (i) any material litigation, investigation, arbitration, proceeding or other claim involving or against the HippoRx Group or (ii) any litigation, arbitration, proceeding or dispute that relates to the
transactions contemplated by the Transaction Agreements; 
 (n) make or change any material Tax election, change any annual tax accounting
period, adopt or change any method of tax accounting, amend any material Tax Returns or file claims for material Tax refunds, enter into any material closing agreement, settle any material Tax claim, audit or assessment, or surrender any right to
claim a material Tax refund, offset or other reduction in Tax liability; 
 (o) take any action (except as permitted under clauses
(a) through (n) of this Section 9.01) that would make any representation or warranty of Hippo hereunder inaccurate in any material respect at, or as of any time before, the Effective Time; or 
 (p) agree, resolve or commit to do any of the foregoing. 
 Section 9.02. No Solicitation; Other Offers.  
 (a) Unless and until this Agreement is terminated
in accordance with Article 14, Hippo shall not, and shall cause its Subsidiaries not to, authorize or permit any of its or their officers, directors, employees, investment bankers, attorneys, accountants, consultants or other agents or advisors to,
directly or indirectly, (i) solicit, initiate or take any action to facilitate or encourage the submission of any HippoRx Acquisition Proposal, (ii) enter into or participate in any discussions or negotiations with or otherwise cooperate
with, or knowingly assist, participate in, facilitate or encourage any effort by, or furnish any information relating to Hippo (to the extent relating to the HippoRx Group), the HippoRx Group or the HippoRx Entities to, or afford access to the
business, properties, assets, books or records of Hippo (to the extent relating to the HippoRx Group), the HippoRx Group or the HippoRx Entities to, any Third Party that is seeking to make, or has made, a HippoRx Acquisition Proposal or
(iii) enter into any agreement, agreement in principle, letter of intent, term sheet or other similar instrument relating to a HippoRx Acquisition Proposal. 
  

 90 

 (b) Hippo shall, and shall cause its Subsidiaries and its or their officers, directors, employees,
investment bankers, attorneys, accountants, consultants or other agents or advisors to, cease immediately and cause to be terminated any and all existing activities, discussions or negotiations, if any, with any Third Party conducted prior to the
date hereof with respect to any HippoRx Acquisition Proposal and shall use all commercially reasonable efforts to cause any such Third Party (or its agents or advisors) in possession of confidential information about the HippoRx Group that was
furnished by or on behalf of Hippo in connection with such activities, discussions or negotiations to return or destroy all such information. 
 Section 9.03. Intercompany Accounts. Except as set forth in Section 9.03 of the Hippo Disclosure Schedule, all intercompany accounts between Hippo or its Subsidiaries (other than the Hippo Institutional Pharmacy Business),
on the one hand, and the Hippo Institutional Pharmacy Business, on the other hand, as of the Effective Time shall be settled (irrespective of the terms of payment of such intercompany accounts) subject to the provisions of this Section 9.03 and
in the manner provided in this Section 9.03. At least three (3) Business Days prior to the Closing Date, Hippo shall prepare and deliver to Rhino a statement setting out in reasonable detail the calculation of all such intercompany account
balances based upon the latest available financial information as of such date and, to the extent requested by Rhino, provide Rhino with supporting documentation to verify the underlying intercompany charges and transactions. Subject to the next
sentence, all such intercompany account balances shall be paid in full in cash at the Effective Time. If the HippoRx Final Financing Amount together with cash on hand of the Hippo Institutional Pharmacy Business is not sufficient to pay all such
intercompany account balances, the remaining balances shall be cancelled at the Effective Time. 
 Section 9.04. HippoRx Financing.
Hippo shall use commercially reasonable efforts to cause HippoRx to obtain the HippoRx Final Financing Amount, including using commercially reasonable efforts to (i) negotiate definitive agreements with respect thereto and (ii) satisfy
all conditions to borrowing (to the extent in the control of Hippo or its Subsidiaries) included in such definitive agreements. 
 Section 9.05. Hippo Financial Statements. As soon as practicable, but in no event later than January 31, 2007, Hippo shall deliver to Rhino the audited balance sheets as of September 30, 2006 and 2005 and the related
audited statements of income and cash flows for each of the years ended September 30, 2006, 2005 and 2004 for the Hippo Institutional Pharmacy Business. Hippo shall also prepare and deliver to Rhino all interim unaudited financial statements
that the parties and their advisors deem necessary or advisable to include or that the applicable securities laws and regulations require to be included in the Registration Statement. All financial statements referenced in this Section 9.05
shall comply with the applicable rules and standards of Regulation S-X required for the inclusion of such financial statements in the Registration Statement. 
  

 91 

 ARTICLE 10 
 COVENANTS OF RHINO 
 Section 10.01. Conduct of Rhino
and RhinoRx. Except as set forth in Section 10.01 of the Rhino Disclosure Schedule or as expressly contemplated by the Transaction Agreements, from the date hereof until the Effective Time, Rhino shall (to the extent relating to the RhinoRx
Group) and shall cause each of the RhinoRx Entities (to the extent relating to the RhinoRx Group) to, conduct its business in the ordinary course consistent with past practice and in all material respects for the benefit of the RhinoRx Group and use
its reasonable best efforts to (i) preserve intact its present business organization, (ii) maintain in effect all of its foreign, federal, state and local licenses, permits, consents, franchises, approvals and authorizations,
(iii) keep available the services of its directors, officers and key employees, subject to limitations on Rhino’s ability to increase their benefits and compensation under this Agreement, (iv) maintain existing relationships with its
customers, lenders, suppliers and others having material business relationships with it and (v) manage its working capital (including the timing of collection of accounts receivable and of the payment of accounts payable and the management of
inventory) in the ordinary course of business consistent with past practice. Without limiting the generality of the foregoing, prior to the Effective Time, except as set forth in Section 10.01 of the Rhino Disclosure Schedule or as expressly
contemplated by the Transaction Agreements, without the prior written consent of Hippo (such consent not to be unreasonably withheld or delayed), Rhino shall not, nor shall it permit the RhinoRx Group or any RhinoRx Entity to: 
 (a) amend its articles of incorporation, bylaws or other similar organizational documents (whether by merger, consolidation or otherwise) ; provided,
however, that Rhino shall be permitted to, and shall permit the Non-RhinoRx Group to, make any such amendment insofar as such amendment would not materially impair, impede or delay the transactions contemplated by this Agreement; 
 (b) split, combine or reclassify any shares of its capital stock or declare, set aside or pay any dividend or other distribution (whether in cash, stock
or property or any combination thereof) in respect of its capital stock, or redeem, repurchase or otherwise acquire, or offer to redeem, repurchase, or otherwise acquire, any RhinoRx Securities, except for (i) repurchases or other acquisitions
of any shares of capital stock of Rhino in the ordinary course of business consistent with past practice or (ii) cash dividends paid to Rhino or its Subsidiaries; provided, however, that Rhino and the Non-RhinoRx Group shall be permitted
to effect any such split, combination, reclassification, declaration, set aside, payment, redemption, repurchase or other acquisition or offer so long as it would not materially impair, impede or delay the transactions contemplated by this
Agreement; 
  

 92 

 (c)(i) issue, deliver or sell, or authorize the issuance, delivery or sale of, or amend any term of
(whether by merger, consolidation or otherwise), any shares of any Rhino Securities or RhinoRx Securities, in a manner that would delay or impair any of the transactions contemplated by this Agreement, (ii) issue any Rhino Restricted Stock
other than in the ordinary course of business consistent with past practice or (iii) grant any Rhino Stock Option to any Transferring Rhino Employee; 
 (d) incur any capital expenditures or any obligations or liabilities in respect thereof, in each case with respect to the RhinoRx Group, except for any such incurrence in the ordinary course of business consistent
with past practice; 
 (e) acquire (by merger, consolidation, acquisition of stock or assets or otherwise), directly or indirectly, any
assets, securities, properties, interests or businesses, in each case with respect to the RhinoRx Group, other than supplies or leases of properties in the ordinary course of business of the RhinoRx Group and the RhinoRx Entities in a manner that is
consistent with past practice; 
 (f) sell, lease or otherwise transfer, or create or incur any Lien on, any assets, securities, properties,
interests or businesses of the RhinoRx Group, other than sales of inventory or leases of properties in the ordinary course of business consistent with past practice; 
 (g) solely with respect to the RhinoRx Group, other than in connection with actions permitted by Section 10.01(d) or Section 10.01(e), make any loans, advances or capital contributions to, or investments in,
any other Person, other than in the ordinary course of business consistent with past practice; 
 (h) create, incur, assume, or otherwise be
liable with respect to any RhinoRx Group indebtedness for borrowed money or guarantees thereof having an aggregate principal amount (together with all other indebtedness for borrowed money of the RhinoRx Group) outstanding at any time greater than
$1,000,000, except for (i) the guarantees of the RhinoRx Group that would be eliminated upon satisfaction of the condition in Section 13.03(d) or (ii) intercompany indebtedness which will be settled in accordance with
Section 10.03; 
 (i) enter into any agreement or arrangement that limits or otherwise restricts in any material respect Rhino (to the
extent relating to the RhinoRx Group), the RhinoRx Group or the RhinoRx Entities or any successor thereto or that could, after the Effective Time, limit or restrict in any material respect Newco or any of its Subsidiaries from engaging or competing
in any line of business, in any location or with any Person; 
 (j) other than in the ordinary course of business, enter into, amend or
modify in any adverse respect or terminate or permit non-renewal of any RhinoRx Material Contract (or any Contract entered into after the date hereof that would have been a RhinoRx Material Contract if such Contract had been entered into 

  

 93 

 
prior to the date hereof) or otherwise waive, release or assign any material rights, claims or benefits of Rhino (to the extent relating to the RhinoRx
Group), the RhinoRx Group or the RhinoRx Entities; 
 (k)(i) grant or increase any severance or termination pay to (or amend any existing
arrangement with) any Transferring Rhino Employee, (ii) increase benefits payable under any existing severance or termination pay policies or employment agreements of or applicable to any Transferring Rhino Employee, (iii) enter into any
employment, deferred compensation, retention, change in control, tax gross-up, special bonus, stay bonus or other similar agreement (or amend any such existing agreement) with any Transferring Rhino Employee, (iv) establish, adopt or amend
(except as required by Applicable Law) any collective bargaining, bonus, profit-sharing, thrift, pension, retirement, deferred compensation, compensation, stock option, restricted stock or other benefit plan or arrangement covering any Transferring
Rhino Employee or (v) increase compensation, bonus or other benefits payable to any Transferring Rhino Employee, other than, in the case of this clause (v), increases in the ordinary course of business consistent with past practice;
provided that in no event shall the aggregate amount of any such increases be more than 10% of the aggregate total of such compensation, bonus or other benefits paid to all Transferring Rhino Employees immediately prior to the date hereof;

 (l) solely with respect to the RhinoRx Group, change in any material respect its methods of accounting, except as required by concurrent
changes in GAAP or Applicable Law, as agreed to by its independent public accountants; 
 (m) settle, or offer or propose to settle,
(i) any material litigation, investigation, arbitration, proceeding or other claim involving or against the RhinoRx Group or (ii) any litigation, arbitration, proceeding or dispute that relates to the transactions contemplated by the
Transaction Agreements; 
 (n) make or change any material Tax election, change any annual tax accounting period, adopt or change any method
of tax accounting, amend any material Tax Returns or file claims for material Tax refunds, enter into any material closing agreement, settle any material Tax claim, audit or assessment, or surrender any right to claim a material Tax refund, offset
or other reduction in Tax liability; 
 (o) take any action (except as permitted under clauses (a) through (n) of this
Section 10.01) that would make any representation or warranty of Rhino hereunder inaccurate in any material respect at, or as of any time before, the Effective Time; or 
 (p) agree, resolve or commit to do any of the foregoing. 
 Section 10.02. No Solicitation; Other Offers.  
  

 94 

 (a) Unless and until this Agreement is terminated in accordance with Article 14, Rhino shall not, and
shall cause its Subsidiaries not to, authorize or permit any of its or their officers, directors, employees, investment bankers, attorneys, accountants, consultants or other agents or advisors to, directly or indirectly, (i) solicit, initiate
or take any action to facilitate or encourage the submission of any RhinoRx Acquisition Proposal, (ii) enter into or participate in any discussions or negotiations with or otherwise cooperate with, or knowingly assist, participate in,
facilitate or encourage any effort by, or furnish any information relating to Rhino (to the extent relating to the RhinoRx Group), the RhinoRx Group or the RhinoRx Entities to, or afford access to the business, properties, assets, books or records
of Rhino (to the extent relating to the RhinoRx Group), the RhinoRx Group or the RhinoRx Entities to, any Third Party that is seeking to make, or has made, a RhinoRx Acquisition Proposal or (iii) enter into any agreement, agreement in
principle, letter of intent, term sheet or other similar instrument relating to a RhinoRx Acquisition Proposal. 
 (b) Rhino shall, and shall
cause its Subsidiaries and its or their officers, directors, employees, investment bankers, attorneys, accountants, consultants or other agents or advisors to, cease immediately and cause to be terminated any and all existing activities, discussions
or negotiations, if any, with any Third Party conducted prior to the date hereof with respect to any RhinoRx Acquisition Proposal and shall use all commercially reasonable efforts to cause any such Third Party (or its agents or advisors) in
possession of confidential information about the RhinoRx Group that was furnished by or on behalf of Rhino in connection with such activities, discussions or negotiations to return or destroy all such information. 
 Section 10.03. Intercompany Accounts. Except as set forth in Section 10.03 of the Rhino Disclosure Schedule, all intercompany accounts
between Rhino or its Subsidiaries (other than the Rhino Institutional Pharmacy Business), on the one hand, and the Rhino Institutional Pharmacy Business, on the other hand, as of the Effective Time shall be settled (irrespective of the terms of
payment of such intercompany accounts) subject to the provisions of this Section 10.03 and in the manner provided in this Section 10.03. At least three (3) Business Days prior to the Closing Date, Rhino shall prepare and deliver to
Hippo a statement setting out in reasonable detail the calculation of all such intercompany account balances based upon the latest available financial information as of such date and, to the extent requested by Hippo, provide Hippo with supporting
documentation to verify the underlying intercompany charges and transactions. Subject to the next sentence, all such intercompany account balances shall be paid in full in cash at the Effective Time. If the RhinoRx Final Financing Amount together
with cash on hand of the Rhino Institutional Pharmacy Business is not sufficient to pay all such intercompany balances, the remaining balances shall be cancelled at the Effective Time. 
 Section 10.04. RhinoRx Financing. Rhino shall use commercially reasonably efforts to cause RhinoRx to obtain the RhinoRx Final Financing

  

 95 

 
Amount, including using commercially reasonable efforts to (i) negotiate definitive agreements with respect thereto and (ii) satisfy all conditions
to borrowing (to the extent in the control of Rhino or its Subsidiaries) included in such definitive agreements. 
 Section 10.05.
Rhino Financial Statements. As soon as practicable, but in no event later than March 31, 2007, Rhino shall deliver to Hippo, the audited balance sheet as of December 31, 2006 and the related audited statements of income and cash flows
for the year ended December 31, 2006 for the Rhino Institutional Pharmacy Business. In addition, to permit the process of preparing and filing the initial Registration Statement to proceed prior to the completion of the balance sheet as of and
statements of income and cash flows end for the year ended December 31, 2006, Rhino shall deliver to Hippo, no later than January 31, 2007, audited balance sheets as of December 31, 2005 and 2004 and the related audited statements of
income and cash flows for each of the years ended December 31, 2005, 2004 and 2003 for the Rhino Institutional Pharmacy Business. Rhino shall also prepare and deliver to Hippo all interim unaudited financial statements that the parties and
their advisors deem necessary or advisable to include or that the applicable securities laws and regulations require to be included in the Registration Statement. All such financial statements referenced in this Section 10.05 shall comply with
the applicable rules and standards of Regulation S-X required for the inclusion of such financial statements in the Registration Statement. 
 ARTICLE 11 
 COVENANTS OF HIPPO, RHINO AND
NEWCO 
 Section 11.01. Reasonable Best Efforts.  
 (a) Subject to the terms and conditions of this Agreement, Hippo and Rhino shall use their reasonable best efforts to take, or cause to be taken, all
actions and to do, or cause to be done, all things necessary, proper or advisable under Applicable Law to consummate the transactions contemplated by the Transaction Agreements, including (i) preparing and filing as promptly as practicable with
any Governmental Authority or other Third Party all documentation to effect all necessary filings, notices, petitions, statements, registrations, submissions of information, applications and other documents and (ii) obtaining and maintaining
all approvals, consents, registrations, permits, authorizations, waivers and other confirmations required to be obtained from any Governmental Authority or other Third Party that are necessary, proper or advisable to consummate the transactions
contemplated by this Agreement; provided that the parties hereto understand and agree that the reasonable best efforts of any party hereto shall not be deemed to include (i) entering into any settlement, undertaking, consent decree,
stipulation or agreement with any Governmental Authority in connection with the transactions contemplated hereby, 

  

 96 

 
(ii) divesting or otherwise holding separate (including by establishing a trust or otherwise), or taking any other action (or otherwise agreeing to do any of
the foregoing) with respect to any of its or Newco’s Subsidiaries (as of immediately following the Effective Time) or any of their respective Affiliates’ businesses, assets or properties or (iii) making any monetary or other payment
in order to obtain any Third Party’s contractual consent. Notwithstanding anything to the contrary contained herein, in connection with consummation of the transactions contemplated by the Transaction Agreements, no party to this Agreement
shall take any action described in clause (i) or (ii) of the immediately preceding sentence prior to the Effective Time without the prior written consent of Hippo and Rhino. 
 (b) In furtherance and not in limitation of the foregoing, subject to the last sentence of Section 11.01(c), if and when any information and
documentary material is requested by a Governmental Authority in connection with obtaining Governmental Approvals, the parties shall confer and cooperate in good faith regarding the response to any such request. 
 (c) Each of Hippo and Rhino shall promptly inform the other party and its counsel of any communications or correspondence, whether written or oral, that
such party or its counsel may receive from time to time from the Department of Justice (the “DOJ”) or the Federal Trade Commission (the “FTC”) or their staff with respect to the Mergers. Each of Hippo and Rhino and
its counsel shall jointly participate in any responses to such communications or correspondence, including by providing copies of any written correspondence to the other party’s counsel and by providing the other party advance notice and an
opportunity to participate in any discussions or meetings with the DOJ or FTC. Until the Closing, each of Hippo and Rhino shall (i) promptly inform the other party and its counsel of any communications or correspondence, whether written or
oral, that such party or its counsel may receive from time to time from any Governmental Authority (other than the DOJ and FTC) in connection with the transactions contemplated by the Transaction Agreements or in connection with obtaining any
Governmental Approvals relating to such transactions and (ii) consult with the other party and its counsel before responding to such communications or correspondence or participating in any discussions or meetings with any Governmental
Authority in connection with the foregoing. Nothing herein shall require Hippo or any of its Subsidiaries, on the one hand, or Rhino or any of its Subsidiaries, on the other hand, to disclose to the other any confidential information about its
businesses other than those of the HippoRx Group and the RhinoRx Group. 
 Section 11.02. Certain Filings. (a) As promptly
as practicable after the date hereof, Hippo and Rhino shall prepare and file the Registration Statement with the SEC. Hippo and Rhino shall cooperate with one another (i) in connection with the preparation of the Registration Statement and any
amendments or supplements thereto and (ii) in timely taking such actions or making such filings, including any filings with a national securities exchange and 

  

 97 

 
furnishing information required in connection therewith or with the Registration Statement. 
 (b) Each of Hippo and Rhino shall provide the other party and its counsel with any comments or other communications, whether written or oral, that such
party or its counsel may receive from time to time from the SEC or its staff with respect to the Registration Statement, including the information statement, promptly after receipt of those comments or other communications. Each of Hippo and Rhino
and its counsel shall jointly participate in the response to such comments, including by participating in any discussions or meetings with the SEC. Hippo and Rhino shall use their reasonable best efforts to cause the Registration Statement to become
effective under the 1934 Act as soon after such filing as practicable and to keep the Registration Statement effective as long as is necessary to consummate the Mergers. The Registration Statement, including the information statement, shall comply
as to form in all material respects with the rules and regulations promulgated by the SEC under the 1934 Act, including compliance with the disclosure and mailing requirements of Schedules 14A and 14C to the extent necessary for the Transactions to
be exempt from registration under the 1933 Act pursuant to SEC Staff Legal Bulletin No. 4. As promptly as practicable after the Registration Statement has become effective, (i) Hippo shall mail the Registration Statement, including the
information statement, to the holders of Hippo Common Stock as of the Record Date and (ii) Rhino shall mail the Registration Statement, including the information statement, to the holders of Rhino Common Stock as of the Record Date. 

Section 11.03. Public Announcements. Hippo and Rhino shall consult with each other before issuing any press release, making any other
public statement or scheduling any press conference or conference call with investors or analysts with respect to the Transaction Agreements or the transactions contemplated thereby and, except as may be required by Applicable Law or any listing
agreement with or rule of any national securities exchange or association and except to the extent the disclosure is either consistent with prior disclosure permitted by this Section 11.03 or relates primarily to the Non-HippoRx Group or
Non-RhinoRx Group, as the case may be, shall not issue any such press release, make any such other public statement or schedule any such press conference or conference call before such consultation. 
 Section 11.04. Further Assurances. At and after the Effective Time, the respective officers and directors of HippoRx Surviving Corporation
and RhinoRx Surviving Corporation shall be authorized to execute and deliver, in the name and on behalf of HippoRx or RhinoRx, as applicable, any deeds, bills of sale, assignments or assurances and to take and do, in the name and on behalf of
HippoRx or RhinoRx, any other actions and things to vest, perfect or confirm of record or otherwise in HippoRx Surviving Corporation or RhinoRx Surviving Corporation any and all right, title and interest in, to and under any of the rights,
properties or assets of HippoRx or RhinoRx acquired or to be acquired by 

  

 98 

 
HippoRx Surviving Corporation or RhinoRx Surviving Corporation as a result of, or in connection with, the applicable Merger. 
 Section 11.05. Access to Information.  
 (a) From the date hereof until the Effective Time or earlier termination of this Agreement, and subject to Applicable Law and the Clean Team Confidentiality Agreement, each of Hippo and Rhino shall (i) give to the other party, its
counsel, financial advisors, auditors and other authorized representatives reasonable access to the offices, properties, books and records of the business of the HippoRx Group or the business of the RhinoRx Group, as the case may be,
(ii) furnish to the other party, its counsel, financial advisors, auditors and other authorized representatives such financial and operating data and other information as such Persons may reasonably request and (iii) instruct its
employees, counsel, financial advisors, auditors and other authorized representatives to cooperate with the other party in its investigation. Any investigation pursuant to this Section 11.05 shall be conducted in such manner as not to interfere
unreasonably with the conduct of the business of the other party. No information or knowledge obtained in any investigation pursuant to this Section 11.05 shall affect or be deemed to modify any representation or warranty made by any party
hereunder. 
 (b) From the date hereof until the Effective Time or earlier termination of this Agreement, and subject to Applicable Law and
the Clean Team Confidentiality Agreement, Hippo shall, no later than the 25th day of each calendar month, provide
Rhino with such unaudited financial statements (which will be derived from and be consistent with the books and records of HippoRx and its Subsidiaries) of the Hippo Institutional Pharmacy Business as are provided to and used by Hippo’s and
HippoRx’s management as of and for the month ending on the last day of the immediately preceding calendar month. 
 (c) From the date
hereof until the Effective Time or earlier termination of this Agreement, and subject to Applicable Law and the Clean Team Confidentiality Agreement, Rhino shall, no later than the 25th day of each calendar month, provide Hippo with such unaudited financial statements (which will be derived from and be consistent with the books and records of
RhinoRx and its Subsidiaries) of the Rhino Institutional Pharmacy Business as are provided to and used by Rhino’s and RhinoRx’s management as of and for the month ending on the last day of the immediately preceding calendar month.

 Section 11.06. Notices of Certain Events. Each of Hippo and Rhino shall promptly notify, and provide copies of related
notices, correspondence and documentation to, the other of: 
 (a) any notice or other communication from any Person alleging that the consent
of such Person is or may be required in connection with the transactions contemplated by the Transaction Agreements; 
  

 99 

 (b) any material notice or other communication from any Governmental Authority in connection with the
transactions contemplated by the Transaction Agreements; 
 (c) any inaccuracy of any representation or warranty contained in this Agreement
at any time during the term hereof that could reasonably be expected to cause the conditions set forth in Section 13.02(a) or Section 13.03(a) not to be satisfied; 
 (d) any failure of that party to comply with or satisfy any covenant, condition or agreement to be complied with or satisfied by it hereunder; and

 (e) any notice of termination, cancellation or non-renewal of any HippoRx Material Contract or RhinoRx Material Contract (or any Contract
entered into after the date hereof that would have been a HippoRx Material Contract or RhinoRx Material Contract if such Contract had been entered into prior to the date hereof); 
 provided, however, that the delivery of any notice pursuant to this Section 11.06 shall not limit or otherwise affect the remedies available hereunder to the party receiving that notice. 
 Section 11.07. Confidentiality. 
 (a) Hippo and Rhino agree that the Base Confidentiality Agreement shall terminate as of the date hereof. 
 (b) Prior to the Closing
Date and after any termination of this Agreement, any party hereto and its Affiliates (the “Receiving Party”) receiving or already in possession of confidential documents and information concerning any other party hereto (the
“Disclosing Party”) furnished in connection with the transactions contemplated by this Agreement will hold, and will use its best efforts to cause its officers, directors, employees, accountants, counsel, consultants, advisors and
agents to hold, in confidence, and not use other than for purposes of evaluating and facilitating the transactions contemplated by this Agreement, unless compelled to disclose by Applicable Law, all such confidential documents and other information,
except to the extent that such information can be shown to have been (i) previously known on a nonconfidential basis by the Receiving Party, (ii) in the public domain through no fault of the Receiving Party or (iii) later lawfully
acquired by the Receiving Party from sources other than the Disclosing Party; provided that the Receiving Party may disclose such information to its officers, directors, employees, accountants, counsel, consultants, advisors and agents in
connection with the transactions contemplated by this Agreement and to its lenders or other Persons in connection with obtaining the financing for the transactions contemplated by this Agreement so long as such Persons are informed by the Receiving
Party of the confidential nature of such information and are directed by the Receiving Party to treat such information 

  

 100 

 
confidentially. The obligation of the Receiving Party and its Affiliates to hold any such information in confidence shall be satisfied if they exercise the
same care with respect to such information as they would take to preserve the confidentiality of their own similar information. If this Agreement is terminated, the Receiving Party and its Affiliates will, and will use their best efforts to cause
their respective officers, directors, employees, accountants, counsel, consultants, advisors and agents to, destroy or deliver to the Disclosing Party, upon request, all documents and other materials, and all copies thereof, obtained by the
Receiving Party or its Affiliates or on their behalf in connection with this Agreement that are subject to such confidence. 
 Section 11.08. Governance of Newco. Hippo and Rhino shall cause Newco to, and Newco shall, take all actions necessary so that at the Effective Time, the Newco Board of Directors shall consist of nine (9) directors, four
(4) of whom shall be designated by Hippo, four (4) of whom shall be designated by Rhino and one of whom shall be the Chief Executive Officer of Newco. Subject to the next sentence, Hippo shall be entitled to designate the Chairman of the
Newco Board of Directors and the Chairman of the Audit Committee of the Newco Board of Directors at the Effective Time, subject to the consent of Rhino, which shall not be unreasonably withheld. Each of the Hippo and Rhino director designees shall
be independent persons with respect to Hippo, Rhino and Newco as defined under applicable New York Stock Exchange rules and the initial Governance Guidelines for Newco; provided that, notwithstanding the foregoing, R. David Yost, Edward L.
Kuntz and Paul J. Diaz may be Hippo or Rhino director designees (but may not serve as Chairman of the Newco Board of Directors). Hippo and Rhino shall designate by mutual agreement the individuals who will serve as Chief Executive Officer, Chief
Financial Officer, Chief Operating Officer, Chief Administrative Officer and General Counsel of Newco from and after the Effective Time until their successors are duly appointed. 
 Section 11.09. Non-Competition; Non-Solicitation.  
 (a) For a period of five (5) years from the Closing Date, Hippo shall not, and shall cause its Affiliates not to, directly or indirectly, alone or in association with any Person, acquire, manage, operate, engage
in, finance, or own any interest in, the Hippo Institutional Pharmacy Business (excluding the HippoRx Retail Pharmacies) in the United States; provided that nothing herein shall limit in any manner Hippo or any of its Affiliates from
(i) merging with, acquiring the assets of or having an investment in any Person that draws 10% or less of its annual revenue or operating income from the Hippo Institutional Pharmacy Business; or (ii) merging with, acquiring the assets of
or having an investment in any Person that draws more than 10% of its annual revenue or operating income from the Hippo Institutional Pharmacy Business; provided that, in the case of this clause (ii), the business that consists of the Hippo
Institutional Pharmacy Business is divested within 12 months of such acquisition or merger. 
  

 101 

 (b) For a period of five (5) years from the Closing Date, Rhino shall not, and shall cause its
Affiliates not to, directly or indirectly, alone or in association with any Person, acquire, manage, operate, engage in, finance, or own any interest in, the Rhino Institutional Pharmacy Business in the United States; provided that nothing
herein shall limit in any manner Rhino or any of its Affiliates from (i) merging with, acquiring the assets of or having an investment in any Person that draws 10% or less of its annual revenue or operating income from the Rhino Institutional
Pharmacy Business; or (ii) merging with, acquiring the assets of or having an investment in any Person that draws more than 10% of its annual revenue or operating income from the Rhino Institutional Pharmacy Business; provided that, in
the case of this clause (ii), the business that consists of the Rhino Institutional Pharmacy Business is divested within 12 months of such acquisition or merger. 
 (c) Subject to the next sentence, each of Hippo and Rhino shall not, and each shall cause its respective Affiliates not to, solicit, induce or attempt to induce any employees of Newco or its Affiliates to leave the
employ of Newco or such Affiliate; provided that Hippo, Rhino and their respective Affiliates shall not be precluded from hiring any employee of Newco or its Affiliates (i) who initiates discussions regarding employment with Hippo,
Rhino, or the applicable Affiliate of Hippo or Rhino, without any direct or indirect solicitation or inducement by Hippo, Rhino or their respective Affiliates, (ii) who responds to a general solicitation to the public or a general advertising
not directly aimed at employees of Newco or its Affiliates or (iii) (A) who has been terminated from his or her employment by Newco or its Affiliate or (B) who has terminated his or her employment with Newco or its Affiliate and in
the case of this clause (iii)(B) at least six months have elapsed since such termination. The covenant set forth in the preceding sentence shall be effective (i) for a period of two (2) years from the Closing Date with respect to employees
of Newco or its Affiliates who are vice-presidents or senior to vice president and (ii) for a period of one (1) year from the Closing Date for all other employees of Newco or its Affiliates. 
 (d) Subject to the next sentence, Newco shall not, and shall cause its Affiliates not to, solicit, induce or attempt to induce any employees of Hippo,
Rhino or their respective Affiliates to leave the employ of Hippo, Rhino or the applicable Affiliate of Hippo or Rhino, as the case may be; provided that Newco and its respective Affiliates shall not be precluded from hiring any employee of
Hippo, Rhino or the applicable Affiliate of Hippo or Rhino (i) who initiates discussions regarding employment with Newco or its Affiliates without any direct or indirect solicitation or inducement by Newco or its Affiliates, (ii) who
responds to a general solicitation to the public or a general advertising not directly aimed at employees of Hippo, Rhino or the applicable Affiliate of Hippo or Rhino or (iii) (A) who has been terminated from his or her employment by
Hippo, Rhino or the applicable Affiliate of Hippo or Rhino or (B) who has terminated his or her employment with Hippo, Rhino or the applicable Affiliate of Hippo or Rhino and in the case of this clause (iii)(B) at least six months have elapsed
since such 

  

 102 

 
termination. The covenant set forth in the preceding sentence shall be effective (i) for a period of two (2) years from the Closing Date with
respect to employees of Hippo, Rhino or their respective Affiliates who are vice-presidents or senior to vice president and (ii) for a period of one (1) year from the Closing Date for all other employees of Hippo, Rhino or their respective
Affiliates. 
 (e) If any provision contained in this Section 11.09 shall for any reason be held invalid, illegal or unenforceable in
any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Section 11.09, but this Section 11.09 shall be construed as if such invalid, illegal or unenforceable provision had never been
contained herein. It is the intention of the parties that if any of the restrictions or covenants contained herein is held to cover a geographic area or to be for a length of time which is not permitted by Applicable Law, or in any way construed to
be too broad or to any extent invalid, such provision shall not be construed to be null, void and of no effect, but to the extent such provision would be valid or enforceable under Applicable Law, a court of competent jurisdiction shall construe and
interpret or reform this Section 11.09 to provide for a covenant having the maximum enforceable geographic area, time period and other provisions (not greater than those contained herein) as shall be valid and enforceable under such applicable
law. The parties acknowledge that Newco, Hippo or Rhino, as the case may be, would be irreparably harmed by any breach of this Section 11.09 and that there would be no adequate remedy at law or in damages to compensate Newco, Hippo or Rhino for
any such breach. The parties agree that Newco, Hippo and Rhino shall be entitled to injunctive relief requiring specific performance by the applicable other party, as the case may be, of this Section 11.09. 
 Section 11.10. Transition Planning Committee.  
 (a) Hippo and Rhino have formed a Transition Planning Committee comprised of three (3) representatives of Hippo (collectively, the “Hippo Representatives”) and three (3) representatives of
Rhino (collectively, the “Rhino Representatives”). Hippo and Rhino may replace any of their respective Representatives at any time or from time to time. The Transition Planning Committee shall be responsible for all aspects of
transition planning for Newco from the date hereof until the Effective Time. All decisions of the Transition Planning Committee shall require the approval of a majority of its members. The Transition Planning Committee shall be entitled to incur
reasonable expenses on behalf of Newco, including expenses in connection with the engagement of legal, financial, accounting and other advisors for Newco. The activities of the Transition Planning Committee will be conducted in accordance with
Applicable Law and the advice of the parties’ respective antitrust counsel. 
 (b) The Transition Planning Committee shall seek to
arrange financing (the “Newco Financing”) in an amount sufficient to (i) refinance the Cash Distribution Amount at the Effective Time and (ii) provide appropriate cash 

  

 103 

 
reserves to fund the operations of Newco after the Effective Time and pay the fees and expenses incurred by or on behalf of Newco prior to the Effective
Time. 
 Section 11.11. Tax-Free Transaction.  
 (a) Prior to the Effective Time, each party hereto shall use its reasonable best efforts to (i) cause the Distributions to qualify as transactions described in Section 355(a) of the Code, and will not take
any action reasonably likely to cause the Distributions not to so qualify, (ii) ensure that the Mergers will not cause the HippoRx Common Stock or the RhinoRx Common Stock to fail to be treated as “qualified property” for purposes of
Section 355(c)(2) or Section 361(c)(2) of the Code and (iii) cause the Mergers to qualify as exchanges described in Section 351 of the Code, and shall not take any action reasonably likely to cause the Mergers not so to qualify.

 (b) Each of Hippo and Rhino shall use its reasonable best efforts to obtain the opinions referred to in Sections 13.02(b) and 13.03(b),
respectively. 
 Section 11.12. Director and Officer Liability.  
 (a) Newco shall indemnify and hold harmless and advance expenses to the present and former officers and directors of Hippo, the Subsidiaries of Hippo, the
HippoRx Entities, and each individual who prior to the Effective Time becomes an officer or director of any such entity (each, a “Hippo D&O Indemnified Person”), and the present and former officers and directors of Rhino, the
Subsidiaries of Rhino and the RhinoRx Entities, and each individual who prior to the Effective Time becomes an officer or director of any such entity (each, a “Rhino D&O Indemnified Person” and together with each Hippo D&O
Indemnified Person, the “D&O Indemnified Persons”), in respect of acts or omissions by them in their capacities as such occurring at or prior to the Effective Time (including for acts or omissions occurring in connection with
the Transaction Agreements and the consummation of the transactions contemplated thereby) to the maximum extent permitted by law (“D&O Indemnified Losses”); provided that notwithstanding the foregoing Newco shall have no
obligation to indemnify and hold harmless and advance expenses to any D&O Indemnified Person in respect of acts or omissions of such D&O Indemnified Person that occurred while such D&O Indemnified Person was acting in a capacity
(i) for Hippo or its Subsidiaries other than in connection with either the HippoRx Group, the HippoRx Entities or the Transaction Agreements and the transactions contemplated thereby or (ii) for Rhino or its Subsidiaries other than in
connection with either the RhinoRx Group, the RhinoRx Entities or the Transaction Agreements and the transactions contemplated thereby. Without limiting the generality of the foregoing, the D&O Indemnified Losses shall include reasonable costs
of prosecuting a claim under this Section 11.12. Newco shall periodically advance or reimburse each D&O Indemnified Person for all reasonable fees and expenses constituting D&O Indemnified Losses as such fees and expenses are incurred;
provided that such D&O Indemnified Person shall agree to promptly 

  

 104 

 
repay to Newco the amount of any such reimbursement if it shall be judicially determined by judgment or order not subject to further appeal or discretionary
review that such D&O Indemnified Person is not entitled to be indemnified by Newco in connection with such matter. In the event that Newco sells, transfers or leases all or substantially all of its assets or is not a surviving corporation in any
merger, consolidation or other business combination in which it may enter with any Person, Newco shall, as a condition of any such transaction, cause such purchaser or such surviving corporation, as the case may be, to assume Newco’s
obligations under this Section 11.12 upon the consummation of any such transaction. 
 (b) For six years after the Effective Time, Newco
shall provide, or shall cause the HippoRx Surviving Corporation to provide, officers’ and directors’ liability insurance in respect of acts or omissions occurring prior to the Effective Time (including for acts or omissions occurring in
connection with the Transaction Agreements and the consummation of the transactions contemplated thereby) covering each Hippo D&O Indemnified Person (but only in respect of acts or omissions of such Person acting in connection with the HippoRx
Group, the HippoRx Entities or the Transaction Agreements and the transactions contemplated thereby) currently covered by the officers’ and directors’ liability insurance policy of Hippo on terms with respect to coverage and amount
(including with respect to the payment of attorneys’ fees) no less favorable than those of such policy in effect on the date hereof; provided that, if the aggregate annual premiums for such insurance during such period shall exceed 300%
of the per annum rate of premium paid by Hippo as of the date hereof for such insurance, then Newco shall provide or cause to be provided a policy for Hippo D&O Indemnified Persons with the best coverage as shall then be available at 300% of the
rate applicable to Hippo. 
 (c) For six years after the Effective Time, Newco shall provide, or shall cause the RhinoRx Surviving
Corporation to provide, officers’ and directors’ liability insurance in respect of acts or omissions occurring prior to the Effective Time (including for acts or omissions occurring in connection with the Transaction Agreements and the
consummation of the transactions contemplated thereby) covering each Rhino D&O Indemnified Person (but only in respect of acts or omissions of such Person acting in connection with the RhinoRx Group, the RhinoRx Entities or the Transaction
Agreements and the transactions contemplated thereby) currently covered by the officers’ and directors’ liability insurance policy of Rhino on terms with respect to coverage and amount (including with respect to the payment of
attorneys’ fees) no less favorable than those of such policy in effect on the date hereof; provided that, if the aggregate annual premiums for such insurance during such period shall exceed 300% of the per annum rate of premium paid by
Rhino as of the date hereof for such insurance, then Newco shall provide or cause to be provided a policy for Rhino D&O Indemnified Persons with the best coverage as shall then be available at 300% of the rate applicable to Rhino. 
  

 105 

 (d) In the event that Newco or its Affiliate shall pay premiums in excess of the applicable rate in order
to cover Hippo D&O Indemnified Persons pursuant to Section 11.12(b) or Rhino D&O Indemnified Persons pursuant to Section 11.12(c), it shall pay premiums at such higher rate to cover the other D&O Indemnified Persons.

 (e) The rights of each D&O Indemnified Person and his or her heirs and legal representatives under this Section 11.12 shall be in
addition to any rights such D&O Indemnified Person may have under the certificate of incorporation or bylaws of Newco, Hippo, any Subsidiary of Hippo, any HippoRx Entity, the HippoRx Surviving Corporation, any Subsidiary of the HippoRx Surviving
Corporation, Rhino, any Subsidiary of Rhino, any RhinoRx Entity, the RhinoRx Surviving Corporation or any Subsidiary of the RhinoRx Surviving Corporation, under any agreement of any D&O Indemnified Person with any such entity, under Delaware Law
or under any other Applicable Law. 
 (f) The obligations of Newco, the HippoRx Surviving Corporation and the RhinoRx Surviving Corporation
shall not be terminated or modified in such a manner as to adversely affect the rights of any D&O Indemnified Person to whom this Section 11.12 applies unless (x) such termination or modification is required by Applicable Law or
(y) the affected D&O Indemnified Person shall have consented in writing to such termination or modification (it being expressly agreed that the D&O Indemnified Persons to whom this Section 11.12 applies shall be third party
beneficiaries of this Section 11.12). 
 Section 11.13. Stock Exchange Listing. Newco, Hippo and Rhino shall use their
respective reasonable best efforts to cause the shares of Newco Common Stock to be issued in connection with the Mergers to be listed on the NYSE (or, if listing on the NYSE is not approved or appears impracticable, the NASDAQ Stock Market), subject
to official notice of issuance. 
 Section 11.14. Certain Agreements. (a) Prior to Closing, Hippo and Rhino shall negotiate
in good faith to prepare an Information Services Agreement substantially on the terms set forth in the term sheet attached as Exhibit C for the provision by Rhino to Newco of certain information services and support following the Closing.

 (b) Hippo and Rhino shall work in good faith with any integration consultant retained by or on behalf of Newco by the Transition Planning
Committee to determine the services to be provided to Newco pursuant to the Information Services Agreement, the Rhino Newco Transition Services Agreement and the Hippo Newco Transition Services Agreement. Any services listed in the schedules or
exhibits to the Rhino Newco Transition Services Agreement and the Hippo Newco Transition Services Agreement are for illustrative purposes only. 
  

 106 

 (c) Hippo and Rhino shall work in good faith with any integration consultant retained by or on behalf of
Hippo to determine the services to be provided to the Hippo Workers’ Compensation Business pursuant to the Rhino Hippo Transition Services Agreement and the Newco Hippo Transition Services Agreement. The parties agree that such services shall
be substantially similar in scope to the services provided by the Hippo Institutional Pharmacy Business to the Hippo Workers’ Compensation Business immediately prior to the Distribution Time. Any services listed in the schedules or exhibits to
the Rhino Hippo Transition Services Agreement and the Newco Hippo Transition Services Agreement are for illustrative purposes only. 
 (d)
Prior to Closing, Rhino shall execute a letter containing the statements set forth in Exhibit S. 
 ARTICLE 12 
 EMPLOYEE MATTERS 
 Section 12.01. Hippo Employee Matters.  
 (a) Effective not later than immediately before the Distribution Time, Hippo
shall cause all Active Transferring Hippo Employees to become, or to continue to be, employees of a HippoRx Entity. Hippo and its Subsidiaries shall not take any action that is not otherwise permitted under this Agreement that would interfere with
such employees so becoming employed, or so remaining employed, as the case may be, by a HippoRx Entity. As of the HippoRx Distribution, the HippoRx Entities shall have no employees other than the Active Transferring Hippo Employees. 
 (b) As of the Distribution Time, except as expressly provided in this Agreement, Hippo and its Subsidiaries (other than the HippoRx Entities) shall
assign to the HippoRx Entities, to the extent applicable, and the HippoRx Entities shall assume or retain, as applicable, and HippoRx hereby agrees to pay, perform, fulfill and discharge, (i) all Liabilities under all HippoRx Benefit Plans,
(ii) all Liabilities with respect to Transferring Hippo Employees under all Hippo Benefit Plans (excluding any such Liability that is a Non-HippoRx Liability, including as set forth on Section 1.01 of the Hippo Disclosure Schedule under
the heading “Non-HippoRx Liabilities”), (iii) all Liabilities with respect to the employment or termination of employment of all Transferring Hippo Employees and their dependents and beneficiaries, including without limitation those
Liabilities arising out of or resulting from employment by Hippo or its Subsidiaries on or before the Closing Date and (iv) all Liabilities with respect to other service providers (including any individual who is, or was, an independent
contractor, temporary employee, temporary service worker, consultant, freelancer, agency employee, leased employee, on-call worker, incidental worker, or nonpayroll worker of Hippo or its Subsidiaries or in any other employment, non-employment, or
retainer arrangement, or relationship with Hippo or its Subsidiaries), to the extent 

  

 107 

 
arising in connection with or as a result of employment with or the performance of services for Hippo and its Subsidiaries in connection with the Hippo
Institutional Pharmacy Business. All Assets held in trust to fund, and all insurance policies funding, any Liabilities expressly assumed or retained by HippoRx Entities pursuant to the operation of this Section 12.01(b) shall be HippoRx Assets,
except to the extent specifically provided otherwise in this Agreement. 
 (c) As of the Distribution Time, except as expressly provided in
this Agreement, Hippo and its Subsidiaries (other than the HippoRx Entities) shall assume or retain, as applicable, and Hippo hereby agrees to pay, perform, fulfill and discharge, (i) all Liabilities under or with respect to the Hippo Benefit
Plans not expressly assumed by the HippoRx Entities pursuant to Section 12.01(b)(ii) above, (ii) all Liabilities with respect to all current and former employees of Hippo and its Subsidiaries (other than the Transferring Hippo Employees)
(the “Non-HippoRx Employees”) under all Hippo Benefit Plans, (iii) all Liabilities with respect to the employment or termination of employment of all Non-HippoRx Employees and their dependents and beneficiaries, (iv) all
Liabilities with respect to other service providers (including any individual who is, or was, an independent contractor, temporary employee, temporary service worker, consultant, freelancer, agency employee, leased employee, on-call worker,
incidental worker, or nonpayroll worker of Hippo or its Subsidiaries or in any other employment, non-employment, or retainer arrangement, or relationship with Hippo or its Subsidiaries), to the extent arising in connection with or as a result of
employment with or the performance of services for Hippo or its Subsidiaries in connection with any business other than the Hippo Institutional Pharmacy Business and (v) any other Liabilities expressly assigned to Hippo or its Subsidiaries
(other than the HippoRx Entities) under this Agreement, including, without limitation, the Non-HippoRx Liabilities. All Assets held in trust to fund, and all insurance policies funding, any Liabilities expressly assumed or retained by Hippo and its
Subsidiaries (other than the HippoRx Entities) pursuant to the operation of this Section 12.01(c) shall be Non-HippoRx Assets, except to the extent specifically provided otherwise in this Agreement. 
 (d) Notwithstanding anything in this Agreement to the contrary, Hippo and its Subsidiaries (other than the HippoRx Entities) shall retain all Liabilities
and Assets relating to health insurance claims incurred by Transferring Hippo Employees prior to the Closing Date under any health insurance policy sponsored or maintained by Hippo or its Subsidiaries (other than the HippoRx Entities). For purposes
of this Section 12.01(d), a health insurance claim relating to a period of continuous hospitalization is deemed to be incurred on the first date of such period of hospitalization. 
 (e) Each Active Transferring Hippo Employee will receive service credit for all periods of employment with Hippo or any of its Subsidiaries or any
predecessor thereof prior to the Effective Time for purposes of vesting, eligibility and benefit levels under any employee benefit plan in which such employee 

  

 108 

 
participates after the Effective Time, to the extent that such service was recognized under any analogous plan of Hippo or any of its Subsidiaries in effect
immediately prior to the Effective Time; provided that no such service credit shall be given for purposes of benefit accruals under any defined benefit pension plan or where such credit would result in a duplication of benefits. 

(f) If on or after the Effective Time any Active Transferring Hippo Employee becomes covered under any benefit plan providing medical, dental, health,
pharmaceutical or vision benefits (a “Successor Plan”), other than the plan in which he or she participated immediately prior to the Effective Time (a “Prior Plan”), any such Successor Plan shall not include any
restrictions or limitations with respect to any pre-existing condition exclusions and actively-at-work requirements (except to the extent such exclusions or requirements were applicable under the corresponding Prior Plan), and any eligible expenses
incurred by such Active Transferring Hippo Employee and his or her covered dependents during the calendar year in which the Active Transferring Hippo Employee becomes covered under any Successor Plan shall be taken into account under any such
Successor Plan for purposes of satisfying all deductible, coinsurance and maximum out-of-pocket requirements applicable to such employee and/or his or her covered dependents for that year, to the extent that such expenses were incurred during a
period in which the Active Transferring Hippo Employee or covered dependent was covered under a corresponding Prior Plan. 
 Section 12.02. Rhino Employee Matters.  
 (a) Effective not later than immediately before the Distribution Time, Rhino
shall cause all Active Transferring Rhino Employees to become, or to continue to be, employees of a RhinoRx Entity. Rhino and its Subsidiaries shall not take any action that is not otherwise permitted under this Agreement that would interfere with
such employees so becoming employed, or so remaining employed, as the case may be, by a RhinoRx Entity. As of the RhinoRx Distribution, the RhinoRx Entities shall have no employees other than the Active Transferring Rhino Employees. 
 (b) As of the Distribution Time, except as expressly provided in this Agreement, Rhino and its Subsidiaries (other than the RhinoRx Entities) shall
assign to the RhinoRx Entities, to the extent applicable, and the RhinoRx Entities shall assume or retain, as applicable, and RhinoRx hereby agrees to pay, perform, fulfill and discharge, (i) all Liabilities under all RhinoRx Benefit Plans,
(ii) all Liabilities with respect to Transferring Rhino Employees under all Rhino Benefit Plans (excluding any such Liability that is a Non-RhinoRx Liability, including as set forth on Section 1.01 of the Rhino Disclosure Schedule under
the heading “Non-RhinoRx Liabilities”), (iii) all Liabilities with respect to the employment or termination of employment of all Transferring Rhino Employees and their dependents and beneficiaries, including without limitation those
Liabilities arising out of or resulting from employment by Rhino or its Subsidiaries on or before the 

  

 109 

 
Closing Date and (iv) all Liabilities with respect to other service providers (including any individual who is, or was, an independent contractor,
temporary employee, temporary service worker, consultant, freelancer, agency employee, leased employee, on-call worker, incidental worker, or nonpayroll worker of the Rhino or its Subsidiaries or in any other employment, non-employment, or retainer
arrangement, or relationship with the Rhino or its Subsidiaries), to the extent arising in connection with or as a result of employment with or the performance of services for Rhino and its Subsidiaries in connection with the Rhino Institutional
Pharmacy Business. All Assets held in trust to fund, and all insurance policies funding, any Liabilities expressly assumed or retained by RhinoRx Entities pursuant to the operation of this Section 12.02(b) shall be RhinoRx Assets, except to the
extent specifically provided otherwise in this Agreement. 
 (c) As of the Distribution Time, except as expressly provided in this Agreement,
Rhino and its Subsidiaries (other than the RhinoRx Entities) shall assume or retain, as applicable, and Rhino hereby agrees to pay, perform, fulfill and discharge, (i) all Liabilities under or with respect to the Rhino Benefit Plans not
expressly assumed by the RhinoRx Entities pursuant to Section 12.02(b)(ii) above, (ii) all Liabilities with respect to all current and former employees of Rhino and its Subsidiaries (other than the Transferring Rhino Employees) (the
“Non-RhinoRx Employees”) under all Rhino Benefit Plans, (iii) all Liabilities with respect to the employment or termination of employment of all Non-RhinoRx Employees and their dependents and beneficiaries, (iv) all
Liabilities with respect to other service providers (including any individual who is, or was, an independent contractor, temporary employee, temporary service worker, consultant, freelancer, agency employee, leased employee, on-call worker,
incidental worker, or nonpayroll worker of Rhino or its Subsidiaries or in any other employment, non-employment, or retainer arrangement, or relationship with Rhino or its Subsidiaries), to the extent arising in connection with or as a result of
employment with or the performance of services to Rhino or its Subsidiaries in connection with any business other than the Rhino Institutional Pharmacy Business and (v) any other Liabilities expressly assigned to Rhino or its Subsidiaries
(other than the RhinoRx Entities) under this Agreement, including, without limitation, the Non-RhinoRx Liabilities. All Assets held in trust to fund, and all insurance policies funding, any Liabilities expressly assumed or retained by Rhino and its
Subsidiaries (other than the RhinoRx Entities) pursuant to the operation of this Section 12.02(c) shall be Non-RhinoRx Assets, except to the extent specifically provided otherwise in this Agreement. 
 (d) Notwithstanding anything in this Agreement to the contrary, Rhino and its Subsidiaries (other than the RhinoRx Entities) shall retain all Liabilities
and Assets relating to health insurance claims incurred by Transferring Rhino Employees prior to the Closing Date under any health insurance policy sponsored or maintained by Rhino or its Subsidiaries (other than the RhinoRx Entities). For purposes
of this Section 12.02(d), a health insurance claim relating to a period of 

  

 110 

 
continuous hospitalization is deemed to be incurred on the first date of such period of hospitalization. 
 (e) Each Active Transferring Rhino Employee will receive service credit for all periods of employment with Rhino or any of its Subsidiaries or any
predecessor thereof prior to the Effective Time for purposes of vesting, eligibility and benefit levels under any employee benefit plan in which such employee participates after the Effective Time, to the extent that such service was recognized
under any analogous plan of Rhino or any of its Subsidiaries in effect immediately prior to the Effective Time; provided that no such service credit shall be given for purposes of benefit accruals under any defined benefit pension plan or
where such credit would result in a duplication of benefits. 
 (f) If on or after the Effective Time any Active Transferring Rhino Employee
becomes covered under any Successor Plan, other than a Prior Plan, any such Successor Plan shall not include any restrictions or limitations with respect to any pre-existing condition exclusions and actively-at-work requirements (except to the
extent such exclusions or requirements were applicable under the corresponding Prior Plan), and any eligible expenses incurred by such Active Transferring Rhino Employee and his or her covered dependents during the calendar year in which the Active
Transferring Rhino Employee becomes covered under any Successor Plan shall be taken into account under any such Successor Plan for purposes of satisfying all deductible, coinsurance and maximum out-of-pocket requirements applicable to such employee
and/or his or her covered dependents for that year, to the extent that such expenses were incurred during a period in which the Active Transferring Rhino Employee or covered dependent was covered under a corresponding Prior Plan. 
 Section 12.03. No Third Party Beneficiaries. No Transferring Hippo Employee or beneficiary or dependent thereof, Transferring Rhino Employee
or beneficiary or dependent thereof, or any other future, present or former employee of Hippo, Rhino, Newco or any of their respective Subsidiaries or Affiliates shall have any third party beneficiary rights or rights to any specific levels of
compensation or benefits or rights to continued employment as a result of the application of this Article 12 or any other provision of this Agreement. 
 Section 12.04. Severance. Notwithstanding anything in this Agreement to the contrary, Newco shall not be responsible for any severance pay or termination pay to any Transferring Hippo Employee or
Transferring Rhino Employee whose employment is terminated (for any reason) prior to or at the Distribution Time. 
 Section 12.05.
Intention and Scope. This Article 12 provides for the treatment of certain specific employee-related liabilities and, except to the extent explicitly set forth herein, nothing in this Article 12 is intended to limit the scope and generality of
Section 2.02 or Section 3.02. 
  

 111 

 Section 12.06. Cooperation. Hippo and Rhino shall work in good faith with the Transition
Planning Committee during the period between the date hereof and the Closing to determine the treatment of, or the effect of the transactions contemplated by this Agreement on, any compensation or benefits earned or received by Transferring Hippo
Employees or Transferring Rhino Employees (if any) that are not specifically addressed in this Article 12. 
 ARTICLE 13 
 CONDITIONS TO THE OBLIGATIONS OF THE PARTIES

 Section 13.01. Conditions to the Obligations of Each Party. The obligations of each party hereto to consummate the
Transactions are subject to the satisfaction of the following conditions: 
 (a) no material provision of any Applicable Law and no judgment,
injunction, order or decree shall prohibit the consummation of the Transactions or the other transactions contemplated hereby; 
 (b) the
Registration Statement shall have been declared effective and no stop order suspending the effectiveness of the Registration Statement shall be in effect and no proceedings for such purpose shall be pending before or threatened by the SEC;

 (c) the shares of Newco Common Stock to be issued in the Mergers shall have been approved for listing on the New York Stock Exchange,
subject to official notice of issuance; 
 (d) the Governmental Approvals set forth in Section 13.01(d) of the Hippo Disclosure Schedule
shall have been, in the case of consents, registrations, approvals, permits, licenses, authorizations and waivers, obtained and in the case of notices, reports or other filings, made (or confirmation reasonably acceptable to the parties shall have
been obtained from the applicable Governmental Authorities that such Governmental Approvals are not required to be obtained or made), other than those Governmental Approvals the failure of which to be made or obtained would not, individually or in
the aggregate, have an effect that would reasonably be expected to be adverse and material to the business and operations of Newco and its Subsidiaries, taken as a whole, after giving effect to the Transactions; 
 (e) the Newco Financing shall be in place with funds available for borrowing thereunder, subject only to the condition that the Effective Time shall have
occurred; 
 (f) there shall not have been instituted any action or proceeding by any Governmental Authority that remains pending before any
Governmental Authority (i) challenging or seeking to make illegal, to delay materially or otherwise directly or indirectly to restrain or prohibit the consummation of the 

  

 112 

 
Transactions, seeking to obtain material damages in connection with the Transactions or otherwise directly or indirectly relating to the transactions
contemplated by the Transaction Agreements, (ii) seeking to restrain or prohibit Newco’s or its Subsidiaries’ (A) ability effectively to exercise full rights of ownership of the HippoRx Common Stock or the RhinoRx Common Stock,
including the right to vote any shares of the HippoRx Common Stock or the RhinoRx Common Stock owned by Newco following the Effective Time, or (B) ownership or operation of all or any material portion of the business or assets of the HippoRx
Group and the RhinoRx Group, taken as a whole, or (iii) seeking to compel Newco or any of its Subsidiaries to dispose of or hold separate all or any material portion of the business or assets of the HippoRx Group and the RhinoRx Group, taken as
a whole; 
 (g) each of the Transaction Agreements shall have been executed and delivered by each of the other parties thereto; 

(h) the Boards of Directors of each of Rhino and Hippo shall be satisfied that at the Effective Time, after giving effect to the transactions
contemplated to be effected on or prior to the Effective Time, Newco will be Solvent, including having obtained any appraisals and solvency opinions deemed appropriate by such Boards of Directors; 
 (i)(i) the Board of Directors of Hippo Operating Sub shall be satisfied that after giving effect to the transfer by Hippo Operating Sub described in
clause (i) of Section 2.05(d) (and taking into account the other transactions contemplated by the Transaction Agreements), Hippo Operating Sub will be Solvent; (ii) the Board of Directors of HippoRx shall be satisfied that the
distribution by HippoRx to Hippo of the HippoRx Final Financing Amount will be made out of surplus within the meaning of Section 170 of Delaware Law and that, after giving effect to such distribution (and taking into account the other
transactions contemplated by the Transaction Agreements), HippoRx will be Solvent; and (iii) the Board of Directors of Hippo shall be satisfied that the HippoRx Distribution will be made out of surplus within the meaning of Section 170 of
Delaware Law and that, after giving effect to such distribution (and taking into account the other transactions contemplated by the Transaction Agreements), Hippo will be Solvent (it being understood that the satisfaction of this condition may be
subject to the obtaining of any appraisals, surplus and solvency opinions as the applicable board of directors deems appropriate); and 
 (j)(i) the Board of Directors of RhinoRx shall be satisfied that the distribution by RhinoRx to Rhino Parent Sub of the RhinoRx Final Financing Amount will be made out of surplus within the meaning of Section 170 of Delaware Law and
that, after giving effect to such distribution (and taking into account the other transactions contemplated by the Transaction Agreements), RhinoRx will be Solvent; (ii) the Board of Directors of Rhino Parent Sub shall be satisfied that the
distribution by Rhino Parent Sub to Rhino of the outstanding stock of RhinoRx will be made out of surplus within the meaning of Section 170 

  

 113 

 
of Delaware Law and that, after giving effect to such distribution (and taking into account the other transactions contemplated by the Transaction
Agreements), Rhino Parent Sub will be Solvent; and (iii) the Board of Directors of Rhino shall be satisfied that the RhinoRx Distribution will be made out of surplus within the meaning of Section 170 of Delaware Law and that, after giving
effect to such distribution (and taking into account the other transactions contemplated by the Transaction Agreements), Rhino will be Solvent (it being understood that the satisfaction of this condition may be subject to the obtaining of any
appraisals, surplus and solvency opinions as the applicable board of directors deems appropriate). 
 Section 13.02. Conditions to
the Obligations of Hippo. The obligations of each of Hippo, HippoRx and Hippo Merger Sub to consummate the Transactions to which it is party are subject to the satisfaction of the following further conditions: 
 (a)(i) Rhino shall have performed in all material respects all of its obligations hereunder required to be performed by it at or prior to the Effective
Time, (ii) subject to the standards set forth in Section 16.01(b), the representations and warranties of Rhino contained in this Agreement, shall be true and correct at and as of the Effective Time, as if made at and as of such time (other
than representations or warranties that address matters only as of a certain date, which shall be true and correct as of such date), and (iii) Hippo shall have received a certificate signed by an executive officer of Rhino to the foregoing
effect; 
 (b) Hippo shall have received an opinion of Pepper Hamilton LLP reasonably acceptable to Hippo dated the Closing Date, to the
effect that (i) the HippoRx Distribution will qualify as a transaction described in Section 355(a) of the Code, (ii) the HippoRx Common Stock will be treated as “qualified property” for purposes of Section 355(c)(2) or
Section 361(c)(2) of the Code, and (iii) the exchange of HippoRx Common Stock for Newco Common Stock pursuant to the HippoRx Merger will be treated for federal income tax purposes as an exchange described in Section 351 of the Code.
In rendering such opinion, such counsel shall be entitled to rely upon appropriate representations of officers of Hippo and Newco, reasonably acceptable to such counsel, which representations shall be substantially finalized by the parties hereto
and such counsel by November 17, 2006; 
 (c) Hippo shall have received a private letter ruling from the Internal Revenue Service,
reasonably acceptable to Hippo, that contains, in all material respects, the rulings included in Exhibit T hereto; 
 (d) the Hippo Lender
Approval shall have been obtained and shall be in effect; and 
  

 114 

 (e) the HippoRx Final Financing Amount shall have been obtained and shall have been paid to Hippo whether
in repayment of intercompany account balances pursuant to Section 9.03 or as a dividend. 
 Section 13.03. Conditions to the
Obligations of Rhino. The obligations of each of Rhino, RhinoRx, Rhino Parent Sub and Rhino Merger Sub to consummate the Transactions to which it is party are subject to the satisfaction of the following further conditions: 
 (a)(i) Hippo shall have performed in all material respects all of its obligations hereunder required to be performed by it at or prior to the Effective
Time, (ii) subject to the standards set forth in Section 16.01(a), the representations and warranties of Hippo contained in this Agreement shall be true and correct at and as of the Effective Time, as if made at and as of such time (other
than representations and warranties that address matters only as of a certain date, which shall be true and correct as of such date) and (iii) Rhino shall have received a certificate signed by an executive officer of Hippo to the foregoing
effect; 
 (b) Rhino shall have received an opinion of Caplin & Drysdale reasonably acceptable to Rhino dated the Closing Date, to
the effect that (i) the RhinoRx Distribution will qualify as a transaction described in Section 355(a) of the Code, (ii) the RhinoRx Common Stock will be treated as “qualified property” for purposes of Section 355(c)(2)
or Section 361(c)(2) of the Code, and (iii) the exchange of RhinoRx Common Stock for Newco Common Stock pursuant to the RhinoRx Merger will be treated for federal income tax purposes as an exchange described in Section 351 of the
Code. In rendering such opinion, such counsel shall be entitled to rely upon appropriate representations of officers of Rhino and Newco, reasonably acceptable to such counsel, which representations shall be substantially finalized by the parties
hereto and such counsel by November 17, 2006; 
 (c) Rhino shall have received a private letter ruling from the Internal Revenue
Service, reasonably acceptable to Rhino, that contains, in all material respects, the rulings included in Exhibit U hereto; 
 (d) the Rhino
Lender Approval shall have been obtained and shall be in effect; and 
 (e) the RhinoRx Final Financing Amount shall have been obtained and
shall have been paid to Rhino Parent Sub whether in repayment of intercompany account balances pursuant to Section 10.03 or as a dividend. 
  

 115 

 ARTICLE 14 
 TERMINATION 
 Section 14.01. Termination. This Agreement may be terminated and
the Transactions may be abandoned at any time prior to the Distribution Time: 
 (a) by mutual written agreement of Hippo and Rhino;

 (b) by either Hippo or Rhino, if: 
 (i) the Transactions have not been consummated on or before June 30, 2007 (the “End Date”); provided that the right to terminate this Agreement pursuant to this Section 14.01(b)(i)
shall not be available to any party whose breach of any provision of this Agreement results in the failure of the Transactions to be consummated by such time; provided, further, that if the Transactions have not been consummated on or before
June 30, 2007 solely by reason of the failure of the condition set forth in Section 13.01(d) to be satisfied, the “End Date” shall be extended to September 30, 2007 in the event either Hippo or Rhino delivers a notice to the
other indicating that it believes in good faith that such condition would reasonably be expected to be satisfied by September 30, 2007; 
 (ii) there shall be any Applicable Law that (A) makes consummation of the Transactions illegal or otherwise prohibited or (B) enjoins Hippo or Rhino from consummating the Transactions and such enjoinment
shall have become final and nonappealable; 
 (iii) the HippoRx Audited EBITDA is less than 75% of the HippoRx Estimated
EBITDA; or 
 (iv) the RhinoRx Audited EBITDA is less than 75% of the RhinoRx Estimated EBITDA; 
 (c) by Hippo, if any of the conditions set forth in Section 13.01 or 13.02 shall have become incapable of being satisfied by the End Date;
provided that the right to terminate this Agreement pursuant to this Section 14.01(c) shall not be available if Hippo’s breach of any provision of this Agreement has resulted in such condition becoming incapable of being satisfied;

 (d) by Hippo, if (i) the audited financial statements described in the second sentence of Section 10.05 have not been delivered
by Rhino to Hippo on or before January 31, 2007 or (ii) the audited financial statements described in the first sentence of Section 10.05 have not been delivered by Rhino to Hippo on or before March 31, 2007; 
  

 116 

 (e) by Rhino, if the audited financial statements described in the first sentence of Section 9.05
have not been delivered by Hippo to Rhino on or before January 31, 2007; or 
 (f) by Rhino, if any of the conditions set forth in
Section 13.01 or 13.03 shall have become incapable of being satisfied by the End Date; provided that the right to terminate this Agreement pursuant to this Section 14.01(d) shall not be available if Rhino’s breach of any
provision of this Agreement has resulted in such condition becoming incapable of being satisfied. 
 The party desiring to terminate this Agreement pursuant
to this Section 14.01 (other than pursuant to Section 14.01(a)) shall give notice of such termination to the other party. 
 Section 14.02. Effect of Termination. If this Agreement is terminated pursuant to Section 14.01, this Agreement shall become void and of no effect without liability of any party (or any stockholder, director, officer,
employee, agent, consultant or representative of such party) to the other party hereto; provided that, if such termination shall result from the knowing and willful (i) failure of either party to use reasonable best efforts to fulfill a
condition to the performance of the obligations of the other party or (ii) breach of any representation or warranty herein or in the Tax Matters Agreement or the failure of either party to perform a covenant herein or in the Tax Matters
Agreement, such party shall be fully liable for any and all liabilities and damages incurred or suffered by the other party (but not to any third party not a party to this Agreement including any stockholder, director, officer, employee, agent
consultant or representative of such party) as a result of such failure. The provisions of this Section 14.02, Section 11.07(b) and Article 16 shall survive any termination hereof pursuant to Section 14.01. 
 ARTICLE 15 
 SURVIVAL
AND INDEMNIFICATION; RELEASES 
 Section 15.01. Survival. The representations and
warranties of the parties hereto contained in this Agreement or in any certificate or other writing delivered pursuant hereto or in connection herewith (and covenants (the “Excluded Covenants”) herein that have the effect of
obligating a party to maintain the accuracy of representations and warranties or to provide notice of an inaccuracy in its representations or warranties) shall survive the Closing Date until the 15-month anniversary of the Closing Date. The
covenants and agreements of the parties hereto contained in this Agreement or in any certificate or other writing delivered pursuant hereto or in connection herewith shall survive the Effective Time indefinitely or for the shorter period explicitly
specified therein, except as specified in the preceding sentence and except that for such covenants and agreements that survive for such shorter period, breaches thereof shall survive indefinitely or until the latest date permitted by law.
Notwithstanding the 

  

 117 

 
preceding sentence, any breach of covenant, agreement, representation or warranty in respect of which indemnity may be sought under this Agreement shall
survive the time at which it would otherwise terminate pursuant to the preceding sentence, if written notice of the inaccuracy or breach thereof giving rise to such right of indemnity, and referencing the right to indemnification hereunder, shall
have been given to the party against whom such indemnity may be sought prior to such time. 
 Section 15.02. Indemnification. 

 (a) Subject to Section 15.02(c), effective at and after the Effective Time, Hippo hereby indemnifies Newco and its Affiliates and
their respective successors and assigns (the “Newco Indemnified Parties”) against, and agrees to hold each of them harmless from, any and all damage, loss, liability and expense (including reasonable expenses of investigation and
reasonable attorneys’ fees and expenses in connection with any action, suit or proceeding whether involving a Third Party claim or a claim solely between the parties hereto) (“Damages”) actually incurred or suffered by such
Newco Indemnified Party arising out of, relating to or resulting from (i) subject to the next sentence, any misrepresentation or breach of warranty in this Agreement as of the date made or at and as of the Effective Time, as if made at and as
of such time (or, in the case of representations and warranties that address matters only as of a certain date, as of such date) (each such misrepresentation or breach of warranty, a “Warranty Breach”) by Hippo; (ii) any breach
of a covenant or agreement in this Agreement (each such breach of covenant or agreement, a “Covenant Breach”) by Hippo (it being understood that the breach of the Excluded Covenants shall be considered Warranty Breaches rather than
Covenants Breaches); or (iii) the Non-HippoRx Group, the Non-HippoRx Assets or the Non-HippoRx Liabilities. Section 15.02(a) shall not apply to any breach of the representation contained in Section 7.08(b). 
 (b) Subject to Section 15.02(c), effective at and after the Effective Time, Rhino hereby indemnifies the Newco Indemnified Parties against, and
agrees to hold each of them harmless from, any and all Damages actually incurred or suffered by such Newco Indemnified Party arising out of, relating to or resulting from (i) subject to the next sentence, any Warranty Breach by Rhino;
(ii) any Covenant Breach by Rhino; or (iii) the Non-RhinoRx Group, the Non-RhinoRx Assets or the Non-RhinoRx Liabilities. Section 15.02(b) shall not apply to any breach of the representation contained in Section 8.08(b).

 (c) With respect to indemnification by Hippo or Rhino pursuant to Section 15.02(a) or Section 15.02(b), the obligations of Hippo
and Rhino, as the case may be, to the Newco Indemnified Parties shall be limited as follows: 
 (i)(A) Hippo shall not be
liable to any Newco Indemnified Party unless the aggregate amount of Damages actually incurred or suffered by the Newco Indemnified Parties with respect to Warranty 

  

 118 

 
Breaches (determined without regard to any materiality or Material Adverse Effect qualification contained in any representation or warranty other than any
such qualifications that set disclosure thresholds) by Hippo exceeds $30,000,000 and then only to the extent of such excess and (B) Hippo’s maximum liability for all such Warranty Breaches shall not exceed $155,000,000; provided
that the limitations set forth in this Section 15.02(c)(i) shall not apply to Warranty Breaches of Section 7.02 or Section 7.14; 
 (ii)(A) Rhino shall not be liable to any Newco Indemnified Party unless the aggregate amount of Damages actually incurred or suffered by the Newco Indemnified Parties with respect to Warranty Breaches (determined
without regard to any materiality or Material Adverse Effect qualification contained in any representation or warranty other than any such qualifications that set disclosure thresholds) by Rhino exceeds $30,000,000 and then only to the extent of
such excess and (B) Rhino’s maximum liability for all such Warranty Breaches shall not exceed $155,000,000; provided that the limitations set forth in this Section 15.02(c)(ii) shall not apply to Warranty Breaches of Section 8.02
or Section 8.14; and 
 (iii) For the avoidance of doubt, (A) Hippo shall not indemnify the Newco Indemnified
Parties for any Warranty Breaches or Covenant Breaches by Rhino and (B) Rhino shall not indemnify the Newco Indemnified Parties for any Warranty Breaches or Covenant Breaches by Hippo; 
 (d) Effective at and after the Effective Time, Hippo hereby indemnifies the Newco Indemnified Parties against, and agrees to hold each of them harmless
from, any and all Damages actually incurred or suffered by such Newco Indemnified Party arising out of, relating to or resulting from, any misrepresentation or breach of warranty by Hippo of the representation in Section 7.08(b). For the
avoidance of doubt, to the extent Damages are recoverable because of a breach of the representation in Section 7.08(b), Damages shall not be recoverable pursuant to a claim of indemnification for a breach of any other representation or warranty
of Hippo in this Agreement. For the avoidance of doubt, Damages recoverable for breach of the representation in Section 7.08(b) include diminution in value, if any, of the Hippo Institutional Pharmacy Business as a result of such breach.

 (e) Effective at and after the Effective Time, Rhino hereby indemnifies the Newco Indemnified Parties against, and agrees to hold each of
them harmless from, any and all Damages actually incurred or suffered by such Newco Indemnified Party arising out of, relating to or resulting from, any misrepresentation or breach of warranty by Rhino of the representation in Section 8.08(b).
For the avoidance of doubt, to the extent Damages are recoverable because of a breach of the representation in Section 8.08(b), Damages shall not be 

  

 119 

 
recoverable pursuant to a claim of indemnification for a breach of any other representation or warranty of Rhino in this Agreement. For the avoidance of
doubt, Damages recoverable for breach of the representation in Section 8.08(b) include diminution in value, if any, of the Rhino Institutional Pharmacy Business as a result of such breach. 
 (f) Effective at and after the Effective Time, Newco hereby indemnifies Hippo, its Subsidiaries and their respective Affiliates and successors and
assigns (the “Hippo Indemnified Parties”) against, and agrees to hold each of them harmless from, any and all Damages incurred or suffered by such Hippo Indemnified Parties arising out of, relating to or resulting from (i) any
Covenant Breach by Newco or (ii) the HippoRx Group, the HippoRx Assets, the HippoRx Liabilities, the RhinoRx Group, the RhinoRx Assets or the RhinoRx Liabilities. 
 (g) Effective at and after the Effective Time, Newco hereby indemnifies Rhino, its Subsidiaries and their respective Affiliates and successors and assigns (the “Rhino Indemnified Parties”) against,
and agrees to hold each of them harmless from, any and all Damages incurred or suffered by such Rhino Indemnified Parties arising out, relating to or resulting from (i) any Covenant Breach by Newco or (ii) the RhinoRx Group, the RhinoRx
Assets, the RhinoRx Liabilities, the HippoRx Group, the HippoRx Assets or the HippoRx Liabilities. 
 (h) From and after the Effective Time
Hippo shall not be liable to the Rhino Indemnified Parties for any Warranty Breaches or Covenant Breaches by Hippo. From and after the Effective Time Rhino shall not be liable to the Hippo Indemnified Parties for any Warranty Breaches or Covenant
Breaches by Rhino. 
 (i) None of Hippo, Rhino or Newco shall be liable to any Newco Indemnified Party, Hippo Indemnified Party or Rhino
Indemnified Party, as the case may be, for any punitive, incidental, consequential, special or indirect damages, including business interruption or loss of future revenue, relating to the breach or alleged breach of this Agreement, except if such
damages were paid by the applicable Indemnified Party to a Third Party and arose from circumstances that constituted a breach of a representation or warranty contained herein. 
 (j) The indemnification provisions contained in this Section 15.02 shall not apply to any misrepresentation or breach of warranty contained in
Section 7.10(a)(xv), 7.15, 7.24, 8.10(a)(xv), 8.15 or 8.24, to any breach of the covenants contained in Section 9.01(n), 10.01(n), or 11.11, or to any Damages with respect to any Tax liability or Tax asset allocated to any Person pursuant
to the Tax Matters Agreement. 
 Section 15.03. Indemnification Procedures.  
 (a) The party seeking indemnification under Section 15.02 (the “Indemnified Party”) agrees to give prompt notice to the party
against whom indemnity is sought (the “Indemnifying Party”) of the assertion of any claim, or 

  

 120 

 
the commencement of any suit, Action or proceeding (each, a “Claim”) in respect of which indemnity may be sought under such Section and will
provide the Indemnifying Party such information with respect thereto that the Indemnifying Party may reasonably request. The failure to so notify the Indemnifying Party shall not relieve the Indemnifying Party of its obligations hereunder, except to
the extent such failure shall have actually materially prejudiced the Indemnifying Party. 
 (b) The Indemnifying Party shall have the right,
at its option, exercisable within 30 days after receipt of such notice to assume the defense of, at its own expense and by its own counsel (which counsel shall be reasonably satisfactory to the Indemnified Party), any matter involving the asserted
liability of the Indemnified Party (“Asserted Liabilities”), subject to the limitations set forth herein. If the Indemnifying Party shall undertake to compromise, settle or defend any such Asserted Liability, it shall promptly
notify the Indemnified Party of its intention to do so, and the Indemnified Party agrees to cooperate fully with the Indemnifying Party and its counsel in the compromise or settlement of, or defense against, any such Asserted Liability; provided,
however, that the Indemnifying Party shall not settle any such Asserted Liability without the written consent of the Indemnified Party unless such settlement releases the Indemnified Party from all liabilities and obligations with respect to the
Asserted Liability and the settlement does not impose injunctive or other equitable relief against the Indemnified Party. Notwithstanding an election by the Indemnifying Party to assume the defense of such action or proceeding, the Indemnified Party
shall have the right to employ separate counsel and to participate in the defense of such action or proceeding at its own expense. Notwithstanding anything herein to the contrary, the Indemnifying Party shall not be entitled to assume control of
such defense but shall pay for the reasonable fees, costs and expenses of the Indemnified Party’s legal counsel, which counsel shall be reasonably satisfactory to the Indemnifying Party, if (i) the claim for indemnification relates to or
arises in connection with any criminal proceeding, action, indictment, allegation or investigation, (ii) the Indemnified Party has been advised by counsel that a reasonable likelihood exists of a conflict of interest between the Indemnifying
Party, on the one hand, and the Indemnified Party, on the other hand, or (iii) the Indemnifying Party failed or is failing to prosecute or defend such claim. If the Indemnified Party shall undertake to compromise, settle or defend any Asserted
Liability in accordance with the immediately preceding sentence or after the Indemnifying Party has declined to exercise its option to assume the defense of an Asserted Liability, the Indemnified Party shall promptly notify the Indemnifying Party of
its intention to do so, and the Indemnifying Party agrees to cooperate fully with the Indemnified Party and its counsel in the compromise or settlement of, or defense against, any such Asserted Liability; provided, however, that the
Indemnified Party shall not settle any such Asserted Liability without the written consent of the Indemnifying Party, which such consent shall not be unreasonably withheld. 
  

 121 

 (c) Each party shall cooperate, and cause their respective Affiliates to cooperate, in the defense or
prosecution of any Claim by a Third Party and shall furnish or cause to be furnished such records, information and testimony, and attend such conferences, discovery proceedings, hearings, trials or appeals, as may be reasonably requested in
connection therewith. 
 Section 15.04. Calculation of Damages. Any Damages payable by an Indemnifying Party pursuant to
Section 15.02 shall be (i) reduced by any proceeds recovered under applicable insurance policies, net of any costs incurred by the Indemnified Party in obtaining such proceeds, (ii) reduced by any indemnity, contribution or other
similar payment paid to the Indemnified Party by any Third Party with respect to such Damages, net of any costs incurred by the Indemnified Party in obtaining such payment and (iii) reduced by an amount equal to any net tax benefit actually
realized as a consequence of such Damages. If an Indemnified Party receives a payment required by this Agreement from an Indemnifying Party in respect of any Liability and subsequently receives insurance proceeds, then the Indemnified Party will pay
to the Indemnifying Party an amount equal to the excess of the payment received over the amount of the payment that would have been due if the insurance proceeds had been received, realized or recovered before the payment was made by the
Indemnifying Party. 
 Section 15.05. Release of Pre-Closing Claims.  
 (a) Except as provided in Section 15.05(c), effective as of the Effective Time, Newco, for itself, its Subsidiaries and each HippoRx Entity and
RhinoRx Entity and their respective successors and assigns, and all shareholders, directors, officers, members, agents or employees of a HippoRx Entity or RhinoRx Entity (in each case, in their respective capacities as such), hereby remises,
releases and forever discharges each of Hippo and Rhino and their respective Subsidiaries (other than the HippoRx Entities and the RhinoRx Entities, respectively), their respective successors and assigns, and all shareholders, directors, officers,
members, agents or employees of any wholly owned member of Hippo or Rhino (in each case, in their respective capacities as such), and their respective heirs, executors, administrators, successors and assigns, from any and all Liabilities whatsoever,
whether at law or in equity (including any right of contribution), whether arising under any contract or agreement, by operation of law or otherwise, existing or arising from any acts or events occurring or failing to occur or alleged to have
occurred or to have failed to occur or any conditions existing or alleged to have existed at or before the Effective Time, whether or not known as of the Effective Time, including in connection with the Transactions. 
 (b) Except as provided in Section 15.05(c), effective as of the Effective Time, each of Hippo and Rhino, for itself and each of its Subsidiaries
(other than any HippoRx Entity or RhinoRx Entity) and their respective successors and assigns, and all shareholders, directors, officers, members, agents or employees of Hippo or Rhino or such Subsidiaries (in each case, in their respective
capacities as such), hereby remises, releases and forever discharges each of Newco and its 

  

 122 

 
Subsidiaries (including the HippoRx Entities and RhinoRx Entities), their respective successors and assigns, and all shareholders, directors, officers,
members, agents or employees of Newco and such Subsidiaries (in each case, in their respective capacities as such), and their respective heirs, executors, administrators, successors and assigns, from any and all Liabilities whatsoever, whether at
law or in equity (including any right of contribution), whether arising under any contract or agreement, by operation of law or otherwise, existing or arising from any acts or events occurring or failing to occur or alleged to have occurred or to
have failed to occur or any conditions existing or alleged to have existed at or before the Effective Time, whether or not known as of the Effective Time, including in connection with the Transactions. 
 (c) Nothing contained in Section 15.05(a) or Section 15.05(b) shall impair any right of any Person to enforce the Transaction Agreements or any
agreements, arrangements, commitments or understandings that are specified in Section 2.04(b) or Section 3.04(b) as surviving the Closing Date, in each case in accordance with its terms. Nothing contained in Section 15.05(a) or
Section 15.05(b) shall release any Person from: 
 (i) any Liability provided in or resulting from any agreement among
Hippo or its Subsidiaries or Rhino or its Subsidiaries, on the one hand, and Newco, any HippoRx Entity or any RhinoRx Entity, on the other hand, that is specified in Section 2.04(b) or Section 3.04(b) as surviving the Closing Date, or any
other Liability specified in such Sections as surviving the Closing Date; or 
 (ii) any Liability, contingent or otherwise,
assumed, transferred, assigned or allocated to Hippo, Rhino, Newco, the HippoRx Entities, the RhinoRx Entities or any of their respective Subsidiaries in accordance with, or any other Liability of any such Person under, the Transaction Agreements.

 (d) If an Indemnified Party receives any payment from an Indemnifying Party in respect of Damages and the Indemnified Party could have
recovered all or a part of such Damages from a Third Party based on the underlying claim or demand asserted against such Indemnifying Party, then such Indemnified Party shall transfer such of its rights to proceed against such Third Party as are
necessary to permit such Indemnifying Party to recover from such Third Party the amount of such payment. 
 Section 15.06.
Exclusivity. After the Effective Time, Article 15 will provide the exclusive remedy for any claims by or against Newco or its Subsidiaries, on the one hand, or by or against Hippo, Rhino or any of their respective Subsidiaries or Affiliates, on
the other hand, arising as a result of or in connection with this Agreement and the transactions contemplated hereby (other than any remedy provided in any of the other Transaction Agreements) except 

  

 123 

 
that the indemnity provisions contained herein shall not limit any party’s liability for fraud or intentional misrepresentation. 
 ARTICLE 16 
 MISCELLANEOUS

 Section 16.01. Representations and Warranties. (a) For purposes of determining whether any representation or warranty of
Hippo contained in Article 7 is untrue or incorrect for any purpose under this Agreement other than Article 15, or whether Hippo shall have breached any such representation or warranty as a result of any such untruth or incorrectness for any purpose
under this Agreement (for the avoidance of doubt, in each case, including for the purpose of determining whether such representation or warranty is true and correct when made and for purposes of determining whether such representation or warranty
can be made on and as of the Effective Time or as of the date specified therein) other than Article 15, the following standards shall apply: 
 (i) the representation and warranty contained in Section 7.10(b) shall be deemed to be untrue and incorrect if such representation and warranty is untrue or incorrect in any respect; 
 (ii) any representation and warranty contained in Sections 7.01, 7.02, 7.03, 7.04 (other than clauses (iii) and (iv) thereof),
7.05, 7.06, 7.14, 7.24 or 7.25 shall be deemed to be untrue and incorrect only if such representation and warranty is untrue or incorrect in any material respect (disregarding for this purpose any reference to materiality or Material Adverse Effect
contained in any such representation or warranty); and 
 (iii) any such representation and warranty (other than those
referred to in clause (i) or (ii) above) shall be deemed to be untrue or incorrect only if the fact, circumstance, change or event that resulted in such untruth or incorrectness, individually or when taken together with all other facts,
circumstances, changes or events that result in any and all other untruth or incorrectness in the representations and warranties contained in Article 7 (other than those referred to in clause (i) or (ii) above), either (x) has had or
would reasonably be expected to have, a Material Adverse Effect on HippoRx (disregarding for this purpose any reference to materiality or Material Adverse Effect contained in any such representation or warranty) or (y) would materially delay or
materially impede or preclude the ability of Hippo or HippoRx to perform its obligations hereunder or their ability to consummate the Closing. 
 (b) For purposes of determining whether any representation or warranty of Rhino contained in Article 8 is untrue or incorrect for any purpose under this Agreement other than Article 15, or whether Rhino shall have breached any such
representation or warranty as a result of any such untruth or incorrectness for any 

  

 124 

 
purpose under this Agreement (for the avoidance of doubt, in each case, including for the purpose of determining whether such representation or warranty is
true and correct when made and for purposes of determining whether such representation or warranty can be made on and as of the Effective Time or as of the date specified therein) other than Article 15, the following standards shall apply:

 (i) the representation and warranty contained in Section 8.10(b) shall be deemed to be untrue and incorrect if such
representation and warranty is untrue or incorrect in any respect; 
 (ii) any representation and warranty contained in
Sections 8.01, 8.02, 8.03, 8.04 (other than clauses (iii) and (iv) thereof), 8.05, 8.06, 8.14, 8.24 or 8.25 shall be deemed to be untrue and incorrect only if such representation and warranty is untrue or incorrect in any material respect
(disregarding for this purpose any reference to materiality or Material Adverse Effect contained in any such representation or warranty); and 
 (iii) any such representation and warranty (other than those referred to in clause (i) or (ii) above) shall be deemed to be untrue or incorrect only if the fact, circumstance, change or event that resulted
in such untruth or incorrectness, individually or when taken together with all other facts, circumstances, changes or events that result in any and all other untruth or incorrectness in the representations and warranties contained in Article 8
(other than those referred to in clause (i) or (ii) above), either (x) has had or would reasonably be expected to have, a Material Adverse Effect on RhinoRx (disregarding for this purpose any reference to materiality or Material
Adverse Effect contained in any such representation or warranty) or (y) would materially delay or materially impede or preclude the ability of Rhino or RhinoRx to perform its obligations hereunder or their ability to consummate the Closing.

 Section 16.02. Notices. All notices, requests and other communications to any party hereunder shall be in writing (including
facsimile transmission) and shall be given, 
 if to Hippo, to: 
 AmerisourceBergen Corporation 
 1300 Morris Drive 
 Chesterbrook, PA 19087 
 Attention: General
Counsel 
 Facsimile No.: (610) 727-3612 
  

 125 

 with a copy (which shall not constitute notice) to: 
 Davis Polk & Wardwell 
 450 Lexington
Avenue 
 New York, New York 10017 
 Attention: William H. Aaronson 
 Facsimile No.: (212) 450-3800 
 if to Rhino, to: 
 Kindred Healthcare, Inc.

 680 South Fourth Street 
 Louisville, Kentucky 40202-2412 
 Attention: Joseph L. Landenwich, Senior Vice President of 
                   Corporate Legal Affairs and Corporate
Secretary 
 Facsimile No.: (502) 596-4075 
 with a copy (which shall not constitute notice) to: 
 Cleary Gottlieb Steen & Hamilton LLP

 One Liberty Plaza 
 New York,
NY 10006 
 Attention: Ethan A. Klingsberg 
 Facsimile No.: (212) 225-3999 
 or to such other address or facsimile number as such party may hereafter specify for
the purpose by notice to the other parties hereto. All such notices, requests and other communications shall be deemed received on the date of receipt by the recipient thereof if received prior to 5:00 p.m. on a Business Day in the place of receipt.
Otherwise, any such notice, request or communication shall be deemed to have been received on the next succeeding Business Day in the place of receipt. 
 Section 16.03. Amendments and Waivers. (a) Any provision of this Agreement may be amended or waived prior to the Effective Time if, but only if, such amendment or waiver is in writing and is signed,
in the case of an amendment, by each party to this Agreement or, in the case of a waiver, by each party against whom the waiver is to be effective. 
 (b) No failure or delay by any party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of
any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by Applicable Law. 
 Section 16.04. Fees and Expenses. All fees and expenses incurred in connection with this Agreement shall be paid by the party incurring such fee or 

  

 126 

 
expense; provided that, notwithstanding the foregoing, Newco shall be responsible for the fees and expenses set forth in Section 16.04 of the
Hippo Disclosure Schedule regardless of which party incurs such fees and expenses. Any fees and expenses for which Newco is responsible but that are incurred and must be paid prior to the Effective Time shall be paid by Hippo and Rhino, with each of
Hippo and Rhino paying one-half of such fees and expenses, and Newco shall reimburse Hippo and Rhino for their payment of such fees and expenses at or promptly after the Effective Time. 
 Section 16.05. Disclosure Schedule References. Any information disclosed in any Section of the Hippo Disclosure Schedule or the Rhino
Disclosure Schedule shall be deemed to be disclosed in any other Section(s) of such Disclosure Schedule where it is reasonably apparent that the disclosure contained in such Section of such Disclosure Schedule is relevant to such other Section(s).
The fact that any item of information is disclosed in a Disclosure Schedule shall not be construed to mean that such information is required to be disclosed by this Agreement. Such information and the dollar thresholds set forth herein shall not be
used as a basis for interpreting the terms “material” or “Material Adverse Effect” or other similar terms in this Agreement, except as otherwise expressly set forth in the applicable Disclosure Schedules. Matters set forth in the
Disclosure Schedules are not necessarily limited to matters required by this Agreement to be reflected therein. Such additional matters are set forth for informational purposes and do not necessarily include other matters of a similar nature.

 Section 16.06. Binding Effect; Benefit; Assignment. (a) The provisions of this Agreement shall be binding upon and inure
to the benefit of the parties hereto and their respective successors and assigns. No provision of this Agreement is intended to confer any rights, benefits, remedies, obligations or liabilities hereunder upon any Person other than the parties hereto
and their respective successors and assigns except that (i) each D&O Indemnified Person is a third party beneficiary of the provisions set forth in Section 11.12 and (ii) each Newco Indemnified Party, Hippo Indemnified Party and
Rhino Indemnified Party is a third party beneficiary of the provisions set forth in Article 15. 
 (b) No party may assign, delegate or
otherwise transfer any of its rights or obligations under this Agreement without the consent of each other party hereto. 
 Section 16.07. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflicts of law rules of such state. 
 Section 16.08. Jurisdiction. The parties hereto agree that any suit, action or proceeding seeking to enforce any provision of, or based on
any matter arising out of or in connection with, the Transaction Agreements or the transactions contemplated thereby shall be brought in any federal or state court located in the 

  

 127 

 
Borough of Manhattan in the State of New York, and each of the parties hereby irrevocably consents to the jurisdiction of such courts (and of the appropriate
appellate courts therefrom) in any such suit, action or proceeding and irrevocably waives, to the fullest extent permitted by law, any objection that it may now or hereafter have to the laying of the venue of any such suit, action or proceeding in
any such court or that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. Process in any such suit, action or proceeding may be served on any party anywhere in the world, whether within or
without the jurisdiction of any such court. Without limiting the foregoing, each party agrees that service of process on such party as provided in Section 16.02 shall be deemed effective service of process on such party. 
 Section 16.09. WAIVER OF JURY TRIAL. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL
PROCEEDING ARISING OUT OF OR RELATED TO THE TRANSACTION AGREEMENTS OR THE TRANSACTIONS CONTEMPLATED THEREBY. 
 Section 16.10.
Counterparts; Effectiveness. This Agreement may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement shall become
effective when each party hereto shall have received a counterpart hereof signed by all of the other parties hereto. Until and unless each party has received a counterpart hereof signed by the other party hereto, this Agreement shall have no effect
and no party shall have any right or obligation hereunder (whether by virtue of any other oral or written agreement or other communication). 
 Section 16.11. Entire Agreement. This Agreement, the other Transaction Agreements and the Clean Team Confidentiality Agreement constitute the entire agreement between the parties with respect to the subject matter of this
Agreement and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter of this Agreement. 
 Section 16.12. Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction or other Governmental Authority to be invalid, void or
unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated so long as the economic or legal substance of the
transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such a determination, the parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as
closely as possible in an acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the fullest extent possible. 
  

 128 

 Section 16.13. Specific Performance. The parties hereto agree that irreparable damage would
occur if any provision of this Agreement were not performed in accordance with the terms hereof and that the parties shall be entitled to an injunction or injunctions to prevent breaches of this Agreement or to enforce specifically the performance
of the terms and provisions hereof in any federal or state court located in the Borough of Manhattan in the State of New York, in addition to any other remedy to which they are entitled at law or in equity. 
  

 129 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective
authorized officers as of the day and year first above written. 
  

			
	AMERISOURCEBERGEN CORPORATION
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	PHARMERICA, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	KINDRED HEALTHCARE, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	KINDRED PHARMACY SERVICES, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	KINDRED HEALTHCARE OPERATING, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	

			
	SAFARI HOLDING CORPORATION
	By:	 	  

	Name:	 	
	Title:	 	
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	HIPPO MERGER CORPORATION
		
	By:	 	  

	Name:	 	
	Title:	 	
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	RHINO MERGER CORPORATION
		
	By:	 	  

	Name:	 	
	Title:	 	
		
	By:	 	  

	Name:	 	
	Title:	 	

 Annex A – Adjustments 
 Section 1. Adjustment Procedures. 
 (a) Not later than 10 Business Days prior to the Closing Date, (i) Hippo shall submit to Rhino a certificate (the “HippoRx Estimate Certificate”) of an authorized officer of Hippo setting forth its good faith estimate
of the HippoRx Working Capital (the “Estimated HippoRx Working Capital”) and (ii) Rhino shall submit to Hippo a certificate (the “RhinoRx Estimate Certificate”) of an authorized officer of Rhino setting forth
its good faith estimate of the RhinoRx Working Capital (the “Estimated RhinoRx Working Capital”). The amounts set forth on the HippoRx Estimate Certificate and the RhinoRx Estimate Certificate, as the case may be, shall be
calculated in accordance with GAAP on a basis consistent with the applicable audited financial statements in the Registration Statement and shall be accompanied by appropriate information and documentation in reasonable detail supporting the
calculations of the Estimated HippoRx Working Capital and the Estimated RhinoRx Working Capital, as the case may be. 
 (b) Following receipt
of the HippoRx Estimate Certificate by Rhino and the RhinoRx Estimate Certificate by Hippo, Hippo and Rhino shall work in good faith to mutually agree on the amounts of the HippoRx Working Capital and the RhinoRx Working Capital. If Hippo and Rhino
are unable to agree on the amounts of the HippoRx Working Capital or the RhinoRx Working Capital, as the case may be, within 3 Business Days following delivery of both certificates, each of Hippo and Rhino shall submit a notice (each such notice, a
“Disagreement Notice”) to a mutually satisfactory nationally recognized accounting firm (the “Accounting Referee”) specifying those items or amounts as to which they each disagree. The Disagreement Notices shall set
forth the nature and basis for each disagreement with respect to the HippoRx Working Capital or the RhinoRx Working Capital, as the case may be. Rhino shall be deemed to have agreed with all items and amounts on the HippoRx Estimate Certificate (as
such items and amounts may have been modified by mutual agreement of Hippo and Rhino) that Rhino does not contest in its Disagreement Notice. Hippo shall be deemed to have agreed with all items and amounts on the RhinoRx Estimate Certificate (as
such items and amounts may have been modified by mutual agreement of Hippo and Rhino) that Hippo does not contest in its Disagreement Notice. 
 (c) Hippo and Rhino shall use their reasonable best efforts to cause the Accounting Referee to promptly review this Agreement and the disputed items or amounts for the purpose of determining the HippoRx Working Capital and the RhinoRx
Working Capital. The Accounting Referee shall deliver to Hippo and Rhino, as promptly as practicable (but in no event more than 5 Business Days after its receipt of the Disagreement Notices), a report setting forth its determination of the HippoRx
Working Capital and the RhinoRx Working 

  

 A-1 

 
Capital. In making such determination, the Accounting Referee shall consider only those items or amounts as to which Hippo and Rhino disagree, as set forth
on their respective Disagreement Notices, and the Accounting Referee’s determination as to each disputed item or amount shall be neither more nor less than the amounts set forth by Hippo and Rhino on their respective Disagreement Notices. The
report of the Accounting Referee and the determinations of the Accounting Referee as to the HippoRx Working Capital and the RhinoRx Working Capital shall be final and binding upon Hippo and Rhino. All fees and expenses of the Accounting Referee
shall be borne equally by Hippo and Rhino. 
 (d) Hippo and Rhino shall, and shall cause their respective independent accountants to,
cooperate and assist in the Accounting Referee’s calculation of the HippoRx Working Capital and the RhinoRx Working Capital, including the making available during normal business hours to the extent necessary of books, records, work papers and
personnel. 
 Section 2. Certain Definitions. As used in this Annex A, the following terms have the following meanings:

 “Current Assets” means current assets of the Hippo Institutional Pharmacy Business or the Rhino Institutional Pharmacy Business,
as applicable, as determined in accordance with GAAP on a basis consistent with the applicable financial statements included in the Registration Statement, but excluding (i) cash and cash equivalents and (ii) Tax Assets (as defined in the
Tax Matters Agreement). 
 “Current Liabilities” means current liabilities of the Hippo Institutional Pharmacy Business or the
Rhino Institutional Pharmacy Business, as applicable, as determined in accordance with GAAP on a basis consistent with the applicable financial statements included in the Registration Statement, but excluding Liabilities relating to Taxes.

 “Excess HippoRx Working Capital” means the amount of the excess, if any, of the HippoRx Working Capital over the HippoRx
Maximum Working Capital. 
 “Excess RhinoRx Working Capital” means the amount of the excess, if any, of the RhinoRx Working
Capital over the RhinoRx Maximum Working Capital. 
 “HippoRx Final Financing Amount” means the HippoRx Initial Financing
Amount, plus the Excess HippoRx Working Capital, if any, less the HippoRx Working Capital Shortfall, if any. 
  

 A-2 

 “HippoRx Initial Financing Amount” means (a) an amount equal to 50% of the lesser
of (i) $300 million and (ii) 3 times LTM EBITDA of Newco (giving effect to the consummation of the Transactions) or (b) an amount equal to 50% of such other amount as is mutually agreed by Hippo and Rhino prior to Closing. 

“HippoRx Maximum Working Capital” means 1.25 multiplied by the HippoRx Target Working Capital. 
 “HippoRx Minimum Working Capital” means 0.75 multiplied by HippoRx Target Working Capital. 
 “HippoRx Target Working Capital” means the excess of (i) Current Assets of the Hippo Institutional Pharmacy Business as of
June 30, 2006, as adjusted to reflect audit adjustments arising from the audit of the financial statements of the Hippo Institutional Pharmacy Business included in the Registration Statement as of and for the fiscal year ended
September 30, 2006, over (ii) Current Liabilities of the Hippo Institutional Pharmacy Business as of June 30, 2006, as adjusted to reflect audit adjustments arising from the audit of the financial statements of the Hippo Institutional
Pharmacy Business included in the Registration Statement as of and for the fiscal year ended September 30, 2006. 
 “HippoRx
Working Capital” means the excess of the Current Assets of the Hippo Institutional Pharmacy Business over the Current Liabilities of the Hippo Institutional Pharmacy Business, determined as of the last day of the calendar month preceding
the month in which the Closing Date occurs. 
 “HippoRx Working Capital Shortfall” means the amount of the excess, if any,
of the HippoRx Minimum Working Capital over the HippoRx Working Capital. 
 “RhinoRx Final Financing Amount” means the
RhinoRx Initial Financing Amount, plus the Excess RhinoRx Working Capital, if any, less the RhinoRx Working Capital Shortfall, if any. 
 “RhinoRx Initial Financing Amount” means (a) an amount equal to 50% of the lesser of (i) $300 million and (ii) 3 times LTM EBITDA of Newco (giving effect to the consummation of the Transactions) or
(b) an amount equal to 50% of such other amount as is mutually agreed by Hippo and Rhino prior to Closing. 
 “RhinoRx Maximum
Working Capital” means 1.25 multiplied by the RhinoRx Target Working Capital. 
 “RhinoRx Minimum Working Capital”
means 0.75 multiplied by the RhinoRx Target Working Capital. 
  

 A-3 

 “RhinoRx Target Working Capital” means the excess of (i) Current Assets of the
Rhino Institutional Pharmacy Business as of September 30, 2006, as adjusted to reflect audit adjustments arising from the audit of the financial statements of the Rhino Institutional Pharmacy Business included in the Registration Statement as
of and for the fiscal year ended December 31, 2006, over (ii) Current Liabilities of the Rhino Institutional Pharmacy Business as of September 30, 2006, as adjusted to reflect audit adjustments arising from the audit of the financial
statements of the Rhino Institutional Pharmacy Business included in the Registration Statement as of and for the fiscal year ended December 31, 2006. 
 “RhinoRx Working Capital” means the excess of the Current Assets of the Rhino Institutional Pharmacy Business over the Current Liabilities of the Rhino Institutional Pharmacy Business, determined as
of the last day of the calendar month preceding the month in which the Closing Date occurs. 
 “RhinoRx Working Capital
Shortfall” means the amount of the excess, if any, of the RhinoRx Minimum Working Capital over the RhinoRx Working Capital. 
  

 A-4Standard Office Lease dated as of December 4, 2006

 Exhibit 10.19 
 STANDARD OFFICE LEASE 
 841 PRUDENTIAL DRIVE

  

 1 

 
INDEX TO 
 STANDARD OFFICE LEASE 
  

					
	  	 	 	  	Page No.
	 LEASE
	 		  	
		 	
BASIC LEASE INFORMATION RIDER	  	3
	 1.
	 	
PREMISES; COMMON AREAS	  	6
	 2.
	 	
LEASE TERM LEASE	  	6
	 3.
	 	
RENT	  	7
	 4.
	 	
SECURITY DEPOSIT	  	11
	 5.
	 	
USE	  	11
	 6.
	 	
ACCEPTANCE OF PREMISES; LANDLORD’S WORK	  	12
	 7.
	 	
PARKING	  	12
	 8.
	 	
BUILDING SERVICES	  	13
	 9.
	 	
SECURITY	  	15
	 10.
	 	
REPAIRS, MAINTENANCE AND UTILITIES	  	15
	 11.
	 	
TENANT’S ALTERATIONS	  	16
	 12.
	 	
LANDLORD’S ADDITIONS AND ALTERATIONS	  	16
	 13.
	 	
ASSIGNMENT AND SUBLETTING	  	16
	 14.
	 	
TENANT’S INSURANCE COVERAGE	  	19
	 15.
	 	
LANDLORD’S INSURANCE COVERAGE	  	21
	 16.
	 	
WAIVER OF RIGHT OF RECOVERY	  	21
	 17.
	 	
DAMAGE OR DESTRUCTION BY CASUALTY	  	21
	 18.
	 	
CONDEMNATION AND EMINENT DOMAIN	  	22
	 19.
	 	
LIMITATION OF LANDLORD’S LIABILITY; INDEMNIFICATION	  	22
	 20.
	 	
RELOCATION OF TENANT	  	23
	 21.
	 	
COMPLIANCE WITH LAWS AND PROCEDURES	  	23
	 22.
	 	
RIGHT OF ENTRY	  	23
	 23.
	 	
DEFAULT	  	24
	 24.
	 	
LANDLORD’S REMEDIES FOR TENANT’S DEFAULT	  	25
	 25.
	 	
LANDLORD’S RIGHT TO PERFORM FOR TENANT’S ACCOUNT	  	25
	 26.
	 	
LIENS	  	25
	 27.
	 	
NOTICES	  	26
	 28.
	 	
MORTGAGE; ESTOPPEL CERTIFICATE; SUBORDINATION	  	26
	 29.
	 	
ATTORNMENT AND MORTGAGEE’S REQUEST	  	27
	 30.
	 	
TRANSFER BY LANDLORD	  	27
	 31.
	 	
SURRENDER OF PREMISES; HOLDING OVER	  	27
	 32.
	 	
NO WAIVER; CUMULATIVE REMEDIES	  	28
	 33.
	 	
WAIVER	  	28
	 34.
	 	
CONSENTS AND APPROVALS	  	29
	 35.
	 	
RULES AND REGULATIONS	  	29
	 36.
	 	
SUCCESSORS AND ASSIGNS	  	29
	 37.
	 	
QUIET ENJOYMENT	  	29
	 38.
	 	
ENTIRE AGREEMENT	  	29
	 39.
	 	
HAZARDOUS MATERIALS	  	29
	 40.
	 	
BANKRUPTCY PROVISIONS	  	31
	 41.
	 	
MISCELLANEOUS	  	32
	 42.
	 	
TELECOMMUNICATIONS	  	34
	 43.
	 	
NO CONSEQUENTIAL DAMAGES	  	35
	 44.
	 	
MONITORING, INSPECTING AND REMEDIATING MOLD	  	35
	 45.
	 	
MOVING ALLOWANCE	  	36
	 46.
	 	
SIGNAGE	  	36

 EXHIBIT(S) 
  

					
	Exhibit “A”	 	Floor Plan	 	38
	Exhibit “B”	 	Work Letter	 	39
	Exhibit “C”	 	Rules and Regulations	 	42
	Exhibit “D”	 	Memorandum of Commencement Date	 	45
	Exhibit “E”	 	Renewal Option	 	46
	Exhibit “F”	 	Right of First Offer	 	47
	Exhibit “G”	 	Exclusions of Operating Costs	 	50

  

 2 

 
BASIC LEASE INFORMATION RIDER 
 STANDARD OFFICE LEASE 
  

					
	Preamble	  	Date of Lease: December 1, 2006
		
	Preamble	  	Landlord: SOUTH SHORE GROUP PARTNERS, LLC
		
	Preamble	  	Tenant: MSC - MEDICAL SERVICES COMPANY
		
	Section 1	  	Premises: Suites 1700, as shown on Exhibit “A”, located on the 7th, 8th, 9th and 17th floors of the office building at 841 Prudential Drive in Jacksonville, Florida,
together with the garage parking facilities included therein are collectively referred to as the “Building”.
		
	Section2	  	Rentable Area of Premises: approximately 100,000 square feet measured in accordance with BOMA Standards, which is stipulated and agreed by the parties as follows: 17th floor
(16,283 rentable square feet); 7th floor (41,754) rentable a square feet); 8th (24,415 rentable square feet ); and 9th floor (15,433 rentable square feet).
		
		  	In addition, Tenant shall lease 1,911 square feet of storage space in the Basement and 1,280 square feet of storage space on the 20th floor of the Building.
		
	Section 3	  	Commencement Date: The Commencement Date shall be the later of (a) May 1, 2007; or (b) upon the date of Landlord’s substantial completion of the Tenant
Improvements.
		
	Section 4	  	Expiration Date: The last day of the ninety fourth (94th) month after the Commencement Date.
		
	Section 5	  	Lease Term: Ninety Four (94) months after the Commencement Date. Once the Commencement Date is determined the parties shall complete and execute the Memorandum of Commencement
Date attached hereto as Exhibit “D.”
		
	Section 6	  	Prepaid Rent: $139,649.27 one month’s Gross Rent, (together with 7% sales tax).
		
	Section 7	  	Base Rent during the Lease Term shall be payable in monthly installments as follows:
		
		  	Base Rent for 17th, 7th, 8th and 9th
floors:
			
		  	        Months 1-10	 	Rent Abated.
			
		  	        Months 11- 24	 	$16.00 per rentable square foot
		  	        Months 25-36	 	$16.75 per rentable square foot
		  	        Months 37-48	 	$17.75 per rentable square foot
		  	        Months 49-60	 	$18.25 per rentable square foot
		  	        Months 61-72	 	$18.75 per rentable square foot
		  	        Months 73-84	 	$19.25 per rentable square foot
		  	        Months 85-94	 	$19.75 per rentable square foot
		
		  	Base Rent for Basement and 20th Floor Storage space:
			
		  	        Months 1-10	 	Rent Abated
		  	        Months 11-94	 	$5.00 per rentable square foot.
		
	Section 8	  	This Lease is a full service Lease. Operating Costs include electricity to Tenant’s Premises for Tenant’s standard business operations.
		
		  	Base Expense Year: 2007
		  	Base Tax Year: 2007
		
	Section 9	  	Tenant’s Share: 17.48%. Landlord and Tenant acknowledge that Tenant’s Share has been obtained by taking the Rentable Area of the Premises and dividing such number by
515,015 square feet, and multiplying such quotient by 100. In the

  

 3 

			
		  	event Tenant’s Share is changed during a calendar year by reason of a change in the Rentable Area of the Premises, Tenant’s Share shall thereafter mean the result obtained by
dividing the new Rentable Area of the Premises by 515,015 and multiplying such quotient by 100.
		
	Section 10	  	Security Deposit: N/A
		
	Section 11	  	Use of Premises: general office use.
		
	Section 12	  	Tenant’s Address for Notices Prior to Commencement Date:
		
		  	MSC - Medical Services Company
		  	841 Prudential Drive, Suite 1700
		  	Jacksonville, Florida 32207
		  	Attn: CEO and General Counsel
		
		  	Tenant’s Address for Notices after Commencement Date:
		
		  	MSC - Medical Services Company
		  	841 Prudential Drive, Suite 1700
		  	Jacksonville, Florida 32207
		  	Attn: CEO and General Counsel
		
		  	Landlord’s Address for Notices:
		
		  	South Shore Group Partners, LLC
		  	c/o SSGP of Florida, LLC
		  	841 Prudential Drive, Suite 150
		  	Jacksonville, Florida 32207
		  	Attn: Elizabeth W. Reichert
		
		  	Copy to:
		
		  	South Shore Group Partners, LLC
		  	5332 SW Orchid Bay Drive
		  	Palm City, Florida 34990
		  	Attn: Harold R. Dodt
		
		  	Copy to:
		
		  	Kelley & Warren, P.A.
		  	1555 Palm Beach Lakes, Blvd., Suite 1006
		  	West Palm Beach, Florida 33401
		  	Attn: Richard B. Warren, Esquire
		
	Section 13	  	Landlord shall provide Tenant with 690 parking spaces. Twenty percent (20%) of Tenant’s parking allotment shall be in the On Site Parking Garage and the remainder shall be in the Main
Surface Lot. The cost of parking shall be included as a component of Base Rent.
		
		  	The Landlord shall provide visitor parking spaces on the ground floor of the on-site parking garage. Landlord may charge a fee for visitor parking as reasonably determined by Landlord in its
sole discretion.
		
	Section 14	  	Amount of General Comprehensive Liability Insurance: As provided in Section 14 of the Lease.
		
	Section 15	  	Landlord’s Real Estate Broker: CB Richard Ellis, Inc. (Eric Ramirez)
		  	Tenant’s Real Estate Broker: CB Richard Ellis, Inc. (Oliver Barakat)
		
	Section 16	  	Guarantor: N/A

  

 4 

 IN WITNESS WHEREOF, Landlord and Tenant have signed this BLI Rider as of this 4th day of December, 2006. 
  

									
		 	WITNESSES:	 		 	TENANT:
			
	 /s/ Timothy A. Crass
	 		 	MSC - MEDICAL SERVICES COMPANY,
	Print Name:	 	 Timothy A. Crass
	 		 	a Florida corporation
			
	 /s/ Kevin M. Bass
	 		 	 /s/ Joseph P. Delaney

					
	Print Name:	 	 Kevin M. Bass
	 		 	By:	 	 Joseph P. Delaney

	(As to Tenant)	 		 	Its:	 	 President, CEO

			
	WITNESSES:	 		 	LANDLORD
				
		 		 		 	SOUTH SHORE GROUP PARTNERS
	 /s/ Jimmie Nettles
	 		 	GROUP, LLC,
	Print Name:	 	 Jimmie Nettles
	 		 	a Delaware limited liability company
				
		 		 		 	 /s/ Harold R. Dodt

				
	 /s/ Shelley A. Dodt
	 		 	By:	 	 Harold R. Dodt

	Print Name:	 	 Shelley A. Dodt
	 		 	Its:	 	 VP

	(As to Landlord)	 		 		 	

  

 5 

 STANDARD OFFICE LEASE 
 THIS LEASE (“Lease”) is made as of the 4th day of December, 2006 by and between SOUTH SHORE GROUP PARTNERS, LLC, a Delaware limited liability company (“Landlord”) and MSC - MEDICAL SERVICES COMPANY, a Florida
corporation (“Tenant”). 
 W I T N E S S E T H: 
 
1. PREMISES; COMMON AREAS. Landlord leases to Tenant and Tenant leases from Landlord the Premises described in the Basic Lease Information Rider (the “BLI Rider”) attached to the front of this Lease and
incorporated into this Lease by this reference, and as more particularly shown on the floor plan attached hereto as Exhibit “A” and by this reference incorporated herein (“Premises”). The parties hereby agree that the Premises
contain the Rentable Area set forth in the BLI Rider in accordance with the methods of calculating areas and volumes of buildings, as promulgated by BOMA standards. Landlord and Tenant acknowledge and accept the square footage as set forth in the
Lease and neither Landlord nor Tenant shall have the right to demand remeasurement or recalculation of the Rentable Square Feet amounts within the Building or the Premises. In addition to the Premises, Tenant has the right to use, in common with
others, the lobby, public entrances, public stairways, public areas, restrooms and public elevators of the Building (the “Common Areas”). The Common Areas serving the Building, will at all times be subject to Landlord’s exclusive
control and management in accordance with the terms and provisions of this Lease. The Premises and the building within which the Premises are located (the “Building”) are located on a tract of land, which includes Common Areas. The
Building including the Common Areas and the underlying land shall hereinafter be referred to as the “Project.” 
 
2. LEASE TERM, LEASE DATE; TERMINATION OPTION 
 A. Lease Term: Lease Date. The lease term (“Lease
Term”) is for the period of time set forth in the BLI Rider, commencing on the Lease commencement date set forth in the BLI Rider (“Commencement Date”) and ending on the Lease expiration date set forth in the BLI Rider
(“Expiration Date”). Tenant’s obligation to pay all rent, including Base Rent, Overhead Rent and Additional Rent, as such terms are hereinafter defined, will commence on the Commencement Date. 
 B. Termination Option, Eighth Floor During Calendar Year 2007 In Accordance With the Terms of this Section 2B. Tenant shall have the option
to terminate this Lease as to the eighth (8th) floor only during the calendar year 2007. In the event Tenant
elects to exercise this option, Tenant shall provide Landlord with not less than thirty (30) days written notice of its intent to terminate the Lease as to the eighth (8th) floor (the “Termination Notice”). The Termination Notice must be delivered prior to November 30, 2007. Upon exercising this Termination
Option, Tenant shall vacate and surrender the eighth (8th) floor in its entirety not sooner than thirty
(30) days after delivering the Termination Notice. Tenant shall surrender possession in accordance with Section 31 of the Lease. Upon timely exercising this Termination Option and timely surrendering possession of the eighth (8th) floor in accordance with this Section, the Lease shall terminate as to the eighth (8th) floor only effective the date Tenant surrenders possession and the parties shall enter into a written amendment to the Lease adjusting
tenant’s Rent obligations accordingly. Tenant shall be obligated to pay Rent for the eighth (8th) floor up
through the date of surrender, including Operating Costs reconciliations as set forth below. 
 C. Termination Option, Eighth Floor During
Calendar Year 2008 In Accordance With the Terms of this Section 2C. Tenant shall have the option to terminate this Lease as to the eighth (8th) floor only during the calendar year 2008. In the event Tenant elects to exercise this option, Tenant shall provide Landlord with not less than thirty (30) days written notice of its intent
to terminate the Lease as to the eighth (8th) floor (the “Termination Notice”) along with a
termination penalty in the amount equal to two years Base Rent for the eighth (8th) floor (the
“Termination Penalty”). The Termination Notice must be delivered prior to November 30, 2008. Upon exercising this Termination Option, Tenant shall vacate and surrender the eighth (8th) floor in its entirety not sooner than thirty (30) days after delivering the Termination Notice and Termination Penalty. Tenant shall surrender
possession in accordance with Section 31 of the Lease. Upon timely exercising this Termination Option, timely payment of the Termination Penalty and timely surrendering possession of the eighth (8th) floor in accordance with this Section, the Lease shall terminate as to the eighth (8th) floor only effective the date Tenant surrenders possession and the parties shall enter into a written amendment to the Lease adjusting tenant’s
Rent obligations accordingly. Tenant shall be obligated to pay Rent for the eighth (8th) floor up through the
date of surrender, including Operating Costs reconciliations as set forth below. 
 D. Termination Option, Basement and 20th Floor Storage Space. Tenant shall have the option to
terminate this Lease as to the Basement and/or 20th Floor Storage Space upon thirty days prior written notice to
Landlord. Upon Landlord’s receipt of said termination notice the Lease shall terminate as to the Basement and/or 20th Floor Storage Space identified in the termination notice effective the date Tenant surrenders possession and the parties shall enter into a written amendment to the 

  

 6 

 
Lease adjusting the Rent obligations accordingly. Tenant shall be obligated to pay Rent for the surrendered space up through the date of surrender.

 E. Commencement Date. . In the event Tenant is unable to occupy the Premises by May 1, 2007 as a result of a Landlord Delay,
Tenant shall receive $1,233.33 per day if such delay occurs for less than the first ten (10) days of any month. If such delay occurs for more than the first ten (10) of any month, Tenant shall receive the full monthly payment of $37,000.00
for the entire month. A Landlord Delay is defined as a delay due to matters within the functional control of Landlord (including prior Tenant’s failure to timely vacate 7th and/or 8th floor) and
shall not include matters such as acts of god, strikes, weather or a Tenant Delay. Tenant Delays are defined as each day of delay in the performance of the Work that occurs (a) because of Tenant’s failure to timely deliver or approve any
required documentation such as the Space Plan or Working Drawings, (b) because Tenant fails to timely furnish any information or deliver or approve any required documents such as the Space Plan, Working Drawings (whether preliminary, interim
revisions or final), pricing estimates, construction bids, and the like, to the extent these items are the responsibility of the Tenant, (c) because of any material change by Tenant to the Space Plan or Working Drawings subsequent to initial
submission and approval of same, (d) because Tenant fails to attend any meeting with Landlord, the Architect, any design professional, or any contractor, or their respective employees or representatives, as may reasonably be required or
scheduled hereunder or otherwise necessary in connection with the preparation or completion of any construction documents, such as the Space Plan, Working Drawings, or in connection with the performance of the Work (after Tenant has been given
reasonable notice of such meeting) , or (e) because a Tenant Party otherwise delays completion of the Work. 
 
3. RENT 
 A. Base Rent. During the Lease Term, Tenant will pay as the base rent for the Premises
(“Base Rent”) the amounts set forth in the BLI Rider, with same being payable without demand, offset or deduction, in advance, on or before the first day of each month, in equal monthly installments of the amounts set forth in the BLI
Rider plus applicable sales and other such taxes as are now or later enacted. Notwithstanding anything to the contrary in the BLI Rider, however, Landlord and Tenant agree to the following terms: 
 (1) Base Rent and Tenant’s Proportionate Share of Operating Expenses (defined below) shall be conditionally abated for the Premises during the first
ten (10) months of the Term. Commencing with the eleventh (11th) month of the Term, Tenant shall make Base Rent payments as otherwise provided in the Lease for the Premises. 
 (2) Notwithstanding such abatement of Rent any increases in Base Rent set forth in the Lease shall occur on the dates scheduled therefor. The abatement
of Base Rent bargained for is conditioned upon Tenant’s full and timely performance of all of its obligations under the Lease. If at any time during the Term an Event of a Monetary Default by Tenant occurs which has not been cured within five
(5) business days following receipt of written notice thereof, then the abatement of Base Rent provided for shall immediately become void, and Tenant shall promptly pay to Landlord, in addition to all other amounts due to Landlord under this
Lease, the full amount of all Base Rent herein abated. 
 B. Operating Costs. 
 (1) Subject to the provisions of this Lease, if Operating Costs (defined below) for the Project for any calendar year increase over the Base Year
Operating Costs, Tenant shall pay to Landlord, pursuant to this Section 3.B, as additional rent, an amount equal to Tenant’s Proportionate Share (defined below)of any increase, plus all applicable Sales Tax thereon. 
 (2) “Outside Common Area” refers to all those areas within the Project that are not within any building or not part of any building or
its foundation, and including within the definition of building all outside stair entries, equipment rooms and equipment shelters used in common by tenants of that building. The Outside Common Area shall include, but not be limited to, landscaped
areas, planters, walkways, parking and driveway areas and the surfaces thereof, grass areas, drainage devices, monument signs, bicycle racks and flagpoles, if any. All tenants and their invitees shall have the non-exclusive right to the use and
enjoyment of the public portions of the Outside Common Area in conjunction with other owners, tenants and their invitees within the Project, subject to the rules and regulations of Landlord and any covenants, conditions and restrictions currently or
hereinafter recorded against the Land. 
 (3) “Tenant’s Proportionate Share” of Operating Costs is, subject to the
provisions of this Section 3, the percentage number described in Item Section 9 of the Basic Lease Provisions BLI Rider. Tenant’s Proportionate Share represents a fraction, the numerator of which is the number of square feet of rentable
area in the Premises specified in Item Section 2 of the Basic Lease Provisions BLI Rider, and the denominator of which is the number of square feet of rentable area in the 

  

 7 

 
Project, as reasonably determined by Landlord which shall not be less than 515,015 square feet. Tenant’s Proportionate Share of Operating Costs shall be
deemed “Additional Rent” pursuant to the Lease. 
 (4) Base Operating Costs means Operating Costs for the base year as
described in Section 8 of the BLI Rider. 
 (5) “Operating Costs” means all costs, expenses and obligations incurred
or payable by Landlord because of or in connection with the operation, ownership, repair, replacement, restoration, management or maintenance of the Project, including but not limited to the Outside Common Area, during or allocable to any Expense
Year during the term of this Lease, all as determined by sound accounting principles generally consistent with the practice of institutional office project owners consistently applied, including without limitation the following: 
 (6) The cost of all utilities (including taxes and other charges incurred in connection therewith), fuel, supplies, equipment, tools, materials, service
contracts, janitorial services, waste and refuse disposal, gardening and landscaping, and insurance (with the nature and extent of such insurance to be carried by Landlord to be determined by Landlord in its sole and absolute discretion);
compensation and other fringe benefits of all persons (including independent contractors) who perform services connected with the operation, maintenance or repair of the Project, personal property taxes on and maintenance and repair of equipment and
other personal property used in connection with the operation, maintenance or repair of the Project, costs incurred for administration and management of the Project, whether by Landlord or by an independent contractor, and other management office
operational expenses (including, without limitation, a management fee), rental expenses for or a reasonable allowance for depreciation of, personal property used in the operation, maintenance or repair of the Project, license, permit and inspection
fees (except for such fees related to Tenant Improvements); and all inspections, activities, alterations and improvements or other matters required by any governmental or quasi-governmental authority or by applicable law, for any reason (except for
Tenant Improvements), including, without limitation, capital improvements, whether capitalized or not; all capital improvements made to the Project or any portion thereof by Landlord (A) of a personal property nature and related to the
operation, repair, maintenance or replacement of systems, facilities, equipment or components of, or which service the Project or portions thereof, (B) required or provided in connection with any law, ordinance, rule, regulation, or insurance
requirement enacted or enforced after the date of this Lease, (C) which are designed to improve the operating efficiency of the Project, or (D) determined by Landlord to be required to keep pace or be consistent with safety or health
advances or improvements not commonly incorporated in office projects at the time of initial construction of the Project [with such capital costs to be amortized over such periods as Landlord shall determine (but which shall be generally consistent
with the practices of institutional office project owners) with a return on capital at such rate as would have been paid by Landlord on funds borrowed for the purpose of constructing such capital improvements]; the cost of air conditioning, heating,
ventilating, plumbing, sign, electrical, mechanical and elevator maintenance and repair, and common area repair, resurfacing, replacement operation and maintenance; security services, if any, deemed appropriate by Landlord, and any other cost or
expense incurred or payable by Landlord in connection with the operation, ownership, repair, replacement, restoration, management or maintenance of the Project. 
 (7) Operating Costs shall not include any costs described on Exhibit “G” attached hereto (the “Excluded Operating costs”). 
 (8) In the event Landlord furnishes any utility or service which is included in Operating Costs to less than ninety-five percent (95%) of the
rentable area of the Property because (i) the average occupancy of the Property for the year in question was not equal to or greater than ninety-five percent (95%), (ii) such utility or service is not required by or provided to one or more
of the tenants of the Property, or (iii) any tenant occupant is itself obtaining or providing any such utility or services, then Operating Costs for such year shall be adjusted to include all additional costs, expenses and disbursements that
Landlord reasonably determines would have been incurred if Landlord had provided such utilities and services to all tenants of the Property, and shall be allocated among the tenants by the Landlord to reflect those costs which would have occurred
had the Property been ninety-five percent (95%) occupied during the year in question and such utilities and services provided to all tenants. The intent of this section is to ensure that the reimbursement of Operating Costs is fairly and
equitably allocated among the tenants receiving the utilities and services in question. 
 (9) Prior to the commencement of (and from time
to time during) each calendar year of the term following the Commencement Date, Landlord shall give to Tenant written estimates of Tenant’s Proportionate Share of the projected excess, if any, of the Operating Costs for the Project for such
calendar year over the Base Operating Costs. Commencing with the first day of the calendar month following the month in which such estimate was delivered to Tenant, Tenant shall pay such estimated amounts (less amounts, if any, previously paid
toward such excess for such year) to Landlord in equal monthly installments over the remainder of such calendar year, in advance on the first day of each month during such year (or remaining months, if less than all of the year remains). Subject to

  

 8 

 
the provisions of this Lease, Landlord shall endeavor to furnish to Tenant within one hundred twenty (120) days after the end of each calendar year, a
statement (“Reconciliation Statement”) indicating in reasonable detail the Operating Costs for such period, and the parties shall, within thirty (30) days thereafter, make any payment or allowance necessary to adjust Tenant’s
estimated payments to Tenant’s actual share thereof as indicated by such annual Reconciliation Statement. Any payment due Landlord shall be payable by Tenant within ten (10) days of written demand from Landlord. Any amount due Tenant shall
be credited against installments next becoming due under this Section 3.9. 
 (10) Tenant shall pay ten (10) days before
delinquency all taxes and assessments levied against any personal property or trade fixtures of Tenant in or about the Premises. If any such taxes or assessments are levied against Landlord or Landlord’s property or if the assessed value of the
Project is increased by the inclusion therein of a value placed upon such personal property or trade fixtures, Tenant shall, within ten (10) days of demand, reimburse Landlord for the taxes and assessments so levied against Landlord, or any
such taxes, levies and assessments resulting from such increase in assessed value. 
 (11) Any delay or failure of Landlord in
(i) delivering any estimate or statement described in this Section 3, or (ii) computing or billing Tenant’s Proportionate Share of excess Operating Costs shall not constitute a waiver of its right to subsequently deliver such
estimate or statement, require any increase in Rent contemplated by this Section 3, or in any way waive or impair the continuing obligations of Tenant under this Section 3. Without limiting the generality of the foregoing, Landlord may at
any time during the term hereof recalculate and correct the amount of Tenant’s Proportionate Share of excess Operating Costs applicable to any Expense Year during the term, and Tenant shall pay any amount so recalculated or corrected within ten
(10) days of written demand by Landlord. Subject to the provisions of this Section 3, provided that Tenant is not then in default hereunder, Tenant shall have the right, for a period of sixty (60) days following the delivery of such
Reconciliation Statement (or any statement recalculating or revising the same), after reasonable notice to Landlord and at reasonable times, to inspect Landlord’s accounting records for the Expense Year covered by such Reconciliation Statement
at the accounting office of Landlord’s management company. If after such inspection, Tenant disputes any additional rental indicated on such Reconciliation Statement, and upon Tenant’s written request therefor, a certification as to the
proper amount of Operating Costs for such Expense Year and the amount due to or payable by Tenant with respect thereto shall be made by an independent certified public accountant selected by Landlord. Such certification shall be final and conclusive
as to all issues relating to Operating Costs in dispute between the parties. Tenant agrees to pay the cost of such certification and the investigation with respect thereto unless it is determined that the Operating Costs stated in such
Reconciliation Statement were overstated in Landlord’s favor by five percent (5%) or more, in which case, Landlord shall pay the cost of same. Tenant waives the right to dispute or contest, and shall have no right to dispute or contest,
any matter relating to the calculation of Operating Costs or other forms of Rent under this Section 3 (and waives the right to inspect Landlord’s records with respect thereto) with respect to each Expense Year for which a Reconciliation
Statement is given to Tenant if no claim or dispute with respect thereto is asserted by Tenant in writing to Landlord within ninety (90) days of delivery to Tenant of the original or most recent Reconciliation Statement with respect thereto.

 (12) Subject to the provisions of this Section 3, the rights and obligations of Landlord and Tenant with respect to payments to be
made hereunder, in regard to Operating Costs incurred or allocable to periods prior to the expiration or sooner termination of this Lease, shall survive such expiration or termination. 
 C. Real Estate Taxes. 
 (1) Subject
to the provisions of this Lease, Tenant shall pay to Landlord as Additional Rent an amount equal to Tenant’s Proportionate Share of Real Estate Taxes, plus all applicable Sales Tax thereon. Landlord shall estimate and administer Tenant’s
payment of Real Estate Taxes in the same manner as Operating Costs provided in Section 3. 
 (2) All real property taxes, assessments,
license fees, excises, levies, charges or impositions and other similar governmental ad valorem or other charges levied on or attributable to the Project or its ownership, operation or transfer, and all taxes, charges, assessments or similar
impositions imposed in lieu or in substitution (partially or totally) of the same (collectively, “Real Estate Taxes”). “Real Estate Taxes” shall also include all taxes, assessments, license fees, excises, levies, charges or
similar impositions (A) on any interest of Landlord, any mortgagee of Landlord in the Project, the Premises or in this Lease, or on the occupancy or use of space in the Project or the Premises; (B) on the gross or net rentals or income
from the Project, the Rent received hereunder, or on Landlord’s “right” or “rights” to any of the foregoing or on Landlord’s business of leasing the Premises, the Building or the Project, including, without limitation,
any gross income tax, excise tax, Sales Tax or gross receipts tax levied by any federal, state or local governmental entity with respect to the receipt of Rent or with respect to the possession, leasing, operation, management, maintenance,
alteration, repair, use or occupancy of 

  

 9 

 
the Project or portions thereof; (C) measured by the gross square footage of the Project, the Premises, or any portion thereof, or by the number of
actual, estimated or potential occupants of the Project, the number of vehicular trips generated by or associated with the Project, or the number of parking spaces contained within the Project, or for any transportation, arts, housing or
environmental plan, fund or system instituted within or for any geographic area in which the Building is located, or any similar measure; (D) on the transfer of or the transaction represented by this Lease or any lease of space in the Project
or on any document creating or transferring an interest in this Lease; (E) on the construction, removal or alteration of improvements in the Project; (F) pursuant to any governmental or private assessment or agreement for the provision of
amenities, services or rights of use, whether or not exclusive, public, quasi-public, private or otherwise made available on a shared use basis, including amenities, services or rights of use such as fire protection, police protection, street,
sidewalk, lighting, sewer or road maintenance, refuse removal or janitorial services or for any other service, without regard to whether such services were formerly provided by governmental or quasi-governmental agencies to property owners or
occupants at no cost or at minimal cost; (G) on any fixtures, machinery, equipment, systems, furniture and other personal property used in connection with the Project; (H) any possessory taxes charged or levied in lieu of real estate
taxes; or (I) related to any transportation plan, fund or system instituted within the geographic area of the Project or otherwise applicable to the Premises, the Project or any portion thereof. Real Estate Taxes shall not include taxes on
Landlord’s net income including state, corporate or franchise taxes or any inheritance, estate, or gift taxes, unless the same are charged or levied in lieu of real estate taxes. 
 D. Computation of Operating Costs/Dispute. For a period of sixty (60) days after receipt of the Reconciliation Statement, Tenant shall have
the right, upon advance notice, to visit Landlord’s office in the Building during Business Hours, as hereinafter defined, to inspect its books and records concerning the Operating Costs. Tenant hereby agrees that the Operating Costs from time
to time computed by Landlord shall be final and binding for all purposes of this Lease unless, within sixty (60) days after Landlord provides Tenant with written notice of the amount thereof Tenant provides Landlord with written notice
(i) disputing the mathematical accuracy of such amount (the “Disputed Amount”), (ii) designating a Florida licensed accounting firm at Tenant’s sole cost and expense, to review the mathematical accuracy of the Disputed
Amount with Landlord and/or its designated representatives, and (iii) agreeing to be bound by all of the following requirements: 
 (1)
No audit shall be conducted at any time if Tenant is in default of any of the terms of the Lease unless such default is cured. 
 (2) The
audit shall be solely for the year, which is the subject of the dispute. 
 (3) Any audit of Landlord’s books and records pertaining to
the calculation of Operating Costs for any calendar year within Lease Term shall be audited only by Tenant or its representatives at Landlord’s office where Operating Costs records are kept, at Tenant’s expense, at any time within ninety
(90) days after Landlord’s reconciliation statement is delivered to Tenant for such calendar year; provided that Tenant shall give Landlord not less than thirty (30) days prior written notice of any such audit and sign a confidential
non-disclosure agreement prior to the audit. If Landlord’s calculations of Tenant’s Additional Rent for the audited calendar year is demonstrated to reflect a mathematical error in excess of five (5%) percent of the amount actually
due from Tenant, then Tenant shall be entitled to a prompt refund of any overpayment and reimbursement of any accounting fees or Tenant shall promptly pay to Landlord the amount of any underpayment, as the case may be. 
 (4) No audit shall be conducted whereby the auditor is paid on a contingency or other incentive basis. 
 (5) Tenant shall deliver to Landlord a copy of the results of such audit within thirty (30) days of its receipt by Tenant. No such audit shall be
conducted if any other tenant has conducted an audit for the time period Tenant intends to audit and Landlord furnishes to Tenant a copy of the results of such audit. 
 (6) No subtenant or assignee shall conduct an audit for any period during which such subtenant or assignee is not in possession of the premises. 
 (7) Tenant understands and agrees that this provision is of material importance to the Landlord and that any violation of the terms of this provision
shall result in immediate and irreparable harm to the Landlord. 
 (8) The obligations within this Section 3.D shall survive the
expiration or earlier termination of this Lease. 
 E. Late Charge. Tenant covenants and agrees to pay a late charge in the amount of
One Hundred Fifty and 00/100 ($150.00) Dollars for any payment of Rent not received by Landlord on or 

  

 10 

 
before the date when same is due following the grace period provided in Section 23.B, of this Lease. Tenant shall also pay Landlord interest at a rate
equal to eighteen (18%) percent per annum accruing after the grace period on any Rent(s) outstanding. Tenant shall pay Landlord any such late charge(s) or interest within five (5) days after Landlord notifies Tenant in writing of same.

 F. Definition of Rent. The term Rent shall refer collectively to Base Rent, Tenant’s Proportionate Share of Operating Costs
and Real Estate Taxes and Additional Rent. The term “Additional Rent” is sometimes used herein to refer to any and all other sums payable by Tenant hereunder, including, but not limited to, visitor parking charges and sums payable on
account of default by Tenant. All Rent shall be paid by Tenant without offset, demand or other credit, and shall be payable only in lawful money of the United States of America which shall be legal tender in payment of all debts and dues, public and
private, at the time of payment. All sums payable by Tenant hereunder by check shall be obtained against a financial institution located in the United States of America. The Rent shall be paid by Tenant at the Building management office located in
the Building or elsewhere as designated by Landlord in writing to Tenant. Any Rent payable for a portion of a month shall be prorated based upon the number of days in the applicable calendar month. 
 G. Rent Taxes. In addition to Base Rent and Tenant’s Proportionate Share of Operating Costs and Additional Rent, Tenant shall and hereby
agrees to pay to Landlord each month a sum equal to any sales tax, tax on Rent and any other similar charges now existing or hereafter imposed, based upon the privilege of leasing the space leased hereunder or based upon the amount of rent collected
therefor. 
 H. Commencement Other Than First Day. If Tenant’s possession of the Premises commences on any day other than the
first day of the month, Tenant shall occupy the Premises under the terms of this Lease and the pro rata portion of the Rent shall be paid by Tenant; provided, however, that in such an event the Commencement Date, for the purposes of this Lease,
shall be deemed to be the first day of the month immediately following the month in which possession is given. 
 I. Operating Costs and
Additional Rent after Expiration Date. Operating Costs for the final months of this Lease is due and payable even though it may not be calculated until subsequent to the Expiration Date of the Lease. Tenant expressly agrees that Landlord, with
written notice, may apply the Security Deposit, as defined in the BLI Rider, in full or partial satisfaction of any Operating Costs and Additional Rent due for the final months of this Lease. If said Security Deposit is greater than the amount of
any such Operating Costs and Additional Rent and there are no other sums or amounts owed Landlord by Tenant by reason of any other terms, provisions, covenants or conditions of this Lease, then Landlord shall refund the balance of said Security
Deposit to Tenant as provided herein. Nothing herein contained shall be construed to relieve Tenant, or imply that Tenant is relieved, of the liability for or the obligation to pay any Operating Costs and Additional Rent due for the final months of
this Lease by reason of the provisions of this paragraph, nor shall Landlord be required first to apply said Security Deposit to such Operating Costs and Additional Rent if there are any other sums or amounts owed Landlord by Tenant by reason of any
other terms, provisions, covenants or conditions of this Lease. 
 
4. SECURITY DEPOSIT 
 N/A 
 
5. USE 
 A. General. Tenant will use and occupy the Premises solely for the operation of the business
set forth in the BLI Rider and for no other use whatsoever. Tenant acknowledges that its type of business, as above specified, is a material consideration for Landlord’s execution of this Lease. Tenant will not commit waste upon the Premises
nor suffer or permit the Premises or any part of them to be used in any manner, or suffer or permit anything to be done in or brought into or kept in the Premises or the Building, which would: (i) violate any law or requirement of public
authorities, (ii) cause injury to the Building or any part thereof, (iii) intentionally annoy or offend other tenants or their patrons or interfere with the normal operations of HVAC, plumbing or other mechanical or electrical systems of
the Building or the elevators installed therein, (iv) intentionally constitute a public or private nuisance, or (v) alter the appearance of the exterior of the Building or of any portion of the interior other than the Premises pursuant to
the provisions of this Lease. Tenant agrees and acknowledges that Tenant shall be responsible for obtaining any special amendments to the Certificate of Occupancy for the Premises and/or the Building and any other governmental permits,
authorizations or consents required solely on account of Tenant’s use of the Premises. 
 B. Prohibited Uses. Notwithstanding
anything to the contrary in this Lease or the BLI Rider, including but not limited to, the “Use of Premises” Section of the BLI Rider, Tenant hereby represents, warrants and agrees that Tenant’s business is not and shall not be, and
that Tenant shall not use the Premises or any part thereof, or permit the Premises or any part thereof to be used, (i) for the business 

  

 11 

 
of photographic, multilith or multigraph reproductions or offset printing; (ii) for a retail banking, trust company, depository, guarantee or safe
deposit business open to the general public, (iii) as a savings bank, a savings and loan company open to the general public, (iv) for the sale to the general public of travelers checks, money orders, drafts, foreign exchange or letters of
credit or for the receipt of money for transmission, (v) as a stock broker’s or dealer’s office or for the underwriting or sale of securities open to the general public, (vi) except in connection with an employee lounge, as a
restaurant or bar or for the sale of confectionery, soda, beverages, sandwiches, ice cream or baked goods or for the preparation, dispensing or consumption of food or beverages in any manner whatsoever, (vii) as a news or cigar stand,
(viii) as an employment agency (except in connection with Tenant’s staffing agency contractor’s duties), labor union office, surgeon’s, outpatient, abortion clinic or dentist’s office, dance or music studio, school (except
for the training of employees of Tenant), (ix) as a barber shop or beauty salon, or (x) for the business of (a) operating a shared office facility, that is, a business which subleases space and/or offers centralized services to
subtenants or customers on a shared basis, such as secretarial, receptionist, telephone, etc., or (b) for a fee to persons inside or outside of the Building, providing as a service word processing, secretarial, video conferencing, conference
services, telephone answering, receptionist or mail receipt services. Nothing in this Section 5.B., shall preclude Tenant from using any part of the Premises for photographic, multilith or multigraph reproductions to the extent that such uses
are incidental to Tenant’s own business or activities. 
 
6. ACCEPTANCE OF PREMISES; LANDLORD’S WORK AND REPRESENTATIONS 
 A. Improvements, if any, to be made to
the Premises by Tenant shall be made in accordance with a Work Letter to be agreed upon between Landlord and Tenant. Leasehold improvements (as distinguished from trade fixtures and apparatus) installed in the Premises at any time, whether by or on
behalf of Tenant or by or on behalf of Landlord, shall not be removed from the Premises at any time, unless such removal is consented to in advance by Landlord; and at the expiration of this Lease (either on the Termination Date or upon such earlier
termination as provided in this Lease), all such leasehold improvements shall be deemed to be part of the Premises, shall not be removed by Tenant when it vacates the Premises, and title thereto shall vest solely in Landlord without payment of any
nature to Tenant. All trade fixtures and apparatus (as distinguished from leasehold improvements) owned by Tenant and installed in the Premises shall remain the property of Tenant and shall be removable at any time, including upon the expiration of
the Term; provided Tenant shall not at such time be in default of any terms or covenants of this Lease, and provided further, that Tenant shall repair any damage to the Premises caused by the removal of said trade fixtures and apparatus and shall
restore the Premises to substantially the same condition as existed prior to the installation of said trade fixtures and apparatus. Except as otherwise provided in writing to Landlord, the taking of possession by Tenant (or any permitted assignee or
subtenant of Tenant) of all or any portion of the Premises for the conduct of business will be deemed conclusive evidence that Tenant has found the Premises, and all of their fixtures and equipment, acceptable. 
 B. Prior to occupancy by Tenant, Tenant shall have the right to examine the Premises and the physical and environmental condition and the utility of the
Premises. Landlord, its agents and employees and other persons acting on behalf of Landlord, represent and warrant that (i) the physical or environmental condition, value, zoning or legal status of the Building is in compliance with all
Environmental Laws; (ii) the Premises is reasonably fit for Tenant’s intended use; (iii); (iv) the condition, capacity or performance of electrical or communications systems or facilities is reasonably suitable for Tenant’s
intended use of the Building; and (v) there are no unreasonably objectionable odors, bright lights or other conditions which may affect Tenant’s reasonable use and enjoyment of the Premises or the Building. 
 
7. PARKING 
 A. General. As long as Tenant is not in default under this Lease, Landlord will provide
Tenant during the Lease Term with the number of unassigned, non-exclusive parking spaces in the surface parking lot and Building parking garage as set forth in the BLI Rider. Such parking spaces may be used only by principals, employees and
contractors of Tenant. Tenant acknowledges that its guests and visitors will be charged for parking at then current rates as established by Landlord. 
 B. Rates. If Tenant fails to pay parking charges when due, as provided in the BLI Rider, Landlord may, by written notice to Tenant, elect to proceed as provided under the default provisions of this Lease and/or
cease to provide all or any of the foregoing parking spaces. 
 C. Reservations. Landlord has and reserves the right to reasonably
alter the methods used to control parking and the right to establish such controls and rules and regulations (such as parking stickers to be affixed to vehicles) regarding parking, that Landlord may reasonably deem desirable. Without liability,
Landlord will have the right to tow or otherwise remove vehicles improperly 

  

 12 

 
parked, blocking ingress or egress lanes, or violating parking rules, at the expense of the offending tenant and/or owner of the vehicle. 
 D. Conditions. Tenant’s right to use, and its right to permit its principals and guests to use, the parking facilities pursuant to this Lease
are subject to the following conditions: (i) Landlord has made no representations or warranties with respect to the parking area, the number of spaces located therein or access thereto; (ii) Landlord reserves the right to reduce the number
of spaces in the parking area by not more than ten percent (10%) of the then number of spaces in the parking area and/or change access thereto provided that the number of spaces specified in the BLI Rider continue to be available for
Tenant’s use; and none of the foregoing shall entitle Tenant to any claim against Landlord or to any abatement of Rent (or any part thereof); (iii) Landlord has no obligation to provide a parking garage attendant and Landlord shall have no
liability on account of any loss or damage to any vehicle or the contents thereof, unless such loss or damage is caused by Landlord, its agents, employees, or invitees; (iv) Tenant, its agents, employees and invitees, shall park their
automobiles and other vehicles only where, and as designated from time to time by Landlord, within the parking area; (v) if and when so requested by Landlord, Tenant shall furnish Landlord with the license numbers of any vehicles of Tenant, its
agents and employees; and (vi) Landlord (or the operator of the parking area) may charge Tenant’s invitees and visitors) directly for the parking fee established by Landlord (or such operator) from time to time for the use of such parking
area. 
 
8. BUILDING SERVICES 
 A. General. The Premises shall be accessible to Tenant on a twenty-four
(24) hour per day, seven (7) days per week, three hundred sixty-five (365) days per year basis, excluding emergency events which cause the Building to limit access to Tenant. In general, the services set forth below will be provided
by Landlord at a service level set, defined and regulated by Landlord consistent with office buildings of similar quality to, and in the same immediate geographic area as, the Building. During the Lease Term, the regular business hours
(“Business Hours”) of the Building will be 7:00 a.m. to 7:00 p.m., Monday through Friday, and on Saturday, 8:00 a.m. to 1:00 p.m., except holidays generally recognized by state and federal governments or as may be shortened in accordance
with applicable policies or regulations adopted by any utility company servicing the Building or government. Landlord reserves the right to increase the Business Hours. The Building will be accessible to Tenant, its subtenants, agents, servants,
employees, contractors, invitees or licensees (collectively, “Tenant’s Agents”) twenty-four hours per day, seven days per week except in the case of temporary closure due to emergencies, repairs, casualty, governmental or
quasi-governmental requirements or as Landlord reasonably deems necessary in order to prevent damage or injury to person or property. 
 B.
Services to be Provided by Landlord. 
 (1) Janitorial Service. Landlord agrees to provide during the Lease Term janitorial
services for the Premises customarily provided in office buildings of similar quality to and in the same immediate geographic area as the Building. Janitorial services will be provided after Business Hours at the Building, but no janitorial services
will be provided on Saturdays, Sundays and holidays generally recognized by state and federal government. Should Tenant require additional janitorial services beyond those customarily provided by Landlord, Tenant may request same in writing from
Landlord and if Landlord agrees to provide such services, Tenant will be billed for same by Landlord at a reasonable rate, as determined by Landlord, and those costs and expenses when billed will be Additional Rent due under this Lease. 

(2) Electricity. During the Lease Term, electric power will be available for the purposes of lighting and general office equipment use in
amounts consistent with Building standard electrical capacities for the hours of 7:00 am – 8:00 pm Monday – Friday (“Tenant’s Business Hours”). The Building standard mechanical and electrical systems are designed to
accommodate loads generated by lights and office equipment such as typewriters, dictating equipment, photocopy equipment, etc., up to the standard maximum capacities as set forth in the Work Letter attached hereto as Exhibit “B”. In the
event Tenant’s use of the Premises requires more electrical power than set forth above, whether by intensity of use, load or type of equipment, Tenant may then be billed for such additional use and such billings will be billed to Tenant as
Additional Rent. Landlord will utilize Landlord’s customary method of billing Tenant for excess electrical power consumption at the standard utility rates charged by the electric service provider. At Landlord’s option, Landlord, at
Tenant’s expense, may have an engineer estimate Tenant’s usage, and bill Tenant at standard utility rates for the excess usage or install a submeter for the purposes of monitoring Tenant’s excess power consumption. Landlord and Tenant
agree that Landlord’s implementation of the electrical monitoring and billing procedures set forth herein shall in no way be construed so as to deem Landlord a private or public utility company. Landlord reserves the right, after Business
Hours, to turn off all unnecessary lighting in the unoccupied areas of the Building to minimize the energy consumption of the Building in the Common Areas and the Premises. Landlord reserves the right, after Tenant’s Business Hours, to turn off
all unnecessary lighting in the unoccupied areas of the Premises to minimize the energy consumption of the Building in the Premises. 
  

 13 

 (3) HVAC Services. Landlord agrees to provide, during Tenant’s Business Hours, heating,
ventilating and air conditioning for the purposes of comfort control. Except for HVAC service provided to Tenant’s server room on the 9th floor, Landlord and Tenant agree that Landlord’s HVAC system is not designed to cool machinery and equipment. The HVAC system installed for use in Tenant’s server rooms shall be separately metered for electricity
usage and billed to Tenant as Additional Rent. If Tenant requires additional HVAC services for comfort control at times other than during Tenant’s Business Hours, Landlord will bill Tenant as Additional Rent for the number of hours used at
Landlord’s then standard prevailing rate for after-hours use of HVAC services as of the date of the execution of this Lease. The current charge for after-hours operation (to include HVAC, lighting, water, sewer and elevator service) is Fifty
Dollars ($50.00) per hour, subject to adjustment as hereinabove provided. This rate will be subject to change during the Lease Term in Landlord’s discretion based upon operational costs and expenses, including wear and tear on the system and
its components. The HVAC air distribution system and control system will remain under the control of Landlord, who will regulate the systems’ setting and adjustment. At Landlord’s option, Landlord may secure HVAC controls (thermostats) in
lockable metal boxes to regulate the efficiency and use of the system. Tenant agrees that Landlord will have complete control over the setting and regulation of all air distribution, vents, vanes and dampers so as to provide comfortable working
conditions. 
 (4) Water and Sewer. Landlord agrees to provide municipally supplied cold water and sewer services to the Common Areas
for lavatory purposes. 
 (5) Elevator Service. Landlord will provide elevator service during Tenant’s Business Hours and,
Landlord shall provide restricted elevator service during hours other than Business Hours. 
 C. Interruption of Services. It is
understood and agreed that Landlord does not warrant that any of the services referred to above, or any other services which Landlord may supply, will be free from interruption except that such interruption shall not be for a period of time longer
than required to reasonably reinstate such services. Tenant acknowledges that any one or more of such services may be suspended by reason of accident or repairs, alterations or improvements necessary to be made, or by strikes or lockouts, or by
reason of operation of law, or other causes beyond the control of Landlord. No such interruption or discontinuance of service will be deemed an eviction or relieve Tenant from the responsibility of performing any of Tenant’s obligations under
this Lease or render Landlord liable to Tenant for damages or abatement of Rent. Notwithstanding the foregoing, if: (i) such utility service is interrupted because of the acts of Landlord, its employees, agents or contractors; (ii) Tenant
notifies Landlord of such interruption; (iii) such interruption does not arise in whole or in part as a result of an act or omission of Tenant or its agents; (iv) such interruption is not caused by a fire or other casualty; (v) the
repair or restoration of such service is reasonably within the control of Landlord; and (vi) as a result of such interruption, the Premises or a material portion thereof, is rendered untenantable (meaning that Tenant is unable to use the
Premises in the normal course of it business) and Tenant in fact ceases to use the Premises, or material portion thereof, then, Tenant’s sole remedy for such interruption shall be as follows: 24 hours after the commencement of the interruption
of service to the Premises (or material portion thereof) and the Premises become untenantable, the Rent payable hereunder shall be abated on a per diem basis for each day after said 24 hour period based upon the percentage of the Premises so
rendered untenantable and not used by Tenant, and such abatement shall continue until the date the Premises become tenantable again. 
 D.
Sorting and Separation of Refuse and Trash. Tenant covenants and agrees, at its sole cost and expense, to comply with all present and future laws, orders and regulations of all state, federal, municipal, and local governments, departments,
commissions and boards regarding the collection, sorting, separation, and recycling of waste products, garbage, refuse and trash. Tenant shall, as required, sort and separate such waste products, garbage, refuse and trash into such categories as
provided by law. Each separately sorted category of waste products, garbage, refuse, and trash shall be placed in separate receptacles reasonably approved by Landlord. Such separate receptacles may, at the Landlord’s option, be removed from the
Premises in accordance with a collection schedule prescribed by law. Landlord reserves the right to refuse to collect or accept from Tenant any waste products, garbage, refuse or trash that is not separated and sorted and required by law, and to
require Tenant to arrange for such collection at Tenant’s sole cost and expense, utilizing a contractor reasonably satisfactory to Landlord. Tenant shall pay all costs, expenses, fines, penalties or damages that may be imposed on Landlord or
Tenant by reason of Tenant’s failure to comply with the provisions of this Section, and, at Tenant’s sole cost and expense shall indemnify, defend, and hold Landlord harmless (including legal fees and expenses) from and against any
actions, claims and suits arising from such non-compliance, utilizing counsel reasonably satisfactory to Landlord. 
 E. Utility
Deregulation. Landlord has advised Tenant that presently Jacksonville Electric Authority (Electric Service Provider) is the utility company selected by Landlord to provide utility service for the Building. Notwithstanding the foregoing, if
permitted by law, Landlord shall have 

  

 14 

 
the right at any time and from time to time during the Lease Term to either contract for service from a different company or companies providing electric
service (such a company shall hereinafter be referred to as an Alternate Service Provider) or continue to contract for service from the Electric Service Provider. 
 
9. SECURITY. With respect to security for the Building and the parking garage(s), Landlord and Tenant hereby agree as follows: 
 A. Landlord’s Responsibilities. Landlord shall: (i) install a system to limit access to the Building and parking garage, (ii) respond to Building alarms and/or reports of an emergency nature on a
twenty-four (24) hour basis, and (iii) provide a security escort service to the parking garage after Business Hours. 
 B.
Tenant’s Responsibilities. Tenant shall: (i) abide by all policies, procedures and rules and regulations for use of the access system, (ii) report promptly the loss or theft of all keys which would permit unauthorized entrance
to the Premises, Building or parking garage(s), (iii) report to Landlord the employment or discharge of employees and their vehicle’s make, model, and license number, (iv) promptly report to Landlord door-to-door solicitation or other
unauthorized activity in the Building, and (v) promptly inform the Landlord’s Building manager in the event of a break-in or other emergency. 
 C. Interruption of Security. Tenant acknowledges that the above security provisions may be suspended or modified at Landlord’s sole discretion or as a result of causes beyond the reasonable control of
Landlord. No such interruption, discontinuance or modification of security service will constitute an eviction, constructive eviction, or a disturbance of Tenant’s use and possession of the Premises, and further, no interruption, discontinuance
or modification of security service will render Landlord liable to Tenant or third-parties for damages, abatement of Rent, or otherwise, or relieve Tenant of the responsibility of performing Tenant’s obligations under this Lease. 
 
10. REPAIRS, MAINTENANCE AND UTILITIES 
 A. Landlord’s Responsibilities. During the Lease Term,
Landlord shall define, set, and maintain the level of repairs and maintenance for the Building, the Common Areas, and all other areas serving the Building, in a manner comparable to office buildings of similar quality to and in the immediate
geographic area of the Building. Landlord’s responsibilities with respect to this paragraph are as follows: (i) the structural and roof systems of the Building, (ii) the Building standard electrical and mechanical systems,
(iii) the primary water and sewer systems of the Building, (iv) the Building Common Areas and the common area furniture, fixtures, and equipment, (v) the landscaped areas in and about the Building, (vi) replacement of Building
standard fluorescent light bulbs in the Common Areas, (vii) all maintenance , repair and replacement of the Common Areas and (viii) HVAC. 
 B. Tenant’s Responsibilities. During the Lease Term, Tenant will repair and maintain the following at Tenant’s expense: 
 (1) The interior portion of the demising walls, the interior partition walls of the Premises and their wall-covering, and the entry door to the Premises. 
 (2) The electrical and mechanical systems not considered Building standard which have been installed by either Landlord or Tenant, for the exclusive use and benefit of Tenant. The following examples are for
clarification and are not all inclusive: (a) electrical services for computers or similar items, (b) projection room equipment such as dimmers, curtains, or similar items, (c) water closet plumbing, kitchen plumbing or similar items,
(d) HVAC for other than comfort cooling in the Premises security systems for the Premises, (e) telephone system for the Premises; and (f) other similar systems. 
 (3) Except for the janitorial services to be provided by Landlord, if any, as set forth in this Lease, the repair and maintenance of the floor covering
of the Premises, including VCT flooring, ceramic tiles, marble, wood flooring, or similar coverings, shall be performed by Tenant, at Tenant’s expense. 
 (4) All cabinets and millwork (regardless of ownership) so long as said cabinets and millwork are for the exclusive use and benefit of Tenant. 
 (5) All other personal property, improvements or fixtures, except any of same expressly designated in this Lease as those which Landlord shall maintain.
Those items to be repaired and maintained by Tenant include, but are not limited to, the following: (a) ceiling tiles and ceiling grid, (b) molding or other woodwork and paneling, (c) light fixtures and bulbs, (d) draperies,
blinds or wall hangings, (e) glass partition walls, (f) water closets and kitchen areas, (g) doors and lockset, and (h) vaults, safes, or secured areas. For the aforesaid items, Landlord may elect, with Tenant’s 

  

 15 

 
approval (which approval will not be unreasonably withheld) to maintain and repair same at Tenant’s expense and Tenant will be billed for same as
Additional Rent. 
 C. Repairs and Maintenance; Miscellaneous. Notwithstanding anything to the contrary in this Lease, Landlord shall
have no responsibility to repair or maintain the Building, any of its components, the Common Areas, the Premises, or any fixture, improvement, trade fixture, or any item of personal property contained in the Building, the Common Areas, and/or the
Premises if such repairs or maintenance are required because of the occurrence of any of the following: (i) the acts, misuse, improper conduct, omission or negligence of Tenant or Tenant’s Agents. Should Landlord, at its sole option, elect
to make repairs or maintenance occasioned by the occurrence of any of the foregoing, Tenant shall pay as Additional Rent all such costs and expenses incurred by Landlord. Any such Additional Rent not promptly paid to the Landlord within five
(5) days of a billing of said Additional Rent to the Tenant shall bear interest at twelve percent (12%), and if not paid within ten (10) days thereafter shall constitute a default of this Lease availing Landlord of remedies provided in
Section 24 hereof. Landlord shall have the right to approve in advance all work, repair, maintenance or otherwise, to be performed under this Lease by Tenant and all of Tenant’s repairmen, contractors, subcontractors and suppliers
performing work or supplying materials. Tenant shall be responsible for all permits, inspections and certificates for accomplishing the above. Tenant shall obtain lien waivers for all work done in or to the Premises. 
 
11. TENANT’S ALTERATIONS 
 A. General. During the Lease Term, Tenant will make no alterations,
additions or improvements in or to the Premises or the Building, of any kind or nature, including, but not limited to, alterations, additions or improvements in, to, or on, telephone or computer installations (any and all of such alterations,
additions or improvements other than those set forth in the Work Letter attached hereto are collectively referred to in this Lease as the “Alteration(s)”), without the prior written consent of Landlord, which consent shall not be
unreasonably withheld; provided however, that Landlord may withhold its consent in its reasonable discretion if: (a) the cost of the work will exceed Twenty Five Thousand and 00/100 Dollars ($25,000.00); (b) a building permit will be
required; or (c) if there will be any material modifications to any exterior or structural components of the Building or any of the Building’s operating systems, including, without limitation, heating, ventilating, air conditioning,
plumbing, electrical, and other operating systems. In connection with Tenant’s request for Landlord’s consent under this Lease, Tenant shall pre-pay to Landlord the sum of Two Hundred Fifty and 00/100 Dollars ($250.00) for Landlord’s
review of applicable documents and plans. Tenant also shall reimburse Landlord for any third-party costs and expenses incurred or to be incurred by Landlord related to such review within ten (10) days of receipt of Landlord’s statement
therefore. Tenant shall submit to Landlord detailed drawings and plans of the proposed Alterations at the time Landlord’s consent is sought. Should Landlord consent to any proposed Alterations by Tenant, such consent will be conditioned upon
Tenant’s agreement to comply with all requirements established by Landlord, including safety requirements and the matters referenced in Section 21 of this Lease. As stated herein, all Alterations made hereunder will become Landlord’s
property when incorporated into or affixed to the Building. However, at Landlord’s option, Landlord may, at the expiration of the Lease Term, require Tenant, at Tenant’s expense, to remove Alterations made by or on behalf of Tenant and to
restore the Premises to their original condition. 
 
12. LANDLORD’S ADDITIONS AND ALTERATIONS. Landlord has the right to make changes in and about the Building, garages and parking areas, including, but not limited to, signs, entrances, address or name of
Building. Such changes may include, but not be limited to, rehabilitation, redecoration, refurbishment and refixturing of the Building and expansion of or structural changes to the Building. The right of Tenant to quiet enjoyment and peaceful
possession given under the Lease will not be deemed breached or interfered with by reason of Landlord’s actions pursuant to this section so long as such actions do not materially deprive Tenant of its use and enjoyment of the Premises.

 
13. ASSIGNMENT AND SUBLETTING 
 A. Landlord’s Consent Required. Except as provided below with
respect to assignment of this Lease, Tenant will not effect a Transfer, (as herein defined) without first obtaining the consent of Landlord, which consent Landlord shall not unreasonably withhold provided that all of the requirements of subsection
B, of this Section 13 are satisfied. As used in this Section 13, any of the following shall be deemed to be a Transfer: (i) an assignment of this Lease, in whole or in part; (ii) any sublet of all or any part of the Premises;
(iii) any license allowing anyone other than Tenant to use or occupy all or any part of the Premises; (iv) any pledge or encumbrance by mortgage or other instrument of Tenant’s interest in this Lease; (v) any transfer of
corporate shares as described in subsection C., of this Section 13; or (vi) any transfer of partnership interest as described in subsection D., of this Section 13. Consent by Landlord to any Transfer shall not constitute a waiver of
the requirement for such consent to any subsequent Transfer. In lieu of approving any Transfer, Landlord may elect to terminate this Lease as to the portion of the Premises affected by such Transfer (together with such additional portion of the
Premises needed by Landlord to render the terminated portion marketable) by giving Tenant notice of such election, in which event this Lease and the rights and obligations of the parties hereunder shall cease 

  

 16 

 
as of a date set forth in such notice which date shall not be less than sixty (60) days after the date of such notice. Tenant’s allotted parking
spaces shall be proportionately reduced based on the amount of space recaptured by Landlord. In the event of any such termination, all Rent (other than any Additional Rent due Landlord by reason of Tenant’s failure to perform any of its
obligations hereunder) shall be adjusted as of the date of such termination. 
 B. Conditions for Transfer Approval. Tenant recognizes
that this Lease and the Premises are unique, and that the nature and character of the operations within and management of the Premises are important to the success of the Building. Accordingly, Landlord shall be entitled to arbitrarily withhold its
consent to any Transfer, unless all of the following conditions are satisfied, in which event, Landlord agrees that it shall not unreasonably withhold its consent to the Transfer in question: 
 (1) At the time consent is requested, or at any time prior to the granting of consent, Tenant is not in default under this Lease beyond any applicable
grace or cure period. 
 (2) In Landlord’s reasonable judgment, the proposed assignee or subtenant or occupant is engaged in a business
or activity, which (a) is in keeping with the then standards of the Building, (b) is limited to the use of the Premises as general and executive office, (c) will not violate any negative covenant as to use contained in any other lease
of office space in the Building, (d) will not entail any alterations which would lessen the value of the leasehold improvements in the Premises, (e) will not result in an increased burden on the Building, the Premises and systems and
structures thereof, (f) will not cause an increase in insurance premiums for insurance policies applicable to the Building, or (g) will not impair the dignity, reputation or character of the Building. 
 (3) No portion of the Building or Premises would become subject to additional or different governmental laws and regulations including, without
limitation, the ADA and Title 24. 
 (4) The proposed assignee or sublessee is not an existing tenant or affiliate of an existing tenant of
the Building and Landlord is not negotiating with, and has not at any time within the past sixty (60) days negotiated with, the proposed assignee or sublessee for space in the Building. 
 (5) The proposed use is not prohibited by law or by any provision of this Lease, including, without limitation, the rules and regulations then in
effect. 
 (6) The proposed assignee or subtenant or occupant is a reputable person of good character and with sufficient financial worth
considering the responsibility involved, and Landlord has been furnished with reasonable proof thereof; 
 (7) The form of the proposed
sublease or instrument of assignment or occupancy shall be reasonably satisfactory to Landlord, and shall comply with the applicable provisions of this Paragraph; 
 (8) The Transfer requested shall not, in view of all previous approved Transfers, render the Premises occupied by more than three (3) different occupying transferees; 
 (9) The proposed subtenant or assignee or occupant shall not be a governmental agency, and shall not be entitled, directly or indirectly, to diplomatic
or sovereign immunity and shall be subject to the service of process in, and the jurisdiction of the courts of the State of Florida; 
 (10)
Such transferee shall assume in writing, in a form acceptable to Landlord, all of Tenant’s obligations hereunder and Tenant shall provide Landlord with a copy of such assumption/transfer document; 
 (11) Tenant shall pay to Landlord a fee of One Thousand and 00/100 Dollars ($1,000.00) prior to the effective date of the Transfer in order to reimburse
Landlord for all of its internal costs and expenses incurred with respect to the Transfer, including, without limitation, costs incurred in connection with the review of financial materials, meetings with representative of transferor and/or
transferee and preparation, review, approval and execution of the required transfer documentation, and, in addition, Tenant shall reimburse Landlord for any out-of-pocket costs and expenses incurred with respect to such Transfer, the foregoing shall
hereinafter be referred to as the Transfer Fee; 
 (12) As of the effective date of the Transfer and continuing throughout the remainder of
the Term, the Base Rent shall not be less than the Base Rent set forth in the BLI Rider; 
 (13) Tenant to which the Premises were initially
leased shall continue to remain liable under this Lease for the performance of all terms, including but not limited to, payment of Rent due under this Lease, unless however, in the instance of an assignment, the proposed assignee exhibits to 

  

 17 

 
Landlord’s reasonable satisfaction that it has a net worth at least equal to that of Tenant, in which case Tenant shall be released of liability under
this Lease; 
 (14) N/A; 
 (15) Each of Landlord’s Mortgagees shall have consented in writing to such Transfer; and 
 (16) Tenant shall give notice of a
requested Transfer to Landlord, which notice shall be accompanied by (a) a conformed or photostatic copy of the proposed assignment or sublease, the effective or commencement date of which shall be at least sixty (60) days after the giving
of such notice, (b) a statement setting forth in reasonable detail the identity of the proposed assignee or subtenant, the nature of its business and its proposed use of the Premises, (c) current financial information with respect to the
proposed assignee or subtenant, including, without limitation, its most recent financial report, and (d) such other information as Landlord may reasonably request. 
 (17) Upon request, the Assignee (in the case of a proposed assignment) or Tenant (in the case of a proposed sub-letting) will increase the original Security Deposit hereunder in such amount as Landlord may reasonably
require (or if no security was initially deposited hereunder), or posted with Landlord such Security Deposit as Landlord may require. 
 C.
Transfer of Corporate Shares. If Tenant is a corporation other than a corporation the outstanding voting stock of which is listed on a “national securities exchange,” as defined in the Securities Exchange Act of 1934, and if at any
time after execution of this Lease any part or all of the corporate shares shall be transferred by sale, assignment, bequest, inheritance, operation of law or other disposition (including, but not limited to, such a transfer to or by a receiver or
trustee in federal or state bankruptcy, insolvency, or other proceedings) so as to result in a change in the present control of said corporation by the person(s) now owning a majority of said corporate shares, a Transfer shall be deemed to have
occurred. Tenant shall give Landlord notice that such Transfer is imminent at least fifteen (15) days prior to the date of such Transfer. If any such Transfer is made (and regardless of whether Tenant has given notice of same), Landlord may
elect to terminate this Lease at any time thereafter by giving Tenant notice of such election, in which event this Lease and the rights and obligations of the parties hereunder shall cease as of a date set forth in such notice which date shall not
be less than sixty (60) days after the date of such notice. In the event of any such termination, all Rent (other than any Additional Rent due Landlord by reason of Tenant’s failure to perform any of its obligations hereunder) shall be
adjusted as of the date of such termination. 
 D. Intentionally deleted. 
 E. Acceptance of Rent from Transferee. The acceptance by Landlord of the payment of Rent following any assignment or other transfer prohibited by
this Section 13 shall not be deemed to be a consent by Landlord to any such assignment or other transfer nor shall the same be deemed to be a waiver of any right or remedy of Landlord hereunder. 
 F. Additional Provisions Respecting Transfers. Without limiting Landlord’s right to withhold its consent to any Transfer by Tenant, and
regardless of whether Landlord shall have consented to any such Transfer, neither Tenant nor any other person having an interest in the possession, use or occupancy of the Premises or any part thereof shall enter into any lease, sublease, license,
concession, assignment or other Transfer or agreement for possession, use or occupancy of all or any portion of the Premises, which provides for Rent or other payment for such use, occupancy or utilization based, in whole or in part, on the net
income or profits derived by any person or entity from the space so leased, used or occupied, and any such purported lease, sublease, license, concession, assignment or other transfer or agreement shall be absolutely void and ineffective as a
conveyance of any right or interest in the possession, use or occupancy of all or any part of the Premises. There shall be no deduction from the Rent payable under any sublease or other Transfer nor from the amount thereof passed on to any person or
entity, for any expenses or costs related in any way to the subleasing or Transfer of any interest under this Lease. 
 G. Transfer
Consideration is Additional Rent. If Landlord shall consent to any Transfer, Tenant shall in consideration therefor, pay to Landlord as Additional Rent an amount equal to the Transfer Consideration. For purposes of this paragraph, the term
Transfer Consideration shall mean in any Lease Year (i) any rents, additional charges or other consideration payable to Tenant by the transferee of the Transfer which is in excess of the Base Rent and Overhead Rent less any reasonable, verified
marketing costs attributable to the Transfer accruing during such Lease Year, (ii) all sums paid for the sale or rental of Tenant’s fixtures, leasehold improvements, equipment, furniture or other personal property in excess of the fair
market sale or rental value thereof as of the date of the Transfer, and (iii) all sums paid for services provided by Tenant to the transferee (including, without limitation, secretarial, word processing, receptionist, conference rooms, and
library) in excess of the fair market value of such 

  

 18 

 
services. The Transfer Consideration shall be paid to Landlord as and when paid by the transferee to Tenant. Landlord shall have the right to audit
Tenant’s books and records upon reasonable notice to determine the amount of Transfer Consideration payable to Landlord. In the event such audit reveals an understatement of Transfer Consideration in excess of five percent (5%) of the
actual Transfer Consideration due Landlord, Tenant shall pay the full amount of the understatement and for the cost of such audit within ten (10) days after Landlord’s written demand for same. 
 H. New Directory Isn’t Consent to Sublet/Assignment. The listing or posting of any name, other than that of Tenant, whether on the door or
exterior wall of the Premises, the Building’s tenant directory in the lobby or elevator, or elsewhere, shall not: (i) constitute a waiver of Landlord’s right to withhold consent to any sublet or assignment pursuant to this
Section 13; (ii) be deemed an implied consent by Landlord to a sublet of the Premises or any portion thereof, to any assignment or transfer of the Lease, or to any unauthorized occupancy of the Premises, except in accordance with the
express terms of the Lease; or (iii) operate to vest any right or interest in the Lease or in the Premises. Any such listing as described in this Section 13.H. shall constitute a privilege extended by Landlord to Tenant, and shall be
immediately revocable at Landlord’s will by notice to Tenant. 
 I. Annual Certification. Upon the execution of this Lease and
upon each succeeding anniversary date, or at any sooner time requested by Landlord, Tenant shall deliver to Landlord a statement, certified as being true and correct and verified by the corporate partnership or entity, secretary, as applicable,
showing the names of all existing shareholders, partners or members as applicable, of record and their respective ownership interests as of that date. 
 J. Permitted Transfers. Notwithstanding Section 13(a), Tenant may Transfer all or part of its interest in this Lease or all or part of the Premises (a “Permitted Transfer”) to the following types
of entities (a “Permitted Transferee”) without the written consent of Landlord: 
 (1) an Affiliate of Tenant; 
 (2) any corporation, limited partnership, limited liability partnership, limited liability company or other business entity in which or with which
Tenant, or its corporate successors or assigns, is merged or consolidated, in accordance with applicable statutory provisions governing merger and consolidation of business entities, so long as (A) Tenant’s obligations hereunder are
assumed by the entity surviving such merger or created by such consolidation; and (B) the Tangible Net Worth of the surviving or created entity is not less than the Tangible Net Worth of Tenant as of the date of execution of this Lease; or

 (3) any corporation, limited partnership, limited liability partnership, limited liability company or other business entity acquiring all
or substantially all of Tenant’s assets if such entity’s Tangible Net Worth after such acquisition is not less than the Tangible Net Worth of Tenant as of the date of execution of this Lease. 
 Tenant shall promptly notify Landlord of any such Permitted Transfer. Tenant shall remain liable for the performance of all of the obligations of Tenant
hereunder, or if Tenant no longer exists because of a merger, consolidation, or acquisition, the surviving or acquiring entity shall expressly assume in writing the obligations of Tenant hereunder. Additionally, the Permitted Transferee shall comply
with all of the terms and conditions of this Lease, including the Permitted Use, and the use of the Premises by the Permitted Transferee may not violate any other agreements affecting the Premises or the Building, Landlord or other tenants of the
Building. No later than five (5) business days after the effective date of any Permitted Transfer, Tenant agrees to furnish Landlord with (A) copies of the instrument effecting any of the foregoing Transfers, (B) documentation
establishing Tenant’s satisfaction of the requirements set forth above applicable to any such Transfer, and (C) evidence of insurance as required under this Lease with respect to the Permitted Transferee. The occurrence of a Permitted
Transfer shall not waive Landlord’s rights as to any subsequent Transfers. “Tangible Net Worth” means the excess of total assets over total liabilities, in each case as determined in accordance with generally accepted accounting
principles consistently applied (“GAAP”), excluding, however, from the determination of total assets all assets which would be classified as intangible assets under GAAP including goodwill, licenses, patents, trademarks, trade names,
copyrights, and franchises. Any subsequent Transfer by a Permitted Transferee shall be subject to the terms of this Section 13. 
 
14. TENANT’S INSURANCE COVERAGE 
 A. Tenant shall, at its sole cost and expense, during the Lease Term,
cause all improvements at any time located in the Premises (other than the Building standard tenant improvements) and all equipment and fixtures from time to time used or intended to be used in connection with the operation and maintenance of the
Premises, to be insured for the mutual benefit of Landlord and Tenant against loss or damage by fire and against loss or damage by other risks now or hereafter included in an 

  

 19 

 
All-Risk insurance policy, in an amount equal to the full insurable value thereof. All proceeds from such insurance shall be used for the repair or
replacement of such improvements, equipment and fixtures. 
 B. All coverage shall be written on an occurrence basis and shall be primary and
non-contributory over any insurance the Landlord may elect to provide on its behalf. Upon the commencement of the Lease Term, and upon renewal of such insurance coverage, Tenant shall deliver to the Landlord certified copies of Tenant’s
insurance policies, or an original certificate of such insurance from the insurer providing a minimum of thirty (30) days’ notice of cancellation or modification, showing that all premiums have been paid for the full policy period. In the
event Tenant shall fail to procure such insurance or to deliver such policies and certificates, Landlord may, at Landlord’s option and in addition to Landlord’s other remedies in the event of a default by Tenant hereunder, procure the same
for the account of Tenant, and the cost thereof shall be paid to Landlord as additional rent. All policies of insurance required to be carried by Tenant under this Section 12 shall be in form satisfactory to Landlord, shall name Landlord,
Landlord’s mortgagee, Landlord’s managing agent and any other party designated by Landlord as additional insureds, shall be issued by responsible insurance companies which are licensed to do business in the State of Florida, and shall have
a Best’s rating of a least AA and a financial rating of not less than AXII and have been approved in writing by Landlord. The policies shall contain cross-liability endorsements or their equivalent, and shall be for the mutual and joint benefit
and protection of Landlord, Tenant and any other party designated by Landlord as an additional insured. 
 Notwithstanding any other
provisions of this Lease, Tenant at its own expense, shall also maintain the following insurance coverage: 
 (1) Worker’s Compensation
and Employer’s Liability. Tenant shall maintain Worker’s Compensation insurance sufficient to comply with all applicable State and/or Federal laws and an Employer’s Liability policy with a limit of not less than One Million Dollars
($1,000,000.00). 
 (2) Commercial General Liability. Tenant shall maintain a Commercial General Liability policy applying to the use and
occupancy of the Premises and the Building, and any part of either, and any areas adjacent thereto, and the business operated by Tenant, or by any other occupant of the Premises with limits of liability not less than Two Million Dollars
($2,000,000.00) per occurrence and Three Million Dollars ($3,000,000.00) general aggregate for Bodily Injury and Property Damage and Three Million Dollars ($3,000,000.00) aggregate products/completed operations coverage. Such policy shall
specifically name the Landlord, Landlord’s mortgagee and Landlord’s managing agent as additional insureds. Landlord may, at its discretion, request evidence of products insurance. All such insurance shall provide for severability of
interests; shall provide that an act or omission of one of the named insureds shall not reduce or avoid coverage to the other named insureds; and shall afford coverage for all claims based on acts, omissions, injury and damage, which claims occurred
or arose (or the onset of which occurred or arose) in whole or in part during the policy period. Tenant’s Commercial General Liability policy shall not provide for a deductible in excess of Two Thousand Dollars ($2,000.00) without the prior
written approval of Landlord. 
 (3) Business Interruption. N/A. 
 (4) Property Insurance. Tenant shall maintain an All-Risk property insurance policy on all personal property, furniture and fixtures of Tenant and
tenant improvements and betterments for not less than one hundred percent (100%) of the replacement cost of the same. Tenant’s property policy shall not provide for a deductible in excess of Two Thousand Dollars ($2,000.00) without the
prior written approval of Landlord. 
 (5) Additional Insurance. Whenever good business practice, in Landlord’s reasonable judgment,
indicates the need for additional insurance coverage or different types of insurance in connection with the Premises or Tenant’s use and occupancy thereof, Tenant shall, upon request, obtain such insurance at Tenant’s expense and provide
Landlord with evidence thereof. 
 C. Except for items for which Landlord is responsible under the Work Letter, before any repairs,
alterations, additions, improvements, or construction are undertaken by or on behalf of Tenant, Tenant shall carry and maintain at its expense, or Tenant shall require any contractor performing work in the Premises to carry and maintain, at no
expense to Landlord, in addition to workers’ compensation insurance as required by the jurisdiction in which the Building is located, All Risk Builder’s Risk Insurance in the amount of the replacement cost of any alterations, additions or
improvements (or such other amount reasonably required by Landlord) and Commercial General Liability Insurance (including, without limitation, Contractor’s Liability coverage), written on an occurrence basis with a minimum combined single limit
of Two Million Dollars ($2,000,000.00) and adding the Owners of the Building and its (or their) respective members, principals, beneficiaries, partners, officers, directors, employees, managing agents, agents (and their respective members and
principals) and mortgagee(s)(and any other designees of Landlord as the interest of such designees shall appear) as additional insureds. 
  

 20 

 D. Tenant shall not do or fail to do anything in, upon or about the Premises which will: (i) violate
the terms of any of Landlord’s insurance policies; (ii) prevent Landlord from obtaining policies of insurance acceptable to Landlord or any mortgagees; or (iii) result in an increase in the rate of any insurance on the Premises, the
Building, any other property of Landlord or of others in the Building. In the event of the occurrence of any of the events set forth in this Section 12(d), Tenant shall pay landlord, upon demand, as additional rent, the cost of the amount of
any increase in any such insurance premium, provided that the acceptance by Landlord of such payment shall not be construed as a waiver of any rights by Landlord in connection with a default by Tenant under the Lease. 
 E. Tenant shall, prior to and throughout the Lease Term, procure from each of its insurers under all policies of fire, theft, public liability,
workers’ compensation and any other insurance policies of Tenant now or hereafter existing, pertaining in any way to the Premises or the Building or any operation therein, a waiver, as set forth in Section 13 of this Lease, of all rights
of subrogation which the insurer might otherwise, if at all, have against the Landlord or any officer, agent or employee of Landlord (including, without limitation, Landlord’s managing agent). 
 
15. LANDLORD’S INSURANCE COVERAGE 
 A. General. Landlord will at all times during the Lease Term
maintain a policy or policies of insurance insuring the Building against loss or damage by fire, explosion or other hazards and contingencies typically covered by insurance for an amount acceptable to the mortgagees encumbering the Building.
Landlord reserves the right to self insure in lieu of maintaining such policies. 
 B. Tenant’s Acts. Tenant will not do or
permit anything to be done upon or bring or keep or permit anything to be brought or kept upon the Premises which will unreasonably increase Landlord’s rate of insurance on the Building. If by reason of the failure of Tenant to comply with the
terms of this Lease, or by reason of Tenant’s occupancy (even though permitted or contemplated by this Lease), the insurance rate shall at any time be unreasonably higher than it would otherwise be, Tenant will reimburse Landlord for that part
of all insurance premiums charged because of such violation or occupancy by Tenant. Tenant agrees to comply with any reasonable requests or recommendation made by Landlord’s insurance underwriter inspectors. 
 
16. WAIVER OF RIGHT OF RECOVERY 
 A. General. Except as provided in section 39, neither Landlord nor
Tenant shall be liable to the other for any damage to any building, structure or other tangible property, or any resulting loss of income, or losses under worker’s compensation laws and benefits, even though such loss or damage might have been
occasioned by the negligence of such party, its agents or employees. The provisions of this Section shall not limit the indemnification for liability to third parties pursuant to section 19. As used in this section 16. A., “damage” refers
to any loss, destruction or other damage. 
 B. Exclusions. Tenant acknowledges that Landlord will not carry insurance on
improvements, furniture, furnishings, trade fixtures, equipment installed in or made to the Premises by or for Tenant, and Tenant agrees that Tenant, and not Landlord, will be obligated to promptly repair any damage thereto or replace the same.

 
17. DAMAGE OR DESTRUCTION BY CASUALTY 
 A. Absolute Right to Terminate. If by fire or other casualty
the Premises are damaged or destroyed to the extent of forty (40%) percent or more of the replacement cost thereof, or the Building is damaged or destroyed to the extent of forty (40%) percent or more of the replacement cost thereof,
Landlord will have the option of terminating this Lease or any renewal thereof by serving written notice upon Tenant within one hundred eighty (180) days from the date of the casualty and any prepaid Rent or Additional Rent will be prorated as
of the date of destruction and the unearned portion of such Rent will be refunded to Tenant without interest. 
 B. Qualified Right to
Terminate. If by fire or other casualty either the Premises or the Building is damaged or destroyed to the extent of less than forty (40%) percent but more than twenty-five (25%) percent of the replacement cost of the Premises or the
Building (as applicable) (or the Premises or Building are damaged to a lesser degree but section 17.C., does not apply because of the number of years remaining in the Lease Term), then Landlord may, so long as it treats Tenant and similarly situated
tenants in a nondiscriminatory manner, either terminate this Lease by serving written notice upon Tenant within one hundred eighty (180) days of the date of destruction or Landlord may restore the Premises. 
 C. Obligation to Restore. If by fire or other casualty either the Premises or the Building is destroyed or damaged, but only to the extent of
twenty-five (25%) or less of the replacement 

  

 21 

 
cost of the Premises or the Building (as applicable), and, also, the unexpired Lease Term, including any previously exercised renewal option, is more than
three years, then Landlord will restore the Premises. 
 D. Rent Adjustments. In the event of restoration by Landlord, all Rent (as
previously defined in this Lease), paid in advance shall be apportioned as of the date of damage or destruction and all such Rent as above described thereafter accruing shall be equitably and proportionately adjusted according to the nature and
extent of the destruction or damage, pending substantial completion of rebuilding, restoration or repair. In the event the destruction or damage is so extensive as to make it unfeasible for Tenant to conduct Tenant’s business in the Premises,
Rent under this Lease will be completely abated until the Premises are substantially restored by Landlord or until Tenant resumes use and occupancy of the Premises, whichever shall first occur. Landlord will not be liable for any damage to or any
inconvenience or interruption of business of Tenant or any of Tenant’s Agents occasioned by fire or other casualty. 
 E.
Qualifications. Said restoration, rebuilding or repairing will exist and will be at Landlord’s sole cost and expense, subject to the availability of applicable insurance proceeds. Landlord shall have no duty to restore, rebuild or
replace Tenant’s personal property and trade fixtures, unless such casualty was caused by Landlord’s negligence. Notwithstanding anything to the contrary in this Lease, including, but not limited to this section 17. Landlord’s
obligation(s) to repair, rebuild or restore the Building or the Premises shall exist (i) only to the extent of insurance proceeds received by Landlord in connection with the condition or event which gave rise to Landlord’s obligation to
repair, rebuild or restore and/or (ii) only so long as the area unaffected by the casualty may, as determined by Landlord using reasonable business judgment, be restored as a profitable, self functioning unit. 
 
18. CONDEMNATION AND EMINENT DOMAIN 
 A. Absolute Right to Terminate. If all or a material part of
the Premises or the Building or the parking spaces is taken for any public or quasi-public use under any governmental law, ordinance or regulation or by right of eminent domain or by purchase in lieu thereof, and the taking would prevent or
materially interfere with the use of the Premises for the purpose for which they are then being used, this Lease will terminate and the Rent and Additional Rent will be abated during the unexpired portion of this Lease effective on the date physical
possession is taken by the condemning authority. Tenant will have no claim to the condemnation award. 
 B. Obligation to Restore. In
the event an immaterial part of the Premises or the Building or the parking spaces is taken for any public or quasi-public use under any governmental law, ordinance or regulation, or by right of eminent domain or by purchase in lieu thereof, and
this Lease is not terminated as provided in section 18.A. above, then Landlord shall, subject to the remaining provisions of this section, at Landlord’s expense, restore the Premises to the extent necessary to make them reasonably tenantable.
The Rent and Additional Rent payable under this Lease during the unexpired portion of the Lease Term shall be adjusted to such an extent as may be fair and reasonable under the circumstances. Tenant shall have no claim to the condemnation award with
respect to the leasehold estate but, in a subsequent, separate proceeding, may make a separate claim for trade fixtures installed in the Premises by and at the expense of Tenant and Tenant’s moving expense. In no event will Tenant have any
claim for the value of the unexpired Lease Term. 
 C. Qualifications. Notwithstanding the foregoing, Landlord’s obligation to
restore exists (i) only if and/or to the extent, that the condemnation or similar award received by Landlord is sufficient to compensate Landlord for its loss and its restoration costs and/or (ii) the area unaffected by the condemnation or
similar proceeding may, as determined by Landlord’s reasonable business judgment, be restored as a profitable, and self functioning unit. 
 
19. LIMITATION OF LANDLORD’S LIABILITY; INDEMNIFICATION 
 A. Personal Property. All personal
property placed or moved into the Building will be at the sole risk of Tenant or other owner. Landlord will not be liable to Tenant or others for any damage to person or property arising from environmental concerns, as hereafter defined, theft,
vandalism, HVAC malfunction, the bursting or leaking of water pipes, any act or omission of any cotenant or occupant of the Building or of any other person, or otherwise unless caused by the act or neglect of Landlord. 
 B. Limitations. Notwithstanding any contrary provision of this Lease: (i) Tenant will look solely (to the extent insurance coverage is not
applicable or available) to the interest of Landlord (or its successor as Landlord hereunder) in the Building for the satisfaction of any judgment or other judicial process requiring the payment of money as a result of any negligence or breach of
this Lease by Landlord or its successor or of Landlord’s managing agent (including any beneficial owners, partners, corporations and/or others affiliated or in any way related to Landlord or such successor or managing agent) and Landlord has no
personal liability hereunder of any kind, and (ii) Tenant’s sole right and 

  

 22 

 
remedy in any action or proceeding concerning Landlord’s reasonableness (where the same is required under this Lease) will be an action for declaratory
judgment and/or specific performance. 
 C. Indemnity. Tenant agrees to indemnify, defend and hold harmless Landlord and
Landlord’s employees, officers, directors and agents (“Landlord’s Agents”) from and against all claims, causes of actions, liabilities, judgments, damages, losses, costs and expenses, including reasonable attorneys’ fees and
costs, including appellate proceedings and bankruptcy proceedings (collectively “Damages”), incurred or suffered by Landlord and arising from or in any way connected with the negligence or willful misconduct of Tenant or any of
Tenant’s Agents, including, but not limited to, any breach of this Lease or any death, personal injury or property damage occurring in or about the Premises or the Building or arising from Environmental concerns, as hereafter defined. Tenant
will reimburse Landlord upon request for all costs incurred by Landlord in the interpretation and enforcement of any provisions of this Lease and/or the collection of any sums due to Landlord under this Lease, including collection of agency fees,
and reasonable attorneys’ fees and costs, regardless of whether litigation is commenced, and through all appellate actions and proceedings, including bankruptcy proceedings, if litigation is commenced. The foregoing claims, causes of actions,
liabilities, judgments, damages, losses, costs and expenses shall include but not be limited to any of same arising from Tenant’s failure to comply with any of the requirements of Americans with Disabilities Act (“ADA”) within the
Premises. 
 Subject to Section 16 hereof, Landlord agrees to indemnify and hold harmless Tenant and Tenant’s employees, officers,
directors and agents (“Tenant’s Agents”) from and against Damages (i) arising from the negligence or willful misconduct of Landlord or any of Landlord’s Agents or any breach by Landlord of its obligations under this
Lease, or (ii) for personal injuries or property damage occurring outside of the Premises within the Common Area or Building to the extent not caused by the gross negligence or willful misconduct of Tenant or Tenant’s Agents, or
(iii) relating to Hazardous Substances that may exist at the Premises or the Building prior to the date of the Lease or that were not brought on to the Premises or the Building by the Tenant, its agents or contractors. Landlord will reimburse
Tenant upon request for all costs reasonably incurred by Tenant in the interpretation and enforcement of any provisions of this Lease and/or the collection of any sums due to Tenant under this Lease, including collection of agency fees, and
reasonable attorneys’ fees and costs, regardless of whether litigation is commenced, and through all appellate actions and proceedings, including bankruptcy proceedings, if litigation is commenced. 
 
20. INTENTIONALLY DELETED 
 
21. COMPLIANCE WITH LAWS AND PROCEDURES 
 A. Compliance. Tenant, at its sole cost, will promptly
comply with all applicable laws, guidelines, rules, regulations and requirements, whether of federal, state, or local origin, applicable to the Premises and the Building, including, but not limited to, the Americans with Disabilities Act, 42 U.S.C.
‘ 12101 et seq, and those for the correction, prevention and abatement of nuisance, unsafe conditions, or other grievances arising from or pertaining to the use or occupancy of the Premises. Any Alterations to the Premises made by or on behalf
of Tenant for the purpose of complying with the ADA or which otherwise require compliance with the ADA shall be done in accordance with this Lease; provided, that Landlord’s consent to such Alterations shall not constitute either
Landlord’s assumption, in whole or in part, of Tenant’s responsibility for compliance with the ADA, or representation or confirmation by Landlord that such Alterations comply with the provisions of the ADA. 
 B. Notice Prior to Work. Tenant shall provide thirty (30) days notice to Landlord prior to the performance by Tenant, Tenant’s Agents or
contractors of any structural repairs, renovation and/or maintenance, to the Premises. Such notice shall include a detailed description of the work contemplated. Tenant shall not perform, or cause to be performed, any such repair, renovation and/or
maintenance without the written consent of Landlord, and, if such consent is granted, the repair, renovation and/or maintenance must be performed in accordance with the terms of Landlord’s consent. 
 C. Indemnification. Tenant shall indemnify, defend, and hold harmless Landlord from and against any and all claims or liability arising from the
performance of the repair, renovation, and/or maintenance described above. This indemnity shall include, but not be limited to, claims or liabilities asserted against Landlord based upon negligence, strict liability or other liability by operation
of law to any third party or government entity, and all costs, attorney’s fees, expenses, and liabilities incurred by Landlord in the defense of any such claim. Landlord shall defend any such claim at Tenant’s expense by counsel selected
by Landlord. 
 
22. RIGHT OF ENTRY. Landlord and its agents will have the right to enter the Premises during all reasonable hours to make necessary repairs to the Premises. In the event of an emergency, Landlord or its agents may
enter the Premises at any time, without notice, to appraise and correct the emergency condition. Said right of entry will, after reasonable notice, likewise exist for the purpose of removing placards, signs, fixtures, alterations, or additions which
do not conform to this Lease. Landlord 

  

 23 

 
or its agents will have the right to exhibit the Premises at any time, with reasonable prior notice to Tenant, to prospective tenants within one hundred and
eighty days (180) before the Expiration Date of the Lease. 
 
23. DEFAULT 
 A. Events of Default By Tenant. If (i) Tenant fails to pay Rent after the grace
period of the due date (a Monetary Default); or (ii) Tenant fails to cure any other default, such as, but not limited to, the performance of any other covenant or agreement of this Lease, or any rules and regulations attached to this Lease, or
promulgated by Landlord under this Lease (a Non-monetary Default); or (iii) Tenant, before the expiration of the Lease Term abandons any part of the Premises, or surrenders all or any part of the Premises prior to the Expiration Date without
prior written notice, or (iv) Tenant fails to fulfill any of the material terms or conditions of this Lease or any other lease heretofore made by Tenant for space in the Building or (v) the appointment of a trustee or a receiver to take
possession of all or substantially all of Tenant’s assets occurs, or if the attachment, execution or other judicial seizure of all or substantially all of Tenant’s assets located at the Premises, or of Tenant’s interest in this Lease,
occurs, or (vi) Tenant or any of its successors or assigns or any guarantor of this Lease (“Guarantor”) or surety of Tenant’s obligations should file any voluntary petition in bankruptcy, reorganization or arrangement, or an
assignment for the benefit of creditors or for similar relief under any present or future statute, law or regulation relating to relief of debtors, or (vii) Tenant or any of its successors or assigns or any Guarantor should be adjudicated
bankrupt or have an involuntary petition in bankruptcy, reorganization or arrangement filed against it, or (viii) Tenant shall permit, allow or suffer to exist any lien, judgment, writ, assessment, charge, attachment or execution upon
Landlord’s or Tenant’s interest in this Lease or to the Premises, and/or the fixtures, improvements and furnishings located thereon; then, Tenant shall be in default hereunder, (ix) Tenant, before the Expiration Date and without the
written consent of the Landlord ceases to conduct fully its business as specified in this Lease for a period of fifteen (15) days; or (x) the leasehold estate granted to Tenant by this Lease is taken on execution or other process of law or
equity in any action against Tenant, then Tenant shall be in default hereunder. Landlord reserves the right to request and receive a current Financial Statement from the Tenant at any time that the Tenant shall receive a notice of default from the
Landlord under this Lease, or in the absence of any such occurrence, not more than one (1) time per calendar year. 
 B.
Tenant’s Grace Period. Notwithstanding anything contained in this Lease to the contrary, all Rent shall be paid within five (5) business days of its due date and provided that the default does not involve an Emergency that must be
addressed in a shorter time frame, Tenant shall have a period of ten (10) days after notice from Landlord of a Non-monetary Default in which to cure the default. In addition, provided that the default does not involve an Emergency that must be
addressed in a shorter time frame, this grace period shall be extended if the default is of the nature that it cannot be completely cured within ten (10) day period solely as a result of nonfinancial circumstances outside of Tenant’s
control, provided that Tenant has promptly commenced all appropriate actions to cure the default within the ten (10) day period and those actions are thereafter diligently and continuously pursued by Tenant in good faith. In no event, however,
shall the grace period exceed a total of thirty (30) days. If the Non-monetary Default is not cured prior to the expiration of the grace period, as extended, then Landlord may pursue all of its remedies. The notice of Non-monetary Default to be
given under this subsection may be combined with the notice required under Section 83.20(3), Florida Statutes, or any successor statute and this Lease shall not be construed to require Landlord to give two separate notices to Tenant before
proceeding with any remedies 
 C. Repeated Late Payment. Regardless of the number of times of Landlord’s prior acceptance of
late payments and/or late charges, (i) if Landlord notifies Tenant twice in any six (6) month period that Base Rent or any Additional Rent has not been paid when due, including applicable grace periods, then any other late payment within
such six (6) month period shall automatically constitute an Event of Default hereunder and (ii) the mere acceptance by Landlord of late payments in the past shall not, regardless of any applicable laws to the contrary, thereafter be deemed
to waive Landlord’s right to strictly enforce this Lease, including Tenant’s obligation to make payment of Rent on the exact day same is due, against Tenant. 
 D. Landlord’s Default. If Tenant asserts that Landlord has failed to meet any of its obligations under this Lease, Tenant shall provide written notice (“Notice of Default”) to Landlord specifying
the alleged failure to perform, and Tenant shall send by certified mail, return receipt requested, a copy of such Notice of Default to any and all mortgage holders, provided that Tenant has been previously advised of the address(es) of such mortgage
holder(s). Landlord and/or such mortgage holder(s) shall have a thirty (30) day period after receipt of the Notice of Default in which to commence curing any non-performance by Landlord, and Landlord shall have as much time thereafter to
complete such cure as is necessary so long as Landlord’s cure efforts are diligent and continuous. 
 E. Tenant’s Remedies.
If Landlord fails in the performance of any of Landlord’s obligations under this Lease and such failure continues for fifteen (15) days after Landlord’s receipt of written notice thereof from Tenant (and an additional reasonable time
after such receipt if (A)

  

 24 

 
such failure cannot be cured within such fifteen (15) day period, and (B) Landlord commences curing such failure within such fifteen (15) day
period and thereafter diligently pursues the curing of such failure), then Tenant shall be entitled to exercise any remedies that Tenant may have at law or in equity. 
 
24. LANDLORD’S REMEDIES FOR TENANT’S DEFAULT 
 A. Landlord’s Options. If Tenant is in
default of this Lease, Landlord may, at its option, in addition to such other remedies as may be available under Florida law: 
 (1)
terminate this Lease and Tenant’s right of possession; or 
 (2) terminate Tenant’s right to possession but not the Lease and/or
proceed in accordance with any and all provisions of section 24 B. below. 
 B. Landlord’s Remedies. (i) Landlord may,
except in instances of emergency, upon the order of the court of applicable jurisdiction without further notice re-enter the Premises without force or breach of the peace or otherwise dispossess Tenant by summary proceedings or otherwise, as well as
the legal representative(s) of Tenant and/or other occupant(s) of the Premises, and remove their effects and hold the Premises as if this Lease had not been made, and/or at Landlord’s option; (ii) all Rent for the balance of the Term will,
at the election of Landlord, be accelerated and the present worth of same for the balance of the Lease Term, net of amounts actually collected by Landlord, shall become immediately due thereupon and be paid, together with all expenses of every
nature which Landlord may incur such as (by way of illustration and not limitation) those for attorneys’ fees, brokerage, advertising, and refurbishing the Premises in good order or preparing them for re-rental. For purposes of the preceding
sentence, “present worth” shall be computed by discounting such amount to present worth at an interest rate equal to one percentage point above the discount rate then in effect at the Federal Reserve Bank nearest to the location of the
Building; and/or at Landlord’s option; (iii) Landlord may re-let the Premises or any part thereof, either in the name of Landlord or otherwise, for a term or terms which may at Landlord’s option be less than or exceed the period which
would otherwise have constituted the balance of the Lease Term, and may grant concessions or free rent or charge a higher rent than that reserved in this Lease; and/or at Landlord’s option; (iv) Tenant or its legal representative(s) shall
also pay to Landlord as liquidated damages any deficiency between the Rent and all Additional Rent hereby reserved and/or agreed to be paid and the net amount, if any, of the rents collected on account of the lease or leases of the Premises for each
month of the period which would otherwise have constituted the balance of the Lease Term. 
 
25. LANDLORD’S RIGHT TO PERFORM FOR TENANT’S ACCOUNT. If Tenant fails to observe or perform any term or condition of this Lease within the grace period, if any, applicable thereto, then Landlord may
immediately or at any time thereafter perform the same for the account of Tenant. If Landlord makes any expenditure or incurs any obligation for the payment of money in connection with such performance for Tenant’s account (including reasonable
attorneys’ fees and costs in instituting, prosecuting and/or defending any action or proceeding through appeal), the sums paid or obligations incurred, with interest at eighteen (18%) percent per annum, will be paid by Tenant to Landlord
within ten (10) days after rendition of a bill or statement to Tenant. In the event Tenant in the performance or non-performance of any term or condition of this Lease should cause an emergency situation to occur or arise within the Premises or
in the Building, Landlord will have all rights set forth in this Section immediately without the necessity of providing Tenant any advance notice. 
 
26. LIENS 
 A. General. In accordance with the applicable provisions of the Florida Mechanic’s
Lien Law and specifically Florida Statutes, Section 713.10, no interest of Landlord whether personally or in the Premises, or in the underlying land or Building of which the Premises are a part or the leasehold interest aforesaid shall be
subject to liens for improvements made by Tenant or caused to be made by Tenant hereunder. Further, Tenant acknowledges that Tenant, with respect to improvements or alterations made by Tenant or caused to be made by Tenant hereunder, shall promptly
notify the contractor making such improvements to the Premises of this provision exculpating Landlord’s liability for such liens. 
 B.
Default. Notwithstanding the foregoing, if any mechanic’s lien or other lien, attachment, judgment, execution, writ, charge or encumbrance is filed against the Building or the Premises or this leasehold, or any alterations, fixtures or
improvements therein or thereto, as a result of any work action or inaction done by or at the direction of Tenant or any of Tenant’s Agents, Tenant will discharge same of record within ten (10) days after the filing thereof, failing which
Tenant will be in default under this Lease. In such event, without waiving Tenant’s default, Landlord, in addition to all other available rights and remedies, without further notice, may discharge the same of record by payment, bonding or
otherwise, as Landlord may elect, and upon request Tenant will reimburse Landlord for all costs and expenses so incurred by Landlord plus interest thereon at the rate of Eighteen (18%) percent per annum. 
  

 25 

 
27. NOTICES. Notices to Tenant under this Lease will be addressed to Tenant and mailed or delivered to the address set forth for Tenant in the BLI Rider. Notices to Landlord under this Lease (as well as the
required copies thereof) will be addressed to Landlord (and its agents) and mailed or delivered to the address set forth in the BLI Rider. Notices will be personally delivered or given by registered or certified mail, return receipt requested.
Notices delivered personally will be deemed to have been given as of the date of delivery and notices given by mail will be deemed to have been given forty-eight (48) hours after the time said properly addressed notice is placed in the mail.
Each party may change its address from time to time by written notice given to the other as specified above. 
 
28. MORTGAGE; ESTOPPEL CERTIFICATE; SUBORDINATION. Landlord has the unrestricted right to convey, mortgage and refinance the Building, or any part thereof. Tenant agrees, within fifteen (15) days after
notice, to execute and deliver to Landlord or its mortgagee or designee such instruments as Landlord or its mortgagee may require, certifying the amount of the Security Deposit and whether this Lease is in full force and effect, and listing any
modifications. This estoppel certificate is intended to be for the benefit of Landlord, any purchaser or mortgagee of Landlord, or any purchaser or assignee of Landlord’s mortgage. The estoppel certificate will also contain such other
information as Landlord or its designee may request. This Lease is and at all times will be subject and subordinate to all present and future mortgages or ground leases which may affect the Building and/or the parking garage(s), and to all
recastings, renewals, modifications, consolidations, replacements, and extensions of any such mortgage(s), and to all increases and voluntary and involuntary advances made thereunder. The foregoing will be self-operative and no further instrument of
subordination will be required. In the event that the holder (“Lender”) of any encumbrance (“Mortgage”) on the Building or any other person acquires title to the Building pursuant to the exercise of any remedy provided for in the
Mortgage or by reason of the acceptance of a deed in lieu of foreclosure (the Lender, any other such person and their participants, successors and assigns being referred to herein as the “Purchaser”), Tenant covenants and agrees to attorn
to and recognize and be bound to Purchaser as its new Landlord, and except as provided below, this Lease shall continue in full force and effect as a direct Lease between Tenant and Purchaser, except that, notwithstanding anything to the contrary
herein or in the Lease, the provisions of the Mortgage will govern with respect to the disposition of proceeds of insurance policies or condemnation or eminent domain awards. So long as the Lease is in full force and effect and Tenant is not in
default under any provision of this Lease, and no event has occurred that has continued to exist for a period of time (after notice, if any, required by this Lease) as would entitle Landlord to terminate this Lease or would cause without further
action by Landlord, the termination of this Lease or would entitle Landlord to dispossess the Tenant thereunder: 
 A. The right of possession
of Tenant to the Premises shall not be terminated or disturbed by any steps or proceedings taken by Lender in the exercise of any of its rights under the Mortgage or the indebtedness secured thereby; 
 B. This Lease shall not be terminated or affected by said exercise of any remedy provided for in the Mortgage, and any sale by Lender of the Building
pursuant to the exercise of any rights and remedies under the Mortgage or otherwise, shall be made subject to this Lease and the rights of Tenant hereunder. 
 C. Without waiving any rights or claims of actions Tenant may have against Landlord, in no event shall Lender be: 
 (1) liable for any act or omission of Landlord or any prior landlord; 
 (2) liable for the return of any security deposit unless
the security deposit shall have been assigned to the Lender; 
 (3) bound by any payment or rent or additional rent that Tenant might have
paid to Landlord or any prior landlord for more than the current month; or 
 (4) bound by any amendment or modifications of the Lease made
without Lender’s or such other Purchaser’s prior written consent. 
 D. Provided that Landlord has previously notified Tenant of
Lender’s address for notice, Tenant agrees to give prompt written notice to Lender of any default by Landlord that would entitle Tenant to cancel this Lease, and agrees that notwithstanding any provision of this Lease, no notice of cancellation
thereof given on behalf of Tenant shall be effective unless Lender has received said notice and has failed within thirty (30) days of the date of receipt thereof to cure Landlord’s default, or if the default cannot be cured within thirty
(30) days, has failed to commence and to diligently pursue the cure of Landlord’s default which gave rise to such right of cancellation. Tenant further agrees to give such notices to any successor of Lender, provided that such successor
shall have given written notice to Tenant 

  

 26 

 
of its acquisition of Lender’s interest in the Mortgage and designated the address to which such notices are to be sent. 
 E. Tenant acknowledges that Landlord may execute and deliver to Lender an Assignment of Leases and Rents conveying the rentals under this Lease as
additional security for the loan secured by the Mortgage, and Tenant hereby expressly consents to such Assignment. 
 F. Tenant agrees that
it will not, without the prior written consent of Lender, do any of the following, and any such purported action without such consent shall be void as against Lender: 
 (1) modify this Lease or any extensions or renewals thereof in such a way as to reduce the Rent, accelerate Rent payments, shorten the original term, or change any renewal option, except as provided by its terms;

 (2) terminate this Lease except as provided by its terms; or 
 (3) tender or accept a surrender of this Lease or make prepayment in excess of one month of rent thereunder. 
 G. Tenant agrees to certify in writing to Lender, upon request, whether or not any default on the part of Landlord exists and the nature of any such
default. 
 H. The foregoing provisions shall be self-operative and effective without the execution of any further instruments on the part of
Lender or Tenant. However, Tenant agrees to execute and deliver to Lender or to any person to whom Tenant herein agrees to attorn such other instruments as either shall request in order to effectuate said provisions. 
 
29. ATTORNMENT AND MORTGAGEE’S REQUEST 
 A. Attornment. If any mortgagee of the Building comes
into possession or ownership of the Premises, or acquires Landlord’s interest by foreclosure of the mortgage or otherwise, upon the mortgagee’s request Tenant will attorn to the mortgagee. 
 B. Mortgage Modification. If a mortgagee of the Building requests modifications to this Lease as a condition to disbursing any monies to be
secured by the mortgage, Tenant agrees that within fifteen (15) days after request by the mortgagee Tenant will execute, acknowledge and deliver to the mortgagee an agreement, in form and substance satisfactory to the mortgagee, evidencing such
modifications, provided they do not increase Tenant’s obligations under this Lease or materially adversely affect the leasehold interest created by this Lease. 
 C. Estoppel Letter. Tenant agrees that within fifteen (15) days after request by any mortgagee of the Building, Tenant will execute, acknowledge and deliver to the mortgagee a notice in form and substance
satisfactory to the mortgagee (as prepared by Landlord), setting forth such information as the mortgagee may require with respect to this Lease and/or the Premises. If for any reason Tenant does not timely comply with the provisions of this
paragraph, Tenant will be deemed to have confirmed that this Lease is in full force and effect with no defaults on the part of either party and without any right of Tenant to offset, deduct or withhold any Rent or Additional Rent. 
 
30. TRANSFER BY LANDLORD. If Landlord’s interest in the Building terminates by reason of a bona fide sale or other transfer, Landlord will, upon transfer of the Security Deposit to the new owner, thereupon be
released from all further liability to Tenant under this Lease, for matters that occur subsequent to said sale or other transfer. At the expiration or termination of the Lease Term, Tenant shall deliver to Landlord all keys to the Premises and make
known to Landlord the location and combination of all safes, locks and similar items. 
 
31. SURRENDER OF PREMISES; HOLDING OVER 
 A. Surrender. Tenant agrees to surrender the Premises to
Landlord on the Expiration Date (or sooner termination of the Lease Term pursuant to other applicable provisions hereof) in as good condition as they were at the commencement of Tenant’s occupancy, ordinary wear and tear, and damage by fire and
windstorm excepted. 
 B. Restoration. In all events, Tenant will promptly restore all damage caused in connection with any removal of
Tenant’s personal property. Tenant will pay to Landlord, upon request, all damages that Landlord may suffer on account of Tenant’s failure to surrender possession as and when aforesaid and will indemnify Landlord against all liabilities,
costs and expenses (including all reasonable 

  

 27 

 
attorneys’ fees and costs if any) arising out of Tenant’s delay in so delivering possession, including claims of any succeeding tenant. 

C. Removal. Upon expiration of the Lease Term, Tenant will not be required to remove from the Premises Building standard items, all of such
Building standard items are the property of Landlord. 
 D. Holdover. If Tenant shall be in possession of the Premises after the
expiration of the Term, in the absence of any agreement extending the Term, the tenancy under this Lease shall become one from month to month, terminable by either party on thirty (30) days prior notice, and shall be subject to all of the terms
and conditions of this Lease as though the Term had been extended from month to month, except that (i) the Base Rent payable hereunder for each month during said holdover period shall be equal to one hundred fifty (150%) the monthly
installment of Base Rent payable during the last month of the Term and (ii) all Overhead Rent payable hereunder shall be prorated for each month during such holdover period. 
 E. No Surrender. No offer of surrender of the Premises, by delivery to Landlord or its agent of keys to the Premises or otherwise, will be binding
on Landlord unless accepted by Landlord, in writing, specifying the effective surrender of the Premises. At the expiration or termination of the Lease Term, Tenant shall deliver to Landlord all keys to the Premises and make known to Landlord the
location and combinations of all locks, safes and similar items. No receipt of money by Landlord from Tenant after the Expiration Date (or sooner termination) shall reinstate, continue or extend the Lease Term, unless Landlord specifically agrees to
same in writing signed by Landlord at the time such payment is made by Tenant. 
 F. If Tenant abandons or surrenders the Premises, or is
dispossessed by process of law or otherwise, Tenant shall remove its personal property from the Premises. If Tenant fails to remove its personal property, Landlord, at its option may treat such failure as a hold over as defined in the Lease, and/or
may (without liability to Tenant for loss thereof), at Tenant’s sole cost and in addition to Landlord’s other rights and remedies under this Lease, at law or in equity: (a) remove and store such items; and /or (b) sell all or any
such items at private or public sale for such price as Landlord at its discretion may obtain. Landlord shall apply the proceeds of any such sale to any amounts due to Landlord under this Lease from Tenant (including Landlord’s attorneys fees
and other costs incurred in the removal, storage and/or sale of such items), with any remainder to be paid to Tenant. 
 
32. NO WAIVER; CUMULATIVE REMEDIES 
 A. No Waiver. No waiver of any provision of this Lease by either
party will be effective unless in writing and signed by the party against whom the waiver is sought to be enforced, and no waiver of any provisions of this Lease by either party will be deemed to imply or constitute a further waiver by such party of
the same or any other provision hereof. The rights and remedies of Landlord under this Lease or otherwise are cumulative and are not intended to be exclusive and the use of one will not be taken to exclude or waive the use of another, and Landlord
will be entitled to pursue all rights and remedies available to landlords under the laws of the State of Florida. Landlord, in addition to all other rights which it may have under this Lease, hereby expressly reserves all rights in connection with
the Building or the Premises not expressly and specifically granted to Tenant under this Lease and Tenant hereby waives all claims for damages, loss, expense, liability, eviction or abatement it has or may have against Landlord on account of
Landlord’s exercise of its reserved rights, including, but not limited to, Landlord’s right to alter the existing name, address, style or configuration of the Building or the Common Areas, signage, suite identifications, parking
facilities, lobbies, entrances and exits, elevators and stairwells. 
 B. Rent Payments. No receipt of money by Landlord from Tenant
at any time, or any act, or thing done by, Landlord or its agent shall be deemed a release of Tenant from any liability whatsoever to pay Rent, Additional Rent, or any other sums due hereunder, unless such release is in writing, subscribed by a duly
authorized officer or agent of Landlord and refers expressly to this Section. Any payment by Tenant or receipt by Landlord of less than the entire amount due at such time shall be deemed to be on account of the earliest sum due. No endorsement or
statement on any check or any letter accompanying any check or payment shall be deemed an accord and satisfaction. In the case of such a partial payment or endorsement, Landlord may accept such payment, check or letter without prejudice to its right
to collect all remaining sums due and pursue all of its remedies under the Lease. 
 
33. WAIVER. LANDLORD AND TENANT HEREBY WAIVE TRIAL BY JURY IN ANY ACTION, PROCEEDING, OR COUNTERCLAIM INVOLVING ANY MATTER WHATSOEVER ARISING OUT OF OR IN CONNECTION WITH (i) THIS LEASE, (ii) THE
PREMISES, (iii) TENANT’S USE OR OCCUPANCY OF THE PREMISES, OR (iv) THE RIGHT TO ANY STATUTORY RELIEF OR REMEDY. TENANT FURTHER WAIVES THE RIGHT TO INTERPOSE ANY PERMISSIVE COUNTERCLAIM OF ANY NATURE IN ANY ACTION OR 

  

 28 

 
PROCEEDING COMMENCED BY LANDLORD TO OBTAIN POSSESSION OF THE PREMISES. IF TENANT VIOLATES THIS PROVISION BY FILING A PERMISSIVE COUNTERCLAIM, WITHOUT
PREJUDICE TO LANDLORD’S RIGHT TO HAVE SUCH COUNTERCLAIM DISMISSED, THE PARTIES STIPULATE THAT SHOULD THE COURT PERMIT TENANT TO MAINTAIN THE COUNTERCLAIM, THE COUNTERCLAIM SHALL BE SEVERED AND TRIED SEPARATELY FROM THE ACTION FOR POSSESSION
PURSUANT TO RULE 1.270(b) OF THE FLORIDA RULES OF CIVIL PROCEDURE OR OTHER SUMMARY PROCEDURES SET FORTH IN SECTION 51.011, FLORIDA STATUTES (1993). THE WAIVERS SET FORTH IN THIS SECTION ARE MADE KNOWINGLY, INTENTIONALLY, AND VOLUNTARILY BY LANDLORD
AND TENANT. TENANT FURTHER ACKNOWLEDGES THAT IT HAS BEEN REPRESENTED IN THE MAKING OF THIS WAIVER BY INDEPENDENT COUNSEL, SELECTED OF ITS OWN FREE WILL, AND THAT IT HAS HAD THE OPPORTUNITY TO DISCUSS THESE WAIVERS WITH COUNSEL. THIS PROVISION IS A
MATERIAL INDUCEMENT TO LANDLORD IN AGREEING TO ENTER INTO THIS LEASE. IN THE EVENT OF ANY DISPUTE HEREUNDER, OR ANY DEFAULT IN THE PERFORMANCE OF ANY TERM OR CONDITION OF THIS LEASE, THE PREVAILING PARTY IN LITIGATION SHALL BE ENTITLED TO RECOVER
ALL COSTS AND EXPENSES ASSOCIATED THEREWITH, INCLUDING REASONABLE ATTORNEYS’ FEES THROUGH ALL APPEALS. 
 
34. CONSENTS AND APPROVALS. If Tenant requests Landlord’s consent or approval under this Lease, and if in connection with such requests Landlord deems it necessary to seek the advice of its attorneys,
architects and/or other experts, then Tenant shall pay the reasonable fee of Landlord’s attorneys, architects and/or other experts in connection with the consideration of such request and/or the preparation of any documents pertaining thereto.
Whenever under this Lease Landlord’s consent or approval is expressly or impliedly required, the same may be arbitrarily withheld except as otherwise specified herein. 
 
35. RULES AND REGULATIONS. Tenant agrees to abide by all rules and regulations attached hereto as Exhibit “C” and incorporated herein by this reference, as reasonably amended and supplemented from time
to time by Landlord. Landlord will not be liable to Tenant for violation of the same or any other act or omission by any other tenant. 
 
36. SUCCESSORS AND ASSIGNS. This Lease will be binding upon and inure to the benefit of the respective heirs, personal and legal representatives, successors and permitted assigns of the parties hereto. 

37. QUIET ENJOYMENT. In accordance with and subject to the terms and provisions of this Lease, Landlord warrants that it has full right to execute and to perform under this Lease and to grant the estate demised
and that Tenant, upon Tenant’s payment of the required Rent and Additional Rent and performing of all of the terms, conditions, covenants, and agreements contained in this Lease, shall peaceably and quietly have, hold and enjoy the Premises
during the full Lease Term. 
 
38. ENTIRE AGREEMENT. This Lease, together with the BLI Rider, exhibits, schedules, addenda and guaranties (as the case may be) fully incorporated into this Lease by this reference, contains the entire agreement
between the parties hereto regarding the subject matters referenced herein and supersedes all prior oral and written agreements between them regarding such matters. This Lease may be modified only by an agreement in writing dated and signed by
Landlord and Tenant after the date hereof. 
 
39. HAZARDOUS MATERIALS 
 A. Representation. Tenant represents, warrants and covenants that
(i) the Premises will not be used for any dangerous, noxious or offensive trade or business and that it will not cause or maintain a nuisance there, (ii) it will not bring, generate, treat, store, use or dispose of Hazardous Substances at
the Premises provided however that if Tenant generates biomedical waste in the operation of its business, it will strictly comply with all environmental laws (as hereinafter defined), including without limitations handling, storage reporting, and
disposal requirements, (iii) it shall at all times comply with all Environmental Laws (as hereinafter defined) and shall cause the Premises to comply, and (iv) Tenant will keep the Premises free of any lien imposed pursuant to any
Environmental Laws. Only for purposes of this paragraph entitled “Representation”, the term “Premises” shall mean the Project including parking areas. 
 B. Reporting Requirements. Tenant warrants that it will promptly deliver to the Landlord, (i) copies of any documents received from the United States Environmental Protection Agency and/or any state,
county or municipal environmental or health agency concerning the Tenant’s operations upon and within the Premises; (ii) copies of any documents submitted by the Tenant to the United States Environmental Protection Agency and/or any state,
county or municipal environmental or health agency concerning its operations on the Premises, including but not limited to copies of permits, licenses, annual 

  

 29 

 
filings, registration forms and, (iii) upon the request of Landlord, Tenant shall provide Landlord with evidence of compliance with Environmental Laws.

 C. Termination, Cancellation, Surrender. At the expiration or earlier termination of this Lease, Tenant shall surrender the
Premises to Landlord free of any and all Hazardous Substances and in compliance with all Environmental Laws and to the complete satisfaction of Landlord. Landlord may require, at Tenant’s sole expense at the end of the term, a clean-site
certification, environmental audit or site assessment. 
 D. Access and Inspection. Landlord shall have the right but not the
obligation, at all times during the term of this Lease to (i) enter upon and inspect the Premises, (ii) conduct tests and investigations and take samples to determine whether Tenant is in compliance with the provisions of this Article, and
(iii) request lists of all Hazardous Substances used, stored or located on the Premises; the cost of all such inspections, tests and investigations to be borne by Tenant. Promptly upon the written request of Landlord, from time to time, Tenant
shall provide Landlord, at Tenant’s expense, with an environmental site assessment or environmental audit report prepared by an environmental engineering firm acceptable to Landlord to assess with a reasonable degree of certainty the presence
or absence of any Hazardous Substances and the potential costs in connection with abatement, cleanup, or removal of any Hazardous Substances found on, under, at, or within the Premises. Tenant will cooperate with Landlord and allow Landlord and
Landlord’s representatives access to any and all parts of the Premises and to the records of Tenant with respect to the Premises for environmental inspection purposes at any time. In connection therewith, Tenant hereby agrees that Landlord or
Landlord’s representatives may perform any testing upon or of the Premises that Landlord deems reasonably necessary for the evaluation of environmental risks, costs, or procedures, including soils or other sampling or coring. 
 E. Violations - Environmental Defaults. Tenant shall give to Landlord immediate verbal and follow-up written notice of any actual or threatened
spills, releases or discharges of Hazardous Substances on the Premises, caused by the acts or omissions of Tenant or its agents, employees, representatives, invitees, licensees, subtenants, customers or contractors. Tenant covenants to promptly
investigate, clean up and otherwise remediate any spill, release or discharge of Hazardous Substances caused by the acts or omissions of Tenant or its agents, employees, representatives, invitees, licensees, subtenants, customers or contractors at
Tenant’s sole cost and expense; such investigation, clean up and remediation to be performed in accordance with all Environmental Laws and to the satisfaction of Landlord and after Tenant has obtained Landlord’s written consent. Tenant
shall return the Premises to the condition existing prior to the introduction of any such Hazardous Substances. In the event of (i) a violation of an Environmental Law, (ii) a release, spill or discharge of a Hazardous Substance on or from
the Premises, or (iii) the discovery of an environmental condition requiring response which violation, release, or condition is attributable to the acts or omissions of Tenant, its agents, employees, representatives, invitees, licensees,
subtenants, customers, or contractors, or (iv) an emergency environmental condition (collectively “Environmental Defaults”), Landlord shall have the right, but not the obligation, to immediately enter the Premises, to supervise and
approve any actions taken by Tenant to address the violation, release or environmental condition; and in the event Tenant fails to immediately address such violation, release, or environmental condition, or if the Landlord deems it necessary, then
Landlord may perform, at Tenant’s expense, any lawful actions necessary to address the violation, release, or environmental condition. Landlord has the right, but not the obligation to cure any Environmental Defaults, has the right to suspend
some or all of the operations of the Tenant until it has determined to its sole satisfaction that appropriate measures have been taken, and has the right to terminate this Lease upon the occurrence of an Environmental Default. 
 F. Additional Rent. Any expenses which the Landlord incurs, which are to be at Tenant’s expense pursuant to this Article, will be considered
Additional Rent under this Lease and shall be paid by Tenant on demand by Landlord. 
 G. Indemnification. Tenant shall indemnify,
defend (with counsel approved by Landlord) and hold Landlord and Landlord’s affiliates, shareholders, directors, officers, employees and agents harmless from and against any and all claims, judgments, damages (including consequential damages),
penalties, fines, liabilities, losses, suits, administrative proceedings, costs and expenses of any kind or nature, known or unknown, contingent or otherwise, which arise out of or in anyway related to the acts or omissions of Tenant, its agents,
employees, representatives, invitees, licensees, subtenants, customers or contractors during or after the term of this Lease (including, but not limited to, attorneys’, consultant, laboratory and expert fees expert fees and including without
limitation, diminution in the value of the Premises, damages for the loss or restriction on use of rentable or usable space or of any amenity of the Premises and damages arising from any adverse impact on marketing of space), arising from or related
to the use, presence, transportation, storage, disposal, spill, release or discharge of Hazardous Substances on or about the Premises. 
  

 30 

 H. Definitions. 
 (1) “Hazardous Substance” means, (a) asbestos and any asbestos containing material and any substance that is then defined or listed in, or otherwise classified pursuant to, any Environmental Laws or any
applicable laws or regulations as a “hazardous substance”, “hazardous material”, “hazardous waste”, “infectious waste”, “toxic substance”, “toxic pollutant” or any other formulation
intended to define, list, or classify substances by reason of deleterious properties such as ignitability, corrosivity, reactivity, carcinogenicity, toxicity, reproductive toxicity, or Toxicity Characteristic Leaching Procedure (TCLP) toxicity,
(b) any petroleum and drilling fluids, produced waters, and other wastes associated with the exploration, development or production of crude oil, natural gas, or geothermal resources and (c) petroleum products, polychlorinated biphenyls,
urea formaldehyde, radon gas, radioactive material (including any source, special nuclear, or by-product material), and medical waste. 
 (2) “Environmental Laws” collectively means and includes all present and future laws and any amendments (whether common law, statute, rule, order, regulation or otherwise), permits, and other requirements or guidelines of
governmental authorities applicable to the Premises and relating to the environment and environmental conditions or to any Hazardous Substance (including, without limitation, CERCLA, 42 U.S.C. ‘ 9601, et. seq.; the Resource Conservation and
Recovery Act of 1976, 42 U.S.C. ‘ 6901, et seq., the Hazardous Materials Transportation Act, 49 U.S.C. ‘ 1801, et seq., the Federal Water Pollution Control Act, 33 U.S.C. ‘1251, et seq., the Clean Air Act, 33 U.S.C. ‘ 7401, et
seq., the Clear Air Act, 42 U.S.C. ‘741, et seq., the Toxic Substances Control Act, 15 U.S.C. ‘ 2601-2629, the Safe Drinking Water Act, 42 U.S.C. ‘ 300f-300j, the Emergency Planning and Community Right-To-Know Act, 42 U.S.C. ‘
1101, et seq., and any so-called “Super Fund” or “Super Lien” law, any law requiring the filing of reports and notices relating to hazardous substances, environmental laws administered by the Environmental Protection Agency, and
any similar state and local laws and regulations, all amendments thereto and all regulations, orders, decisions, and decrees now or hereafter promulgated thereunder concerning the environment, industrial hygiene or public health or safety.)

 I. Radon. RADON GAS: Radon is a naturally occurring radioactive gas that, when it has accumulated in a building in sufficient
quantities, may present health risk to persons who are exposed to it over time. Levels of radon that exceed Federal and State Guidelines have been found in buildings in Florida. Additional information regarding radon and radon testing may be
obtained from your county public health unit. 
 
40. BANKRUPTCY PROVISIONS 
 A. Event of Bankruptcy. If this Lease is assigned to any person or
entity pursuant to the provisions of the United States Bankruptcy Code, 11 U.S.C. Section 101 et seq. (the “Bankruptcy Code”), any and all monies or other consideration payable or otherwise to be delivered in connection with such
assignment shall be paid or delivered to Landlord, shall be and remain the exclusive property of Landlord, and shall not constitute the property of Tenant or of the estate of Tenant within the meaning of the Bankruptcy Code. Any and all monies or
other considerations constituting Landlord’s property under this Section not paid or delivered to Landlord shall be held in trust for the benefit of Landlord and shall be promptly paid or delivered to Landlord. Any person or entity to which
this Lease is assigned pursuant to the provisions of the Bankruptcy Code shall be deemed without further act or deed to have assumed all of the obligations arising under this Lease on and after the date of such assignment. 
 B. Additional Remedies. In addition to any rights or remedies hereinbefore or hereinafter conferred upon Landlord under the terms of this Lease,
the following remedies and provisions shall specifically apply in the event Tenant is in default of this Lease: 
 (1) In all events, any
receiver or trustee in bankruptcy shall either expressly assume or reject this Lease within sixty (60) days following the entry of an “Order for Relief” or within such earlier time as may be provided by applicable law. 
 (2) In the event of an assumption of this Lease by a debtor or by a trustee, such debtor or trustee shall within fifteen (15) days after such
assumption (a) cure any default or provide adequate assurance that defaults will be promptly cured; (b) compensate Landlord for actual pecuniary loss or provide adequate assurance that compensation will be made for actual monetary loss,
including, but not limited to, all attorneys’ fees and costs incurred by Landlord resulting from any such proceedings; and (c) provide adequate assurance of future performance. 
 (3) Where a default exists under this Lease, the trustee or debtor assuming this Lease may not require Landlord to provide services or supplies
incidental to this Lease before its assumption by such trustee or debtor, unless Landlord is compensated under the terms of this Lease for such services and supplies provided before the assumption of such Lease. 
  

 31 

 (4) The debtor or trustee may only assign this Lease if (a) it is assumed and the assignee agrees
to be bound by this Lease, (b) adequate assurance of future performance by the assignee is provided, whether or not there has been a default under this Lease, and (c) the debtor or trustee has received Landlord’s prior written consent
pursuant to the provisions of this Lease. Any consideration paid by any assignee in excess of the Rent reserved in this Lease shall be the sole property of, and paid to, Landlord. 
 (5) Landlord shall be entitled to the fair market value for the Premises and the services provided by Landlord (but in no event less than the Rent
reserved in this Lease) subsequent to the commencement of a bankruptcy event. 
 (6) Any Security Deposit given by Tenant to Landlord to
secure the future performance by Tenant of all or any of the terms and conditions of this Lease shall be automatically transferred to Landlord upon the entry of an “Order of Relief”. 
 (7) The parties agree that Landlord is entitled to adequate assurance of future performance of the terms and provisions of this Lease in the event of an
assignment under the provisions of the Bankruptcy Code. For purposes of any such assumption or assignment of this Lease, the parties agree that the term “adequate assurance” shall include, without limitation, at least the following:
(a) any proposed assignee must have, as demonstrated to Landlord’s satisfaction, a net worth (as defined in accordance with generally accepted accounting principles consistently applied) in an amount sufficient to assure that the proposed
assignee will have the resources to meet the financial responsibilities under this Lease, including the payment of all Rent; the financial condition and resources of Tenant are material inducements to Landlord entering into this Lease; (b) any
proposed assignee must have engaged in the permitted use described in the BLI Rider for at least five (5) years prior to any such proposed assignment, the parties hereby acknowledging that in entering into this Lease, Landlord considered
extensively Tenant’s permitted use and determined that such permitted business would add substantially to the tenant balance in the Building, and were it not for Tenant’s agreement to operate only Tenant’s permitted business on the
Premises, Landlord would not have entered into this Lease, and that Landlord’s operation of the Building will be materially impaired if a trustee in bankruptcy or any assignee of this Lease operates any business other than Tenant’s
permitted business; (c) any assumption of this Lease by a proposed assignee shall not adversely affect Landlord’s relationship with any of the remaining tenants in the Building taking into consideration any and all other “use”
clauses and/or “exclusivity” clauses which may then exist under their leases with Landlord; and (d) any proposed assignee must not be engaged in any business or activity which it will conduct on the Premises and which will subject the
Premises to contamination by any Hazardous Materials. 
 
41. MISCELLANEOUS 
 A. If Tenant has a lease for other space in the Building (including storage space), any
default by Tenant under such lease will constitute a default hereunder. 
 B. If any term or condition of this Lease or the application
thereof to any person or circumstance is, to any extent, invalid or unenforceable, the remainder of this Lease, or the application of such term or condition to persons or circumstances other than those as to which it is held invalid or
unenforceable, is not to be affected thereby and each term and condition of this Lease is to be valid and enforceable to the fullest extent permitted by law. This Lease will be construed in accordance with the laws of the State of Florida.

 C. Submission of this Lease to Tenant does not constitute an offer, and this Lease becomes effective only upon execution and delivery by
both Landlord and Tenant. 
 D. Tenant acknowledges that it has not relied upon any statement, representation, prior or contemporaneous
written or oral promises, agreements or warranties, except such as are expressed herein. 
 E. Tenant will pay before delinquency all taxes
assessed during the Lease Term against any occupancy interest in the Premises or personal property of any kind owned by or placed in, upon or about the Premises by Tenant. 
 F. If Tenant, with Landlord’s consent, occupies the Premises or any part thereof prior to the beginning of the Lease Term, all provisions of this
Lease will be in full force and effect commencing upon such occupancy, and Base Rent and Additional Rent, where applicable, for such period will be paid by Tenant at the same rate herein specified. 
 G. Each party represents and warrants that it has not dealt with any agent or broker in connection with this transaction except for the agents or
brokers specifically set forth in the BLI Rider with respect to each Landlord and Tenant. If either party’s representation and warranty proves to be 

  

 32 

 
untrue, such party will indemnify the other party against all resulting liabilities, costs, expenses, claims, demands and causes of action, including
reasonable attorneys’ fees and costs through all appellate actions and proceedings, if any. The foregoing will survive the end of the Lease Term. 
 H. Neither this Lease nor any memorandum hereof will be recorded by Tenant. 
 I. Nothing contained in this
Lease shall be deemed by the parties hereto or by any third party to create the relationship of principal and agent, partnership, joint venturer or any association between Landlord and Tenant, it being expressly understood and agreed that neither
the method of computation of Rent nor any other provisions contained in this Lease nor any act of the parties hereto shall be deemed to create any relationship between Landlord and Tenant other than the relationship of landlord and tenant.

 J. Whenever in this Lease the context allows, the word “including” will be deemed to mean “including without
limitation”. The headings of articles, sections or paragraphs are for convenience only and shall not be relevant for purposes of interpretation of the provisions of this Lease. 
 K. This Lease does not create, nor will Tenant have, any express or implied easement for or other rights to air, light or view over or about the Building
or any part thereof. 
 L. Landlord reserves the right to use, install, monitor, and repair pipes, ducts and conduits within the walls,
columns, and ceilings of the Premises. 
 M. Any acts to be performed by Landlord under or in connection with this Lease may be delegated by
Landlord to its managing agent or other authorized person or firm. 
 N. It is acknowledged that each of the parties hereto has been fully
represented by legal counsel and that each of such legal counsel has contributed substantially to the content of this Lease. Accordingly, this Lease shall not be more strictly construed against either party hereto by reason of the fact that one
party may have drafted or prepared any or all of the terms and provisions hereof. 
 O. Landlord and Tenant acknowledge that the terms and
provisions of this Lease have been negotiated based upon a variety of factors, occurring at a coincident point in time, including, but not limited to: (i) the individual principals involved and the financial strength of Tenant, (ii) the
nature of Tenant’s business and use of the Premises, (iii) the current leasing market place and the economic conditions affecting rental rates, (iv) the present and projected tenant mix of the Building, and (v) the projected
juxtaposition of tenants on the floor(s) upon which the Premises are located and the floors within the Building. Therefore, recognizing the totality, uniqueness, complexity and interrelation of the aforementioned factors, the Tenant agrees to use
its best efforts not to disseminate in any manner whatsoever, (whether by word of mouth, mechanical reproduction, physical tender or by any manner of visual or aural transmission or review) the terms and conditions of this Lease to third parties who
could in any way be considered presently or in the future as prospective tenants for this or any other leasehold property with which Landlord may be involved. 
 P. If more than one person or entity is named herein as Tenant, their liability hereunder will be joint and several. In case Tenant is a corporation, Tenant (i) represents and warrants that this Lease has been
duly authorized, executed and delivered by and on behalf of Tenant and constitutes the valid and binding agreement of Tenant in accordance with the terms hereof, and (ii) Tenant shall deliver to Landlord or its agent, concurrently with the
delivery of this Lease, executed by Tenant, certified resolutions of the board of directors (and shareholders, if required) in the form attached hereto as Exhibit AE, attached hereto and made a part hereof authorizing Tenant’s execution and
delivery of this Lease and the performance of Tenant’s obligations hereunder. In case Tenant is a partnership, Tenant represents and warrants that all of the persons who are general or managing partners in said partnership have executed this
Lease on behalf of Tenant, or that this Lease has been executed and delivered pursuant to and in conformity with a valid and effective authorization therefor by all of the general or managing partners of such partnership, and is and constitutes the
valid and binding agreement of the partnership every partner therein in accordance with its terms. It is agreed that each and every present and future partner in Tenant shall be and remain at all times jointly and severally liable hereunder and that
neither the death, resignation or withdrawal of any partner, nor the subsequent modification or waiver of any of the terms and provisions of this Lease, shall release the liability of such partner under the terms of this Lease unless and until
Landlord shall have consented in writing to such release. 
 Q. Landlord has made no inquiries about and makes no representations (express or
implied) concerning whether Tenant’s proposed use of the Premises is permitted under applicable law, including applicable zoning law; should Tenant’s proposed use be prohibited, Tenant shall be obligated to comply with applicable law and
this Lease shall nevertheless remain in full force and effect. 
  

 33 

 R. Notwithstanding anything to the contrary in this Lease, if Landlord cannot perform any of its
obligations due to events beyond Landlord’s control, the time provided for performing such obligations shall be extended by a period of time equal to the duration of such events. Events beyond Landlord’s control include, but are not
limited to, hurricanes and floods and other acts of God, war, civil commotion, labor disputes, strikes, fire, flood or other casualty, shortages of labor or material, government regulation or restriction and weather conditions. 
 S. Tenant agrees to pay, before delinquency, all taxes assessed during the Lease Term agreement (i) all personal property, trade fixtures, and
improvements located in or upon the Premises and (ii) any occupancy interest of Tenant in the Premises. 
 T. Tenant acknowledges that
Landlord has relied on Tenant’s Certificate of Financial Statement attached hereto and made a part hereof as Exhibit AF. In the event that it is subsequently determined that the Certificate of Tenant’s Financial Statement contains material
misrepresentations that Landlord shall treat any such misrepresentation or omission as an Event of Default under section 23 of this Lease which will entitle Landlord to all remedies provided for in section 24 of this Lease. 
 
42. TELECOMMUNICATIONS 
 A. Tenant’s Responsibility. Tenant acknowledges and agrees that all
telephone and telecommunications services desired by Tenant shall be ordered and utilized at the sole expense of Tenant. Unless Landlord otherwise requests or consents in writing, all of Tenant’s telecommunications equipment shall be and remain
solely in the Premises and the telephone closets on the floor on which the Premises is located, in accordance with the rules and regulations adopted by Landlord from time to time. Unless otherwise specifically agreed to in writing, Landlord shall
have no responsibility for the maintenance of Tenant’s telecommunications equipment, including wiring; nor for any wiring or other infrastructure to which Tenant’s telecommunications equipment may be connected. Tenant agrees that, to the
extent any such service is interrupted, curtailed or discontinued, Landlord shall have no obligation or liability with respect thereto and it shall be the sole obligation of Tenant at its expense to obtain substitute service. 
 B. Necessary Service Interruptions. Landlord shall have the right, upon reasonable prior notice to interrupt or turn off telecommunications
facilities in the event of emergency. Landlord shall also have the right upon reasonable prior notice to interrupt or turn off telecommunications facilities as is necessary with repairs to the Building or installation of telecommunication equipment
for other tenants in the Building, provided that such repairs or installation occur after Tenant’s normal business hours. 
 C.
Removal of Equipment and Wiring and Other Facilities. Any and all telecommunications equipment installed in the Premises or elsewhere in the Building by or on behalf of Tenant, including wiring, or other facilities for telecommunications
transmittal, shall be removed prior to the expiration or earlier termination of the Term, by Tenant at its sole cost or, at Landlord’s election, by Landlord at Tenant’s sole cost, with the cost therefor to be paid as Additional Rent.
Landlord shall have the right, however, upon written notice to Tenant given no later than thirty (30) days prior to the expiration or earlier termination of the Term, to require Tenant to abandon and leave in place, without additional payment
to Tenant or credit against Rent, any and all telecommunication, writing and related infrastructure, or selected components thereof, whether located in the Premises or elsewhere in the Building. 
 D. New Telecommunications Provider Installations. In the event that Tenant wishes at any time to utilize the services of a telephone or
telecommunications provider whose equipment is not then servicing the Building, no such provider shall be permitted to install its line through other equipment within the Building without first securing the prior written approval of Landlord, which
approval may be arbitrarily withheld. The Landlord’s approval, if given, shall not be deemed any kind of warranty or representation by Landlord, including without limitation, any warranty or representation as to the suitability, confidence, or
financial strength of the provider without limitation of the foregoing standard. If Landlord gives its approval, the following shall be applicable: (i) Landlord shall incur no expense whatsoever with respect to any aspect of the provider’s
provision of its service, including without limitation, the cost of installation, materials and services; (ii) prior to commencement of any work in or about the Building by the provider, the provider shall supply Landlord with such written
indemnities, insurance, financial statements, and such other items as Landlord reasonably determines to be necessary to protect its financial interest and the interest of the Building relating to proposed activities of the provider; and
(iii) the provider agrees to abide by such rules and regulations, Building and other codes, job site rules and such other requirements as are reasonably determined by Landlord to be necessary to protect the interest of the Building, the other
tenants in the Building and Landlord, in the same or similar matter as Landlord has the right to protect himself and the Building with respect to proposed Alterations as described in this Lease; and (iv) Landlord reasonably determines that
there is sufficient space in the Building for the placement of all of the provider’s equipment and material; (v) provider agrees to abide by 

  

 34 

 
Landlord’s requirements, if any, that provider use existing building conduits and pipes or use Landlord’s contractors; (vi) Landlord receives
from the provider such compensation as reasonably determined by Landlord to compensate for space used in the Building for the storage and maintenance of the provider’s equipment, for the fair market value of a provider’s access to the
Building, and the cost which may be reasonably be expected to be incurred by Landlord; (vii) the provider agrees to deliver to Landlord details, “as built”, plans immediately after the installation of the provider’s equipment is
complete; and (viii) all the foregoing matters are documented in a written license agreement between Landlord and the provider, the form and content of which is reasonably satisfactory to Landlord. 
 E. Limits on Provider Relationship. Notwithstanding anything herein to the contrary, no telephone or telecommunications provider shall be deemed a
third party beneficiary of this Lease. 
 F. Installation and Use of Wireless Technologies. Tenant shall not utilize any wireless
communications equipment (other than usual and customary cellular telephones), including antenna and satellite receiver dishes, within the Premises, or the Building, without Landlord’s prior written consent, which consent may be arbitrarily
withheld. Such consent may be conditioned in such manner so as to protect Landlord’s financial interest and the interest of the Building and the other tenants therein, in a manner similar to the arrangement described in the immediately
preceding paragraphs. 
 G. Liability for Equipment Interference. In the event that telecommunications equipment, wiring and
facilities or satellites and antenna equipment of any kind installed by or at the request of Tenant within the Premises, on the roof, or elsewhere within or on the Building causes interference to equipment used by another party, Tenant shall assume
all liability related to such interference. Tenant shall use reasonable efforts, and shall cooperate with Landlord and other parties to promptly eliminate such interference. In the event that Tenant is unable to do so, Tenant will substitute
alternative equipment which remedies the situation. If such interference persists, Tenant shall discontinue the use of such equipment, and at Landlord’s discretion, remove such equipment according to the foregoing specifications. Tenant agrees
to and shall indemnify and hold Landlord harmless or any liabilities and claims against Landlord resulting from such interference. 
 
43. NO CONSEQUENTIAL DAMAGES. Notwithstanding any other provision of this Lease, Landlord shall not be liable for any consequential damages, nor shall Landlord be liable for loss of or damage to artwork, currency,
jewelry, bullion, unique or valuable documents, securities or other valuables, or for other property not in the nature of ordinary fixtures, furnishings and equipment used in general administrative and executive office activities and functions.

 
44. MONITORING, INSPECTING AND REMEDIATING MOLD 
 A. Monitoring of Premises. Tenant, as its sole cost
and expense, shall: 
 (1) Regularly monitor the Premises for the presence of mold or for any conditions that reasonable can be expected to
give rise to mold (the “Mold Conditions”), including, but not limited to, observed or suspected instances of water damage, mold growth, repeated complaints of respiratory ailment or eye irritation by Tenant’s employees or any other
occupants in the Premises, or any notice from a governmental agency of complaints regarding the indoor air quality at the Premises; and 
 (2) Promptly notify Landlord in writing if it suspects molds or Mold Conditions at the Premises. 
 B. Inspection of
Premises. In the event of suspected mold or Mold Conditions at the Premises, Landlord, at its sole cost and expense, shall promptly cause an inspection of the Premises to be conducted, to determine if mold or Mold Conditions are present
at the Premises, and shall: 
 (1) Notify Tenant, in writing, at least three (3) days prior to the inspection, of the date on which the
inspection shall occur and which portion of the Premises shall be subject to the inspection; 
 (2) Prepare an inspection report, keep the
results of the inspection report confidential, and promptly provide a copy to Tenant upon demand. 
 C. Remediation of Mold. In
the event the inspection required by Paragraph b hereof determines that mold or Mold Conditions are present at the Premises, then Landlord shall determine the cause of the Mold Conditions. Landlord, at its sole cost and expense, shall promptly:

 (1) Hire trained and experienced mold remediation contractors to prepare a remediation plan and to remediate the mold or Mold Conditions
at the Premises; 
  

 35 

 (2) Send Tenant notice, in writing, with a copy of the remediation plan, at least three (3) days prior
to the mold remediation. 
 (3) Provide Tenant with a draft of the mold remediation report, promptly provide Tenant with a copy of the final
remediation report. 
 If such Mold Conditions are present at the Premises due to the negligence or willful misconduct of Tenant, then Tenant
shall reimburse Landlord for any reasonable cost and expense for such remediation described herein. 
 D. Post-Remediation Inspection.
Tenant acknowledges and agrees that Landlord shall have a reasonable opportunity to inspect the remediated portion of the Premises after the conclusion of the mold remediation. If the results of Landlord’s inspection indicate that the
remediation does not comply with the final remediation report or any other applicable federal, state, or local laws, regulatory standards or guidelines, including, without limitation, the EPA Guidelines, then Landlord, at its sole cost and expenses,
shall immediately take all further actions necessary to ensure such compliance. 
 
45. MOVING ALLOWANCE. Landlord shall on or before the Commencement Date reimburse Tenant up to the sum of Four Hundred Fifty Thousand Dollars ($450,000.00) (“the Moving Allowance”) for moving expenses
incurred by Tenant arising out of Tenant’s move from the offices Tenant is occupying at the time Tenant enters into this Lease to the Premises. Landlord shall tender the Moving Allowance to Tenant and Tenant shall be permitted to use the Moving
Allowance for any purpose Tenant deems necessary in Tenant’s sole discretion. 
 
46. SIGNAGE. Landlord shall provide to Tenant at all times during the Lease Term signage on the directory located on the first floor in the main entrance lobby of the Building, in the elevator lobby of each floor
that Tenant occupies and suite signage, at no expense to Tenant. Tenant shall also have the right to place signage on the Building’s monument sign (street level) and a parapet sign on the Building, at Tenant’s sole cost and expense.
Landlord shall have the right to approve, in advance, the design of the monument signage and parapet signage, which approval shall not be unreasonably withheld, conditioned or delayed. Tenant shall comply with all governmental codes, ordinances and
regulations with respect to the installation of said signage. Tenant shall remove said signage upon the termination of the Lease and repair and damage caused by said removal. 
  

 36 

 IN WITNESS WHEREOF, the parties have signed and delivered this Lease as of the day and year first
above written. 
  

									
	WITNESSES:	 		 	TENANT
			
	 /s/ Timothy A. Crass
	 		 	MSC - MEDICAL SERVICES COMPANY,
	Print Name:	 	 Timothy A. Crass
	 		 	a                      corporation
			
		 		 	 /s/ Joseph P. Delaney

				
	 /s/ Kevin M. Bass
	 		 	By:	 	 Joseph P. Delaney

	Print Name:	 	 Kevin M. Bass
	 		 	Its:	 	 President, CEO

	(As to Tenant)	 		 		 	
			
	WITNESSES:	 		 	LANDLORD
			
	 /s/ Jimmie Nettles
	 		 	SOUTH SHORE PARTNERS GROUP, LLC
	Print Name:	 	 Jimmie Nettles
	 		 	a Delaware limited liability company
				
		 		 		 	 /s/ Harold R. Dodt

				
	 /s/ Shelley A. Dodt
	 		 	By:	 	 Harold R. Dodt

	Print Name:	 	 Shelley A. Dodt
	 		 	Its:	 	 VP

	(As to Landlord)	 		 		 	

  

 37 

 EXHIBIT “A” 
 FLOOR PLAN 
  

 38 

 EXHIBIT “B” 
 TENANT WORK LETTER: ALLOWANCE 
 1. Acceptance of Premises. Except as set forth in this
Exhibit, Tenant accepts the Premises in their “AS-IS” condition on the Commencement Date. Landlord shall perform tenant improvements to the Premises in accordance with the terms of this Tenant Work Letter. As used herein, the
“Working Drawings” shall mean the final working drawings approved by Landlord, as amended from time to time by any approved changes thereto. To the extent that the Working Drawings contain landlord improvements to the Premises
(“Landlord Improvements”) and associated costs that are inapplicable to the Construction Allowance (hereinafter defined), such Landlord Improvements shall be noted as such in the Working Drawings. For purposes of this Exhibit,
“Work” shall mean all improvements to be constructed in accordance with and as indicated on the Working Drawings, excluding any Landlord Improvements, together with any work required by governmental authorities to be made to other
areas of the Building as a result of the improvements indicated by the Working Drawings. Landlord’s approval of the Working Drawings shall not be a representation or warranty of Landlord that such drawings are adequate for any use or comply
with any Law, but shall merely be the consent of Landlord thereto. Tenant shall, at Landlord’s request, sign the Working Drawing to evidence its review and approval thereof. After the Working Drawings have been approved, Landlord shall cause
the Work to be performed in substantial accordance with the Working Drawings. 
 2. Space Plans and Working Drawings.

 (a) Preparation and Delivery and Approval Process: 
 Tenant shall cooperate with Landlord’s efforts to proceed with the preparation, delivery and approval of the Construction documents pursuant to the Design Construction Scheduled (as Revised November 1, 2006)
attached hereto as Exhibit “B-1”) 
 Any delay caused by Tenant’s unreasonable withholding of its consent or delay in giving
its written approval in accordance with the Design Construction Schedule shall constitute a Tenant Delay Day (defined below). 
 3.
Bidding of Work. Prior to commencing the Work, Landlord shall select a General Contractor, whose fees shall be commercially reasonable and said General Contractor shall competitively bid all the Work excluding the Mechanical
Contractor, whose fees shall be commercially reasonable. 
 4. Change Orders. Tenant may initiate changes in the Work. Each
such change must receive the prior written approval of Landlord, such approval not to be unreasonably withheld or delayed; however, (a) if such requested change would adversely affect (in the reasonable discretion of Landlord) (b) the
Building’s Structure or the Building’s Systems (including the Building’s restrooms or mechanical rooms), (c) the exterior appearance of the Building, or (d) the appearance of the Building’s Common Areas or elevator
lobby areas (if any) or (5) if any requested change might delay the Commencement Date, Landlord may withhold its consent in its sole and absolute discretion. Tenant shall, upon completion of the Work, furnish Landlord with an accurate
architectural “as-built” plan of the Work as constructed, which plan shall be incorporated into this Exhibit D by this reference for all purposes. If Tenant requests any changes to the Work described in the Space Plans or the Working
Drawings, then such increased costs and any additional design costs incurred in connection therewith as the result of any such change shall be added to the Total Construction Costs. 
 5. Definitions. As used herein, a “Tenant Delay Day” shall mean each day of delay in the performance of the Work
that occurs (a) because of Tenant’s failure to timely deliver or approve any required documentation such as the Space Plans or Working Drawings, (b) because Tenant fails to timely furnish any information or deliver or approve any
required documents such as the Space Plans, Working Drawings (whether preliminary, interim revisions or final), pricing estimates, construction bids, and the like, (c) because of any change by Tenant to the Space Plans or Working Drawings,
(d) because Tenant fails to attend any meeting with Landlord, the Architect, any design professional, or any contractor, or their respective employees or representatives, as may be required or scheduled hereunder or otherwise necessary in
connection with the preparation or completion of any construction documents, such as the Space Plans, Working Drawings, or in connection with the performance of the Work, (e) because of any specification by Tenant of materials or installations
in addition to or other than Landlord’s standard finish-out materials, or (f) because a Tenant Party otherwise delays completion of the Work. As used herein “Substantial Completion,” “Substantially
Completed,” and any derivations thereof mean the Work in the Premises has been performed in substantial accordance with the Working Drawings, as reasonably determined by Landlord (other than any details of construction, mechanical
adjustment or other similar matter, the noncompletion of which does not materially interfere with Tenant’s use or occupancy of the Premises). 
  

 39 

 6. Walk-Through; Punchlist. When Landlord considers the Work in the Premises to be
Substantially Completed, Landlord will notify Tenant and within three (3) Business Days thereafter, Landlord’s representative and Tenant’s representative shall conduct a walk-through of the Premises and identify any necessary touch-up
work, repairs and minor completion items that are necessary for final completion of the Work. Neither Landlord’s representative nor Tenant’s representative shall unreasonably withhold his or her agreement on punchlist items. Landlord shall
use reasonable efforts to cause the contractor performing the Work to complete all punchlist items within thirty (30) days after agreement thereon; however, Landlord shall not be obligated to engage overtime labor in order to complete such
items. 
 7. Excess Costs. The entire cost of performing the Work (including design of the Work and preparation of the Working
Drawings, costs of construction labor and materials, electrical usage during construction, additional janitorial services, general tenant signage, related taxes and insurance costs, all of which costs are herein collectively called the
“Total Construction Costs”) in excess of the Construction Allowance shall be paid by Tenant. Upon approval of the Working Drawings and selection of a contractor, Tenant shall promptly execute a work order agreement prepared
by Landlord which identifies such drawings and itemizes the Total Construction Costs and sets forth the Construction Allowance. Upon Substantial Completion of the Work and before Tenant occupies the Premises to conduct business therein, Tenant shall
pay to Landlord an amount equal to the Total Construction Costs (as adjusted for any approved changes to the Work ), less the amount of the Construction Allowance. Notwithstanding the foregoing, Tenant may, at its option amortize the amount by
which the actual construction costs exceed the Construction Allowance over the term of the lease at a rate of eight percent (8%), such amount being Additional Rent. If Tenant does not elect to amortize the excess costs, it shall remit payment to
Landlord within thirty (30) days of receipt of Landlord’s invoice for excess costs (Landlord shall not deliver the invoice until after substantial completion and Landlord has received final invoices from the Contractor). In the event of
default of payment of such excess costs, Landlord (in addition to all other remedies) shall have the same rights as for an Event of Default under the Lease. 
 8. Construction Allowance. Landlord shall provide to Tenant a construction allowance not to exceed $24.15 per rentable square foot in the Premises (the “Construction Allowance”) to be applied
toward the Total Construction Costs, as adjusted for any changes to the Work (which sum includes $2.00) per rentable square foot space planning and architectural expenses). The Construction Allowance shall not be disbursed to Tenant in cash, but
shall be applied by Landlord to the payment of the Total Construction Costs, if, as, and when the cost of the Work is actually incurred and paid by Landlord. In the event the Construction Allowance exceeds the Total Construction Costs, the Landlord
shall pay the excess amount to Tenant upon Tenant’s occupancy of the Premises. Tenants such excess amount shall be used in Tenant’s sole discretion. The Construction Allowance must be used within six (6) months following the
Commencement Date or shall be deemed forfeited with no further obligation by Landlord with respect thereto. 
 9. Construction
Representatives. Landlord’s and Tenant’s representatives for coordination of construction and approval of change orders will be as follows, provided that either party may change its representative upon written notice to the other:

  

			
	Landlord’s Representative:	 	
		
		 	Elizabeth Reichert
		 	Vice President of Property Management
		 	SSGP of Florida
		 	841 Prudential Dr., #150
		 	Jacksonville, FL 32207
		 	Telephone: 904-398-7330 #101
		 	Facsimile: 904-398-7308
		
	Tenant’s Representative:	 	
		
		 	c/o
                                        
                                        
                                        
  
		 	Telephone:                                     
                                        
                              
		 	Telecopy:                                     
                                        
                                

  

 40 

 EXHIBIT B-1 
 DESIGN AND CONSTRUCTION SCHEDULE 
 REVISED NOV 1, 2006 
  

											
	 Line
	 	 Task
	  	Start
begin of
day	  	Duration	  	Complete
end of
day	  	 Remarks

	1	 	KBJ prepare DD plans from tenant sketches	  		  		  		  	Completed prior to Lease execution
						
	2	 	Tenant sign off on Design Development (DD) Documents	  		  		  		  	Completed prior to Lease execution
						
	3	 	Tenant sign off on Technical Docs	  		  		  		  	Completed prior to Lease execution
						
	4	 	Landlord review and accept DD Docs.	  		  		  		  	Completed prior to Lease execution
						
	5	 	Architect prepare permit Documents	  	Mon,
Nov 13	  	4 wk	  	Fri
Dec 8	  	
						
	6	 	Engineer prepare Permit Documents	  	Mon,
Nov 20	  	3 wk	  	Fri,
Dec 8	  	
						
	7	 	Tenant Review Permit Docs	  	Mon
Dec 11	  	2 days	  	Tue,
Dec 12	  	
						
	8	 	AE incorporate Tenant comments, sign and seal docs	  	Wed,
Dec 13	  	3 days	  	Fri,
Dec 15	  	
						
	9	 	Jacksonville Building Dept Permit review.	  	Mon
Dec 18	  	4 wk	  	Fri
Jan 12	  	Optimistic duration. Actually 3 weeks, considering holidays.
						
	10	 	AE incorporate Permit comments, prepare Contract Docs	  	Tue,
Jan 2	  	9 days	  	Mon,
Jan 15	  	Final finish colors, post addendums, etc
						
	11	 	Construction, Levels 7, 8, 9, 17	  	Mon,
Jan 15	  	10 weeks	  	Fri.
Mar 23	  	Demolition on Lev 7, 8, 9 can begin Jan 2.
						
	12	 	Construction of chiller, etc	  	Mon,
Jan 8	  	11 weeks	  	Fri,
Mar 23	  	Separate, but related project
						
	13	 	Tenant move-in	  	Mon,
Mar 26	  	7 days	  	Tue,
May 1	  	Phased move-in schedule to be determined.

  

 41 

 EXHIBIT “C” 
 Rules and Regulations 
 The following rules and regulations shall apply, where applicable, to the
Premises, the Building, the parking garage associated therewith (if any), the Property and the appurtenances thereto: 
 1. Sidewalks,
doorways, vestibules, halls, stairways and other similar areas shall not be obstructed by Tenant or used by Tenant for any purpose other than ingress and egress to and from the Premises. No rubbish, litter, trash, or material of any nature shall be
placed, emptied, or thrown in those areas. At no time shall Tenant permit Tenant’s employees to loiter in common areas or elsewhere in or about the Building or Property. 
 2. Plumbing fixtures and appliances shall be used only for the purposes for which designed, and no sweepings, rubbish, rags or other unsuitable material
shall be thrown or placed therein. Damage resulting to any such fixtures or appliances from misuse by Tenant or its agents, employees or invitees, shall be paid for by Tenant, and Landlord shall not in any case be responsible therefor. 

3. No signs, advertisements or notices shall be painted or affixed on or to any windows, doors or other parts of the Building, except those of such
color, size, style and in such places as shall be first approved in writing by Landlord. No nails, hooks or screws shall be driven or inserted into any part of the Premises or Building except by the Building maintenance personnel, nor shall any part
of the Building be defaced by Tenant. 
 4. Landlord may provide and maintain in the first floor (main lobby) of the Building an alphabetical
directory board listing all Tenants, and no other directory shall be permitted unless previously consented to by Landlord in writing. 
 5.
Tenant shall not place any additional lock or locks on any door in the Premises or Building without Landlord’s prior written consent. A reasonable number of keys to the locks on the doors in the Premises shall be furnished by Landlord to Tenant
at the cost of Tenant, and Tenant shall not have any duplicate keys made. All keys shall be returned to Landlord at the expiration or earlier termination of this Lease. 
 6. All contractors, contractor’s representatives, and installation technicians performing work in the Building shall be subject to Landlord’s prior approval and shall be required to comply with
Landlord’s standard rules, regulations, policies and procedures, as the same may be revised from time to time. Tenant shall be solely responsible for complying with all applicable laws, codes and ordinances pursuant to which said work shall be
performed. 
 7. Movement in or out of the Building of furniture or office equipment, or dispatch or receipt by Tenant of any merchandise or
materials which require the use of elevators, stairways, lobby areas, or loading dock areas, shall be restricted to hours designated by Landlord. Tenant must seek Landlord’s prior approval by providing in writing a detailed listing of any such
activity. If approved by Landlord, such activity shall be under the supervision of Landlord and performed in the manner stated by Landlord. Landlord may prohibit any article, equipment or any other item from being brought into the Building. Tenant
is to assume all risk for damage to articles moved and injury to any persons resulting from such activity. If any equipment, property, and/or personnel of Landlord or of any other tenant is damaged or injured as a result of or in connection with
such activity, Tenant shall be solely liable for any and all damage or loss resulting therefrom. 
 8. Landlord shall have the power to
prescribe the weight and position of safes and other heavy equipment or items, which in all cases shall not in the opinion of Landlord exceed acceptable floor loading and weight distribution requirements. All damage done to the Building by the
installation, maintenance, operation, existence or removal of any property of Tenant shall be repaired at the expense of Tenant. 
 9.
Corridor doors, when not in use, shall be kept closed. 
 10. Tenant shall not: (1) make or permit any improper, objectionable or
unpleasant noises or odors in the Building, or otherwise interfere in any way with other tenants or persons having business with them; (2) solicit business or distribute, or cause to be distributed, in any portion of the Building any handbills,
promotional materials or other advertising; or (3) conduct or permit any other activities in the Building that might constitute a nuisance. 
 11. No animals, except seeing eye dogs, shall be brought into or kept in, on or about the Premises. 
  

 42 

 12. No inflammable, explosive or dangerous fluid or substance shall be used or kept by Tenant in the
Premises or Building. Tenant shall not, without Landlord’s prior written consent, use, store, install, spill, remove, release or dispose of within or about the Premises or any other portion of the Property, any asbestos-containing materials or
any solid, liquid or gaseous material now or hereafter considered toxic or hazardous under the provisions of 42 U.S.C. Section 9601 et seq. or any other applicable environmental law which may now or hereafter be in effect. If Landlord does give
written consent to Tenant pursuant to the foregoing sentence, Tenant shall comply with all applicable laws, rules and regulations pertaining to and governing such use by Tenant, and shall remain liable for all costs of cleanup or removal in
connection therewith. 
 13. Tenant shall not use or occupy the Premises in any manner or for any purpose which would injure the reputation
or impair the present or future value of the Premises or the Building; without limiting the foregoing, Tenant shall not use or permit the Premises or any portion thereof to be used for lodging, sleeping or for any illegal purpose. 
 14. Tenant shall not take any action which would violate Landlord’s labor contracts affecting the Building or which would cause any work stoppage,
picketing, labor disruption or dispute, or any interference with the business of Landlord or any other tenant or occupant of the Building or with the rights and privileges of any person lawfully in the Building. Tenant shall take any actions
necessary to resolve any such work stoppage, picketing, labor disruption, dispute or interference and shall have pickets removed and, at the request of Landlord, immediately terminate at any time any construction work being performed in the Premises
giving rise to such labor problems, until such time as Landlord shall have given its written consent for such work to resume. Tenant shall have no claim for damages of any nature against Landlord or any of the Landlord Related Parties in connection
therewith, nor shall the date of the commencement of the Term be extended as a result thereof. 
 15. Tenant shall utilize the termite and
pest extermination service designated by Landlord to control termites and pests in the Premises. Except as included in Basic Costs, Tenant shall bear the cost and expense of such extermination services. 
 16. Tenant shall not install, operate or maintain in the Premises or in any other area of the Building, any electrical equipment which does not bear the
U/L (Underwriters Laboratories) seal of approval, or which would overload the electrical system or any part thereof beyond its capacity for proper, efficient and safe operation as determined by Landlord, taking into consideration the overall
electrical system and the present and future requirements therefor in the Building. Tenant shall not furnish any cooling or heating to the Premises, including, without limitation, the use of any electronic or gas heating devices, without
Landlord’s prior written consent. Tenant shall not use more than its proportionate share of telephone lines available to service the Building. 
 17. Tenant shall not operate or permit to be operated on the Premises any coin or token operated vending machine or similar device (including, without limitation, telephones, lockers, toilets, scales, amusement devices and machines for sale
of beverages, foods, candy, cigarettes or other goods), except for those vending machines or similar devices which are for the sole and exclusive use of Tenant’s employees, and then only if such operation does not violate the lease of any other
tenant of the Building. 
 18. Bicycles and other vehicles are not permitted inside or on the walkways outside the Building, except in those
areas specifically designated by Landlord for such purposes. 
 19. Landlord may from time to time adopt appropriate systems and procedures
for the security or safety of the Building, its occupants, entry and use, or its contents. Tenant, Tenant’s agents, employees, contractors, guests and invitees shall comply with Landlord’s reasonable requirements relative thereto.

 20. Landlord shall have the right to prohibit the use of the name of the Building or any other publicity by Tenant that in Landlord’s
opinion may tend to impair the reputation of the Building or its desirability for Landlord or other tenants. Upon written notice from Landlord, Tenant will refrain from and/or discontinue such publicity immediately. 
 21. Tenant shall carry out Tenant’s permitted repair, maintenance, alterations, and improvements in the Premises only during times agreed to in
advance by Landlord and in a manner which will not interfere with the rights of other tenants in the Building. 
 22. Canvassing, soliciting,
and peddling in or about the Building is prohibited. Tenant shall cooperate and use its best efforts to prevent the same. 
  

 43 

 23. At no time shall Tenant permit or shall Tenant’s agents, employees, contractors, guests, or
invitees smoke in any common area of the Building, unless such common area has been declared a designated smoking area by Landlord, or to allow any smoke from the Premises to emanate into the common areas or any other tenant’s premises.
Landlord shall have the right at any time to designate the Building as a non-smoking building. 
 24. Tenant shall observe Landlord’s
rules with respect to maintaining standard window coverings at all windows in the Premises so that the Building presents a uniform exterior appearance. Tenant shall ensure that to the extent reasonably practicable, window coverings are closed on all
windows in the Premises while they are exposed to the direct rays of the sun. 
 25. All deliveries to or from the Premises shall be made
only at such times, in the areas and through the entrances and exits designated for such purposes by Landlord. Tenant shall not permit the process of receiving deliveries to or from the Premises outside of said areas or in a manner which may
interfere with the use by any other tenant of its premises or of any common areas, any pedestrian use of such area, or any use which is inconsistent with good business practice. 
 26. The work of cleaning personnel shall not be hindered by Tenant after 5:30 p.m., and such cleaning work may be done at any time when the offices are
vacant. Windows, doors and fixtures may be cleaned at any time. Tenant shall provide adequate waste and rubbish receptacles necessary to prevent unreasonable hardship to Landlord regarding cleaning service. 
  

 44 

 EXHIBIT “D” 
 ***** SAMPLE ***** 
 MEMORANDUM OF COMMENCEMENT DATE 
 Pursuant to that certain Lease (“Lease”) between South (“Landlord’) and
             (“Tenant”) dated                     . 

Landlord and Tenant have agreed that              is the Commencement date of Lease
and              is the Expiration of Date of such lease and that such Lease will remain in full force and effect according to its terms. 
 The Premises consist              rentable square feet. Tenant certifies that all of
the Tenant Improvements, as defined in the Lease, have been completed and are accepted by Tenant, and Tenant knows of no contractor, subcontractor or supplier claiming or possessing any lien against the Premises. 
 The Security Deposit is $            . 
 Tenant’s Proportionate Share shall be         %. 
 IN WITNESS THEREOF, the parties have caused this Memorandum of Commencement Date to be executed this      day of
                    , 20    . 
  

									
	WITNESSES:	 		 	TENANT
			
	  
	 		 	MSC -MEDICAL SERVICES COMPANY,
	Print Name:	 	  
	 		 	a                      corporation
				
		 		 		 	  

				
	  
	 		 	By:	 	  

	Print Name:	 		 		 	Its:	 	  

	(As to Tenant)	 		 		 	
			
	WITNESSES:	 		 	LANDLORD
			
	  
	 		 	SOUTH SHORE PARTNERS GROUP, LLC
	Print Name:	 	  
	 		 	a Delaware limited liability company
				
		 		 		 	  

				
	  
	 		 	By:	 	  

	Print Name:	 	  
	 		 	Its:	 	  

	(As to Landlord)	 		 		 	

  

 45 

 EXHIBIT “E” 
 RENEWAL OPTION 
 Provided that the Lease is in full force and effect, and Tenant is not in
default of any of the terms, covenants, or conditions of the Lease beyond any applicable cure period, and Tenant has not been in monetary default more than three times during the last five (5) years of any lease term or five times during any
term of the lease, Tenant shall have the option (the “Extension Option”) to extend the term of the Lease for two (2) extension terms of five (5) years each (“Extension Term”). The First Extension Term shall commence on
the day next succeeding the expiration date of the initial lease term in accordance with and subject to the terms, covenants, and conditions hereinafter set forth. The Second Extension Term shall commence on the day next succeeding the expiration
date of the First Extension Term in accordance with and subject to the terms, covenants, and conditions hereinafter set forth. 
 (a) Tenant
shall exercise the Extension Option by sending a written notice thereof (the “Extension Notice”) to the Landlord on or before the date that is one hundred and eighty (180) days prior to the expiration date, time being of the essence.
If Tenant shall send the Extension Notice within the time and in the manner herein above provided, the term of the Lease shall be deemed extended for the Extension Term upon the terms, covenants, and conditions hereinafter contained in paragraph
(b) (2), below. 
 If Tenant shall fail to send the Extension Notice within the time and in the manner herein above provided, the
Extension Option shall cease and terminate, and Tenant shall have no further option to extend the term of this Lease. 
 (b) The Extension
Terms shall be upon, and subject to, all of the terms, covenants, and conditions provided in the Lease for the initial term hereof, without any further right of extension, except: 
  

	 	(1)	for any terms, covenants, or conditions in the Lease that are either expressly or by their nature inapplicable to the Extension Term; and 

  

	 	(2)	the annual Base Rent payable by Tenant during the first Extension Term shall be $18.50 per rentable square foot and escalating $0.50 per rentable square foot annually.

  

	 	(3)	the annual Base Rent payable by Tenant during the second Extension Term shall be $19.70 per rentable square foot and escalating $0.50 per rentable square foot annually.

 (c) If this Lease is extended as herein before expressly provided, then Landlord shall have no obligations or duties to
improve or to otherwise prepare the Premises, or to perform work or make any installations in connection with the Extension Term, other than providing Tenant with a $5.00 per rentable square foot Rehabilitation Allowance upon Tenant’s
exercising the first Extension Term only. When used in subparagraphs (a) and (b), above, the term “Tenant” shall mean only the named tenant in the Lease and no assignee, subtenant, or successor thereof. 
  

 46 

 EXHIBIT “F” 
 RIGHT OF FIRST OFFER 
 Subject to then-existing renewal or expansion options of other tenants (or,
even if not a right under such tenant’s lease, the renewal of a lease of any tenant by Landlord for the Offer Space (hereinafter defined)) (“Prior Rights”), and provided no Event of Default then exists, Landlord shall, prior to
offering the same to any party (other than tenants with Prior Rights), first offer to lease to Tenant space that becomes available on the 10th floor of the Building or any space that Tenant relinquishes during the term of the Lease (the “Offer Space”) in an “AS-IS” condition on the same terms and conditions as Tenant’s existing Lease; such
offer shall be in writing and specify the lease terms for the Offer Space, including the rent to be paid for the Offer Space and the date on which the Offer Space shall be included in the Premises (the “Offer Notice”). The Offer Notice
shall be substantially similar to the Offer Notice attached to this Exhibit. Tenant shall notify Landlord in writing whether Tenant elects to lease the entire Offer Space on the terms set forth in the Offer Notice, within ten (10) days after
Landlord delivers to Tenant the Offer Notice. If Tenant timely elects to lease the Offer Space, then Landlord and Tenant shall execute an amendment to this Lease, effective as of the date the Offer Space is to be included in the Premises, on the
terms set forth in the Offer Notice and, to the extent not inconsistent with the Offer Notice terms, the terms of this Lease; however, Tenant shall accept the Offer Space in an “AS-IS” condition and Landlord shall not provide to Tenant any
allowances, except a construction allowance as set forth in the existing Lease prorated to reflect the remaining Lease Term. Landlord shall not be obligated to pay any moving allowance or other tenant inducements except as specifically provided in
the Offer Notice. Tenant’s ratio of parking spaces per one thousand (1,000) rental square feet leased shall be the same as the ratio provided for in the initial premises. The Base Rent for the Offer Space shall coincide with the Base Rent
then being paid for the initial premises through the remainder of the Lease Term. The term of the Lease for the Offer Space shall be co-terminus with the initial premises. Notwithstanding the foregoing, if prior to Landlord’s delivery to Tenant
of the Offer Notice, Landlord has received an offer to lease all or part of the Offer Space from a third party (a “Third Party Offer”) and such Third Party Offer includes space in excess of the Offer Space, Tenant must exercise its rights
hereunder, if at all, as to all of the space contained in the Third Party Offer. 
 If Tenant fails or is unable to timely exercise its right
hereunder, then such right shall lapse, time being of the essence with respect to the exercise thereof (it being understood that Tenant’s right hereunder is a one-time right only), and Landlord may lease all or a portion of the Offer Space to
third parties on such terms as Landlord may elect. Tenant may not exercise its rights under this Exhibit if an Event of Default exists or Tenant is not then occupying the entire Premises. For purposes hereof, if an Offer Notice is delivered for less
than all of the Offer Space but such notice provides for an expansion, right of first refusal, or other preferential right to lease some of the remaining portion of the Offer Space, then such remaining portion of the Offer Space shall thereafter be
excluded from the provisions of this Exhibit. In no event, except as may be payable under Landlord’s commission agreement with CBRE, shall Landlord be obligated to pay any additional commission with respect to any space leased by Tenant under
this Exhibit, and Tenant shall indemnify, defend, and hold Landlord harmless from and against all costs, expenses, attorneys’ fees, and other liability for commissions or other compensation claimed by any broker or agent claiming the same by,
through, or under Tenant. 
 Tenant’s rights under this Exhibit shall terminate if (a) this Lease or Tenant’s right to
possession of the Premises is terminated, (b) Tenant assigns any of its interest in this Lease or sublets any portion of the Premises, or (c) less than two (2) full calendar years remain in the initial Term of this Lease. 

 

 47 

 FORM OF OFFER NOTICE 
  

			
	[Insert Date of Notice]	 	
	BY TELECOPY AND FEDERAL EXPRESS	 	
	  
	 	
	  
	 	
	  
	 	
	  
	 	

  

			
	 Re:
	  	Lease Agreement (the “Lease”) dated                     ,
200  , between                     , a             
(“Landlord”), and             , a              (“Tenant”). Capitalized terms used herein but
not defined shall be given the meanings assigned to them in the Lease.

 Ladies and Gentlemen: 
 Pursuant to the Right of First Offer attached to the Lease, enclosed please find an Offer Notice on Suite             . The basic terms and conditions
are as follows: 
  

			
	LOCATION:	  	  

		
	SIZE:	  	             rentable square feet
		
	BASE RENT RATE:	  	                    
$             per month
		
	TERM:	  	  

		
	IMPROVEMENTS	  	  

		
	COMMENCEMENT:	  	  

		
	PARKING TERMS:	  	  

		
	OTHER MATERIAL TERMS:	  	  

 Under the terms of the Right of First Offer, you must exercise your rights, if at all, as to the
Offer Space on the depiction attached to this Offer Notice within      days after Landlord delivers such Offer Notice. Accordingly, you have until 5:00 p.m. local time on
                    , 200  , to exercise your rights under the Right of First Offer and accept the terms as contained herein,
failing which your rights under the Right of First Offer shall terminate and Landlord shall be free to lease the Offer Space to any third party. If possible, any earlier response would be appreciated. Please note that your acceptance of this Offer
Notice shall be irrevocable and may not be rescinded. 
 Upon receipt of your acceptance herein, Landlord and Tenant shall execute an
amendment to the Lease memorializing the terms of this Offer Notice including the inclusion of the Offer Space in the Premises; provided, however, that the failure by Landlord and Tenant to execute such amendment shall not affect the inclusion of
such Offer Space in the Premises in accordance with this Offer Notice. 
 THE FAILURE TO ACCEPT THIS OFFER NOTICE BY (1) DESIGNATING THE
“ACCEPTED” BOX, AND (2) EXECUTING AND RETURNING THIS OFFER NOTICE TO LANDLORD WITHOUT MODIFICATION WITHIN SUCH TIME PERIOD SHALL BE DEEMED A WAIVER OF TENANT’S RIGHTS UNDER THE RIGHT OF FIRST OFFER, AND TENANT SHALL HAVE NO
FURTHER RIGHTS TO THE OFFER SPACE. THE FAILURE TO EXECUTE THIS LETTER WITHIN SUCH TIME PERIOD SHALL BE DEEMED A WAIVER OF THIS OFFER NOTICE. 
 Should you have any questions, do not hesitate to call. 
  

	
	Sincerely,
	  

	  

	  

 [please check appropriate box] 
 ACCEPTED   ̈ 
 REJECTED    ̈ 
  

			
	[TENANT’S SIGNATURE BLOCK]
		
	 By:
	 	  

  

 48 

			
	 Name:
	 	  

	 Title:
	 	  

	 Date:
	 	  

 Enclosure [attach depiction of Offer Space] 
  

 49 

 EXHIBIT “G” 
 EXCLUDED OPERATING COSTS 
  

	 	A.	Depreciation of the Project 

  

	 	B.	Principal and interest on any loans secured by the Project 

  

	 	C.	Ground lease and debt service payments; 

  

	 	D.	Costs for which the Landlord is reimbursable or indemnified; 

  

	 	E.	Capital expenditures and major structural repairs and replacements, even if not “capital”; 

  

	 	F.	Replacement of any item covered under warranty; 

  

	 	G.	Any cost of any item or service reimbursable by other tenants or for which Tenant separately reimburses Landlord or pays to third parties; 

  

	 	H.	Accounting and Legal fees relating to the ownership, construction, leasing, or sale of the Property; 

  

	 	I.	Any interest, fines or penalties including late payment penalties; 

  

	 	J.	Cost of correcting any applicable building or fire code violation(s) existing on the Commencement Date of the lease, or 

  

	 	K.	The cost of any penalty or fine incurred for noncompliance with the applicable Building or fire code violation(s); 

  

	 	L.	Costs incurred to test, sample, survey, clean-up, contain, abate or remove environmental or hazardous waste or materials; 

  

	 	M.	Personal property taxes of Landlord for equipment or items not used directly in the operation or maintenance of the Building; 

  

	 	N.	Rentals and other related expenses, if any, incurred in leasing capital items; 

  

	 	O.	Contributions to Operating Expense reserves; 

  

	 	P.	Cost of overtime or other expense to Landlord in performing work expressly provided in the lease, unless reasonably necessary and/or customary in the operation of similar
properties; services which are not provided to all tenants, or costs related to a specialty improvement (athletic facility, cafeteria, etc.); 

  

	 	Q.	Expenses directly resulting from the gross negligence of Landlord, its agents, servants or other employees; 

  

	 	R.	All bad debt loss, Rent loss, or reserve for bad debt or Rent loss; 

  

	 	S.	Any amount paid to an entity related to Landlord, which exceeds the amount that would be paid for similar goods or services on an arms-length basis between unrelated parties;

  

	 	T.	Costs to generate rental and other income: 

  

	 	1.	Leasing commissions 

  

	 	2.	Legal fees for negotiating and enforcing tenant leases 

  

	 	3.	Space planning costs 

  

	 	4.	Advertising 

  

	 	5.	Costs to prepare space for tenants; 

  

 50 

	 	U.	Repair and reconstruction of casualty damage, whether or not covered by insurance and whether or not subject to insurance deductibles; and 

  

	 	V.	Costs of defending of Landlord’s title, and costs of defending legal suits due to accidents or other claims, whether or not covered by insurance; costs of paying any judgments
rendered against the Landlord. 

  

 51

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]